PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30057680-0	2018	Puerarin Mitigates Diabetic Hepatic Steatosis and Fibrosis by Inhibiting TGF-beta Signaling Pathway Activation in Type 2 Diabetic Rats.	puerarin	0-8	transforming growth factor, beta 1	Rattus norvegicus	73-81
29710508-0	2018	Puerarin improves methotrexate-induced renal damage by up-regulating renal expression of Oat1 and Oat3 in vivo and in vitro.	puerarin	0-8	solute carrier family 22 member 6	Rattus norvegicus	89-93
29710508-0	2018	Puerarin improves methotrexate-induced renal damage by up-regulating renal expression of Oat1 and Oat3 in vivo and in vitro.	puerarin	0-8	solute carrier family 22 member 8	Rattus norvegicus	98-102
29710508-2	2018	The purpose of this study was to investigate whether the effect of puerarin (Pur) on renal damage induced by methotrexate (MTX) is related to the expression of renal Oat1/3 in vivo and in vitro, and to explore the related mechanisms.	puerarin	67-75	solute carrier family 22 member 6	Rattus norvegicus	166-172
29928229-0	2018	Nrf2 Is a Key Regulator on Puerarin Preventing Cardiac Fibrosis and Upregulating Metabolic Enzymes UGT1A1 in Rats.	puerarin	27-35	NFE2 like bZIP transcription factor 2	Rattus norvegicus	0-4
30028336-7	2018	At 7 days after model establishment, quantitative real-time reverse transcriptase-polymerase chain reaction results showed that puerarin administration reversed mRNA expression of transient receptor potential vanilloid 1 (Trpv1) and transient receptor potential ankyrin 1 (Trpa1) in a dose-dependent manner in dorsal root ganglion neurons after peripheral nerve injury.	puerarin	128-136	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	180-220
30028336-7	2018	At 7 days after model establishment, quantitative real-time reverse transcriptase-polymerase chain reaction results showed that puerarin administration reversed mRNA expression of transient receptor potential vanilloid 1 (Trpv1) and transient receptor potential ankyrin 1 (Trpa1) in a dose-dependent manner in dorsal root ganglion neurons after peripheral nerve injury.	puerarin	128-136	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	222-227
30028336-7	2018	At 7 days after model establishment, quantitative real-time reverse transcriptase-polymerase chain reaction results showed that puerarin administration reversed mRNA expression of transient receptor potential vanilloid 1 (Trpv1) and transient receptor potential ankyrin 1 (Trpa1) in a dose-dependent manner in dorsal root ganglion neurons after peripheral nerve injury.	puerarin	128-136	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	233-271
30028336-7	2018	At 7 days after model establishment, quantitative real-time reverse transcriptase-polymerase chain reaction results showed that puerarin administration reversed mRNA expression of transient receptor potential vanilloid 1 (Trpv1) and transient receptor potential ankyrin 1 (Trpa1) in a dose-dependent manner in dorsal root ganglion neurons after peripheral nerve injury.	puerarin	128-136	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	273-278
30028336-8	2018	These results suggest that puerarin dose-dependently ameliorates neuropathic pain by suppressing Trpv1 and Trpa1 up-regulation in dorsal root ganglion of neuropathic pain rats.	puerarin	27-35	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	97-102
30028336-8	2018	These results suggest that puerarin dose-dependently ameliorates neuropathic pain by suppressing Trpv1 and Trpa1 up-regulation in dorsal root ganglion of neuropathic pain rats.	puerarin	27-35	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	107-112
29733861-0	2018	Effects of puerarin on estrogen-regulated gene expression in gonadotropin-releasing hormone pulse generator of ovariectomized rats.	puerarin	11-19	gonadotropin releasing hormone 1	Rattus norvegicus	61-91
29733861-1	2018	Effects of puerarin on the hypothalamic gonadotropin-releasing hormone (GnRH) pulse generator function is investigated, for the first time, in ovariectomized rats at the level of mRNA expression of estrogen-responsive genes, e.g., estrogen receptor (ER), GnRH and its receptor (GnRHR).	puerarin	11-19	gonadotropin releasing hormone 1	Rattus norvegicus	40-70
29733861-1	2018	Effects of puerarin on the hypothalamic gonadotropin-releasing hormone (GnRH) pulse generator function is investigated, for the first time, in ovariectomized rats at the level of mRNA expression of estrogen-responsive genes, e.g., estrogen receptor (ER), GnRH and its receptor (GnRHR).	puerarin	11-19	gonadotropin releasing hormone 1	Rattus norvegicus	72-76
29733861-9	2018	This is the first study to demonstrate that in ovariectomized rat models of ovarian hormone deprivation, puerarin acted as a weak estrogen-active compound in the hypothalamic GnRH pulse generator through the downregulation of MPOA/AH ERalpha mRNA expression.	puerarin	105-113	gonadotropin releasing hormone 1	Rattus norvegicus	175-179
29733861-9	2018	This is the first study to demonstrate that in ovariectomized rat models of ovarian hormone deprivation, puerarin acted as a weak estrogen-active compound in the hypothalamic GnRH pulse generator through the downregulation of MPOA/AH ERalpha mRNA expression.	puerarin	105-113	estrogen receptor 1	Rattus norvegicus	234-241
29925761-10	2018	This change could be caused by upregulated uridine diphosphate (UDP)-glucuronosyltransferase activity, which may enhance puerarin clearance, and alter its therapeutic effects.	puerarin	121-129	UDP glycosyltransferase 2 family, polypeptide B	Rattus norvegicus	43-92
29928229-5	2018	The results of histopathological analysis, as well as measurements of collagen expression and cardiac fibroblast proliferation indicated that puerarin administration significantly inhibited cardiac fibrosis induced by AB and AngII.	puerarin	142-150	angiotensinogen	Rattus norvegicus	225-230
29928229-6	2018	These effects of puerarin may reflect activation of Nrf2/ROS pathway.	puerarin	17-25	NFE2 like bZIP transcription factor 2	Rattus norvegicus	52-56
29928229-8	2018	Inhibition of Nrf2 with specific Nrf2 siRNA or Nrf2 inhibitor brusatol attenuated anti-fibrotic and anti-oxidant effects of puerarin.	puerarin	124-132	NFE2 like bZIP transcription factor 2	Rattus norvegicus	14-18
29928229-8	2018	Inhibition of Nrf2 with specific Nrf2 siRNA or Nrf2 inhibitor brusatol attenuated anti-fibrotic and anti-oxidant effects of puerarin.	puerarin	124-132	NFE2 like bZIP transcription factor 2	Rattus norvegicus	33-37
29928229-8	2018	Inhibition of Nrf2 with specific Nrf2 siRNA or Nrf2 inhibitor brusatol attenuated anti-fibrotic and anti-oxidant effects of puerarin.	puerarin	124-132	NFE2 like bZIP transcription factor 2	Rattus norvegicus	33-37
29928229-9	2018	The metabolic effects of puerarin were mediated by Nrf2 through upregulation of UDP-glucuronosyltransferase (UGT) 1A1.	puerarin	25-33	NFE2 like bZIP transcription factor 2	Rattus norvegicus	51-55
29928229-9	2018	The metabolic effects of puerarin were mediated by Nrf2 through upregulation of UDP-glucuronosyltransferase (UGT) 1A1.	puerarin	25-33	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	80-117
29928229-11	2018	Treatment with Nrf2 siRNA or brusatol dramatically decreased UGT1A1 expression in puerarin-treated fibroblasts.	puerarin	82-90	NFE2 like bZIP transcription factor 2	Rattus norvegicus	15-19
29928229-11	2018	Treatment with Nrf2 siRNA or brusatol dramatically decreased UGT1A1 expression in puerarin-treated fibroblasts.	puerarin	82-90	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	61-67
29928229-12	2018	The results of chromatin immunoprecipitation-qPCR further confirmed that puerarin significantly increased binding of Nrf2 to the promoter region of Ugt1a1.	puerarin	73-81	NFE2 like bZIP transcription factor 2	Rattus norvegicus	117-121
29928229-12	2018	The results of chromatin immunoprecipitation-qPCR further confirmed that puerarin significantly increased binding of Nrf2 to the promoter region of Ugt1a1.	puerarin	73-81	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	148-154
29928229-13	2018	Western blot analysis showed that puerarin significantly inhibited AngII-induced phosphorylation of p38-MAPK.	puerarin	34-42	angiotensinogen	Rattus norvegicus	67-72
29928229-13	2018	Western blot analysis showed that puerarin significantly inhibited AngII-induced phosphorylation of p38-MAPK.	puerarin	34-42	mitogen activated protein kinase 14	Rattus norvegicus	100-103
29928229-15	2018	Together, these results suggest that puerarin prevents cardiac fibrosis via activation of Nrf2 and inactivation of p38-MAPK.	puerarin	37-45	NFE2 like bZIP transcription factor 2	Rattus norvegicus	90-94
29928229-15	2018	Together, these results suggest that puerarin prevents cardiac fibrosis via activation of Nrf2 and inactivation of p38-MAPK.	puerarin	37-45	mitogen activated protein kinase 14	Rattus norvegicus	115-118
29928229-17	2018	Autoregulatory circuits between puerarin and Nrf2-regulated UGT1A1 attenuates side effects associated with treatment, but it does not weaken puerarin"s pharmacological effects.	puerarin	32-40	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	60-66
29345333-10	2018	Moreover, puerarin suppressed cell migration, invasion and up-regulated E-Cadherin expression as well as down-regulated Vimentin and alpha-SMA expression.	puerarin	10-18	cadherin 1	Homo sapiens	72-82
29345333-10	2018	Moreover, puerarin suppressed cell migration, invasion and up-regulated E-Cadherin expression as well as down-regulated Vimentin and alpha-SMA expression.	puerarin	10-18	vimentin	Homo sapiens	120-128
29345333-11	2018	Furthermore, puerarin treatment suppressed the expression of p-MEK and p-ERK in RB cells.	puerarin	13-21	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	71-76
29926825-0	2018	Puerarin protects rat brain against ischemia/reperfusion injury by suppressing autophagy via the AMPK-mTOR-ULK1 signaling pathway.	puerarin	0-8	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	97-101
29620183-8	2018	The present study reported that puerarin treatment markedly decreased interleukin (IL)-1beta, IL-17A and tumor necrosis factor-alpha expression levels in mice with neovascular glaucoma.	puerarin	32-40	interleukin 17A	Mus musculus	94-132
29620183-11	2018	Mechanism analysis demonstrated that treatment with puerarin effectively inhibited nuclear factor (NF)-kappaB activity and its target protein levels p65, inhibitor of NF-kappaB kinase subunit beta and inhibitor of NF-kappaB kinase subunit alpha in vascular endothelial cells.	puerarin	52-60	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	83-109
29620183-11	2018	Mechanism analysis demonstrated that treatment with puerarin effectively inhibited nuclear factor (NF)-kappaB activity and its target protein levels p65, inhibitor of NF-kappaB kinase subunit beta and inhibitor of NF-kappaB kinase subunit alpha in vascular endothelial cells.	puerarin	52-60	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	149-152
29926825-0	2018	Puerarin protects rat brain against ischemia/reperfusion injury by suppressing autophagy via the AMPK-mTOR-ULK1 signaling pathway.	puerarin	0-8	mechanistic target of rapamycin kinase	Rattus norvegicus	102-106
29926825-0	2018	Puerarin protects rat brain against ischemia/reperfusion injury by suppressing autophagy via the AMPK-mTOR-ULK1 signaling pathway.	puerarin	0-8	unc-51 like autophagy activating kinase 1	Rattus norvegicus	107-111
29926825-1	2018	Puerarin suppresses autophagy to alleviate cerebral ischemia/reperfusion injury, and accumulating evidence indicates that the AMPK-mTOR signaling pathway regulates the activation of the autophagy pathway through the coordinated phosphorylation of ULK1.	puerarin	0-8	mechanistic target of rapamycin kinase	Rattus norvegicus	131-135
29926825-1	2018	Puerarin suppresses autophagy to alleviate cerebral ischemia/reperfusion injury, and accumulating evidence indicates that the AMPK-mTOR signaling pathway regulates the activation of the autophagy pathway through the coordinated phosphorylation of ULK1.	puerarin	0-8	unc-51 like autophagy activating kinase 1	Rattus norvegicus	247-251
29926825-2	2018	In this study, we investigated the mechanisms underlying the neuroprotective effect of puerarin and its role in modulating autophagy via the AMPK-mTOR-ULK1 signaling pathway in the rat middle cerebral artery occlusion model of cerebral ischemia/reperfusion injury.	puerarin	87-95	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	141-145
29926825-2	2018	In this study, we investigated the mechanisms underlying the neuroprotective effect of puerarin and its role in modulating autophagy via the AMPK-mTOR-ULK1 signaling pathway in the rat middle cerebral artery occlusion model of cerebral ischemia/reperfusion injury.	puerarin	87-95	mechanistic target of rapamycin kinase	Rattus norvegicus	146-150
29926825-2	2018	In this study, we investigated the mechanisms underlying the neuroprotective effect of puerarin and its role in modulating autophagy via the AMPK-mTOR-ULK1 signaling pathway in the rat middle cerebral artery occlusion model of cerebral ischemia/reperfusion injury.	puerarin	87-95	unc-51 like autophagy activating kinase 1	Rattus norvegicus	151-155
29926825-8	2018	Puerarin substantially reduced the Longa score and infarct volume, and it lessened autophagosome formation in the hippocampal CA1 area following cerebral ischemia/reperfusion injury in a dose-dependent manner.	puerarin	0-8	carbonic anhydrase 1	Rattus norvegicus	126-129
29926825-9	2018	Pretreatment with puerarin (50 or 100 mg/kg) reduced Beclin-1 expression and the LC3-II/LC3-I ratio, as well as p-AMPK and pS317-ULK1 levels.	puerarin	18-26	beclin 1	Rattus norvegicus	53-61
29926825-9	2018	Pretreatment with puerarin (50 or 100 mg/kg) reduced Beclin-1 expression and the LC3-II/LC3-I ratio, as well as p-AMPK and pS317-ULK1 levels.	puerarin	18-26	annexin A3	Rattus norvegicus	81-84
29926825-9	2018	Pretreatment with puerarin (50 or 100 mg/kg) reduced Beclin-1 expression and the LC3-II/LC3-I ratio, as well as p-AMPK and pS317-ULK1 levels.	puerarin	18-26	annexin A3	Rattus norvegicus	88-91
29926825-9	2018	Pretreatment with puerarin (50 or 100 mg/kg) reduced Beclin-1 expression and the LC3-II/LC3-I ratio, as well as p-AMPK and pS317-ULK1 levels.	puerarin	18-26	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	114-118
29926825-9	2018	Pretreatment with puerarin (50 or 100 mg/kg) reduced Beclin-1 expression and the LC3-II/LC3-I ratio, as well as p-AMPK and pS317-ULK1 levels.	puerarin	18-26	unc-51 like autophagy activating kinase 1	Rattus norvegicus	129-133
29926825-11	2018	Furthermore, puerarin at 100 mg/kg dramatically increased the levels of p-mTOR and pS757-ULK1 in the hippocampus on the ischemic side.	puerarin	13-21	mechanistic target of rapamycin kinase	Rattus norvegicus	74-78
29926825-11	2018	Furthermore, puerarin at 100 mg/kg dramatically increased the levels of p-mTOR and pS757-ULK1 in the hippocampus on the ischemic side.	puerarin	13-21	unc-51 like autophagy activating kinase 1	Rattus norvegicus	89-93
29926825-12	2018	Our findings suggest that puerarin alleviates autophagy by activating the APMK-mTOR-ULK1 signaling pathway.	puerarin	26-34	mechanistic target of rapamycin kinase	Rattus norvegicus	79-83
29926825-12	2018	Our findings suggest that puerarin alleviates autophagy by activating the APMK-mTOR-ULK1 signaling pathway.	puerarin	26-34	unc-51 like autophagy activating kinase 1	Rattus norvegicus	84-88
29728095-0	2018	Puerarin inhibits vascular smooth muscle cells proliferation induced by fine particulate matter via suppressing of the p38 MAPK signaling pathway.	puerarin	0-8	mitogen-activated protein kinase 14	Homo sapiens	119-122
29950085-8	2018	It was found that puerarin could be given in anoxia to promote the expressions of CD31, VE-cadherin, inhibit the expressions of alpha-SMA, vimentin and fibronection, namely the inhibition of vascular wall thickening.	puerarin	18-26	platelet and endothelial cell adhesion molecule 1	Rattus norvegicus	82-86
29950085-8	2018	It was found that puerarin could be given in anoxia to promote the expressions of CD31, VE-cadherin, inhibit the expressions of alpha-SMA, vimentin and fibronection, namely the inhibition of vascular wall thickening.	puerarin	18-26	cadherin 5	Rattus norvegicus	88-99
29950085-8	2018	It was found that puerarin could be given in anoxia to promote the expressions of CD31, VE-cadherin, inhibit the expressions of alpha-SMA, vimentin and fibronection, namely the inhibition of vascular wall thickening.	puerarin	18-26	vimentin	Rattus norvegicus	139-147
29368357-0	2018	Puerarin inhibits TRPM3/miR-204 to promote MC3T3-E1 cells proliferation, differentiation and mineralization.	puerarin	0-8	transient receptor potential cation channel, subfamily M, member 3	Mus musculus	18-23
29368357-0	2018	Puerarin inhibits TRPM3/miR-204 to promote MC3T3-E1 cells proliferation, differentiation and mineralization.	puerarin	0-8	microRNA 204	Mus musculus	24-31
29368357-4	2018	Following treatment with puerarin, the expression levels of transient receptor potential Melastatin 3 (TRPM3) and microRNA-204 (miR-204) were decreased, whereas that of Runt-related transcription Factor 2 (Runx2) increased.	puerarin	25-33	transient receptor potential cation channel, subfamily M, member 3	Mus musculus	60-101
29368357-4	2018	Following treatment with puerarin, the expression levels of transient receptor potential Melastatin 3 (TRPM3) and microRNA-204 (miR-204) were decreased, whereas that of Runt-related transcription Factor 2 (Runx2) increased.	puerarin	25-33	transient receptor potential cation channel, subfamily M, member 3	Mus musculus	103-108
29368357-4	2018	Following treatment with puerarin, the expression levels of transient receptor potential Melastatin 3 (TRPM3) and microRNA-204 (miR-204) were decreased, whereas that of Runt-related transcription Factor 2 (Runx2) increased.	puerarin	25-33	microRNA 204	Mus musculus	114-126
29368357-4	2018	Following treatment with puerarin, the expression levels of transient receptor potential Melastatin 3 (TRPM3) and microRNA-204 (miR-204) were decreased, whereas that of Runt-related transcription Factor 2 (Runx2) increased.	puerarin	25-33	microRNA 204	Mus musculus	128-135
29368357-4	2018	Following treatment with puerarin, the expression levels of transient receptor potential Melastatin 3 (TRPM3) and microRNA-204 (miR-204) were decreased, whereas that of Runt-related transcription Factor 2 (Runx2) increased.	puerarin	25-33	runt related transcription factor 2	Mus musculus	169-204
29368357-4	2018	Following treatment with puerarin, the expression levels of transient receptor potential Melastatin 3 (TRPM3) and microRNA-204 (miR-204) were decreased, whereas that of Runt-related transcription Factor 2 (Runx2) increased.	puerarin	25-33	runt related transcription factor 2	Mus musculus	206-211
29368357-6	2018	In addition, puerarin induced the changes of intracellular Ca2+ concentration ([Ca2+ ]i ) and extracellular Ca2+ concentration ([Ca2+ ]0 ) through TRPM3 might be involved in the biological process of MC3T3-E1 cells.	puerarin	13-21	transient receptor potential cation channel, subfamily M, member 3	Mus musculus	147-152
29368357-7	2018	These results suggested that puerarin may promote MC3T3-E1 cell proliferation, differentiation and mineralization, which may be related to the downregulation of TRPM3/miR-204 and following regulating [Ca2+ ]i and [Ca2+ ]0 , and activation of Runx2.	puerarin	29-37	transient receptor potential cation channel, subfamily M, member 3	Mus musculus	161-166
29368357-7	2018	These results suggested that puerarin may promote MC3T3-E1 cell proliferation, differentiation and mineralization, which may be related to the downregulation of TRPM3/miR-204 and following regulating [Ca2+ ]i and [Ca2+ ]0 , and activation of Runx2.	puerarin	29-37	microRNA 204	Mus musculus	167-174
29368357-7	2018	These results suggested that puerarin may promote MC3T3-E1 cell proliferation, differentiation and mineralization, which may be related to the downregulation of TRPM3/miR-204 and following regulating [Ca2+ ]i and [Ca2+ ]0 , and activation of Runx2.	puerarin	29-37	runt related transcription factor 2	Mus musculus	242-247
29728095-8	2018	RESULTS: Compared to the PM2.5-treated cells, in addition to inhibiting the PM2.5-induced VSMCs proliferation, puerarin also down-regulated the protein expressions of p-p38 MAPK and PCNA, decreased the levels of ET-1, VCAM-1, IL-6, TNF-alpha and MDA, increased the levels of NO and SOD.	puerarin	111-119	mitogen-activated protein kinase 14	Homo sapiens	169-172
29728095-8	2018	RESULTS: Compared to the PM2.5-treated cells, in addition to inhibiting the PM2.5-induced VSMCs proliferation, puerarin also down-regulated the protein expressions of p-p38 MAPK and PCNA, decreased the levels of ET-1, VCAM-1, IL-6, TNF-alpha and MDA, increased the levels of NO and SOD.	puerarin	111-119	proliferating cell nuclear antigen	Homo sapiens	182-186
29728095-8	2018	RESULTS: Compared to the PM2.5-treated cells, in addition to inhibiting the PM2.5-induced VSMCs proliferation, puerarin also down-regulated the protein expressions of p-p38 MAPK and PCNA, decreased the levels of ET-1, VCAM-1, IL-6, TNF-alpha and MDA, increased the levels of NO and SOD.	puerarin	111-119	endothelin 1	Homo sapiens	212-216
29728095-8	2018	RESULTS: Compared to the PM2.5-treated cells, in addition to inhibiting the PM2.5-induced VSMCs proliferation, puerarin also down-regulated the protein expressions of p-p38 MAPK and PCNA, decreased the levels of ET-1, VCAM-1, IL-6, TNF-alpha and MDA, increased the levels of NO and SOD.	puerarin	111-119	vascular cell adhesion molecule 1	Homo sapiens	218-224
29728095-8	2018	RESULTS: Compared to the PM2.5-treated cells, in addition to inhibiting the PM2.5-induced VSMCs proliferation, puerarin also down-regulated the protein expressions of p-p38 MAPK and PCNA, decreased the levels of ET-1, VCAM-1, IL-6, TNF-alpha and MDA, increased the levels of NO and SOD.	puerarin	111-119	interleukin 6	Homo sapiens	226-230
29728095-8	2018	RESULTS: Compared to the PM2.5-treated cells, in addition to inhibiting the PM2.5-induced VSMCs proliferation, puerarin also down-regulated the protein expressions of p-p38 MAPK and PCNA, decreased the levels of ET-1, VCAM-1, IL-6, TNF-alpha and MDA, increased the levels of NO and SOD.	puerarin	111-119	tumor necrosis factor	Homo sapiens	232-241
29728095-9	2018	Moreover, the anti-proliferative effects of puerarin were significantly enhanced by the co-incubation of puerarin with SB203580, a selective inhibitor of p38 MAPK, as compared to the puerarin-treated cells.	puerarin	44-52	mitogen-activated protein kinase 14	Homo sapiens	154-162
30788926-8	2018	The chloride channel blockers tamoxifen (20 mumol/L) and ATP (10 mmol/L) significantly inhibited the hemolysis induced by puerarin injection (n=3~5, P<0.01).	puerarin	122-130	cystic fibrosis transmembrane conductance regulator	Oryctolagus cuniculus	4-20
30788926-9	2018	Application of low concentration ATP (50 mumol/L) to activate the chloride channel significantly increased puerarin injection induced hemolysis (n=4, P<0.01).	puerarin	107-115	cystic fibrosis transmembrane conductance regulator	Oryctolagus cuniculus	66-82
30788926-10	2018	CONCLUSIONS: The hemolytic effect of puerarin injection is dose-dependent in vitro, and the activation of chloride channel is closely related to the hemolysis induced by puerarin injection.	puerarin	37-45	cystic fibrosis transmembrane conductance regulator	Oryctolagus cuniculus	106-122
30788926-10	2018	CONCLUSIONS: The hemolytic effect of puerarin injection is dose-dependent in vitro, and the activation of chloride channel is closely related to the hemolysis induced by puerarin injection.	puerarin	170-178	cystic fibrosis transmembrane conductance regulator	Oryctolagus cuniculus	106-122
29728095-9	2018	Moreover, the anti-proliferative effects of puerarin were significantly enhanced by the co-incubation of puerarin with SB203580, a selective inhibitor of p38 MAPK, as compared to the puerarin-treated cells.	puerarin	105-113	mitogen-activated protein kinase 14	Homo sapiens	154-162
29728095-9	2018	Moreover, the anti-proliferative effects of puerarin were significantly enhanced by the co-incubation of puerarin with SB203580, a selective inhibitor of p38 MAPK, as compared to the puerarin-treated cells.	puerarin	105-113	mitogen-activated protein kinase 14	Homo sapiens	154-162
29728095-10	2018	CONCLUSION: These results suggest that puerarin might suppress the PM2.5-induced VSMCs proliferation via the inhibition of the p38 MAPK signaling pathway.	puerarin	39-47	mitogen-activated protein kinase 14	Homo sapiens	127-130
29327124-0	2018	Puerarin Up-regulates Methyl-CpG Binding Protein 2 Phosphorylation in Hippocampus of Vascular Dementia Rats.	puerarin	0-8	methyl CpG binding protein 2	Rattus norvegicus	22-50
29327124-1	2018	OBJECTIVE: To observe the effect of puerarin on methyl-CpG binding protein 2 (MeCP2) phosphorylation (pMeCP2) in the hippocampus of a rat model of vascular dementia (VD).	puerarin	36-44	methyl CpG binding protein 2	Rattus norvegicus	48-76
29327124-1	2018	OBJECTIVE: To observe the effect of puerarin on methyl-CpG binding protein 2 (MeCP2) phosphorylation (pMeCP2) in the hippocampus of a rat model of vascular dementia (VD).	puerarin	36-44	methyl CpG binding protein 2	Rattus norvegicus	78-83
29571724-0	2018	Puerarin prevents LPS-induced acute lung injury via inhibiting inflammatory response.	puerarin	0-8	toll-like receptor 4	Mus musculus	18-21
29731828-0	2018	Puerarin alleviates delayed-type hypersensitivity via cytokine inhibition by modulating Th1/Th2 balance.	puerarin	0-8	negative elongation factor complex member C/D, Th1l	Mus musculus	88-91
29731828-0	2018	Puerarin alleviates delayed-type hypersensitivity via cytokine inhibition by modulating Th1/Th2 balance.	puerarin	0-8	heart and neural crest derivatives expressed 2	Mus musculus	92-95
29731828-2	2018	The aim of the current study was to investigate the effect of puerarin on delayed-type hypersensitivity (DTH) induced by ovalbumin (OVA) in mice and explore its underlying mechanisms.	puerarin	62-70	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	121-130
29731828-4	2018	In the homogenized supernatant of footpad tissues, the classic Th1-cytokines, including interferon (IFN)-gamma was suppressed following puerarin treatment.	puerarin	136-144	negative elongation factor complex member C/D, Th1l	Mus musculus	63-66
29731828-4	2018	In the homogenized supernatant of footpad tissues, the classic Th1-cytokines, including interferon (IFN)-gamma was suppressed following puerarin treatment.	puerarin	136-144	interferon gamma	Mus musculus	88-110
29731828-5	2018	Furthermore, a high dose of puerarin inhibited interleukin (IL)-4 production, the classic Th2-cytokine.	puerarin	28-36	heart and neural crest derivatives expressed 2	Mus musculus	90-93
29731828-6	2018	The concanavalin A stimulation and MTT assays indicated a suppressive effect of puerarin on Th1 response via decreasing IFN-gamma production in OVA-primed lymphocytes.	puerarin	80-88	negative elongation factor complex member C/D, Th1l	Mus musculus	92-95
29731828-6	2018	The concanavalin A stimulation and MTT assays indicated a suppressive effect of puerarin on Th1 response via decreasing IFN-gamma production in OVA-primed lymphocytes.	puerarin	80-88	interferon gamma	Mus musculus	120-129
29731828-7	2018	Detailed studies revealed that puerarin modulated the Th1/Th2 balance in DTH responses, attributing to lower T-bet/GATA binding protein-3 mRNA and protein level ratios, which led to the shift change of IFN-gamma/IL-4 with puerarin treatment.	puerarin	31-39	negative elongation factor complex member C/D, Th1l	Mus musculus	54-57
29731828-7	2018	Detailed studies revealed that puerarin modulated the Th1/Th2 balance in DTH responses, attributing to lower T-bet/GATA binding protein-3 mRNA and protein level ratios, which led to the shift change of IFN-gamma/IL-4 with puerarin treatment.	puerarin	31-39	heart and neural crest derivatives expressed 2	Mus musculus	58-61
29731828-7	2018	Detailed studies revealed that puerarin modulated the Th1/Th2 balance in DTH responses, attributing to lower T-bet/GATA binding protein-3 mRNA and protein level ratios, which led to the shift change of IFN-gamma/IL-4 with puerarin treatment.	puerarin	31-39	T-box 21	Mus musculus	109-114
29731828-7	2018	Detailed studies revealed that puerarin modulated the Th1/Th2 balance in DTH responses, attributing to lower T-bet/GATA binding protein-3 mRNA and protein level ratios, which led to the shift change of IFN-gamma/IL-4 with puerarin treatment.	puerarin	31-39	GATA binding protein 3	Mus musculus	115-137
29731828-7	2018	Detailed studies revealed that puerarin modulated the Th1/Th2 balance in DTH responses, attributing to lower T-bet/GATA binding protein-3 mRNA and protein level ratios, which led to the shift change of IFN-gamma/IL-4 with puerarin treatment.	puerarin	31-39	interferon gamma	Mus musculus	202-211
29731828-7	2018	Detailed studies revealed that puerarin modulated the Th1/Th2 balance in DTH responses, attributing to lower T-bet/GATA binding protein-3 mRNA and protein level ratios, which led to the shift change of IFN-gamma/IL-4 with puerarin treatment.	puerarin	31-39	interleukin 4	Mus musculus	212-216
29731828-7	2018	Detailed studies revealed that puerarin modulated the Th1/Th2 balance in DTH responses, attributing to lower T-bet/GATA binding protein-3 mRNA and protein level ratios, which led to the shift change of IFN-gamma/IL-4 with puerarin treatment.	puerarin	222-230	negative elongation factor complex member C/D, Th1l	Mus musculus	54-57
29731828-7	2018	Detailed studies revealed that puerarin modulated the Th1/Th2 balance in DTH responses, attributing to lower T-bet/GATA binding protein-3 mRNA and protein level ratios, which led to the shift change of IFN-gamma/IL-4 with puerarin treatment.	puerarin	222-230	T-box 21	Mus musculus	109-114
29731828-7	2018	Detailed studies revealed that puerarin modulated the Th1/Th2 balance in DTH responses, attributing to lower T-bet/GATA binding protein-3 mRNA and protein level ratios, which led to the shift change of IFN-gamma/IL-4 with puerarin treatment.	puerarin	222-230	interferon gamma	Mus musculus	202-211
29731828-8	2018	These findings demonstrate that puerarin alleviated inflammation in DTH triggered by OVA application via curbing inflammatory cytokines by modulating the Th1/Th2 balance.	puerarin	32-40	negative elongation factor complex member C/D, Th1l	Mus musculus	154-157
29731828-8	2018	These findings demonstrate that puerarin alleviated inflammation in DTH triggered by OVA application via curbing inflammatory cytokines by modulating the Th1/Th2 balance.	puerarin	32-40	heart and neural crest derivatives expressed 2	Mus musculus	158-161
29571724-3	2018	The purpose of this study was to investigate the effect of puerarin on lipopolysaccharide (LPS)-induced ALI in mice.	puerarin	59-67	toll-like receptor 4	Mus musculus	91-94
29571724-7	2018	The results showed that puerarin significantly inhibited LPS-stimulated MPO activity in lung tissues.	puerarin	24-32	toll-like receptor 4	Mus musculus	57-60
29571724-7	2018	The results showed that puerarin significantly inhibited LPS-stimulated MPO activity in lung tissues.	puerarin	24-32	myeloperoxidase	Mus musculus	72-75
29571724-9	2018	We also found that the expression of pro-inflammatory cytokines, TNF-alpha, IL-6 and IL-1beta were inhibited by puerarin.	puerarin	112-120	tumor necrosis factor	Mus musculus	65-74
29571724-9	2018	We also found that the expression of pro-inflammatory cytokines, TNF-alpha, IL-6 and IL-1beta were inhibited by puerarin.	puerarin	112-120	interleukin 6	Mus musculus	76-80
29568901-10	2018	The protective effect of puerarin was markedly decreased by 6-aminonicotinamide, an inhibitor of glucose-6-phosphate dehydrogenase (G6PD).	puerarin	25-33	glucose-6-phosphate dehydrogenase 2	Mus musculus	97-130
29568901-10	2018	The protective effect of puerarin was markedly decreased by 6-aminonicotinamide, an inhibitor of glucose-6-phosphate dehydrogenase (G6PD).	puerarin	25-33	glucose-6-phosphate dehydrogenase 2	Mus musculus	132-136
29568901-11	2018	In conclusion, the results of the present study suggested that puerarin may increase the activity of G6PD, decreased the level of oxidative stress in MIN6 cells, protect mitochondria and promote MIN6 cell survival.	puerarin	63-71	glucose-6-phosphate dehydrogenase 2	Mus musculus	101-105
29568939-10	2018	These results demonstrated that the myocardial protective effect of puerarin serves to reduce myocardial I/R injury, via upregulation of VEGFA/Ang-1 and suppression of apoptosis, in diabetic rats with myocardial I/R.	puerarin	68-76	angiogenin	Rattus norvegicus	143-148
29571724-9	2018	We also found that the expression of pro-inflammatory cytokines, TNF-alpha, IL-6 and IL-1beta were inhibited by puerarin.	puerarin	112-120	interleukin 1 beta	Mus musculus	85-93
29568939-9	2018	Furthermore, puerarin activated the protein expression levels of VEGFA and Ang-I, and increased nitric oxide production, phosphorylated-endothelial nitric oxide synthase protein expression and caspase-3 activity.	puerarin	13-21	vascular endothelial growth factor A	Rattus norvegicus	65-70
29571724-10	2018	Puerarin also inhibited LPS-induced TNF-alpha in RAW264.7 cells and IL-8 in A549 cells.	puerarin	0-8	toll-like receptor 4	Mus musculus	24-27
29568939-9	2018	Furthermore, puerarin activated the protein expression levels of VEGFA and Ang-I, and increased nitric oxide production, phosphorylated-endothelial nitric oxide synthase protein expression and caspase-3 activity.	puerarin	13-21	caspase 3	Rattus norvegicus	193-202
29568939-10	2018	These results demonstrated that the myocardial protective effect of puerarin serves to reduce myocardial I/R injury, via upregulation of VEGFA/Ang-1 and suppression of apoptosis, in diabetic rats with myocardial I/R.	puerarin	68-76	vascular endothelial growth factor A	Rattus norvegicus	137-142
29571724-10	2018	Puerarin also inhibited LPS-induced TNF-alpha in RAW264.7 cells and IL-8 in A549 cells.	puerarin	0-8	tumor necrosis factor	Mus musculus	36-45
29571724-10	2018	Puerarin also inhibited LPS-induced TNF-alpha in RAW264.7 cells and IL-8 in A549 cells.	puerarin	0-8	chemokine (C-X-C motif) ligand 15	Mus musculus	68-72
29571724-11	2018	From the results of western blotting, puerarin significantly suppressed LPS-stimulated NF-kappaB activation.	puerarin	38-46	toll-like receptor 4	Mus musculus	72-75
29571724-11	2018	From the results of western blotting, puerarin significantly suppressed LPS-stimulated NF-kappaB activation.	puerarin	38-46	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	87-96
29571724-12	2018	And the expression of LXRalpha was dose-dependently increased by treatment of puerarin.	puerarin	78-86	nuclear receptor subfamily 1, group H, member 3	Mus musculus	22-30
29571724-13	2018	The inhibition of puerarin on TNF-alpha production in RAW264.7 cells and IL-8 production in A549 cells were blocked by LXRalpha inhibitor geranylgeranyl pyrophosphate (GGPP).	puerarin	18-26	tumor necrosis factor	Mus musculus	30-39
29571724-13	2018	The inhibition of puerarin on TNF-alpha production in RAW264.7 cells and IL-8 production in A549 cells were blocked by LXRalpha inhibitor geranylgeranyl pyrophosphate (GGPP).	puerarin	18-26	nuclear receptor subfamily 1, group H, member 3	Mus musculus	119-127
29571724-14	2018	These results suggested that puerarin attenuated ALI by activating LXRalpha, which subsequently inhibited LPS-induced inflammatory response.	puerarin	29-37	nuclear receptor subfamily 1, group H, member 3	Mus musculus	67-75
29571724-14	2018	These results suggested that puerarin attenuated ALI by activating LXRalpha, which subsequently inhibited LPS-induced inflammatory response.	puerarin	29-37	toll-like receptor 4	Mus musculus	106-109
29238980-0	2018	Influence of paeoniflorin and menthol on puerarin transport across MDCK and MDCK-MDR1 cells as blood-brain barrier in vitro model.	puerarin	41-49	ATP binding cassette subfamily B member 1	Canis lupus familiaris	76-85
29636885-0	2018	Protective role of puerarin on LPS/D-Gal induced acute liver injury via restoring autophagy.	puerarin	19-27	galanin and GMAP prepropeptide	Mus musculus	37-40
29636885-3	2018	This study investigated the protective effects of puerarin against lipopolysaccharide (LPS)/D-galactosamine (D-Gal)-induced liver injury and the potential mechanisms in mice.	puerarin	50-58	galanin and GMAP prepropeptide	Mus musculus	111-114
29636885-5	2018	The results showed that administration of puerarin substantially alleviated LPS/D-Gal-induced acute liver injury in mice by increased survival rates, improved liver histopathology, reduced plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, alleviated production of pro-inflammatory cytokines, and suppressed hepatocyte apoptosis.	puerarin	42-50	galanin and GMAP prepropeptide	Mus musculus	82-85
29636885-5	2018	The results showed that administration of puerarin substantially alleviated LPS/D-Gal-induced acute liver injury in mice by increased survival rates, improved liver histopathology, reduced plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, alleviated production of pro-inflammatory cytokines, and suppressed hepatocyte apoptosis.	puerarin	42-50	glutamic pyruvic transaminase, soluble	Mus musculus	196-220
29636885-5	2018	The results showed that administration of puerarin substantially alleviated LPS/D-Gal-induced acute liver injury in mice by increased survival rates, improved liver histopathology, reduced plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, alleviated production of pro-inflammatory cytokines, and suppressed hepatocyte apoptosis.	puerarin	42-50	glutamic pyruvic transaminase, soluble	Mus musculus	222-225
29636885-5	2018	The results showed that administration of puerarin substantially alleviated LPS/D-Gal-induced acute liver injury in mice by increased survival rates, improved liver histopathology, reduced plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, alleviated production of pro-inflammatory cytokines, and suppressed hepatocyte apoptosis.	puerarin	42-50	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	231-257
29636885-5	2018	The results showed that administration of puerarin substantially alleviated LPS/D-Gal-induced acute liver injury in mice by increased survival rates, improved liver histopathology, reduced plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, alleviated production of pro-inflammatory cytokines, and suppressed hepatocyte apoptosis.	puerarin	42-50	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	259-262
29636885-6	2018	Moreover, puerarin pretreatment activated autophagy by increased the ratio of LC3B-II/I and the protein levels of Beclin-1, decreased the levels of p62 protein expression.	puerarin	10-18	liver cell immortalization	Mus musculus	78-87
29636885-6	2018	Moreover, puerarin pretreatment activated autophagy by increased the ratio of LC3B-II/I and the protein levels of Beclin-1, decreased the levels of p62 protein expression.	puerarin	10-18	beclin 1, autophagy related	Mus musculus	114-122
29636885-6	2018	Moreover, puerarin pretreatment activated autophagy by increased the ratio of LC3B-II/I and the protein levels of Beclin-1, decreased the levels of p62 protein expression.	puerarin	10-18	nucleoporin 62	Mus musculus	148-151
29636885-7	2018	Taken together, these findings demonstrated that puerarin could prevent the LPS/D-Gal-induced liver injury in mice, and its mechanisms might be associated with the increments of autophagy and suppression of apoptosis.	puerarin	49-57	galanin and GMAP prepropeptide	Mus musculus	82-85
29511236-0	2018	Publisher Correction: Puerarin attenuates diabetic kidney injury through the suppression of NOX4 expression in podocytes.	puerarin	22-30	NADPH oxidase 4	Homo sapiens	92-96
29393465-7	2018	Moreover, puerarin slightly induced cell autophagy through the PI3K/Akt and MAPK/Erk1/2 signaling pathways.	puerarin	10-18	thymoma viral proto-oncogene 1	Mus musculus	68-71
29393465-7	2018	Moreover, puerarin slightly induced cell autophagy through the PI3K/Akt and MAPK/Erk1/2 signaling pathways.	puerarin	10-18	mitogen-activated protein kinase 3	Mus musculus	81-87
29238980-1	2018	OBJECTIVE: Our objective of this research was (1) to investigate the transport characteristics of puerarin through MDCK-MDR1 and MDCK cells and (2) to evaluate the effects of paeoniflorin and menthol on puerarin transport so as to (3) explore the enhancement mechanism.	puerarin	98-106	ATP binding cassette subfamily B member 1	Canis lupus familiaris	115-124
29238980-5	2018	However, the efflux ratio of puerarin was <2 in MDCK-MDR1 models, which suggested puerarin was not P-gp substrates so as to the P-glycoprotein activity determination of puerarin.	puerarin	29-37	ATP binding cassette subfamily B member 1	Canis lupus familiaris	56-60
29238980-5	2018	However, the efflux ratio of puerarin was <2 in MDCK-MDR1 models, which suggested puerarin was not P-gp substrates so as to the P-glycoprotein activity determination of puerarin.	puerarin	85-93	ATP binding cassette subfamily B member 1	Canis lupus familiaris	56-60
29238980-5	2018	However, the efflux ratio of puerarin was <2 in MDCK-MDR1 models, which suggested puerarin was not P-gp substrates so as to the P-glycoprotein activity determination of puerarin.	puerarin	85-93	ATP binding cassette subfamily B member 1	Canis lupus familiaris	56-60
29359784-0	2018	Puerarin protects endothelial progenitor cells from damage of angiotensin II via activation of ERK1/2-Nrf2 signaling pathway.	puerarin	0-8	angiotensinogen	Homo sapiens	62-76
29359784-0	2018	Puerarin protects endothelial progenitor cells from damage of angiotensin II via activation of ERK1/2-Nrf2 signaling pathway.	puerarin	0-8	mitogen-activated protein kinase 3	Homo sapiens	95-101
29359784-0	2018	Puerarin protects endothelial progenitor cells from damage of angiotensin II via activation of ERK1/2-Nrf2 signaling pathway.	puerarin	0-8	NFE2 like bZIP transcription factor 2	Homo sapiens	102-106
29359784-2	2018	It has been demonstrated that angiotensin II (Ang II) may impair the function of EPCs and puerarin, a natural product, possesses cardiovascular protective effects against oxidative stress and inflammation.	puerarin	90-98	angiotensinogen	Homo sapiens	30-44
29359784-2	2018	It has been demonstrated that angiotensin II (Ang II) may impair the function of EPCs and puerarin, a natural product, possesses cardiovascular protective effects against oxidative stress and inflammation.	puerarin	90-98	angiotensinogen	Homo sapiens	46-52
29359784-3	2018	Therefore, the present study aimed to investigate the beneficial effects of puerarin in Ang II-induced EPC injury, and to elucidate the underlying mechanisms.	puerarin	76-84	angiotensinogen	Homo sapiens	88-94
29359784-9	2018	The results of the present study indicated that puerarin protected Ang II-induced EPC dysfunction via activation of the ERK1/2-Nrf2 signaling pathway.	puerarin	48-56	angiotensinogen	Homo sapiens	67-73
29359784-9	2018	The results of the present study indicated that puerarin protected Ang II-induced EPC dysfunction via activation of the ERK1/2-Nrf2 signaling pathway.	puerarin	48-56	mitogen-activated protein kinase 3	Homo sapiens	120-126
29359784-9	2018	The results of the present study indicated that puerarin protected Ang II-induced EPC dysfunction via activation of the ERK1/2-Nrf2 signaling pathway.	puerarin	48-56	NFE2 like bZIP transcription factor 2	Homo sapiens	127-131
29540127-0	2018	Targeted delivery of puerarin/glycyrrhetinic acid-PEG-PBLA complex attenuated liver ischemia/reperfusion injury via modulating Toll-like receptor 4/nuclear factor-kappaB pathway.	puerarin	21-29	toll-like receptor 4	Rattus norvegicus	127-147
29375675-0	2018	Puerarin promotes the proliferation and differentiation of MC3T3-E1 cells via microRNA-106b by targeting receptor activator of nuclear factor-kappaB ligand.	puerarin	0-8	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	105-155
29256352-0	2018	Puerarin Stimulates Osteogenic Differentiation and Bone Formation Through the ERK1/2 and p38-MAPK Signaling Pathways.	puerarin	0-8	mitogen activated protein kinase 3	Rattus norvegicus	78-84
29256352-0	2018	Puerarin Stimulates Osteogenic Differentiation and Bone Formation Through the ERK1/2 and p38-MAPK Signaling Pathways.	puerarin	0-8	mitogen activated protein kinase 14	Rattus norvegicus	89-92
29256352-10	2018	Further detailed study revealed that ERK1/2-Runx2 signaling pathway had more prominent effect than p38 signaling pathway in puerarin-induced differentiation of BMSCs toward the osteogenic phenotype.	puerarin	124-132	mitogen activated protein kinase 3	Rattus norvegicus	37-43
29256352-10	2018	Further detailed study revealed that ERK1/2-Runx2 signaling pathway had more prominent effect than p38 signaling pathway in puerarin-induced differentiation of BMSCs toward the osteogenic phenotype.	puerarin	124-132	mitogen activated protein kinase 14	Rattus norvegicus	99-102
29256352-12	2018	CONCLUSION: Our findings revealed the functional mechanism of puerarin in promoting osteogenic differentiation which involved ERK1/2 and p38-MAPK pathway and provided experimental evidence for the potential application of puerarin for estrogen replacement therapy of osteoporosis.	puerarin	62-70	mitogen activated protein kinase 3	Rattus norvegicus	126-132
29256352-12	2018	CONCLUSION: Our findings revealed the functional mechanism of puerarin in promoting osteogenic differentiation which involved ERK1/2 and p38-MAPK pathway and provided experimental evidence for the potential application of puerarin for estrogen replacement therapy of osteoporosis.	puerarin	62-70	mitogen activated protein kinase 14	Rattus norvegicus	137-140
29256352-12	2018	CONCLUSION: Our findings revealed the functional mechanism of puerarin in promoting osteogenic differentiation which involved ERK1/2 and p38-MAPK pathway and provided experimental evidence for the potential application of puerarin for estrogen replacement therapy of osteoporosis.	puerarin	222-230	mitogen activated protein kinase 14	Rattus norvegicus	137-140
29054452-0	2018	Mechanism of aquaporin 4 (AQP 4) up-regulation in rat cerebral edema under hypobaric hypoxia and the preventative effect of puerarin.	puerarin	124-132	aquaporin 4	Rattus norvegicus	13-24
29054452-0	2018	Mechanism of aquaporin 4 (AQP 4) up-regulation in rat cerebral edema under hypobaric hypoxia and the preventative effect of puerarin.	puerarin	124-132	aquaporin 4	Rattus norvegicus	26-31
29054452-1	2018	AIM: We aim to investigate the mechanism of aquaporin 4 (AQP 4) up-regulation during high-altitude cerebral edema (HACE) in rats under hypobaric hypoxia and preventative effect of puerarin.	puerarin	180-188	aquaporin 4	Rattus norvegicus	44-55
29054452-9	2018	AQP4, phosphorylation of NF-kappaB and MAPK signal pathway of cortex increased after hypoxia exposure and decreased with preventative treatment of puerarin.	puerarin	147-155	aquaporin 4	Rattus norvegicus	0-4
29054452-12	2018	AQP4 showed a decrease after administered with p38 inhibitor, NF-kappaB inhibitor or puerarin.	puerarin	85-93	aquaporin 4	Rattus norvegicus	0-4
29054452-14	2018	Puerarin can exert a preventative effect on the increase of AQP4 through inhibiting the release of TNF-alpha and phosphorylation of NF-kappaB, MAPK pathway.	puerarin	0-8	aquaporin 4	Rattus norvegicus	60-64
29054452-14	2018	Puerarin can exert a preventative effect on the increase of AQP4 through inhibiting the release of TNF-alpha and phosphorylation of NF-kappaB, MAPK pathway.	puerarin	0-8	tumor necrosis factor	Rattus norvegicus	99-108
29425589-0	2018	Puerarin attenuates angiotensin II-induced cardiac fibroblast proliferation via the promotion of catalase activity and the inhibition of hydrogen peroxide-dependent Rac-1 activation.	puerarin	0-8	angiotensinogen	Homo sapiens	20-34
29425589-0	2018	Puerarin attenuates angiotensin II-induced cardiac fibroblast proliferation via the promotion of catalase activity and the inhibition of hydrogen peroxide-dependent Rac-1 activation.	puerarin	0-8	Rac family small GTPase 1	Homo sapiens	165-170
29425589-1	2018	The aims of the present study were to evaluate the effects of puerarin on angiotensin II-induced cardiac fibroblast proliferation and to explore the molecular mechanisms of action.	puerarin	62-70	angiotensinogen	Homo sapiens	74-88
29425589-4	2018	Puerarin blocked the phosphorylation of extracellular regulated protein kinases (ERK)1/2, abolished activator protein (AP)-1 binding activity, and eventually attenuated cardiac fibroblast proliferation through the inhibition of H2O2-dependent Rac1 activation.	puerarin	0-8	mitogen-activated protein kinase 3	Homo sapiens	40-88
29425589-4	2018	Puerarin blocked the phosphorylation of extracellular regulated protein kinases (ERK)1/2, abolished activator protein (AP)-1 binding activity, and eventually attenuated cardiac fibroblast proliferation through the inhibition of H2O2-dependent Rac1 activation.	puerarin	0-8	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	100-124
29425589-4	2018	Puerarin blocked the phosphorylation of extracellular regulated protein kinases (ERK)1/2, abolished activator protein (AP)-1 binding activity, and eventually attenuated cardiac fibroblast proliferation through the inhibition of H2O2-dependent Rac1 activation.	puerarin	0-8	Rac family small GTPase 1	Homo sapiens	243-247
29425589-5	2018	Further studies revealed that angiotensin II treatment resulted in decreased catalase protein expression and enzyme activity, which was disrupted by puerarin via the upregulation of catalase protein expression at the transcriptional level and the prolonged protein degradation.	puerarin	149-157	angiotensinogen	Homo sapiens	30-44
29207080-6	2018	Following puerarin treatment, the expression levels of TIMP-1, and COL I and III were enhanced, whereas MMP-2 and -9 were inhibited.	puerarin	10-18	TIMP metallopeptidase inhibitor 1	Homo sapiens	55-61
29207080-6	2018	Following puerarin treatment, the expression levels of TIMP-1, and COL I and III were enhanced, whereas MMP-2 and -9 were inhibited.	puerarin	10-18	matrix metallopeptidase 2	Homo sapiens	104-116
30525896-8	2018	Puerarin may directly benefit DM by decreasing blood glucose levels, improving insulin resistance, protecting islets, inhibiting inflammation, decreasing oxidative stress and inhibiting Maillard reaction and advanced glycation end products (AGEs) formation.	puerarin	0-8	insulin	Homo sapiens	79-86
29375675-9	2018	In addition, miR-106b was significantly upregulated in MC3T3-E1 cells following treatment with 20 microM puerarin (P<0.01), and a known target for miR-106b, receptor activator of nuclear factor-kappaB ligand (RANKL) was demonstrated using the luciferase reporter assay.	puerarin	105-113	microRNA 106b	Mus musculus	150-210
29375675-9	2018	In addition, miR-106b was significantly upregulated in MC3T3-E1 cells following treatment with 20 microM puerarin (P<0.01), and a known target for miR-106b, receptor activator of nuclear factor-kappaB ligand (RANKL) was demonstrated using the luciferase reporter assay.	puerarin	105-113	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	212-217
29375675-10	2018	Furthermore, inhibition of miR-106b significantly reversed the promotion of cell differentiation induced by puerarin in MC3T3-E1 cells (P<0.01).	puerarin	108-116	microRNA 106b	Mus musculus	27-35
29375675-11	2018	In conclusion, the present study demonstrated that puerarin exerts its role in MC3T3-E1 osteogenesis through miR-106b by targeting RANKL.	puerarin	51-59	microRNA 106b	Mus musculus	109-117
29375675-11	2018	In conclusion, the present study demonstrated that puerarin exerts its role in MC3T3-E1 osteogenesis through miR-106b by targeting RANKL.	puerarin	51-59	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	131-136
29375675-9	2018	In addition, miR-106b was significantly upregulated in MC3T3-E1 cells following treatment with 20 microM puerarin (P<0.01), and a known target for miR-106b, receptor activator of nuclear factor-kappaB ligand (RANKL) was demonstrated using the luciferase reporter assay.	puerarin	105-113	microRNA 106b	Mus musculus	13-21
29375709-0	2018	Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway.	puerarin	0-8	mechanistic target of rapamycin kinase	Homo sapiens	64-68
29375709-0	2018	Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway.	puerarin	0-8	ribosomal protein S6 kinase B1	Homo sapiens	69-75
29375709-7	2018	The expression levels of p-mTOR and p-p70S6K proteins were downregulated, while no change was observed in the expression levels of mTOR and p70S6K proteins when T-24 and EJ cells were treated by puerarin.	puerarin	195-203	ribosomal protein S6 kinase B1	Homo sapiens	38-44
29375709-9	2018	These effects may be due to the puerarin-induced downregulation of proteins in the mTOR/p70S6K signaling pathway, and the present study may provide the experimental basis for puerarin to be considered as a promising novel anti-tumor drug for the treatment of bladder cancer.	puerarin	32-40	mechanistic target of rapamycin kinase	Homo sapiens	83-87
29375709-9	2018	These effects may be due to the puerarin-induced downregulation of proteins in the mTOR/p70S6K signaling pathway, and the present study may provide the experimental basis for puerarin to be considered as a promising novel anti-tumor drug for the treatment of bladder cancer.	puerarin	32-40	ribosomal protein S6 kinase B1	Homo sapiens	88-94
29375709-9	2018	These effects may be due to the puerarin-induced downregulation of proteins in the mTOR/p70S6K signaling pathway, and the present study may provide the experimental basis for puerarin to be considered as a promising novel anti-tumor drug for the treatment of bladder cancer.	puerarin	175-183	mechanistic target of rapamycin kinase	Homo sapiens	83-87
29375709-9	2018	These effects may be due to the puerarin-induced downregulation of proteins in the mTOR/p70S6K signaling pathway, and the present study may provide the experimental basis for puerarin to be considered as a promising novel anti-tumor drug for the treatment of bladder cancer.	puerarin	175-183	ribosomal protein S6 kinase B1	Homo sapiens	88-94
29037842-0	2017	Puerarin inhibits expression of tissue factor induced by oxidative low-density lipoprotein through activating the PI3K/Akt/eNOS pathway and inhibiting activation of ERK1/2 and NF-kappaB.	puerarin	0-8	coagulation factor III, tissue factor	Homo sapiens	32-45
29961054-0	2018	Puerarin Attenuates Osteoarthritis via Upregulating AMP-Activated Protein Kinase/Proliferator-Activated Receptor-gamma Coactivator-1 Signaling Pathway in Osteoarthritis Rats.	puerarin	0-8	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	52-80
29961054-7	2018	The dependence of AMP-activated protein kinase (AMPK) pathway on puerarin-regulated mitochondrial function was analyzed by applying AMPK inhibitor Compound C. RESULTS: Puerarin treatment alleviated mechanical hyperalgesia and cartilage damage in osteoarthritis rats.	puerarin	65-73	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	18-46
29961054-7	2018	The dependence of AMP-activated protein kinase (AMPK) pathway on puerarin-regulated mitochondrial function was analyzed by applying AMPK inhibitor Compound C. RESULTS: Puerarin treatment alleviated mechanical hyperalgesia and cartilage damage in osteoarthritis rats.	puerarin	65-73	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	48-52
29961054-7	2018	The dependence of AMP-activated protein kinase (AMPK) pathway on puerarin-regulated mitochondrial function was analyzed by applying AMPK inhibitor Compound C. RESULTS: Puerarin treatment alleviated mechanical hyperalgesia and cartilage damage in osteoarthritis rats.	puerarin	168-176	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	18-46
29961054-7	2018	The dependence of AMP-activated protein kinase (AMPK) pathway on puerarin-regulated mitochondrial function was analyzed by applying AMPK inhibitor Compound C. RESULTS: Puerarin treatment alleviated mechanical hyperalgesia and cartilage damage in osteoarthritis rats.	puerarin	168-176	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	48-52
29961054-7	2018	The dependence of AMP-activated protein kinase (AMPK) pathway on puerarin-regulated mitochondrial function was analyzed by applying AMPK inhibitor Compound C. RESULTS: Puerarin treatment alleviated mechanical hyperalgesia and cartilage damage in osteoarthritis rats.	puerarin	168-176	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	132-136
29961054-9	2018	AMPK inhibitor Compound C abolished puerarin"s effects.	puerarin	36-44	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	0-4
29961054-10	2018	CONCLUSION: Puerarin attenuates osteoarthritis by upregulating the AMPK/proliferator-activated receptor-gamma coactivator signaling pathway in osteoarthritis rats.	puerarin	12-20	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	67-71
29273749-0	2017	Publisher Correction: Puerarin attenuates diabetic kidney injury through the suppression of NOX4 expression in podocytes.	puerarin	22-30	NADPH oxidase 4	Homo sapiens	92-96
29037842-0	2017	Puerarin inhibits expression of tissue factor induced by oxidative low-density lipoprotein through activating the PI3K/Akt/eNOS pathway and inhibiting activation of ERK1/2 and NF-kappaB.	puerarin	0-8	AKT serine/threonine kinase 1	Homo sapiens	119-122
29037842-0	2017	Puerarin inhibits expression of tissue factor induced by oxidative low-density lipoprotein through activating the PI3K/Akt/eNOS pathway and inhibiting activation of ERK1/2 and NF-kappaB.	puerarin	0-8	nitric oxide synthase 3	Homo sapiens	123-127
29037842-0	2017	Puerarin inhibits expression of tissue factor induced by oxidative low-density lipoprotein through activating the PI3K/Akt/eNOS pathway and inhibiting activation of ERK1/2 and NF-kappaB.	puerarin	0-8	mitogen-activated protein kinase 3	Homo sapiens	165-171
29037842-0	2017	Puerarin inhibits expression of tissue factor induced by oxidative low-density lipoprotein through activating the PI3K/Akt/eNOS pathway and inhibiting activation of ERK1/2 and NF-kappaB.	puerarin	0-8	nuclear factor kappa B subunit 1	Homo sapiens	176-185
29037842-6	2017	Pre-treatment with puerarin (50-200muM) for 1h significantly attenuated the ox-LDL-induced TF expression, augmented the phosphorylation of Akt, with a resultant increase of the NO production, and inhibited the activation of ERK1/2 and NF-kappaB (P<0.01).	puerarin	19-27	coagulation factor III, tissue factor	Homo sapiens	91-93
29037842-6	2017	Pre-treatment with puerarin (50-200muM) for 1h significantly attenuated the ox-LDL-induced TF expression, augmented the phosphorylation of Akt, with a resultant increase of the NO production, and inhibited the activation of ERK1/2 and NF-kappaB (P<0.01).	puerarin	19-27	AKT serine/threonine kinase 1	Homo sapiens	139-142
29037842-6	2017	Pre-treatment with puerarin (50-200muM) for 1h significantly attenuated the ox-LDL-induced TF expression, augmented the phosphorylation of Akt, with a resultant increase of the NO production, and inhibited the activation of ERK1/2 and NF-kappaB (P<0.01).	puerarin	19-27	mitogen-activated protein kinase 3	Homo sapiens	224-230
29037842-6	2017	Pre-treatment with puerarin (50-200muM) for 1h significantly attenuated the ox-LDL-induced TF expression, augmented the phosphorylation of Akt, with a resultant increase of the NO production, and inhibited the activation of ERK1/2 and NF-kappaB (P<0.01).	puerarin	19-27	nuclear factor kappa B subunit 1	Homo sapiens	235-244
29037842-8	2017	SIGNIFICANCE: These results suggested that puerarin suppressed TF expression in HUVECs through activating the PI3K/Akt/endothelial nitric oxide synthase signaling pathway and inhibiting the activation of ERK1/2 and NF-kappaB.	puerarin	43-51	coagulation factor III, tissue factor	Homo sapiens	63-65
29037842-8	2017	SIGNIFICANCE: These results suggested that puerarin suppressed TF expression in HUVECs through activating the PI3K/Akt/endothelial nitric oxide synthase signaling pathway and inhibiting the activation of ERK1/2 and NF-kappaB.	puerarin	43-51	AKT serine/threonine kinase 1	Homo sapiens	115-118
29037842-8	2017	SIGNIFICANCE: These results suggested that puerarin suppressed TF expression in HUVECs through activating the PI3K/Akt/endothelial nitric oxide synthase signaling pathway and inhibiting the activation of ERK1/2 and NF-kappaB.	puerarin	43-51	nitric oxide synthase 3	Homo sapiens	119-152
29037842-8	2017	SIGNIFICANCE: These results suggested that puerarin suppressed TF expression in HUVECs through activating the PI3K/Akt/endothelial nitric oxide synthase signaling pathway and inhibiting the activation of ERK1/2 and NF-kappaB.	puerarin	43-51	mitogen-activated protein kinase 3	Homo sapiens	204-210
29037842-8	2017	SIGNIFICANCE: These results suggested that puerarin suppressed TF expression in HUVECs through activating the PI3K/Akt/endothelial nitric oxide synthase signaling pathway and inhibiting the activation of ERK1/2 and NF-kappaB.	puerarin	43-51	nuclear factor kappa B subunit 1	Homo sapiens	215-224
29285079-9	2017	In summary, puerarin can reduce the oxidative stress damage of the retina, and its mechanism is related to the inhibition of STAT3 expression.	puerarin	12-20	signal transducer and activator of transcription 3	Rattus norvegicus	125-130
28937704-8	2017	Treatment with puerarin dose-dependently reduced high concentration FFA-elevated P2X4R expression and inhibited P2X4R-mediated inflammatory signalling, including high concentration FFA-evoked [Ca2+]i, ERK phosphorylation, expression of TNF-alpha and iNOS mRNA and release of TNF-alpha and NO.	puerarin	15-23	mitogen-activated protein kinase 1	Mus musculus	201-204
28937704-8	2017	Treatment with puerarin dose-dependently reduced high concentration FFA-elevated P2X4R expression and inhibited P2X4R-mediated inflammatory signalling, including high concentration FFA-evoked [Ca2+]i, ERK phosphorylation, expression of TNF-alpha and iNOS mRNA and release of TNF-alpha and NO.	puerarin	15-23	tumor necrosis factor	Mus musculus	236-245
28937704-8	2017	Treatment with puerarin dose-dependently reduced high concentration FFA-elevated P2X4R expression and inhibited P2X4R-mediated inflammatory signalling, including high concentration FFA-evoked [Ca2+]i, ERK phosphorylation, expression of TNF-alpha and iNOS mRNA and release of TNF-alpha and NO.	puerarin	15-23	nitric oxide synthase 2, inducible	Mus musculus	250-254
28937704-8	2017	Treatment with puerarin dose-dependently reduced high concentration FFA-elevated P2X4R expression and inhibited P2X4R-mediated inflammatory signalling, including high concentration FFA-evoked [Ca2+]i, ERK phosphorylation, expression of TNF-alpha and iNOS mRNA and release of TNF-alpha and NO.	puerarin	15-23	tumor necrosis factor	Mus musculus	275-284
28673004-9	2017	Furthermore, puerarin inhibited the TNF-alpha-induced decrease in the phosphorylation of Akt, which was abolished by LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, suggesting that the PI3K/Akt pathway participated in the suppressive effect of puerarin.	puerarin	256-264	tumor necrosis factor	Rattus norvegicus	36-45
28990074-0	2017	Puerarin inhibits beta-amyloid peptide 1-42-induced tau hyperphosphorylation via the Wnt/beta-catenin signaling pathway.	puerarin	0-8	amyloid beta precursor protein	Homo sapiens	18-43
28990074-0	2017	Puerarin inhibits beta-amyloid peptide 1-42-induced tau hyperphosphorylation via the Wnt/beta-catenin signaling pathway.	puerarin	0-8	catenin beta 1	Homo sapiens	89-101
28990074-3	2017	The present study aimed to investigate the possible mechanism underlying the inhibitory effects of puerarin on beta-amyloid peptide (Abeta)1-42-induced tau protein hyperphosphorylation in SH-SY5Y cells.	puerarin	99-107	amyloid beta precursor protein	Homo sapiens	111-131
28990074-7	2017	In addition, puerarin inhibited the degree of Abeta1-42-induced tau phosphorylation at Ser396, Ser199 and Thr231 in SH-SY5Y cells, and reduced the expression of GSK-3beta by increasing the expression of p-GSK-3beta (Ser9).	puerarin	13-21	glycogen synthase kinase 3 beta	Homo sapiens	161-170
28990074-7	2017	In addition, puerarin inhibited the degree of Abeta1-42-induced tau phosphorylation at Ser396, Ser199 and Thr231 in SH-SY5Y cells, and reduced the expression of GSK-3beta by increasing the expression of p-GSK-3beta (Ser9).	puerarin	13-21	glycogen synthase kinase 3 beta	Homo sapiens	205-214
28990074-8	2017	Furthermore, puerarin increased the protein expression levels of beta-catenin and cyclin D1, which are key factors involved in the Wnt/beta-catenin signaling pathway.	puerarin	13-21	catenin beta 1	Homo sapiens	65-77
28990074-8	2017	Furthermore, puerarin increased the protein expression levels of beta-catenin and cyclin D1, which are key factors involved in the Wnt/beta-catenin signaling pathway.	puerarin	13-21	cyclin D1	Homo sapiens	82-91
28990074-8	2017	Furthermore, puerarin increased the protein expression levels of beta-catenin and cyclin D1, which are key factors involved in the Wnt/beta-catenin signaling pathway.	puerarin	13-21	catenin beta 1	Homo sapiens	135-147
29290948-0	2017	Puerarin attenuates locomotor and cognitive deficits as well as hippocampal neuronal injury through the PI3K/Akt1/GSK-3beta signaling pathway in an in vivo model of cerebral ischemia.	puerarin	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	109-113
29290948-0	2017	Puerarin attenuates locomotor and cognitive deficits as well as hippocampal neuronal injury through the PI3K/Akt1/GSK-3beta signaling pathway in an in vivo model of cerebral ischemia.	puerarin	0-8	glycogen synthase kinase 3 beta	Rattus norvegicus	114-123
29290948-10	2017	The number of live cells in the hippocampus is sharply increased by puerarin pretreatment.We further observed that the levels of phosphorylated Akt1, GSK-3beta and MCL-1were elevated and those of cleaved-caspase-3 were reduced in the puerarin-treatment group.	puerarin	68-76	AKT serine/threonine kinase 1	Rattus norvegicus	144-148
29290948-10	2017	The number of live cells in the hippocampus is sharply increased by puerarin pretreatment.We further observed that the levels of phosphorylated Akt1, GSK-3beta and MCL-1were elevated and those of cleaved-caspase-3 were reduced in the puerarin-treatment group.	puerarin	68-76	glycogen synthase kinase 3 beta	Rattus norvegicus	150-159
29290948-10	2017	The number of live cells in the hippocampus is sharply increased by puerarin pretreatment.We further observed that the levels of phosphorylated Akt1, GSK-3beta and MCL-1were elevated and those of cleaved-caspase-3 were reduced in the puerarin-treatment group.	puerarin	68-76	MCL1 apoptosis regulator, BCL2 family member	Rattus norvegicus	164-169
29290948-12	2017	Our findings suggest that puerarin protects the hippocampus from I/R damage by activating the PI3K/Akt1/GSK-3beta/MCL-1 signaling pathway.	puerarin	26-34	AKT serine/threonine kinase 1	Rattus norvegicus	99-103
29290948-12	2017	Our findings suggest that puerarin protects the hippocampus from I/R damage by activating the PI3K/Akt1/GSK-3beta/MCL-1 signaling pathway.	puerarin	26-34	glycogen synthase kinase 3 beta	Rattus norvegicus	104-113
29290948-12	2017	Our findings suggest that puerarin protects the hippocampus from I/R damage by activating the PI3K/Akt1/GSK-3beta/MCL-1 signaling pathway.	puerarin	26-34	MCL1 apoptosis regulator, BCL2 family member	Rattus norvegicus	114-119
28901520-0	2017	Puerarin promotes the viability and differentiation of MC3T3-E1 cells by miR-204-regulated Runx2 upregulation.	puerarin	0-8	microRNA 204	Mus musculus	73-80
28901520-0	2017	Puerarin promotes the viability and differentiation of MC3T3-E1 cells by miR-204-regulated Runx2 upregulation.	puerarin	0-8	runt related transcription factor 2	Mus musculus	91-96
28901520-3	2017	The results indicated that 0.01, 0.1 and 1 mg/ml puerarin significantly promoted the viability of osteoblasts, enhanced alkaline phosphatase (ALP) activity and increased the expression of transforming growth factor-beta1, Smad2, Smad3 and Runt-related transcription factor (Runx)2.	puerarin	49-57	transforming growth factor, beta 1	Mus musculus	188-220
28901520-3	2017	The results indicated that 0.01, 0.1 and 1 mg/ml puerarin significantly promoted the viability of osteoblasts, enhanced alkaline phosphatase (ALP) activity and increased the expression of transforming growth factor-beta1, Smad2, Smad3 and Runt-related transcription factor (Runx)2.	puerarin	49-57	SMAD family member 2	Mus musculus	222-227
28901520-3	2017	The results indicated that 0.01, 0.1 and 1 mg/ml puerarin significantly promoted the viability of osteoblasts, enhanced alkaline phosphatase (ALP) activity and increased the expression of transforming growth factor-beta1, Smad2, Smad3 and Runt-related transcription factor (Runx)2.	puerarin	49-57	SMAD family member 3	Mus musculus	229-234
28901520-3	2017	The results indicated that 0.01, 0.1 and 1 mg/ml puerarin significantly promoted the viability of osteoblasts, enhanced alkaline phosphatase (ALP) activity and increased the expression of transforming growth factor-beta1, Smad2, Smad3 and Runt-related transcription factor (Runx)2.	puerarin	49-57	runt related transcription factor 2	Mus musculus	239-280
28901520-5	2017	Following treatment with 0.1 mg/ml puerarin for 48 h, the expression level of miR-204 was downregulated.	puerarin	35-43	microRNA 204	Mus musculus	78-85
28901520-9	2017	The results suggested that puerarin may promote MC3T3-E1 osteoblast-like cell viability and differentiation, which may be related to the downregulation of miR-204 and the following activation of Runx2.	puerarin	27-35	microRNA 204	Mus musculus	155-162
28901520-9	2017	The results suggested that puerarin may promote MC3T3-E1 osteoblast-like cell viability and differentiation, which may be related to the downregulation of miR-204 and the following activation of Runx2.	puerarin	27-35	runt related transcription factor 2	Mus musculus	195-200
29113186-0	2017	Puerarin induces cell apoptosis in human chondrosarcoma cell line SW1353 via inhibition of the PI3K/Akt signaling pathway.	puerarin	0-8	AKT serine/threonine kinase 1	Homo sapiens	100-103
29113186-10	2017	In addition, puerarin significantly increased the enzymatic activities of caspase-3 and caspase-9.	puerarin	13-21	caspase 3	Homo sapiens	74-83
29113186-10	2017	In addition, puerarin significantly increased the enzymatic activities of caspase-3 and caspase-9.	puerarin	13-21	caspase 9	Homo sapiens	88-97
29113186-11	2017	Puerarin treatment suppressed the expression of p-Akt and Bcl-2 but promoted the expression of Bax and cleaved caspase-3 in SW1353 cells.	puerarin	0-8	AKT serine/threonine kinase 1	Homo sapiens	50-53
29113186-11	2017	Puerarin treatment suppressed the expression of p-Akt and Bcl-2 but promoted the expression of Bax and cleaved caspase-3 in SW1353 cells.	puerarin	0-8	BCL2 apoptosis regulator	Homo sapiens	58-63
29113186-11	2017	Puerarin treatment suppressed the expression of p-Akt and Bcl-2 but promoted the expression of Bax and cleaved caspase-3 in SW1353 cells.	puerarin	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	95-98
29113186-11	2017	Puerarin treatment suppressed the expression of p-Akt and Bcl-2 but promoted the expression of Bax and cleaved caspase-3 in SW1353 cells.	puerarin	0-8	caspase 3	Homo sapiens	111-120
29113186-12	2017	Notably, the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 abrogated the decreased phosphorylation of Akt, suggesting that the PI3K/Akt signaling pathway is involved in mediating the anticancer effects of puerarin.	puerarin	215-223	AKT serine/threonine kinase 1	Homo sapiens	112-115
29113186-12	2017	Notably, the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 abrogated the decreased phosphorylation of Akt, suggesting that the PI3K/Akt signaling pathway is involved in mediating the anticancer effects of puerarin.	puerarin	215-223	AKT serine/threonine kinase 1	Homo sapiens	142-145
28576406-0	2017	Puerarin promotes ABCA1-mediated cholesterol efflux and decreases cellular lipid accumulation in THP-1 macrophages.	puerarin	0-8	ATP binding cassette subfamily A member 1	Homo sapiens	18-23
28576406-0	2017	Puerarin promotes ABCA1-mediated cholesterol efflux and decreases cellular lipid accumulation in THP-1 macrophages.	puerarin	0-8	GLI family zinc finger 2	Homo sapiens	97-102
28576406-1	2017	It was reported that puerarin decreases the total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) and increases high-density lipoprotein cholesterol (HDL-C) level, but the underlying mechanism is unclear.	puerarin	21-29	component of oligomeric golgi complex 2	Homo sapiens	63-98
28576406-1	2017	It was reported that puerarin decreases the total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) and increases high-density lipoprotein cholesterol (HDL-C) level, but the underlying mechanism is unclear.	puerarin	21-29	component of oligomeric golgi complex 2	Homo sapiens	100-105
28576406-2	2017	This study was designed to determine whether puerarin decreased lipid accumulation via up-regulation of ABCA1-mediated cholesterol efflux in THP-1 macrophage-derived foam cells.	puerarin	45-53	ATP binding cassette subfamily A member 1	Homo sapiens	104-109
28576406-2	2017	This study was designed to determine whether puerarin decreased lipid accumulation via up-regulation of ABCA1-mediated cholesterol efflux in THP-1 macrophage-derived foam cells.	puerarin	45-53	GLI family zinc finger 2	Homo sapiens	141-146
28576406-3	2017	Our results showed that puerarin significantly promoted the expression of ATP-binding cassette transporter A1 (ABCA1) mRNA and protein via the AMP-activated protein kinase (AMPK)-peroxisome proliferator-activated receptor gamma (PPARgamma)-liver X receptor-alpha (LXR-alpha) pathway and decreased cellular lipid accumulation in human THP-1 macrophage-derived foam cells.	puerarin	24-32	ATP binding cassette subfamily A member 1	Homo sapiens	74-109
28576406-3	2017	Our results showed that puerarin significantly promoted the expression of ATP-binding cassette transporter A1 (ABCA1) mRNA and protein via the AMP-activated protein kinase (AMPK)-peroxisome proliferator-activated receptor gamma (PPARgamma)-liver X receptor-alpha (LXR-alpha) pathway and decreased cellular lipid accumulation in human THP-1 macrophage-derived foam cells.	puerarin	24-32	ATP binding cassette subfamily A member 1	Homo sapiens	111-116
28576406-3	2017	Our results showed that puerarin significantly promoted the expression of ATP-binding cassette transporter A1 (ABCA1) mRNA and protein via the AMP-activated protein kinase (AMPK)-peroxisome proliferator-activated receptor gamma (PPARgamma)-liver X receptor-alpha (LXR-alpha) pathway and decreased cellular lipid accumulation in human THP-1 macrophage-derived foam cells.	puerarin	24-32	nuclear receptor subfamily 1 group H member 3	Homo sapiens	264-273
28576406-3	2017	Our results showed that puerarin significantly promoted the expression of ATP-binding cassette transporter A1 (ABCA1) mRNA and protein via the AMP-activated protein kinase (AMPK)-peroxisome proliferator-activated receptor gamma (PPARgamma)-liver X receptor-alpha (LXR-alpha) pathway and decreased cellular lipid accumulation in human THP-1 macrophage-derived foam cells.	puerarin	24-32	GLI family zinc finger 2	Homo sapiens	334-339
28576406-5	2017	Transfection with miR-7 mimic significantly reduced STK11 expression in puerarin-treated macrophages, decreased the phosphorylation of AMPK, down-regulated the expression of the PPARgamma-LXR-alpha-ABCA1 expression.	puerarin	72-80	leukocyte immunoglobulin like receptor B1	Homo sapiens	18-23
28576406-5	2017	Transfection with miR-7 mimic significantly reduced STK11 expression in puerarin-treated macrophages, decreased the phosphorylation of AMPK, down-regulated the expression of the PPARgamma-LXR-alpha-ABCA1 expression.	puerarin	72-80	serine/threonine kinase 11	Homo sapiens	52-57
28576406-5	2017	Transfection with miR-7 mimic significantly reduced STK11 expression in puerarin-treated macrophages, decreased the phosphorylation of AMPK, down-regulated the expression of the PPARgamma-LXR-alpha-ABCA1 expression.	puerarin	72-80	nuclear receptor subfamily 1 group H member 3	Homo sapiens	188-197
28576406-7	2017	Our study demonstrates that puerarin promotes ABCA1-mediated cholesterol efflux and decreases intracellular cholesterol levels through the pathway involving miR-7, STK11, and the AMPK-PPARgamma-LXR-alpha-ABCA1 cascade.	puerarin	28-36	ATP binding cassette subfamily A member 1	Homo sapiens	46-51
28576406-7	2017	Our study demonstrates that puerarin promotes ABCA1-mediated cholesterol efflux and decreases intracellular cholesterol levels through the pathway involving miR-7, STK11, and the AMPK-PPARgamma-LXR-alpha-ABCA1 cascade.	puerarin	28-36	leukocyte immunoglobulin like receptor B1	Homo sapiens	157-162
28576406-7	2017	Our study demonstrates that puerarin promotes ABCA1-mediated cholesterol efflux and decreases intracellular cholesterol levels through the pathway involving miR-7, STK11, and the AMPK-PPARgamma-LXR-alpha-ABCA1 cascade.	puerarin	28-36	serine/threonine kinase 11	Homo sapiens	164-169
28576406-7	2017	Our study demonstrates that puerarin promotes ABCA1-mediated cholesterol efflux and decreases intracellular cholesterol levels through the pathway involving miR-7, STK11, and the AMPK-PPARgamma-LXR-alpha-ABCA1 cascade.	puerarin	28-36	nuclear receptor subfamily 1 group H member 3	Homo sapiens	194-203
28576406-7	2017	Our study demonstrates that puerarin promotes ABCA1-mediated cholesterol efflux and decreases intracellular cholesterol levels through the pathway involving miR-7, STK11, and the AMPK-PPARgamma-LXR-alpha-ABCA1 cascade.	puerarin	28-36	ATP binding cassette subfamily A member 1	Homo sapiens	204-209
27966208-13	2017	Furthermore, puerarin and zinc additively up-regulated OPG, OPN protein levels, Ca ion level and down-regulated RANKL, TRAP protein levels.	puerarin	13-21	TNF receptor superfamily member 11B	Rattus norvegicus	55-58
27966208-13	2017	Furthermore, puerarin and zinc additively up-regulated OPG, OPN protein levels, Ca ion level and down-regulated RANKL, TRAP protein levels.	puerarin	13-21	secreted phosphoprotein 1	Rattus norvegicus	60-63
27966208-13	2017	Furthermore, puerarin and zinc additively up-regulated OPG, OPN protein levels, Ca ion level and down-regulated RANKL, TRAP protein levels.	puerarin	13-21	TNF superfamily member 11	Rattus norvegicus	112-117
27966208-13	2017	Furthermore, puerarin and zinc additively up-regulated OPG, OPN protein levels, Ca ion level and down-regulated RANKL, TRAP protein levels.	puerarin	13-21	acid phosphatase 5, tartrate resistant	Rattus norvegicus	119-123
28740098-5	2017	Furthermore, puerarin (60 and 120 mg/kg, i.g) blocked the increased corticotropin releasing hormone (CRH), corticosterone (Cort) and adrenocorticotropic hormone (ACTH).	puerarin	13-21	corticotropin releasing hormone	Rattus norvegicus	68-99
28740098-5	2017	Furthermore, puerarin (60 and 120 mg/kg, i.g) blocked the increased corticotropin releasing hormone (CRH), corticosterone (Cort) and adrenocorticotropic hormone (ACTH).	puerarin	13-21	corticotropin releasing hormone	Rattus norvegicus	101-104
28673004-0	2017	Puerarin prevents tumor necrosis factor-alpha-induced apoptosis of PC12 cells via activation of the PI3K/Akt signaling pathway.	puerarin	0-8	tumor necrosis factor	Rattus norvegicus	18-45
28673004-0	2017	Puerarin prevents tumor necrosis factor-alpha-induced apoptosis of PC12 cells via activation of the PI3K/Akt signaling pathway.	puerarin	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	105-108
28673004-3	2017	The aim of the present study was to explore the effect of puerarin on apoptosis induced by TNF-alpha (3x105 U/l) and its detailed mechanisms in PC12 cells.	puerarin	58-66	tumor necrosis factor	Rattus norvegicus	91-100
28673004-7	2017	The results showed that puerarin (25 and 50 microM) significantly suppressed TNF-alpha-induced apoptosis in PC12 cells.	puerarin	24-32	tumor necrosis factor	Rattus norvegicus	77-86
28673004-8	2017	The TNF-alpha-induced in crease in the Bax/Bcl-2 ratio was markedly inhibited by pre-treatment with puerarin for 2 h. In addition, puerarin decreased the level of TNF-alpha-induced cleaved caspase-3.	puerarin	100-108	tumor necrosis factor	Rattus norvegicus	4-13
28673004-8	2017	The TNF-alpha-induced in crease in the Bax/Bcl-2 ratio was markedly inhibited by pre-treatment with puerarin for 2 h. In addition, puerarin decreased the level of TNF-alpha-induced cleaved caspase-3.	puerarin	100-108	BCL2 associated X, apoptosis regulator	Rattus norvegicus	39-42
28673004-8	2017	The TNF-alpha-induced in crease in the Bax/Bcl-2 ratio was markedly inhibited by pre-treatment with puerarin for 2 h. In addition, puerarin decreased the level of TNF-alpha-induced cleaved caspase-3.	puerarin	100-108	BCL2, apoptosis regulator	Rattus norvegicus	43-48
28673004-8	2017	The TNF-alpha-induced in crease in the Bax/Bcl-2 ratio was markedly inhibited by pre-treatment with puerarin for 2 h. In addition, puerarin decreased the level of TNF-alpha-induced cleaved caspase-3.	puerarin	100-108	tumor necrosis factor	Rattus norvegicus	163-172
28673004-8	2017	The TNF-alpha-induced in crease in the Bax/Bcl-2 ratio was markedly inhibited by pre-treatment with puerarin for 2 h. In addition, puerarin decreased the level of TNF-alpha-induced cleaved caspase-3.	puerarin	100-108	caspase 3	Rattus norvegicus	189-198
28673004-8	2017	The TNF-alpha-induced in crease in the Bax/Bcl-2 ratio was markedly inhibited by pre-treatment with puerarin for 2 h. In addition, puerarin decreased the level of TNF-alpha-induced cleaved caspase-3.	puerarin	131-139	tumor necrosis factor	Rattus norvegicus	4-13
28673004-8	2017	The TNF-alpha-induced in crease in the Bax/Bcl-2 ratio was markedly inhibited by pre-treatment with puerarin for 2 h. In addition, puerarin decreased the level of TNF-alpha-induced cleaved caspase-3.	puerarin	131-139	BCL2 associated X, apoptosis regulator	Rattus norvegicus	39-42
28673004-8	2017	The TNF-alpha-induced in crease in the Bax/Bcl-2 ratio was markedly inhibited by pre-treatment with puerarin for 2 h. In addition, puerarin decreased the level of TNF-alpha-induced cleaved caspase-3.	puerarin	131-139	BCL2, apoptosis regulator	Rattus norvegicus	43-48
28673004-8	2017	The TNF-alpha-induced in crease in the Bax/Bcl-2 ratio was markedly inhibited by pre-treatment with puerarin for 2 h. In addition, puerarin decreased the level of TNF-alpha-induced cleaved caspase-3.	puerarin	131-139	tumor necrosis factor	Rattus norvegicus	163-172
28673004-8	2017	The TNF-alpha-induced in crease in the Bax/Bcl-2 ratio was markedly inhibited by pre-treatment with puerarin for 2 h. In addition, puerarin decreased the level of TNF-alpha-induced cleaved caspase-3.	puerarin	131-139	caspase 3	Rattus norvegicus	189-198
28673004-9	2017	Furthermore, puerarin inhibited the TNF-alpha-induced decrease in the phosphorylation of Akt, which was abolished by LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, suggesting that the PI3K/Akt pathway participated in the suppressive effect of puerarin.	puerarin	13-21	tumor necrosis factor	Rattus norvegicus	36-45
28673004-9	2017	Furthermore, puerarin inhibited the TNF-alpha-induced decrease in the phosphorylation of Akt, which was abolished by LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, suggesting that the PI3K/Akt pathway participated in the suppressive effect of puerarin.	puerarin	13-21	AKT serine/threonine kinase 1	Rattus norvegicus	89-92
28673004-9	2017	Furthermore, puerarin inhibited the TNF-alpha-induced decrease in the phosphorylation of Akt, which was abolished by LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, suggesting that the PI3K/Akt pathway participated in the suppressive effect of puerarin.	puerarin	13-21	AKT serine/threonine kinase 1	Rattus norvegicus	202-205
28181078-10	2017	Further study demonstrated that puerarin suppressed activation of apoptosis-related proteins including PARP and caspase-3, downregulation of bcl-2, and upregulation of intracellular distribution of bax from cytosol to mitochondria, which was induced by glucose fluctuation.	puerarin	32-40	collagen type XI alpha 2 chain	Homo sapiens	103-107
28181078-10	2017	Further study demonstrated that puerarin suppressed activation of apoptosis-related proteins including PARP and caspase-3, downregulation of bcl-2, and upregulation of intracellular distribution of bax from cytosol to mitochondria, which was induced by glucose fluctuation.	puerarin	32-40	caspase 3	Homo sapiens	112-121
28181078-10	2017	Further study demonstrated that puerarin suppressed activation of apoptosis-related proteins including PARP and caspase-3, downregulation of bcl-2, and upregulation of intracellular distribution of bax from cytosol to mitochondria, which was induced by glucose fluctuation.	puerarin	32-40	BCL2 apoptosis regulator	Homo sapiens	141-146
28181078-10	2017	Further study demonstrated that puerarin suppressed activation of apoptosis-related proteins including PARP and caspase-3, downregulation of bcl-2, and upregulation of intracellular distribution of bax from cytosol to mitochondria, which was induced by glucose fluctuation.	puerarin	32-40	BCL2 associated X, apoptosis regulator	Homo sapiens	198-201
29039532-0	2017	Puerarin attenuates the daunorubicin-induced apoptosis of H9c2 cells by activating the PI3K/Akt signaling pathway via the inhibition of Ca2+ influx.	puerarin	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	92-95
29039532-6	2017	Our results revealed that puerarin pre-treatment protected the H9c2 cells against DNR-induced cytotoxicity by inhibiting cell apoptosis, which was also confirmed by the decrease in the expression of cleaved caspase-3.	puerarin	26-34	caspase 3	Rattus norvegicus	207-216
29039532-7	2017	Additionally, p-Akt activation was associated with the suppressive effects of puerarin.	puerarin	78-86	AKT serine/threonine kinase 1	Rattus norvegicus	16-19
29039532-9	2017	The inhibition of Ca2+ influx suggested that the PI3K/Akt signaling pathway participated in the suppressive effects of puerarin against H9c2 cell apoptosis.	puerarin	119-127	AKT serine/threonine kinase 1	Rattus norvegicus	54-57
29039532-10	2017	Taken togher, our findings demonstrate that puerarin attenuates the DNR-induced apoptosis of H9c2 cells by activating the PI3K/Akt signaling pathway via the inhibition of Ca2+ influx, suggesting that puerarin may be a potential cardioprotective agent for use in the clinical treatment of cardiomyopathy triggered by DNR.	puerarin	44-52	AKT serine/threonine kinase 1	Rattus norvegicus	127-130
28990074-9	2017	The results of the present study demonstrated that puerarin may attenuate Abeta1-42-induced tau hyperphosphorylation in SH-SY5Y cells, by inhibiting the expression of GSK-3beta and activating the Wnt/beta-catenin signaling pathway; therefore, puerarin may exert protective effects against Alzheimer"s disease.	puerarin	51-59	glycogen synthase kinase 3 beta	Homo sapiens	167-176
28990074-9	2017	The results of the present study demonstrated that puerarin may attenuate Abeta1-42-induced tau hyperphosphorylation in SH-SY5Y cells, by inhibiting the expression of GSK-3beta and activating the Wnt/beta-catenin signaling pathway; therefore, puerarin may exert protective effects against Alzheimer"s disease.	puerarin	51-59	catenin beta 1	Homo sapiens	200-212
28335679-0	2017	Puerarin attenuates renal fibrosis by reducing oxidative stress induced-epithelial cell apoptosis via MAPK signal pathways in vivo and in vitro.	puerarin	0-8	mitogen-activated protein kinase 1	Mus musculus	102-106
28734961-15	2017	Moreover, upregulation of actin-related protein 2 (ARP2) in RPE and puerarin treated brain neurons suggest that RPE and puerarin induced synaptic plasticity might be associated, at least in part, with ARP2-mediated actin-dependent regulation of spinogenesis.	puerarin	68-76	actin related protein 2	Rattus norvegicus	26-49
28734961-15	2017	Moreover, upregulation of actin-related protein 2 (ARP2) in RPE and puerarin treated brain neurons suggest that RPE and puerarin induced synaptic plasticity might be associated, at least in part, with ARP2-mediated actin-dependent regulation of spinogenesis.	puerarin	68-76	actin related protein 2	Rattus norvegicus	51-55
28734961-15	2017	Moreover, upregulation of actin-related protein 2 (ARP2) in RPE and puerarin treated brain neurons suggest that RPE and puerarin induced synaptic plasticity might be associated, at least in part, with ARP2-mediated actin-dependent regulation of spinogenesis.	puerarin	68-76	actin related protein 2	Rattus norvegicus	201-205
28734961-15	2017	Moreover, upregulation of actin-related protein 2 (ARP2) in RPE and puerarin treated brain neurons suggest that RPE and puerarin induced synaptic plasticity might be associated, at least in part, with ARP2-mediated actin-dependent regulation of spinogenesis.	puerarin	120-128	actin related protein 2	Rattus norvegicus	26-49
28734961-15	2017	Moreover, upregulation of actin-related protein 2 (ARP2) in RPE and puerarin treated brain neurons suggest that RPE and puerarin induced synaptic plasticity might be associated, at least in part, with ARP2-mediated actin-dependent regulation of spinogenesis.	puerarin	120-128	actin related protein 2	Rattus norvegicus	51-55
28734961-15	2017	Moreover, upregulation of actin-related protein 2 (ARP2) in RPE and puerarin treated brain neurons suggest that RPE and puerarin induced synaptic plasticity might be associated, at least in part, with ARP2-mediated actin-dependent regulation of spinogenesis.	puerarin	120-128	actin related protein 2	Rattus norvegicus	201-205
28583762-0	2017	Puerarin inhibits amyloid beta-induced NLRP3 inflammasome activation in retinal pigment epithelial cells via suppressing ROS-dependent oxidative and endoplasmic reticulum stresses.	puerarin	0-8	NLR family pyrin domain containing 3	Homo sapiens	39-44
28583762-4	2017	In this study, we investigated the protective effect and underlying mechanism of puerarin against Abeta1-40-induced NLRP3 inflammasome activation in LPS-primed ARPE-19 cells.	puerarin	81-89	NLR family pyrin domain containing 3	Homo sapiens	116-121
28583762-5	2017	The results showed that Abeta1-40 induced NLRP3 inflammasome activation mainly via triggering ROS-dependent oxidative stress, particularly lipid peroxidation, and endoplasmic reticulum stress in LPS-primed ARPE-19 cells; however, such effect could be significantly reversed by puerarin in a dose-dependent manner.	puerarin	277-285	NLR family pyrin domain containing 3	Homo sapiens	42-47
28583762-6	2017	Furthermore, the effect of puerarin was potentially mediated through activating Nrf2/HO-1 antioxidant signaling pathway and inhibiting Abeta1-40-induced phosphorylation of IRE1 and PERK as well as nuclear expression of ATF6alpha.	puerarin	27-35	NFE2 like bZIP transcription factor 2	Homo sapiens	80-84
28583762-6	2017	Furthermore, the effect of puerarin was potentially mediated through activating Nrf2/HO-1 antioxidant signaling pathway and inhibiting Abeta1-40-induced phosphorylation of IRE1 and PERK as well as nuclear expression of ATF6alpha.	puerarin	27-35	heme oxygenase 1	Homo sapiens	85-89
28583762-6	2017	Furthermore, the effect of puerarin was potentially mediated through activating Nrf2/HO-1 antioxidant signaling pathway and inhibiting Abeta1-40-induced phosphorylation of IRE1 and PERK as well as nuclear expression of ATF6alpha.	puerarin	27-35	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	172-176
28583762-6	2017	Furthermore, the effect of puerarin was potentially mediated through activating Nrf2/HO-1 antioxidant signaling pathway and inhibiting Abeta1-40-induced phosphorylation of IRE1 and PERK as well as nuclear expression of ATF6alpha.	puerarin	27-35	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	181-185
28583762-6	2017	Furthermore, the effect of puerarin was potentially mediated through activating Nrf2/HO-1 antioxidant signaling pathway and inhibiting Abeta1-40-induced phosphorylation of IRE1 and PERK as well as nuclear expression of ATF6alpha.	puerarin	27-35	activating transcription factor 6	Homo sapiens	219-228
28558356-0	2017	Puerarin suppresses LPS-induced breast cancer cell migration, invasion and adhesion by blockage NF-kappaB and Erk pathway.	puerarin	0-8	mitogen-activated protein kinase 1	Homo sapiens	110-113
28558356-9	2017	The mRNA and protein levels revealed that puerarin treatment effectively negated the expression of CCR7, CXCR4, MMP-2, MMP-9, ICAM and VCAM in LPS- activated MCF-7 and MDA-MB-231 cells.	puerarin	42-50	C-C motif chemokine receptor 7	Homo sapiens	99-103
28558356-9	2017	The mRNA and protein levels revealed that puerarin treatment effectively negated the expression of CCR7, CXCR4, MMP-2, MMP-9, ICAM and VCAM in LPS- activated MCF-7 and MDA-MB-231 cells.	puerarin	42-50	C-X-C motif chemokine receptor 4	Homo sapiens	105-110
28558356-9	2017	The mRNA and protein levels revealed that puerarin treatment effectively negated the expression of CCR7, CXCR4, MMP-2, MMP-9, ICAM and VCAM in LPS- activated MCF-7 and MDA-MB-231 cells.	puerarin	42-50	matrix metallopeptidase 2	Homo sapiens	112-117
28558356-9	2017	The mRNA and protein levels revealed that puerarin treatment effectively negated the expression of CCR7, CXCR4, MMP-2, MMP-9, ICAM and VCAM in LPS- activated MCF-7 and MDA-MB-231 cells.	puerarin	42-50	matrix metallopeptidase 9	Homo sapiens	119-124
28558356-11	2017	Finally, the result indicated that puerarin abrogated the NF-kappaB activation in breast cancer cells stimulated by LPS, which is mediated through inhibition of phosphorylation of p65 and IkappaBalpha.	puerarin	35-43	RELA proto-oncogene, NF-kB subunit	Homo sapiens	180-183
28558356-11	2017	Finally, the result indicated that puerarin abrogated the NF-kappaB activation in breast cancer cells stimulated by LPS, which is mediated through inhibition of phosphorylation of p65 and IkappaBalpha.	puerarin	35-43	NFKB inhibitor alpha	Homo sapiens	188-200
28558356-12	2017	Also, puerarin inhibited phosphorylation of Erk in breast cancer cells LPS-induced.	puerarin	6-14	mitogen-activated protein kinase 1	Homo sapiens	44-47
27461151-5	2017	Galangin, puerarin, and ursolic acid (10, 100, 500, 1000, 2000, 5000, 10 000, and 20 000 muM) were found to have antioxidant activities at the studied concentrations.	puerarin	10-18	latexin	Homo sapiens	89-92
27461151-6	2017	IC50 values of galangin, puerarin, and ursolic acid in V79 cells were found to be 275.48 muM, 2503.712 muM, and 224.85 muM, respectively.	puerarin	25-33	latexin	Homo sapiens	89-92
27461151-6	2017	IC50 values of galangin, puerarin, and ursolic acid in V79 cells were found to be 275.48 muM, 2503.712 muM, and 224.85 muM, respectively.	puerarin	25-33	latexin	Homo sapiens	103-106
27461151-6	2017	IC50 values of galangin, puerarin, and ursolic acid in V79 cells were found to be 275.48 muM, 2503.712 muM, and 224.85 muM, respectively.	puerarin	25-33	latexin	Homo sapiens	103-106
28673004-9	2017	Furthermore, puerarin inhibited the TNF-alpha-induced decrease in the phosphorylation of Akt, which was abolished by LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, suggesting that the PI3K/Akt pathway participated in the suppressive effect of puerarin.	puerarin	256-264	AKT serine/threonine kinase 1	Rattus norvegicus	89-92
28673004-10	2017	Taken together, these findings indicated that puerarin prevented TNF-alpha-induced apoptosis in PC12 cells via activating of the PI3K/Akt signaling pathway, suggesting that puerarin may be a potential neuroprotective drug in the clinical treatment of neuroinflammation via anti-apoptotic mechanisms.	puerarin	46-54	tumor necrosis factor	Rattus norvegicus	65-74
28673004-10	2017	Taken together, these findings indicated that puerarin prevented TNF-alpha-induced apoptosis in PC12 cells via activating of the PI3K/Akt signaling pathway, suggesting that puerarin may be a potential neuroprotective drug in the clinical treatment of neuroinflammation via anti-apoptotic mechanisms.	puerarin	46-54	AKT serine/threonine kinase 1	Rattus norvegicus	134-137
28673004-10	2017	Taken together, these findings indicated that puerarin prevented TNF-alpha-induced apoptosis in PC12 cells via activating of the PI3K/Akt signaling pathway, suggesting that puerarin may be a potential neuroprotective drug in the clinical treatment of neuroinflammation via anti-apoptotic mechanisms.	puerarin	173-181	tumor necrosis factor	Rattus norvegicus	65-74
28673004-10	2017	Taken together, these findings indicated that puerarin prevented TNF-alpha-induced apoptosis in PC12 cells via activating of the PI3K/Akt signaling pathway, suggesting that puerarin may be a potential neuroprotective drug in the clinical treatment of neuroinflammation via anti-apoptotic mechanisms.	puerarin	173-181	AKT serine/threonine kinase 1	Rattus norvegicus	134-137
28620169-3	2017	In present study, we have performed detailed biophysical studies for the interaction of human c-myc G-quadruplex DNA with nine representative flavonoids: Luteolin, Quercetin, Rutin, Genistein, Kaempferol, Puerarin, Hesperidin, Myricetin and Daidzein.	puerarin	205-213	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	94-99
29039314-11	2017	However, the difference of TNF-alpha in myocardial tissue in the three puerarin-combined groups was statistically significant.	puerarin	71-79	tumor necrosis factor	Rattus norvegicus	27-36
29039314-12	2017	This study confirms that puerarin can improve LPS-induced contractile dysfunction in isolated heart and inhibit LPS-stimulated myocardial TNF-alpha production.	puerarin	25-33	tumor necrosis factor	Rattus norvegicus	138-147
28236703-3	2017	OBJECTIVE: RGD modified and PEGylated solid lipid nanoparticles loaded with puerarin (RGD/PEG-PUE-SLN) were developed to improve bioavailability of PUE, to prolong retention time in vivo and to enhance its protective effect on acute myocardial ischemia model.	puerarin	76-84	sarcolipin	Rattus norvegicus	98-101
28393209-0	2017	Puerarin attenuates myocardial hypoxia/reoxygenation injury by inhibiting autophagy via the Akt signaling pathway.	puerarin	0-8	AKT serine/threonine kinase 1	Homo sapiens	92-95
29926595-10	2017	Compared with the A549 cells group, the protein expression of Apelin/APJ was decreased in puerarin groups.	puerarin	90-98	apelin	Homo sapiens	62-68
29926595-10	2017	Compared with the A549 cells group, the protein expression of Apelin/APJ was decreased in puerarin groups.	puerarin	90-98	apelin receptor	Homo sapiens	69-72
29926595-11	2017	CONCLUSIONS: Puerarin induces apoptosis in A549 cells, and its mechanism may through the regulation of Apelin/APJ expression.	puerarin	13-21	apelin	Homo sapiens	103-109
29926595-11	2017	CONCLUSIONS: Puerarin induces apoptosis in A549 cells, and its mechanism may through the regulation of Apelin/APJ expression.	puerarin	13-21	apelin receptor	Homo sapiens	110-113
27013468-9	2017	Collectively, these results suggest that puerarin may ameliorate the SNI-induced depression and pain via activating ERK, CREB, and BDNF pathways.	puerarin	41-49	mitogen-activated protein kinase 1	Mus musculus	116-119
27013468-9	2017	Collectively, these results suggest that puerarin may ameliorate the SNI-induced depression and pain via activating ERK, CREB, and BDNF pathways.	puerarin	41-49	cAMP responsive element binding protein 1	Mus musculus	121-125
27013468-9	2017	Collectively, these results suggest that puerarin may ameliorate the SNI-induced depression and pain via activating ERK, CREB, and BDNF pathways.	puerarin	41-49	brain derived neurotrophic factor	Mus musculus	131-135
27762461-0	2017	Restoration of autophagy by puerarin in lead-exposed primary rat proximal tubular cells via regulating AMPK-mTOR signaling.	puerarin	28-36	mechanistic target of rapamycin kinase	Rattus norvegicus	108-112
28192195-9	2017	However, these effects of puerarin could be counteracted by Tat-Beclin-1.	puerarin	26-34	beclin 1	Rattus norvegicus	64-72
27762461-6	2017	Collectively, these evidence suggested that PU restored the impaired autophagic flux in Pb-treated rPT cells partly by activating autophagy via AMPK/mTOR-mediated signaling pathway.	puerarin	44-46	mechanistic target of rapamycin kinase	Rattus norvegicus	149-153
28182789-0	2017	Puerarin attenuates cisplatin-induced rat nephrotoxicity: The involvement of TLR4/NF-kappaB signaling pathway.	puerarin	0-8	toll-like receptor 4	Rattus norvegicus	77-81
27923632-2	2017	In this study, we investigated the protective function of puerarin (a phytoestrogen isolated from puerarin lobate) against amyloid beta (Abeta1-42)-induced toxicity in cortical neurons and established the connection between such a protection and estrogen receptor (ER) activation.	puerarin	58-66	estrogen receptor 1	Homo sapiens	246-263
27923632-2	2017	In this study, we investigated the protective function of puerarin (a phytoestrogen isolated from puerarin lobate) against amyloid beta (Abeta1-42)-induced toxicity in cortical neurons and established the connection between such a protection and estrogen receptor (ER) activation.	puerarin	58-66	estrogen receptor 1	Homo sapiens	265-267
28182789-0	2017	Puerarin attenuates cisplatin-induced rat nephrotoxicity: The involvement of TLR4/NF-kappaB signaling pathway.	puerarin	0-8	nuclear factor kappa B subunit 1	Homo sapiens	82-91
28182789-12	2017	The promotion effects might be attributed to suppression of cisplatin-increased NF-kappaB p65 expression by puerarin.	puerarin	108-116	nuclear factor kappa B subunit 1	Homo sapiens	80-89
28182789-12	2017	The promotion effects might be attributed to suppression of cisplatin-increased NF-kappaB p65 expression by puerarin.	puerarin	108-116	RELA proto-oncogene, NF-kB subunit	Homo sapiens	90-93
28182789-13	2017	Taken together, findings in this study suggested that puerarin exhibited renal protection against cisplatin nephrotoxicity via inhibiting TLR4/NF-kappaB signaling, with no inhibition but promotion effect on the antitumor activity of cisplatin.	puerarin	54-62	toll like receptor 4	Homo sapiens	138-142
28182789-13	2017	Taken together, findings in this study suggested that puerarin exhibited renal protection against cisplatin nephrotoxicity via inhibiting TLR4/NF-kappaB signaling, with no inhibition but promotion effect on the antitumor activity of cisplatin.	puerarin	54-62	nuclear factor kappa B subunit 1	Homo sapiens	143-152
28101568-0	2017	Puerarin inhibits M2 polarization and metastasis of tumor-associated macrophages from NSCLC xenograft model via inactivating MEK/ERK 1/2 pathway.	puerarin	0-8	mitogen-activated protein kinase kinase 7	Homo sapiens	125-128
27796870-0	2017	GPR30 Activation Contributes to the Puerarin-Mediated Neuroprotection in MPP+-Induced SH-SY5Y Cell Death.	puerarin	36-44	G protein-coupled estrogen receptor 1	Homo sapiens	0-5
27796870-4	2017	In this study, we investigated whether puerarin prevented against 1-methyl-4-phenylpyridinium (MPP+)-induced cell death via GPR30.	puerarin	39-47	G protein-coupled estrogen receptor 1	Homo sapiens	124-129
27796870-5	2017	Our results showed that the GPR30 agonist, G1, exhibited puerarin-mediated neuroprotection against MPP+-induced cell death of SH-SY5Y cells.	puerarin	57-65	G protein-coupled estrogen receptor 1	Homo sapiens	28-33
28101568-0	2017	Puerarin inhibits M2 polarization and metastasis of tumor-associated macrophages from NSCLC xenograft model via inactivating MEK/ERK 1/2 pathway.	puerarin	0-8	mitogen-activated protein kinase 3	Homo sapiens	129-136
28101568-5	2017	The results demonstrated that puerarin inhibited tumor growth and tumor volumes in NSCLC xenograft model, increased M1 markers [CD197+, inducible nitric oxide synthase (iNOS)+, CD40+)] and reduced M2 markers (CD206+, Arg-1+ and CD163+).	puerarin	30-38	arginase 1	Homo sapiens	217-222
28101568-6	2017	Besides, puerarin elevated the level of pro-inflammatory cytokine interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha and interleukin (IL)-12, decreased the expression of pro-tumor cytokines IL-10, IL-4 and transforming growth factor (TGF)-beta.	puerarin	9-17	tumor necrosis factor	Homo sapiens	90-123
28101568-6	2017	Besides, puerarin elevated the level of pro-inflammatory cytokine interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha and interleukin (IL)-12, decreased the expression of pro-tumor cytokines IL-10, IL-4 and transforming growth factor (TGF)-beta.	puerarin	9-17	interleukin 10	Homo sapiens	197-202
28101568-6	2017	Besides, puerarin elevated the level of pro-inflammatory cytokine interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha and interleukin (IL)-12, decreased the expression of pro-tumor cytokines IL-10, IL-4 and transforming growth factor (TGF)-beta.	puerarin	9-17	interleukin 4	Homo sapiens	204-208
28101568-6	2017	Besides, puerarin elevated the level of pro-inflammatory cytokine interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha and interleukin (IL)-12, decreased the expression of pro-tumor cytokines IL-10, IL-4 and transforming growth factor (TGF)-beta.	puerarin	9-17	transforming growth factor beta 1	Homo sapiens	213-250
28101568-9	2017	Puerarin also inhibited the activation of mitogen-activated extracellular signal-regulated kinase (MEK)/extracellular signal-regulated kinase (ERK) 1/2 pathway through inhibition of ERK nucleus translocation.	puerarin	0-8	mitogen-activated protein kinase kinase 7	Homo sapiens	42-97
28101568-9	2017	Puerarin also inhibited the activation of mitogen-activated extracellular signal-regulated kinase (MEK)/extracellular signal-regulated kinase (ERK) 1/2 pathway through inhibition of ERK nucleus translocation.	puerarin	0-8	mitogen-activated protein kinase kinase 7	Homo sapiens	99-102
28101568-9	2017	Puerarin also inhibited the activation of mitogen-activated extracellular signal-regulated kinase (MEK)/extracellular signal-regulated kinase (ERK) 1/2 pathway through inhibition of ERK nucleus translocation.	puerarin	0-8	mitogen-activated protein kinase 3	Homo sapiens	104-151
28101568-9	2017	Puerarin also inhibited the activation of mitogen-activated extracellular signal-regulated kinase (MEK)/extracellular signal-regulated kinase (ERK) 1/2 pathway through inhibition of ERK nucleus translocation.	puerarin	0-8	mitogen-activated protein kinase 1	Homo sapiens	143-146
28101568-10	2017	Finally, IL-4 induced M2 macrophage polarization and metastasis were partially offset by puerarin through inactivating the MEK/ERK 1/2 pathway.	puerarin	89-97	interleukin 4	Homo sapiens	9-13
28101568-10	2017	Finally, IL-4 induced M2 macrophage polarization and metastasis were partially offset by puerarin through inactivating the MEK/ERK 1/2 pathway.	puerarin	89-97	mitogen-activated protein kinase kinase 7	Homo sapiens	123-126
28101568-10	2017	Finally, IL-4 induced M2 macrophage polarization and metastasis were partially offset by puerarin through inactivating the MEK/ERK 1/2 pathway.	puerarin	89-97	mitogen-activated protein kinase 3	Homo sapiens	127-134
29179218-0	2017	Puerarin Enhances Ca2+ Reuptake and Ca2+ Content of Sarcoplasmic Reticulum in Murine Embryonic Stem Cell-Derived Cardiomyocytes via Upregulation of SERCA2a.	puerarin	0-8	ATPase, Ca++ transporting, cardiac muscle, slow twitch 2	Mus musculus	148-155
27796870-7	2017	Moreover, a time- and concentration-dependent effect of puerarin on GPR30 expression was verified at the protein level but not at the mRNA level.	puerarin	56-64	G protein-coupled estrogen receptor 1	Homo sapiens	68-73
27796870-8	2017	Further, we showed that an mTor-dependent new GPR30 synthesis contributed to the protection conferred by puerarin.	puerarin	105-113	mechanistic target of rapamycin kinase	Homo sapiens	27-31
27796870-8	2017	Further, we showed that an mTor-dependent new GPR30 synthesis contributed to the protection conferred by puerarin.	puerarin	105-113	G protein-coupled estrogen receptor 1	Homo sapiens	46-51
27796870-10	2017	Taken together, our data strongly suggest that puerarin prevents MPP+-induced cell death via facilitating GPR30 expression and GDNF release.	puerarin	47-55	G protein-coupled estrogen receptor 1	Homo sapiens	106-111
27796870-10	2017	Taken together, our data strongly suggest that puerarin prevents MPP+-induced cell death via facilitating GPR30 expression and GDNF release.	puerarin	47-55	glial cell derived neurotrophic factor	Homo sapiens	127-131
29121799-8	2017	In addition, PRE markedly suppressed cAMP response element-binding protein (CREB) activation and the induction of peroxisome proliferator-activated receptor gamma coactivator 1beta (PGC1beta), which stimulate osteoclastogenesis - an effect that was not observed for puerarin and 17-beta estradiol.	puerarin	266-274	peroxisome proliferative activated receptor, gamma, coactivator 1 beta	Mus musculus	182-190
27925234-0	2017	Puerarin offsets the anticoagulation effect of warfarin in rats by inducing rCyps, upregulating vitamin K epoxide reductase and inhibiting thrombomodulin.	puerarin	0-8	thrombomodulin	Rattus norvegicus	139-153
27925234-12	2017	Further mechanistic studies suggested that both oral and intravenous administration of puerarin significantly induced the activities and expressions of rCyp2b1, rCyp2c6 and rCyp1a1.	puerarin	87-95	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	152-159
27925234-12	2017	Further mechanistic studies suggested that both oral and intravenous administration of puerarin significantly induced the activities and expressions of rCyp2b1, rCyp2c6 and rCyp1a1.	puerarin	87-95	cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1	Rattus norvegicus	161-168
27925234-12	2017	Further mechanistic studies suggested that both oral and intravenous administration of puerarin significantly induced the activities and expressions of rCyp2b1, rCyp2c6 and rCyp1a1.	puerarin	87-95	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	173-180
27925234-13	2017	In addition, co-administration of puerarin reduced the prothrombin time of rat plasma by enhancing VKOR and inhibiting thrombomodulin.	puerarin	34-42	thrombomodulin	Rattus norvegicus	119-133
27771118-6	2017	The results showed that puerarin treatment suppressed the production of reactive oxygen species and decreased the oxidative damage of the bSCs subjected to heat stress, as indicated by changes in superoxide dismutase, catalase, and glutathione peroxidase activities and malondialdehyde content.	puerarin	24-32	catalase	Bos taurus	218-226
27771118-7	2017	Moreover, puerarin treatment also suppressed the initiation of mitochondria-dependent apoptotic pathway, as revealed by changes in Bax to Bcl-2 ratio, mitochondrial membrane potential, cytochrome C release, caspase-3 activation, and apoptotic rate compared with the heat stress group.	puerarin	10-18	BCL2 associated X, apoptosis regulator	Bos taurus	131-134
27771118-7	2017	Moreover, puerarin treatment also suppressed the initiation of mitochondria-dependent apoptotic pathway, as revealed by changes in Bax to Bcl-2 ratio, mitochondrial membrane potential, cytochrome C release, caspase-3 activation, and apoptotic rate compared with the heat stress group.	puerarin	10-18	BCL2 apoptosis regulator	Bos taurus	138-143
27771118-7	2017	Moreover, puerarin treatment also suppressed the initiation of mitochondria-dependent apoptotic pathway, as revealed by changes in Bax to Bcl-2 ratio, mitochondrial membrane potential, cytochrome C release, caspase-3 activation, and apoptotic rate compared with the heat stress group.	puerarin	10-18	LOC104968582	Bos taurus	185-197
27771118-7	2017	Moreover, puerarin treatment also suppressed the initiation of mitochondria-dependent apoptotic pathway, as revealed by changes in Bax to Bcl-2 ratio, mitochondrial membrane potential, cytochrome C release, caspase-3 activation, and apoptotic rate compared with the heat stress group.	puerarin	10-18	caspase 3	Bos taurus	207-216
27925234-14	2017	CONCLUSION: Puerarin increased warfarin metabolism and offset warfarin anticoagulation by inducing rCyps, upregulating VKOR and inhibiting thrombomodulin in rats.	puerarin	12-20	thrombomodulin	Rattus norvegicus	139-153
29179218-10	2017	Long-term application of puerarin asynchronously upregulates the mRNA and protein expression of SERCA2a, as well as the transcripts of calsequestrin and triadin in developing ES-CMs.	puerarin	25-33	ATPase, Ca++ transporting, cardiac muscle, slow twitch 2	Mus musculus	96-103
29179218-11	2017	Application of puerarin during the stage of post-cardiac differentiation upregulates dose-dependently the transcripts of SERCA2a, phospholamban and tridin which can be reversed by the inhibitors of the PI3K/Akt and MAPK/ERK signaling pathways, but shows no effect on the protein expression of SERCA2a.	puerarin	15-23	ATPase, Ca++ transporting, cardiac muscle, slow twitch 2	Mus musculus	121-128
29179218-11	2017	Application of puerarin during the stage of post-cardiac differentiation upregulates dose-dependently the transcripts of SERCA2a, phospholamban and tridin which can be reversed by the inhibitors of the PI3K/Akt and MAPK/ERK signaling pathways, but shows no effect on the protein expression of SERCA2a.	puerarin	15-23	thymoma viral proto-oncogene 1	Mus musculus	207-210
29179218-11	2017	Application of puerarin during the stage of post-cardiac differentiation upregulates dose-dependently the transcripts of SERCA2a, phospholamban and tridin which can be reversed by the inhibitors of the PI3K/Akt and MAPK/ERK signaling pathways, but shows no effect on the protein expression of SERCA2a.	puerarin	15-23	ATPase, Ca++ transporting, cardiac muscle, slow twitch 2	Mus musculus	293-300
29179218-12	2017	CONCLUSION: This study demonstrates that long-term puerarin treatment enhances Ca2+ reuptake and Ca2+ content via upregulation of SERCA2a.	puerarin	51-59	ATPase, Ca++ transporting, cardiac muscle, slow twitch 2	Mus musculus	130-137
28638404-0	2017	Puerarin Protects against Cardiac Fibrosis Associated with the Inhibition of TGF-beta1/Smad2-Mediated Endothelial-to-Mesenchymal Transition.	puerarin	0-8	transforming growth factor, beta 1	Mus musculus	77-86
28060542-9	2017	Our results demonstrate that in Ang II-induced hypertensive rats, puerarin protects against endothelial dysfunction and end organ damage with a mild reduction in SBP, and that the cardiovascular beneficial effects of puerarin may be in part attributed to its anti-oxidant and upregulation of phosphor-eNOS.	puerarin	66-74	spermine binding protein	Rattus norvegicus	162-165
27677221-1	2016	In this study, we aim to explore the potential benefits of puerarin on metabolic function of liver fibrosis (LF) rat induced by carbon tetrachloride (CCl4), and to investigate with the underlying molecular mechanism targeted on liver and pancreas tissues.	puerarin	59-67	C-C motif chemokine ligand 4	Rattus norvegicus	150-154
27677221-4	2016	The findings showed that puerarin-administered rats resulted in reduced glucose tolerance, blood insulin level, sero-enzymes of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and increased plasma level of high-density lipoprotein cholesterol (HDL-C) and reduced low-density lipoprotein cholesterol (LDL-C) content in serum.	puerarin	25-33	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	163-189
27677221-4	2016	The findings showed that puerarin-administered rats resulted in reduced glucose tolerance, blood insulin level, sero-enzymes of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and increased plasma level of high-density lipoprotein cholesterol (HDL-C) and reduced low-density lipoprotein cholesterol (LDL-C) content in serum.	puerarin	25-33	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	191-194
27677221-5	2016	Further, the intrahepatic collagen deposits were lessened and positive cell of alpha smooth muscle actin (alpha-SMA) was lessened in puerarin treatment, while the pro-apoptotic cell numbers of Caspase 3, Bax in pancreatic islets were reduced dose-dependently.	puerarin	133-141	actin gamma 2, smooth muscle	Rattus norvegicus	79-104
27677221-5	2016	Further, the intrahepatic collagen deposits were lessened and positive cell of alpha smooth muscle actin (alpha-SMA) was lessened in puerarin treatment, while the pro-apoptotic cell numbers of Caspase 3, Bax in pancreatic islets were reduced dose-dependently.	puerarin	133-141	actin gamma 2, smooth muscle	Rattus norvegicus	106-115
27677221-5	2016	Further, the intrahepatic collagen deposits were lessened and positive cell of alpha smooth muscle actin (alpha-SMA) was lessened in puerarin treatment, while the pro-apoptotic cell numbers of Caspase 3, Bax in pancreatic islets were reduced dose-dependently.	puerarin	133-141	BCL2 associated X, apoptosis regulator	Rattus norvegicus	204-207
27677221-8	2016	Our findings demonstrate that puerarin contributes to attenuating the metabolic dysfunctions of CCl4-damaged liver and pancreas, in which the possible mechanisms may be linked to inhibition of inflammatory stress and normalization of metabolic homoeostasis in the liver and pancreas.	puerarin	30-38	C-C motif chemokine ligand 4	Rattus norvegicus	96-100
28638404-0	2017	Puerarin Protects against Cardiac Fibrosis Associated with the Inhibition of TGF-beta1/Smad2-Mediated Endothelial-to-Mesenchymal Transition.	puerarin	0-8	SMAD family member 2	Mus musculus	87-92
28638404-11	2017	TGF-beta1/Smad2 signaling pathway was blunted and PPAR-gamma expression was upregulated in puerarin-treated mice and HUVECs.	puerarin	91-99	transforming growth factor, beta 1	Mus musculus	0-9
28638404-11	2017	TGF-beta1/Smad2 signaling pathway was blunted and PPAR-gamma expression was upregulated in puerarin-treated mice and HUVECs.	puerarin	91-99	SMAD family member 2	Mus musculus	10-15
28638404-11	2017	TGF-beta1/Smad2 signaling pathway was blunted and PPAR-gamma expression was upregulated in puerarin-treated mice and HUVECs.	puerarin	91-99	peroxisome proliferator activated receptor gamma	Mus musculus	50-60
27717697-7	2016	In addition, PU reversed Cd-induced ATP depletion by restoring DeltaPsim to affect ATP production and by regulating expression levels of ANT-1 and ANT-2 to improve ATP transport.	puerarin	13-15	solute carrier family 25 member 4	Rattus norvegicus	137-142
28638404-13	2017	CONCLUSION: Puerarin protected against TAC-induced cardiac fibrosis, and this protective effect may be attributed to the upregulation of PPAR-gamma and the inhibition of TGF-beta1/Smad2-mediated EndMT.	puerarin	12-20	peroxisome proliferator activated receptor gamma	Mus musculus	137-147
28638404-13	2017	CONCLUSION: Puerarin protected against TAC-induced cardiac fibrosis, and this protective effect may be attributed to the upregulation of PPAR-gamma and the inhibition of TGF-beta1/Smad2-mediated EndMT.	puerarin	12-20	transforming growth factor, beta 1	Mus musculus	170-179
27717697-7	2016	In addition, PU reversed Cd-induced ATP depletion by restoring DeltaPsim to affect ATP production and by regulating expression levels of ANT-1 and ANT-2 to improve ATP transport.	puerarin	13-15	solute carrier family 25 member 5	Rattus norvegicus	147-152
28638404-13	2017	CONCLUSION: Puerarin protected against TAC-induced cardiac fibrosis, and this protective effect may be attributed to the upregulation of PPAR-gamma and the inhibition of TGF-beta1/Smad2-mediated EndMT.	puerarin	12-20	SMAD family member 2	Mus musculus	180-185
27697446-10	2016	Next, combined administration of puerarin and zinc promoted the serological level of osteocalcin, bone marrow stromal cell (BMSC) proliferation, and the expression of alkaline phosphatase (ALP), and suppressed the serological level of adiponectin and adiposity in bone marrow (BM).	puerarin	33-41	bone gamma-carboxyglutamate protein	Rattus norvegicus	85-96
26753818-9	2016	The results show that puerarin-PG-liposome prolonged drug retention time and decreased elimination of puerarin in mice (AUC of liposome system and solution was 9.5 and 4.0 mg h L-1, respectively).	puerarin	22-30	L1 cell adhesion molecule	Mus musculus	177-180
27697446-10	2016	Next, combined administration of puerarin and zinc promoted the serological level of osteocalcin, bone marrow stromal cell (BMSC) proliferation, and the expression of alkaline phosphatase (ALP), and suppressed the serological level of adiponectin and adiposity in bone marrow (BM).	puerarin	33-41	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	235-246
27615593-7	2016	SIGNIFICANCE: This is the first report in ovariectomized rats the effects of puerarin on somatotropes and pituitary estrogen-responsive mRNA expressions, which are very weakly estrogenic by acting through ERbeta- and TERP-1/-2 mediated pathways.	puerarin	77-85	estrogen receptor 2	Rattus norvegicus	205-211
27886150-1	2016	P-glycoprotein (P-gp) affects the transport of many drugs; including puerarin and vincristine.	puerarin	69-77	PGP	Canis lupus familiaris	0-14
27886150-1	2016	P-glycoprotein (P-gp) affects the transport of many drugs; including puerarin and vincristine.	puerarin	69-77	PGP	Canis lupus familiaris	16-20
27886150-2	2016	Our previous study demonstrated that imperatorin increased the intestinal absorption of puerarin and vincristine by inhibiting P-gp-mediated drug efflux.	puerarin	88-96	PGP	Canis lupus familiaris	127-131
27615593-5	2016	KEY FINDINGS: Puerarin possessed weak E2B-like activities on pituitary function by acting as ERbeta and TERP-1/-2 agonists, which resulted in the downregulation and upregulation of ERbeta and TERP-1/-2 mRNA expressions, respectively, and elevation of growth hormone levels.	puerarin	14-22	estrogen receptor 2	Rattus norvegicus	93-99
27615593-5	2016	KEY FINDINGS: Puerarin possessed weak E2B-like activities on pituitary function by acting as ERbeta and TERP-1/-2 agonists, which resulted in the downregulation and upregulation of ERbeta and TERP-1/-2 mRNA expressions, respectively, and elevation of growth hormone levels.	puerarin	14-22	estrogen receptor 2	Rattus norvegicus	181-187
27116952-5	2016	Moreover, PU can reverse Pb-induced ATP depletion by restoring mitochondrial fragmentation to affect ATP production and by regulating expression levels of ANT-1 and ANT-2 to improve ATP transport.	puerarin	10-12	solute carrier family 25 member 5	Rattus norvegicus	165-170
27762288-7	2016	Millimolar concentrations of puerarin significantly inhibited inward rectified K+ channels in a dosage dependent manner, and exhibited bigger effects upon Kir2.1 vs Kir2.3 in transfected HEK293 cells.	puerarin	29-37	potassium inwardly rectifying channel subfamily J member 2	Homo sapiens	155-161
27643664-10	2016	Moreover, puerarin could prevent lung and cerebrum injury of rats exposed to hypobaric hypoxia via down-regulation of inflammatory cytokines, AQP1 and AQP4 expression and NF-kappaB signaling pathway.	puerarin	10-18	aquaporin 1	Rattus norvegicus	142-146
27643664-10	2016	Moreover, puerarin could prevent lung and cerebrum injury of rats exposed to hypobaric hypoxia via down-regulation of inflammatory cytokines, AQP1 and AQP4 expression and NF-kappaB signaling pathway.	puerarin	10-18	aquaporin 4	Rattus norvegicus	151-155
27116952-4	2016	Simultaneously, upregulation and downregulation of Bcl-2 and Bax with increased Bcl-2/Bax ratio due to PU administration further alleviated Pb-induced mitochondrial apoptosis.	puerarin	103-105	BCL2, apoptosis regulator	Rattus norvegicus	51-56
27116952-4	2016	Simultaneously, upregulation and downregulation of Bcl-2 and Bax with increased Bcl-2/Bax ratio due to PU administration further alleviated Pb-induced mitochondrial apoptosis.	puerarin	103-105	BCL2 associated X, apoptosis regulator	Rattus norvegicus	61-64
27116952-4	2016	Simultaneously, upregulation and downregulation of Bcl-2 and Bax with increased Bcl-2/Bax ratio due to PU administration further alleviated Pb-induced mitochondrial apoptosis.	puerarin	103-105	BCL2, apoptosis regulator	Rattus norvegicus	80-85
27116952-4	2016	Simultaneously, upregulation and downregulation of Bcl-2 and Bax with increased Bcl-2/Bax ratio due to PU administration further alleviated Pb-induced mitochondrial apoptosis.	puerarin	103-105	BCL2 associated X, apoptosis regulator	Rattus norvegicus	86-89
27116952-5	2016	Moreover, PU can reverse Pb-induced ATP depletion by restoring mitochondrial fragmentation to affect ATP production and by regulating expression levels of ANT-1 and ANT-2 to improve ATP transport.	puerarin	10-12	solute carrier family 25 member 4	Rattus norvegicus	155-160
27762288-7	2016	Millimolar concentrations of puerarin significantly inhibited inward rectified K+ channels in a dosage dependent manner, and exhibited bigger effects upon Kir2.1 vs Kir2.3 in transfected HEK293 cells.	puerarin	29-37	potassium inwardly rectifying channel subfamily J member 4	Homo sapiens	165-171
29949318-6	2016	RESULTS: Puerarin reduced the inhibition in cell proliferation, MMP-2 activity, mRNA, protein expressionof HFSFs exposed to ELF-EMFs and enhanced the COL1A1 mRNA and protein expression.	puerarin	9-17	matrix metallopeptidase 2	Homo sapiens	64-69
27830026-0	2016	Puerarin inhibits cardiac fibrosis via monocyte chemoattractant protein (MCP)-1 and the transforming growth factor-beta1 (TGF-beta1) pathway in myocardial infarction mice.	puerarin	0-8	chemokine (C-C motif) ligand 2	Mus musculus	39-79
27830026-0	2016	Puerarin inhibits cardiac fibrosis via monocyte chemoattractant protein (MCP)-1 and the transforming growth factor-beta1 (TGF-beta1) pathway in myocardial infarction mice.	puerarin	0-8	transforming growth factor, beta 1	Mus musculus	88-120
27830026-0	2016	Puerarin inhibits cardiac fibrosis via monocyte chemoattractant protein (MCP)-1 and the transforming growth factor-beta1 (TGF-beta1) pathway in myocardial infarction mice.	puerarin	0-8	transforming growth factor, beta 1	Mus musculus	122-131
27830026-7	2016	The results displayed that puerarin could inhibit the recruitment and activation of monocytes/macrophages, decrease the expression of TGF-beta1 in the cardiac tissues, and consequently significantly attenuated cardiac fibrosis after MI.	puerarin	27-35	transforming growth factor, beta 1	Mus musculus	134-143
27830026-9	2016	Thus, this study revealed the mechanism by which prevented cardiac fibrosis after MI through a decrease in MCP-1 expression and an inhibition TGF-beta1 pathway, and indicated puerarin could be a potential agent in attenuating MI-induced cardiac fibrosis.	puerarin	175-183	chemokine (C-C motif) ligand 2	Mus musculus	107-112
27830026-9	2016	Thus, this study revealed the mechanism by which prevented cardiac fibrosis after MI through a decrease in MCP-1 expression and an inhibition TGF-beta1 pathway, and indicated puerarin could be a potential agent in attenuating MI-induced cardiac fibrosis.	puerarin	175-183	transforming growth factor, beta 1	Mus musculus	142-151
26712108-6	2016	Importantly, pre-incubation of oocytes with a caspase-3-specific inhibitor effectively blocked puerarin-triggered deleterious effects, clearly implying that embryonic injury induced by puerarin is mediated by a caspase-dependent apoptotic mechanism.	puerarin	95-103	caspase 3	Mus musculus	46-55
26712108-6	2016	Importantly, pre-incubation of oocytes with a caspase-3-specific inhibitor effectively blocked puerarin-triggered deleterious effects, clearly implying that embryonic injury induced by puerarin is mediated by a caspase-dependent apoptotic mechanism.	puerarin	185-193	caspase 3	Mus musculus	46-55
29949318-6	2016	RESULTS: Puerarin reduced the inhibition in cell proliferation, MMP-2 activity, mRNA, protein expressionof HFSFs exposed to ELF-EMFs and enhanced the COL1A1 mRNA and protein expression.	puerarin	9-17	collagen type I alpha 1 chain	Homo sapiens	150-156
27552519-10	2016	CONCLUSIONS: The present results of this study demonstrated that puerarin protected against NMDA-induced apoptosis and RGCs damage through the JNK/p38 MAPK pathway.	puerarin	65-73	mitogen-activated protein kinase 8	Rattus norvegicus	143-146
27318789-0	2016	Puerarin protects against CCl4-induced liver fibrosis in mice: possible role of PARP-1 inhibition.	puerarin	0-8	chemokine (C-C motif) ligand 4	Mus musculus	26-30
27318789-0	2016	Puerarin protects against CCl4-induced liver fibrosis in mice: possible role of PARP-1 inhibition.	puerarin	0-8	poly (ADP-ribose) polymerase family, member 1	Mus musculus	80-86
27318789-4	2016	This study aimed to investigate the effects of puerarin on liver function and fibrosis process in mice induced by CCl4.	puerarin	47-55	chemokine (C-C motif) ligand 4	Mus musculus	114-118
27318789-6	2016	As indicated by the ameliorative serum hepatic enzymes and the reduced histopathologic abnormalities, the data collected showed that puerarin can protect against CCl4-induced chronic liver injury.	puerarin	133-141	chemokine (C-C motif) ligand 4	Mus musculus	162-166
27318789-7	2016	Moreover, CCl4-induced development of fibrosis, as evidenced by increasing expression of alpha smooth muscle actin(alpha-SMA), collagen-1, transforming growth factor (TGF)-beta and connective tissue growth factor(CTGF) in liver, were suppressed by puerarin.	puerarin	248-256	chemokine (C-C motif) ligand 4	Mus musculus	10-14
27318789-7	2016	Moreover, CCl4-induced development of fibrosis, as evidenced by increasing expression of alpha smooth muscle actin(alpha-SMA), collagen-1, transforming growth factor (TGF)-beta and connective tissue growth factor(CTGF) in liver, were suppressed by puerarin.	puerarin	248-256	cellular communication network factor 2	Mus musculus	213-217
27318789-9	2016	In addition, these protective inhibition mentioned above were driven by down-regulation of PARP-1 due to puerarin because puerarin can attenuate the PARP-1 expression in CCl4-damaged liver and PJ34, a kind of PARP-1 inhibitor, mimicked puerarin"s protection.	puerarin	105-113	poly (ADP-ribose) polymerase family, member 1	Mus musculus	91-97
27318789-9	2016	In addition, these protective inhibition mentioned above were driven by down-regulation of PARP-1 due to puerarin because puerarin can attenuate the PARP-1 expression in CCl4-damaged liver and PJ34, a kind of PARP-1 inhibitor, mimicked puerarin"s protection.	puerarin	105-113	poly (ADP-ribose) polymerase family, member 1	Mus musculus	149-155
27318789-9	2016	In addition, these protective inhibition mentioned above were driven by down-regulation of PARP-1 due to puerarin because puerarin can attenuate the PARP-1 expression in CCl4-damaged liver and PJ34, a kind of PARP-1 inhibitor, mimicked puerarin"s protection.	puerarin	105-113	chemokine (C-C motif) ligand 4	Mus musculus	170-174
27318789-9	2016	In addition, these protective inhibition mentioned above were driven by down-regulation of PARP-1 due to puerarin because puerarin can attenuate the PARP-1 expression in CCl4-damaged liver and PJ34, a kind of PARP-1 inhibitor, mimicked puerarin"s protection.	puerarin	105-113	poly (ADP-ribose) polymerase family, member 1	Mus musculus	149-155
27318789-9	2016	In addition, these protective inhibition mentioned above were driven by down-regulation of PARP-1 due to puerarin because puerarin can attenuate the PARP-1 expression in CCl4-damaged liver and PJ34, a kind of PARP-1 inhibitor, mimicked puerarin"s protection.	puerarin	122-130	poly (ADP-ribose) polymerase family, member 1	Mus musculus	91-97
27318789-9	2016	In addition, these protective inhibition mentioned above were driven by down-regulation of PARP-1 due to puerarin because puerarin can attenuate the PARP-1 expression in CCl4-damaged liver and PJ34, a kind of PARP-1 inhibitor, mimicked puerarin"s protection.	puerarin	122-130	poly (ADP-ribose) polymerase family, member 1	Mus musculus	149-155
27318789-9	2016	In addition, these protective inhibition mentioned above were driven by down-regulation of PARP-1 due to puerarin because puerarin can attenuate the PARP-1 expression in CCl4-damaged liver and PJ34, a kind of PARP-1 inhibitor, mimicked puerarin"s protection.	puerarin	122-130	chemokine (C-C motif) ligand 4	Mus musculus	170-174
27318789-9	2016	In addition, these protective inhibition mentioned above were driven by down-regulation of PARP-1 due to puerarin because puerarin can attenuate the PARP-1 expression in CCl4-damaged liver and PJ34, a kind of PARP-1 inhibitor, mimicked puerarin"s protection.	puerarin	122-130	poly (ADP-ribose) polymerase family, member 1	Mus musculus	149-155
27318789-9	2016	In addition, these protective inhibition mentioned above were driven by down-regulation of PARP-1 due to puerarin because puerarin can attenuate the PARP-1 expression in CCl4-damaged liver and PJ34, a kind of PARP-1 inhibitor, mimicked puerarin"s protection.	puerarin	122-130	poly (ADP-ribose) polymerase family, member 1	Mus musculus	91-97
27318789-9	2016	In addition, these protective inhibition mentioned above were driven by down-regulation of PARP-1 due to puerarin because puerarin can attenuate the PARP-1 expression in CCl4-damaged liver and PJ34, a kind of PARP-1 inhibitor, mimicked puerarin"s protection.	puerarin	122-130	poly (ADP-ribose) polymerase family, member 1	Mus musculus	149-155
27318789-9	2016	In addition, these protective inhibition mentioned above were driven by down-regulation of PARP-1 due to puerarin because puerarin can attenuate the PARP-1 expression in CCl4-damaged liver and PJ34, a kind of PARP-1 inhibitor, mimicked puerarin"s protection.	puerarin	122-130	chemokine (C-C motif) ligand 4	Mus musculus	170-174
27318789-9	2016	In addition, these protective inhibition mentioned above were driven by down-regulation of PARP-1 due to puerarin because puerarin can attenuate the PARP-1 expression in CCl4-damaged liver and PJ34, a kind of PARP-1 inhibitor, mimicked puerarin"s protection.	puerarin	122-130	poly (ADP-ribose) polymerase family, member 1	Mus musculus	149-155
27318789-10	2016	In conclusion, puerarin played a protective role in CCl4-induced liver fibrosis probably through inhibition of PARP-1 and subsequent attenuation of NF-kappaB, ROS production and mitochondrial dysfunction.	puerarin	15-23	chemokine (C-C motif) ligand 4	Mus musculus	52-56
27318789-10	2016	In conclusion, puerarin played a protective role in CCl4-induced liver fibrosis probably through inhibition of PARP-1 and subsequent attenuation of NF-kappaB, ROS production and mitochondrial dysfunction.	puerarin	15-23	poly (ADP-ribose) polymerase family, member 1	Mus musculus	111-117
27318789-10	2016	In conclusion, puerarin played a protective role in CCl4-induced liver fibrosis probably through inhibition of PARP-1 and subsequent attenuation of NF-kappaB, ROS production and mitochondrial dysfunction.	puerarin	15-23	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	148-157
27552519-0	2016	Puerarin Attenuates N-Methyl-D-aspartic Acid-induced Apoptosis and Retinal Ganglion Cell Damage Through the JNK/p38 MAPK Pathway.	puerarin	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	108-111
27552519-0	2016	Puerarin Attenuates N-Methyl-D-aspartic Acid-induced Apoptosis and Retinal Ganglion Cell Damage Through the JNK/p38 MAPK Pathway.	puerarin	0-8	mitogen activated protein kinase 14	Rattus norvegicus	112-115
27552519-6	2016	Compared with the NMDA-treated group, puerarin pretreatment significantly reduced ROS and malondialdehyde levels, promoted SOD and NO production, and downregulated nNOS and iNOS expression in the RGCs.	puerarin	38-46	nitric oxide synthase 1	Rattus norvegicus	164-168
27552519-6	2016	Compared with the NMDA-treated group, puerarin pretreatment significantly reduced ROS and malondialdehyde levels, promoted SOD and NO production, and downregulated nNOS and iNOS expression in the RGCs.	puerarin	38-46	nitric oxide synthase 2	Rattus norvegicus	173-177
27552519-7	2016	Mechanism analysis showed that pretreatment with puerarin could effectively offset the increase of Bax expression and caspase-3 activity brought by NMDA, and promote Bcl-2 expression in the RGCs.	puerarin	49-57	BCL2 associated X, apoptosis regulator	Rattus norvegicus	99-102
27552519-7	2016	Mechanism analysis showed that pretreatment with puerarin could effectively offset the increase of Bax expression and caspase-3 activity brought by NMDA, and promote Bcl-2 expression in the RGCs.	puerarin	49-57	caspase 3	Rattus norvegicus	118-127
27552519-7	2016	Mechanism analysis showed that pretreatment with puerarin could effectively offset the increase of Bax expression and caspase-3 activity brought by NMDA, and promote Bcl-2 expression in the RGCs.	puerarin	49-57	BCL2, apoptosis regulator	Rattus norvegicus	166-171
27552519-8	2016	Puerarin pretreatment also effectively inhibited NMDA-induced JNK and p38 phosphorylation in the RGCs, whereas pretreatment with either JNK agonist anisomycin or p38 agonist P79350 could significantly compensate the effects caused by puerarin.	puerarin	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	62-65
27552519-8	2016	Puerarin pretreatment also effectively inhibited NMDA-induced JNK and p38 phosphorylation in the RGCs, whereas pretreatment with either JNK agonist anisomycin or p38 agonist P79350 could significantly compensate the effects caused by puerarin.	puerarin	0-8	mitogen activated protein kinase 14	Rattus norvegicus	70-73
27552519-10	2016	CONCLUSIONS: The present results of this study demonstrated that puerarin protected against NMDA-induced apoptosis and RGCs damage through the JNK/p38 MAPK pathway.	puerarin	65-73	mitogen activated protein kinase 14	Rattus norvegicus	147-150
27409614-7	2016	Furthermore, our data indicated that the neuroprotective effect of puerarin was potentially mediated through the inhibition of glutamate-induced activation of mitochondrial-dependent signaling pathway and calmodulin-dependent protein kinase II (CaMKII)-dependent apoptosis signal-regulating kinase 1(ASK-1)/c-Jun N-terminal kinase (JNK)/p38 signaling pathway.	puerarin	67-75	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	300-305
28920384-9	2016	Puerarin improves the learning and memory impairment by reducing the formation of Abeta, activating the GSK3beta signaling pathway, inhibiting the phosphorylation of tau in APP/PS1 double transgenic mice.	puerarin	0-8	amyloid beta (A4) precursor protein	Mus musculus	82-87
28920384-9	2016	Puerarin improves the learning and memory impairment by reducing the formation of Abeta, activating the GSK3beta signaling pathway, inhibiting the phosphorylation of tau in APP/PS1 double transgenic mice.	puerarin	0-8	glycogen synthase kinase 3 alpha	Mus musculus	104-112
28920384-9	2016	Puerarin improves the learning and memory impairment by reducing the formation of Abeta, activating the GSK3beta signaling pathway, inhibiting the phosphorylation of tau in APP/PS1 double transgenic mice.	puerarin	0-8	presenilin 1	Mus musculus	177-180
27278131-0	2016	Puerarin attenuates inflammation and oxidation in mice with collagen antibody-induced arthritis via TLR4/NF-kappaB signaling.	puerarin	0-8	toll-like receptor 4	Mus musculus	100-104
27278131-0	2016	Puerarin attenuates inflammation and oxidation in mice with collagen antibody-induced arthritis via TLR4/NF-kappaB signaling.	puerarin	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	105-114
27278131-2	2016	The aim of the present study is to contribute to the existing knowledge of the effect of puerarin in the attenuation of inflammation and oxidation in mice with collagen antibody-induced arthritis via toll-like receptor 4 (TLR4)/nuclear factor-kappaB (NF-kappaB) signaling.	puerarin	89-97	toll-like receptor 4	Mus musculus	200-220
27278131-2	2016	The aim of the present study is to contribute to the existing knowledge of the effect of puerarin in the attenuation of inflammation and oxidation in mice with collagen antibody-induced arthritis via toll-like receptor 4 (TLR4)/nuclear factor-kappaB (NF-kappaB) signaling.	puerarin	89-97	toll-like receptor 4	Mus musculus	222-226
27278131-2	2016	The aim of the present study is to contribute to the existing knowledge of the effect of puerarin in the attenuation of inflammation and oxidation in mice with collagen antibody-induced arthritis via toll-like receptor 4 (TLR4)/nuclear factor-kappaB (NF-kappaB) signaling.	puerarin	89-97	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	251-260
27278131-5	2016	Furthermore, puerarin was demonstrated to inhibit mRNA expression of matrix metalloproteinase-9 and protein expression of TLR4 following collagen antibody-induced arthritis in mice.	puerarin	13-21	matrix metallopeptidase 9	Mus musculus	69-95
27278131-5	2016	Furthermore, puerarin was demonstrated to inhibit mRNA expression of matrix metalloproteinase-9 and protein expression of TLR4 following collagen antibody-induced arthritis in mice.	puerarin	13-21	toll-like receptor 4	Mus musculus	122-126
27278131-6	2016	The effect of puerarin may be associated with the suppression of NF-kappaB activity in collagen antibody-induced arthritis mice.	puerarin	14-22	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	65-74
27278131-7	2016	Furthermore, upregulation of phosphorylated (p)-Janus kinase 2 and p-signal transducer and activator of transcription 3 protein expression was suppressed by puerarin.	puerarin	157-165	Janus kinase 2	Mus musculus	48-62
27278131-8	2016	The results of the present study indicate, for the first time, the effect of puerarin to attenuate inflammation and oxidation in mice with collagen antibody-induced arthritis via TLR4/NF-kappaB signaling.	puerarin	77-85	toll-like receptor 4	Mus musculus	179-183
27278131-8	2016	The results of the present study indicate, for the first time, the effect of puerarin to attenuate inflammation and oxidation in mice with collagen antibody-induced arthritis via TLR4/NF-kappaB signaling.	puerarin	77-85	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	184-193
27409614-7	2016	Furthermore, our data indicated that the neuroprotective effect of puerarin was potentially mediated through the inhibition of glutamate-induced activation of mitochondrial-dependent signaling pathway and calmodulin-dependent protein kinase II (CaMKII)-dependent apoptosis signal-regulating kinase 1(ASK-1)/c-Jun N-terminal kinase (JNK)/p38 signaling pathway.	puerarin	67-75	mitogen-activated protein kinase 8	Homo sapiens	332-335
27409614-7	2016	Furthermore, our data indicated that the neuroprotective effect of puerarin was potentially mediated through the inhibition of glutamate-induced activation of mitochondrial-dependent signaling pathway and calmodulin-dependent protein kinase II (CaMKII)-dependent apoptosis signal-regulating kinase 1(ASK-1)/c-Jun N-terminal kinase (JNK)/p38 signaling pathway.	puerarin	67-75	mitogen-activated protein kinase 14	Homo sapiens	337-340
28901078-0	2016	[Puerarin attenuates PM2.5-induced vascular endothelial cells injury via ERK1/2 signaling pathway].	puerarin	1-9	mitogen-activated protein kinase 3	Homo sapiens	73-79
27367654-8	2016	Puerarin and daidzin are the major constituents of Gegen, and the pharmacokinetics of G-1 and G-2 puerarin conformed with the two compartment open model, while for G-3 and G-4, they conformed to a one compartment open model.	puerarin	0-8	myosin regulatory light chain 2, skeletal muscle isoform type 2	Oryctolagus cuniculus	86-97
27367654-8	2016	Puerarin and daidzin are the major constituents of Gegen, and the pharmacokinetics of G-1 and G-2 puerarin conformed with the two compartment open model, while for G-3 and G-4, they conformed to a one compartment open model.	puerarin	98-106	myosin regulatory light chain 2, skeletal muscle isoform type 2	Oryctolagus cuniculus	86-97
27514556-8	2016	After exposure for 24 hours, the radiation groups showed significantly lower protein expression of collagen type I and significantly higher protein expression of MMP-2 (t=7.917 and 7.831, both P<0.01) ; compared with the 0.0 mumol/L puerarin group, the 1.0, 5.0, and 10.0 mumol/L puerarin groups showed significant increases in the protein expression of collagen type I and significant reductions in the protein expression of MMP-2 (all P<0.01).	puerarin	236-244	matrix metallopeptidase 2	Homo sapiens	162-167
27514556-8	2016	After exposure for 24 hours, the radiation groups showed significantly lower protein expression of collagen type I and significantly higher protein expression of MMP-2 (t=7.917 and 7.831, both P<0.01) ; compared with the 0.0 mumol/L puerarin group, the 1.0, 5.0, and 10.0 mumol/L puerarin groups showed significant increases in the protein expression of collagen type I and significant reductions in the protein expression of MMP-2 (all P<0.01).	puerarin	283-291	matrix metallopeptidase 2	Homo sapiens	162-167
27514556-9	2016	Compared with the control group, the radiation groups showed significant reductions in the mRNA expression of collagen type I and MMP-2 (t=17.293 and 16.378, both P<0.01) ; compared with the 0.0 mumol/L puerarin group, the 1.0, 5.0, and 10.0 mumol/L puerarin groups showed significant increases in the mRNA expression of collagen type I and significant reductions in the mRNA expression of MMP-2 (P<0.01).	puerarin	206-214	matrix metallopeptidase 2	Homo sapiens	130-135
27514556-9	2016	Compared with the control group, the radiation groups showed significant reductions in the mRNA expression of collagen type I and MMP-2 (t=17.293 and 16.378, both P<0.01) ; compared with the 0.0 mumol/L puerarin group, the 1.0, 5.0, and 10.0 mumol/L puerarin groups showed significant increases in the mRNA expression of collagen type I and significant reductions in the mRNA expression of MMP-2 (P<0.01).	puerarin	253-261	matrix metallopeptidase 2	Homo sapiens	130-135
27514556-10	2016	CONCLUSION: Puerarin can inhibit the reduction in the proliferative activity of HFSFs in the power frequency electromagnetic field, upregulate the expression of collagen type I, downregulate the expression of MMP-2, and thus exert its protective effect.	puerarin	12-20	matrix metallopeptidase 2	Homo sapiens	209-214
28901078-5	2016	Compared with PM2.5 group, puerarin increased the cells survival rate, down-regulated p-ERK1/2 protein level and Bax/Bcl-2 ratio in a dose dependent manner to inhibit the apoptosis; decreased the contents of TNF-alpha, IL-6 and MDA, the activity of LDH, but increased SOD activity in the EA.hy926 cells (P<0.05).	puerarin	27-35	mitogen-activated protein kinase 3	Homo sapiens	88-94
28901078-5	2016	Compared with PM2.5 group, puerarin increased the cells survival rate, down-regulated p-ERK1/2 protein level and Bax/Bcl-2 ratio in a dose dependent manner to inhibit the apoptosis; decreased the contents of TNF-alpha, IL-6 and MDA, the activity of LDH, but increased SOD activity in the EA.hy926 cells (P<0.05).	puerarin	27-35	BCL2 associated X, apoptosis regulator	Homo sapiens	113-116
28901078-5	2016	Compared with PM2.5 group, puerarin increased the cells survival rate, down-regulated p-ERK1/2 protein level and Bax/Bcl-2 ratio in a dose dependent manner to inhibit the apoptosis; decreased the contents of TNF-alpha, IL-6 and MDA, the activity of LDH, but increased SOD activity in the EA.hy926 cells (P<0.05).	puerarin	27-35	BCL2 apoptosis regulator	Homo sapiens	117-122
28901078-5	2016	Compared with PM2.5 group, puerarin increased the cells survival rate, down-regulated p-ERK1/2 protein level and Bax/Bcl-2 ratio in a dose dependent manner to inhibit the apoptosis; decreased the contents of TNF-alpha, IL-6 and MDA, the activity of LDH, but increased SOD activity in the EA.hy926 cells (P<0.05).	puerarin	27-35	tumor necrosis factor	Homo sapiens	208-217
28901078-5	2016	Compared with PM2.5 group, puerarin increased the cells survival rate, down-regulated p-ERK1/2 protein level and Bax/Bcl-2 ratio in a dose dependent manner to inhibit the apoptosis; decreased the contents of TNF-alpha, IL-6 and MDA, the activity of LDH, but increased SOD activity in the EA.hy926 cells (P<0.05).	puerarin	27-35	interleukin 6	Homo sapiens	219-223
28901078-6	2016	The results indicated that puerarin could attenuate PM2.5-induced EA.hy926 cells injury via the inhibition of ERK1/2 pathway.	puerarin	27-35	mitogen-activated protein kinase 3	Homo sapiens	110-116
27074962-12	2016	Further assays showed depressed up-regulation of caspase-3 and caspase-9 after puerarin pretreatment.	puerarin	79-87	caspase 3	Rattus norvegicus	49-58
27145790-0	2016	Puerarin Attenuates Cardiac Hypertrophy Partly Through Increasing Mir-15b/195 Expression and Suppressing Non-Canonical Transforming Growth Factor Beta (Tgfbeta) Signal Pathway.	puerarin	0-8	microRNA 15b	Mus musculus	66-73
27145790-0	2016	Puerarin Attenuates Cardiac Hypertrophy Partly Through Increasing Mir-15b/195 Expression and Suppressing Non-Canonical Transforming Growth Factor Beta (Tgfbeta) Signal Pathway.	puerarin	0-8	transforming growth factor, beta 1	Mus musculus	152-159
27145790-2	2016	This study aimed to explore whether the effect of puerarin on attenuating cardiac hypertrophy is related to regulation of microRNAs (miRNAs) and the transforming growth factor beta (TGFbeta) signal pathway.	puerarin	50-58	transforming growth factor, beta 1	Mus musculus	182-189
27145790-8	2016	RESULTS Puerarin attenuated cardiac hypertrophy and increased miR-15b and miR-195 expression in the mouse cardiac hypertrophy model and in primary cardiomyocytes.	puerarin	8-16	microRNA 15b	Mus musculus	62-69
27145790-8	2016	RESULTS Puerarin attenuated cardiac hypertrophy and increased miR-15b and miR-195 expression in the mouse cardiac hypertrophy model and in primary cardiomyocytes.	puerarin	8-16	microRNA 195a	Mus musculus	74-81
27145790-13	2016	CONCLUSIONS Puerarin administration enhances miR-15b and miR-195 expression in an Ang II-induced cardiac hypertrophy model, through which it suppresses both canonical and non-canonical TGFbeta signal pathways at the same time.	puerarin	12-20	microRNA 15b	Mus musculus	45-52
27145790-13	2016	CONCLUSIONS Puerarin administration enhances miR-15b and miR-195 expression in an Ang II-induced cardiac hypertrophy model, through which it suppresses both canonical and non-canonical TGFbeta signal pathways at the same time.	puerarin	12-20	microRNA 195a	Mus musculus	57-64
27145790-13	2016	CONCLUSIONS Puerarin administration enhances miR-15b and miR-195 expression in an Ang II-induced cardiac hypertrophy model, through which it suppresses both canonical and non-canonical TGFbeta signal pathways at the same time.	puerarin	12-20	transforming growth factor, beta 1	Mus musculus	185-192
27145790-14	2016	However, the effect of puerarin on attenuating cardiac hypertrophy is mainly through the non-canonical TGFbeta pathway.	puerarin	23-31	transforming growth factor, beta 1	Mus musculus	103-110
25952544-0	2016	Botanical Drug Puerarin Attenuates 6-Hydroxydopamine (6-OHDA)-Induced Neurotoxicity via Upregulating Mitochondrial Enzyme Arginase-2.	puerarin	15-23	arginase 2	Rattus norvegicus	122-132
25952544-7	2016	As one of puerarin-upregulated proteins, mitochondrial arginase-2 hydrolyzes L-arginine to L-ornithine, thereby competing with neuronal NOS for substrate L-arginine in mitochondria.	puerarin	10-18	arginase 2	Rattus norvegicus	55-65
25952544-12	2016	The activation of arginase-2 by puerarin represents an endogenous mechanism for specific control of NO-mediated mitochondrial damage.	puerarin	32-40	arginase 2	Rattus norvegicus	18-28
25952544-14	2016	Graphical Abstract Arginase-2 dependent mechanism underlying the neuroprotective activity of puerarin.	puerarin	93-101	arginase 2	Rattus norvegicus	19-29
27074962-12	2016	Further assays showed depressed up-regulation of caspase-3 and caspase-9 after puerarin pretreatment.	puerarin	79-87	caspase 9	Rattus norvegicus	63-72
27074962-13	2016	CONCLUSIONS Puerarin pretreatment can decrease activity of caspase-3 and caspase-9 activity in PC12 cells, thus protecting cells from oxidative injury.	puerarin	12-20	caspase 3	Rattus norvegicus	59-68
27074962-13	2016	CONCLUSIONS Puerarin pretreatment can decrease activity of caspase-3 and caspase-9 activity in PC12 cells, thus protecting cells from oxidative injury.	puerarin	12-20	caspase 9	Rattus norvegicus	73-82
28884552-8	2016	The SOD level was significantly increased and IL-6 concentration was significantly decreased in plasma, indicating that as compared with the normal group, puerarin in FFLMN had a higher plasma concentration, slower elimination rate and higher bioavailability.	puerarin	155-163	interleukin 6	Rattus norvegicus	46-50
26972494-8	2016	Furthermore, both cyclosporine A (P-glycoprotein inhibitor) and MK-571 (MRP-2 inhibitor) significantly increased the cellular uptake and transport of (+)-catechin and puerarin.	puerarin	167-175	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	34-48
26972494-8	2016	Furthermore, both cyclosporine A (P-glycoprotein inhibitor) and MK-571 (MRP-2 inhibitor) significantly increased the cellular uptake and transport of (+)-catechin and puerarin.	puerarin	167-175	ATP binding cassette subfamily C member 2	Rattus norvegicus	72-77
26972494-10	2016	The competitive efflux of (+)-catechin and puerarin by P-glycoprotein and MRP-2 might lead to this interaction during their absorption process in the small intestine.	puerarin	43-51	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	55-69
26972494-10	2016	The competitive efflux of (+)-catechin and puerarin by P-glycoprotein and MRP-2 might lead to this interaction during their absorption process in the small intestine.	puerarin	43-51	ATP binding cassette subfamily C member 2	Rattus norvegicus	74-79
27400476-8	2016	A comparison between the IUGR plus puerarin intervention group and the IUGR group revealed differences in the levels of BALP and IGF-1 at 3 weeks of age (P = 0.008 and 0.003, respectively).	puerarin	35-43	insulin-like growth factor 1	Rattus norvegicus	129-134
26789107-0	2016	Puerarin Protects Pancreatic beta-Cells in Obese Diabetic Mice via Activation of GLP-1R Signaling.	puerarin	0-8	glucagon-like peptide 1 receptor	Mus musculus	81-87
26789107-4	2016	In this study, puerarin, a diet isoflavone, was evaluated its beneficial effects on beta-cell survival and GLP-1R pathway.	puerarin	15-23	glucagon-like peptide 1 receptor	Mus musculus	107-113
26789107-9	2016	However, puerarin enhanced GLP-1R signaling by up-regulating expressions of GLP-1R and pancreatic and duodenal homeobox 1, which subsequently led to protein kinase B (Akt) activation but forkhead box O1 inactivation, and promoted beta-cell survival.	puerarin	9-17	glucagon-like peptide 1 receptor	Mus musculus	27-33
26789107-9	2016	However, puerarin enhanced GLP-1R signaling by up-regulating expressions of GLP-1R and pancreatic and duodenal homeobox 1, which subsequently led to protein kinase B (Akt) activation but forkhead box O1 inactivation, and promoted beta-cell survival.	puerarin	9-17	glucagon-like peptide 1 receptor	Mus musculus	76-82
26789107-9	2016	However, puerarin enhanced GLP-1R signaling by up-regulating expressions of GLP-1R and pancreatic and duodenal homeobox 1, which subsequently led to protein kinase B (Akt) activation but forkhead box O1 inactivation, and promoted beta-cell survival.	puerarin	9-17	thymoma viral proto-oncogene 1	Mus musculus	167-170
26789107-10	2016	The protective effect of puerarin was remarkably suppressed by Exendin(9-39), an antagonist of GLP-1R.	puerarin	25-33	glucagon-like peptide 1 receptor	Mus musculus	95-101
26789107-11	2016	Our study demonstrated puerarin improved glucose homeostasis in obese diabetic mice and identified a novel role of puerarin in protecting beta-cell survival by mechanisms involving activation of GLP-1R signaling and downstream targets.	puerarin	115-123	glucagon-like peptide 1 receptor	Mus musculus	195-201
26686502-12	2016	Moreover, the pretreatment with Puerarin also significantly increased the Bcl-2 expression.	puerarin	32-40	BCL2, apoptosis regulator	Rattus norvegicus	74-79
27329882-0	2016	[The role of Wnt5b in the promotion of osteogenic differentiation by puerarin].	puerarin	69-77	Wnt family member 5B	Rattus norvegicus	13-18
27329882-6	2016	RESULTS: After induction with puerarin, the level of alkaline phosphatase activity, osteocalcin and Wnt5b increased.10(-5) mol/L group showed the best effect.	puerarin	30-38	bone gamma-carboxyglutamate protein	Rattus norvegicus	84-95
27329882-6	2016	RESULTS: After induction with puerarin, the level of alkaline phosphatase activity, osteocalcin and Wnt5b increased.10(-5) mol/L group showed the best effect.	puerarin	30-38	Wnt family member 5B	Rattus norvegicus	100-105
27011313-0	2016	Puerarin Attenuates Anoxia/Reoxygenation Injury Through Enhancing Bcl-2 Associated Athanogene 3 Expression, a Modulator of Apoptosis and Autophagy.	puerarin	0-8	BAG cochaperone 3	Rattus norvegicus	66-95
27011313-2	2016	This study explored the effect of puerarin on the expression of Bcl-2 associated athanogene 3 (BAG3) in an in vitro model of anoxia/reoxygenation injury (A/RI) in neonate rat primary cardiomyocytes and the functions of BAG3 in A/RI.	puerarin	34-42	BAG cochaperone 3	Rattus norvegicus	64-93
27011313-2	2016	This study explored the effect of puerarin on the expression of Bcl-2 associated athanogene 3 (BAG3) in an in vitro model of anoxia/reoxygenation injury (A/RI) in neonate rat primary cardiomyocytes and the functions of BAG3 in A/RI.	puerarin	34-42	BAG cochaperone 3	Rattus norvegicus	95-99
27011313-3	2016	MATERIAL/METHODS: BAG3 expression in cardiomyocytes with or without puerarin pre-treatment was quantified using qRT-PCR and Western blot analysis.	puerarin	68-76	BAG cochaperone 3	Rattus norvegicus	18-22
27011313-6	2016	RESULTS: Puerarin significantly promoted BAG3 expression in the rat primary cardiomyocytes after A/RI.	puerarin	9-17	BAG cochaperone 3	Rattus norvegicus	41-45
27011313-10	2016	CONCLUSIONS: Puerarin can directly increase BAG3 transcription and translation in cardiomyocytes after A/RI.	puerarin	13-21	BAG cochaperone 3	Rattus norvegicus	44-48
27011313-11	2016	The elevated BAG3 expression presents protective effects on A/RI at least through enhancing autophagy and reducing apoptosis, which is a novel protective mechanism of puerarin in ARI.	puerarin	167-175	BAG cochaperone 3	Rattus norvegicus	13-17
26795076-7	2016	Previous studies have shown that Angelicae dahuricae essential oil (ADO) enhanced puerarin internalization into ABCB1-overexpressed Caco-2 cells.	puerarin	82-90	ATP binding cassette subfamily B member 1	Homo sapiens	112-117
28884552-9	2016	Therefore, puerarin concentration in plasma has correlation with the anti-myocardial ischemia effect of FFLMN, which could increase SOD level and inhibit the release of IL-6.	puerarin	11-19	interleukin 6	Rattus norvegicus	169-173
26946623-0	2016	Puerarin reduces apoptosis in rat hippocampal neurons culturea in high glucose medium by modulating the p38 mitogen activated protein kinase and c-Jun N-terminal kinase signaling pathways.	puerarin	0-8	mitogen activated protein kinase 14	Rattus norvegicus	104-140
26893624-8	2016	Following treatment with various concentrations of puerarin, the expression levels of IL-1beta and TNF-alpha were markedly blunted, particularly in the LPS + 40 microM puerarin group (P<0.05 vs. the LPS group).	puerarin	51-59	interleukin 1 beta	Homo sapiens	86-94
26893624-8	2016	Following treatment with various concentrations of puerarin, the expression levels of IL-1beta and TNF-alpha were markedly blunted, particularly in the LPS + 40 microM puerarin group (P<0.05 vs. the LPS group).	puerarin	51-59	tumor necrosis factor	Homo sapiens	99-108
26893624-8	2016	Following treatment with various concentrations of puerarin, the expression levels of IL-1beta and TNF-alpha were markedly blunted, particularly in the LPS + 40 microM puerarin group (P<0.05 vs. the LPS group).	puerarin	168-176	interleukin 1 beta	Homo sapiens	86-94
26893624-8	2016	Following treatment with various concentrations of puerarin, the expression levels of IL-1beta and TNF-alpha were markedly blunted, particularly in the LPS + 40 microM puerarin group (P<0.05 vs. the LPS group).	puerarin	168-176	tumor necrosis factor	Homo sapiens	99-108
26893624-10	2016	In addition, puerarin significantly decreased LPS-induced phosphorylated nuclear factor (p-NF)-kappaB p65 and Bax expression levels, and increased the expression levels of Bcl-2, as compared with the LPS group (P<0.05).	puerarin	13-21	RELA proto-oncogene, NF-kB subunit	Homo sapiens	102-105
26893624-10	2016	In addition, puerarin significantly decreased LPS-induced phosphorylated nuclear factor (p-NF)-kappaB p65 and Bax expression levels, and increased the expression levels of Bcl-2, as compared with the LPS group (P<0.05).	puerarin	13-21	BCL2 associated X, apoptosis regulator	Homo sapiens	110-113
26893624-10	2016	In addition, puerarin significantly decreased LPS-induced phosphorylated nuclear factor (p-NF)-kappaB p65 and Bax expression levels, and increased the expression levels of Bcl-2, as compared with the LPS group (P<0.05).	puerarin	13-21	BCL2 apoptosis regulator	Homo sapiens	172-177
26946623-9	2016	Moreover, protein levels of p-p38 and p-JNK were significantly reduced, and the p-p38/p38 and p-JNK/JNK ratios were decreased in the puerarin group compared with the high-glucose group.	puerarin	133-141	mitogen-activated protein kinase 8	Rattus norvegicus	94-103
26946623-11	2016	CONCLUSION: Puerarin attenuates neuronal apoptosis induced by high glucose by reducing the phosphorylation of p38 and JNK.	puerarin	12-20	mitogen activated protein kinase 14	Rattus norvegicus	110-113
26946623-11	2016	CONCLUSION: Puerarin attenuates neuronal apoptosis induced by high glucose by reducing the phosphorylation of p38 and JNK.	puerarin	12-20	mitogen-activated protein kinase 8	Rattus norvegicus	118-121
26985919-0	2016	Effect of puerarin on the expression of NMU, NPY, and POMC genes in the hypothalamus.	puerarin	10-18	neuromedin U	Homo sapiens	40-43
26985919-0	2016	Effect of puerarin on the expression of NMU, NPY, and POMC genes in the hypothalamus.	puerarin	10-18	neuropeptide Y	Homo sapiens	45-48
26985919-0	2016	Effect of puerarin on the expression of NMU, NPY, and POMC genes in the hypothalamus.	puerarin	10-18	proopiomelanocortin	Homo sapiens	54-58
26985919-3	2016	We investigated the effect of puerarin on the expression of NMU, NPY, and POMC genes in the hypothalamus.	puerarin	30-38	neuromedin U	Homo sapiens	60-63
26985919-3	2016	We investigated the effect of puerarin on the expression of NMU, NPY, and POMC genes in the hypothalamus.	puerarin	30-38	neuropeptide Y	Homo sapiens	65-68
26985919-3	2016	We investigated the effect of puerarin on the expression of NMU, NPY, and POMC genes in the hypothalamus.	puerarin	30-38	proopiomelanocortin	Homo sapiens	74-78
26946623-0	2016	Puerarin reduces apoptosis in rat hippocampal neurons culturea in high glucose medium by modulating the p38 mitogen activated protein kinase and c-Jun N-terminal kinase signaling pathways.	puerarin	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	145-168
26946623-9	2016	Moreover, protein levels of p-p38 and p-JNK were significantly reduced, and the p-p38/p38 and p-JNK/JNK ratios were decreased in the puerarin group compared with the high-glucose group.	puerarin	133-141	mitogen activated protein kinase 14	Rattus norvegicus	30-33
26946623-9	2016	Moreover, protein levels of p-p38 and p-JNK were significantly reduced, and the p-p38/p38 and p-JNK/JNK ratios were decreased in the puerarin group compared with the high-glucose group.	puerarin	133-141	mitogen-activated protein kinase 8	Rattus norvegicus	40-43
26946623-9	2016	Moreover, protein levels of p-p38 and p-JNK were significantly reduced, and the p-p38/p38 and p-JNK/JNK ratios were decreased in the puerarin group compared with the high-glucose group.	puerarin	133-141	mitogen activated protein kinase 14	Rattus norvegicus	82-85
26946623-9	2016	Moreover, protein levels of p-p38 and p-JNK were significantly reduced, and the p-p38/p38 and p-JNK/JNK ratios were decreased in the puerarin group compared with the high-glucose group.	puerarin	133-141	mitogen activated protein kinase 14	Rattus norvegicus	82-85
26758514-13	2016	In addition, PQ-induced activation of NF-kappaB, Nrf2 and alpha-SMA were enhanced by puerarin.	puerarin	85-93	actin alpha 2, smooth muscle, aorta	Mus musculus	58-67
27904045-0	2016	Puerarin Prevents LPS-Induced Osteoclast Formation and Bone Loss via Inhibition of Akt Activation.	puerarin	0-8	toll-like receptor 4	Mus musculus	18-21
26607348-0	2016	Puerarin protects mouse liver against nickel-induced oxidative stress and inflammation associated with the TLR4/p38/CREB pathway.	puerarin	0-8	toll-like receptor 4	Mus musculus	107-111
26607348-0	2016	Puerarin protects mouse liver against nickel-induced oxidative stress and inflammation associated with the TLR4/p38/CREB pathway.	puerarin	0-8	mitogen-activated protein kinase 14	Mus musculus	112-115
26607348-0	2016	Puerarin protects mouse liver against nickel-induced oxidative stress and inflammation associated with the TLR4/p38/CREB pathway.	puerarin	0-8	cAMP responsive element binding protein 1	Mus musculus	116-120
26607348-7	2016	Puerarin decreased the level of pro-inflammatory cytokines TNF-alpha and IL-6 in livers.	puerarin	0-8	tumor necrosis factor	Mus musculus	59-68
26607348-7	2016	Puerarin decreased the level of pro-inflammatory cytokines TNF-alpha and IL-6 in livers.	puerarin	0-8	interleukin 6	Mus musculus	73-77
26607348-8	2016	Puerarin significantly inhibited the TLR4 activation and p38 MAPK phosphorylation, which in turn inhibited NF-kappaB activity.	puerarin	0-8	toll-like receptor 4	Mus musculus	37-41
26607348-8	2016	Puerarin significantly inhibited the TLR4 activation and p38 MAPK phosphorylation, which in turn inhibited NF-kappaB activity.	puerarin	0-8	mitogen-activated protein kinase 14	Mus musculus	57-60
26607348-9	2016	Likewise, Ni-induced inflammatory responses were diminished by puerarin as observed by a remarkable reduction in the levels of phosphorylated CREB.	puerarin	63-71	cAMP responsive element binding protein 1	Mus musculus	142-146
26607348-10	2016	Furthermore, puerarin also reduced inflammatory mediators such as cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) levels in livers.	puerarin	13-21	prostaglandin-endoperoxide synthase 2	Mus musculus	66-82
26607348-10	2016	Furthermore, puerarin also reduced inflammatory mediators such as cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) levels in livers.	puerarin	13-21	prostaglandin-endoperoxide synthase 2	Mus musculus	84-89
26607348-11	2016	Data from this study suggested that the inhibition of Ni-induced oxidative stress and inflammatory responses by puerarin is due to its ability to modulate the TLR4/p38/CREB signaling pathway.	puerarin	112-120	toll-like receptor 4	Mus musculus	159-163
26607348-11	2016	Data from this study suggested that the inhibition of Ni-induced oxidative stress and inflammatory responses by puerarin is due to its ability to modulate the TLR4/p38/CREB signaling pathway.	puerarin	112-120	mitogen-activated protein kinase 14	Mus musculus	164-167
26607348-11	2016	Data from this study suggested that the inhibition of Ni-induced oxidative stress and inflammatory responses by puerarin is due to its ability to modulate the TLR4/p38/CREB signaling pathway.	puerarin	112-120	cAMP responsive element binding protein 1	Mus musculus	168-172
27251500-3	2016	Kaempferol, kaempferol 7-O-alpha-L-rhamnopyranoside, puerarin and ferulic acid showed strong inhibition of nicotine-induced vascular cell adhesion molecule (VCAM-1) expression while kaempferol, kaempferin, and caffeic acid attenuated intercellular adhesion molecule (ICAM-1) expression.	puerarin	53-61	vascular cell adhesion molecule 1	Homo sapiens	157-163
27251500-3	2016	Kaempferol, kaempferol 7-O-alpha-L-rhamnopyranoside, puerarin and ferulic acid showed strong inhibition of nicotine-induced vascular cell adhesion molecule (VCAM-1) expression while kaempferol, kaempferin, and caffeic acid attenuated intercellular adhesion molecule (ICAM-1) expression.	puerarin	53-61	intercellular adhesion molecule 1	Homo sapiens	267-273
27904045-0	2016	Puerarin Prevents LPS-Induced Osteoclast Formation and Bone Loss via Inhibition of Akt Activation.	puerarin	0-8	thymoma viral proto-oncogene 1	Mus musculus	83-86
27904045-3	2016	In this study, we assessed the effect of puerarin, a natural isoflavone isolated from Pueraria lobata OHWI root, on LPS-induced osteoclastogenesis and bone loss.	puerarin	41-49	toll-like receptor 4	Mus musculus	116-119
27904045-4	2016	Our in vitro study showed that puerarin significantly inhibited LPS-induced osteoclast differentiation from osteoclast precursor RAW264.7 cells.	puerarin	31-39	toll-like receptor 4	Mus musculus	64-67
27904045-6	2016	Furthermore, LPS triggered activation of Akt in osteoclast precursor RAW264.7 cells, which was inhibited by puerarin treatment.	puerarin	108-116	toll-like receptor 4	Mus musculus	13-16
27904045-6	2016	Furthermore, LPS triggered activation of Akt in osteoclast precursor RAW264.7 cells, which was inhibited by puerarin treatment.	puerarin	108-116	thymoma viral proto-oncogene 1	Mus musculus	41-44
27904045-7	2016	In vivo, puerarin attenuated LPS-induced bone loss in a murine calvarial osteolysis model.	puerarin	9-17	toll-like receptor 4	Mus musculus	29-32
27904045-8	2016	Collectively, puerarin prevents LPS-induced osteoclast formation, function and bone loss, where the inhibition of Akt activation plays an important role.	puerarin	14-22	toll-like receptor 4	Mus musculus	32-35
27904045-8	2016	Collectively, puerarin prevents LPS-induced osteoclast formation, function and bone loss, where the inhibition of Akt activation plays an important role.	puerarin	14-22	thymoma viral proto-oncogene 1	Mus musculus	114-117
26881260-8	2016	In addition, puerarin improved the pathological alterations and inhibited the expression of ICAM-1, LOX-1, NOX2, and NOX4 at both mRNA and protein levels.	puerarin	13-21	intercellular adhesion molecule 1	Rattus norvegicus	92-98
27008508-10	2016	Further assays showed that puerarin up-regulated the transcription of Cyclin A2, Cyclin B1 and Cdk1 in ES-CMs.	puerarin	27-35	cyclin A2	Mus musculus	70-79
27008508-10	2016	Further assays showed that puerarin up-regulated the transcription of Cyclin A2, Cyclin B1 and Cdk1 in ES-CMs.	puerarin	27-35	cyclin B1	Mus musculus	81-90
27008508-10	2016	Further assays showed that puerarin up-regulated the transcription of Cyclin A2, Cyclin B1 and Cdk1 in ES-CMs.	puerarin	27-35	cyclin-dependent kinase 1	Mus musculus	95-99
27008508-11	2016	The ERK1/2 specific inhibitor PD0325901 and the PI3K specific inhibitor Wortmannin successfully reversed puerarin-induced up-regulation of Cdk1 but not Cyclin A2 and B1.	puerarin	105-113	mitogen-activated protein kinase 3	Mus musculus	4-10
27008508-11	2016	The ERK1/2 specific inhibitor PD0325901 and the PI3K specific inhibitor Wortmannin successfully reversed puerarin-induced up-regulation of Cdk1 but not Cyclin A2 and B1.	puerarin	105-113	cyclin-dependent kinase 1	Mus musculus	139-143
27008508-11	2016	The ERK1/2 specific inhibitor PD0325901 and the PI3K specific inhibitor Wortmannin successfully reversed puerarin-induced up-regulation of Cdk1 but not Cyclin A2 and B1.	puerarin	105-113	cyclin A2	Mus musculus	152-161
26889237-4	2016	The present study demonstrated that serum levels of total cholesterol, alanine transaminase and low-density lipoproteins were significantly decreased in the puerarin-dominated groups (P<0.05 vs. the model group), whereas the concentrations of tumor necrosis factor-alpha and interleukin-6 were significantly improved in the baicalin- and berberine-dominated groups (P<0.05 vs. the model group).	puerarin	157-165	tumor necrosis factor	Rattus norvegicus	246-273
26889237-4	2016	The present study demonstrated that serum levels of total cholesterol, alanine transaminase and low-density lipoproteins were significantly decreased in the puerarin-dominated groups (P<0.05 vs. the model group), whereas the concentrations of tumor necrosis factor-alpha and interleukin-6 were significantly improved in the baicalin- and berberine-dominated groups (P<0.05 vs. the model group).	puerarin	157-165	interleukin 6	Rattus norvegicus	278-291
26889237-6	2016	In conclusion, a combination of puerarin, baicalin and berberine induced favorable effects on NAFLD by upregulating hepatic PPAR-gamma and IR expression levels, and different proportions of monomer compositions exerted variable positive effects on various stages of NAFLD.	puerarin	32-40	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	124-134
26889237-6	2016	In conclusion, a combination of puerarin, baicalin and berberine induced favorable effects on NAFLD by upregulating hepatic PPAR-gamma and IR expression levels, and different proportions of monomer compositions exerted variable positive effects on various stages of NAFLD.	puerarin	32-40	insulin receptor	Rattus norvegicus	139-141
26890737-3	2016	In the present study, we found that treatment of D-galactose rats with Puerarin could significantly improve behavioral performance and ameliorate the enhanced neurogenesis and microtubule-associated protein tau hyperphosphorylation in the hippocampus of D-galactose rat brains.	puerarin	71-79	microtubule-associated protein tau	Rattus norvegicus	176-210
26890737-4	2016	FGF-2/GSK-3 signaling pathway might be involved in the effects of Puerarin on hippocampal neurogenesis and tau hyperphosphorylation.	puerarin	66-74	fibroblast growth factor 2	Rattus norvegicus	0-5
26881260-8	2016	In addition, puerarin improved the pathological alterations and inhibited the expression of ICAM-1, LOX-1, NOX2, and NOX4 at both mRNA and protein levels.	puerarin	13-21	oxidized low density lipoprotein receptor 1	Rattus norvegicus	100-105
26881260-8	2016	In addition, puerarin improved the pathological alterations and inhibited the expression of ICAM-1, LOX-1, NOX2, and NOX4 at both mRNA and protein levels.	puerarin	13-21	cytochrome b-245 beta chain	Rattus norvegicus	107-111
26881260-8	2016	In addition, puerarin improved the pathological alterations and inhibited the expression of ICAM-1, LOX-1, NOX2, and NOX4 at both mRNA and protein levels.	puerarin	13-21	NADPH oxidase 4	Rattus norvegicus	117-121
26881260-9	2016	Puerarin also significantly reduced the number of cells showing positive staining for ICAM-1, NOX2, NOX4, and NF-kappaB p65.	puerarin	0-8	intercellular adhesion molecule 1	Rattus norvegicus	86-92
26881260-9	2016	Puerarin also significantly reduced the number of cells showing positive staining for ICAM-1, NOX2, NOX4, and NF-kappaB p65.	puerarin	0-8	cytochrome b-245 beta chain	Rattus norvegicus	94-98
26881260-9	2016	Puerarin also significantly reduced the number of cells showing positive staining for ICAM-1, NOX2, NOX4, and NF-kappaB p65.	puerarin	0-8	NADPH oxidase 4	Rattus norvegicus	100-104
26881260-9	2016	Puerarin also significantly reduced the number of cells showing positive staining for ICAM-1, NOX2, NOX4, and NF-kappaB p65.	puerarin	0-8	synaptotagmin 1	Rattus norvegicus	120-123
28202848-9	2016	In subsequent macrophage activation assays using Tumor necrosis factor (TNFalpha) and CaPO4 crystals in vitro, puerarin decreased Mmp9 mRNA expression and secreted protein levels.	puerarin	111-119	tumor necrosis factor	Mus musculus	72-80
28202848-9	2016	In subsequent macrophage activation assays using Tumor necrosis factor (TNFalpha) and CaPO4 crystals in vitro, puerarin decreased Mmp9 mRNA expression and secreted protein levels.	puerarin	111-119	matrix metallopeptidase 9	Mus musculus	130-134
28202848-10	2016	Moreover, induction of IkappaB, ERK, and p38 phosphorylation by TNFalpha and CaPO4 in macrophages was suppressed by puerarin treatments.	puerarin	116-124	mitogen-activated protein kinase 1	Mus musculus	32-35
28202848-10	2016	Moreover, induction of IkappaB, ERK, and p38 phosphorylation by TNFalpha and CaPO4 in macrophages was suppressed by puerarin treatments.	puerarin	116-124	mitogen-activated protein kinase 14	Mus musculus	41-44
28202848-10	2016	Moreover, induction of IkappaB, ERK, and p38 phosphorylation by TNFalpha and CaPO4 in macrophages was suppressed by puerarin treatments.	puerarin	116-124	tumor necrosis factor	Mus musculus	64-72
28202848-11	2016	Finally, puerarin attenuated reactive oxygen species production, following induction by TNFalpha and CaPO4.	puerarin	9-17	tumor necrosis factor	Mus musculus	88-96
28202848-12	2016	Taken together, the present data demonstrate that puerarin suppresses macrophage activation by inhibiting IkappaB, ERK, and p38 activity and reactive oxygen species production in a CaPO4-induced mouse model of aneurysm.	puerarin	50-58	mitogen-activated protein kinase 1	Mus musculus	115-118
28202848-12	2016	Taken together, the present data demonstrate that puerarin suppresses macrophage activation by inhibiting IkappaB, ERK, and p38 activity and reactive oxygen species production in a CaPO4-induced mouse model of aneurysm.	puerarin	50-58	mitogen-activated protein kinase 14	Mus musculus	124-127
26514700-10	2015	RESULTS: After the 30% TBSA full-thickness burn injury, serum CK-MB activities and cTnT levels increased markedly, both of which were significantly decreased by the puerarin treatment.	puerarin	165-173	troponin T2, cardiac type	Rattus norvegicus	83-87
26514700-13	2015	Administration of puerarin improved the ultrastructural changes in cardiomyocytes, decreased TNF-alpha concentration in serum as well as suppressed cardiac MPO activity and reduced MDA content, and abolished the activation of p38 MAP kinase in heart tissue after severe burn.	puerarin	18-26	mitogen activated protein kinase 14	Rattus norvegicus	226-229
26514700-13	2015	Administration of puerarin improved the ultrastructural changes in cardiomyocytes, decreased TNF-alpha concentration in serum as well as suppressed cardiac MPO activity and reduced MDA content, and abolished the activation of p38 MAP kinase in heart tissue after severe burn.	puerarin	18-26	tumor necrosis factor	Rattus norvegicus	93-102
26514700-13	2015	Administration of puerarin improved the ultrastructural changes in cardiomyocytes, decreased TNF-alpha concentration in serum as well as suppressed cardiac MPO activity and reduced MDA content, and abolished the activation of p38 MAP kinase in heart tissue after severe burn.	puerarin	18-26	myeloperoxidase	Rattus norvegicus	156-159
26885006-0	2015	Puerarin accelerate scardiac angiogenesis and improves cardiac function of myocardial infarction by upregulating VEGFA, Ang-1 and Ang-2 in rats.	puerarin	0-8	vascular endothelial growth factor A	Rattus norvegicus	113-118
25645818-12	2015	Puerarin (200 mg/kg) also reduced the ratio of receptor activator of nuclear factor kappa B ligand/osteoprotegerin and osteoclast activity.	puerarin	0-8	TNF superfamily member 11	Rattus norvegicus	47-98
25645818-12	2015	Puerarin (200 mg/kg) also reduced the ratio of receptor activator of nuclear factor kappa B ligand/osteoprotegerin and osteoclast activity.	puerarin	0-8	TNF receptor superfamily member 11B	Rattus norvegicus	99-114
25645818-13	2015	Western blot analysis showed that puerarin (200 mg/kg) inhibited the activation of nuclear factor-kappa B p65, which is associated with lower IL-1beta and TNF-alpha production, and reduced the glycosylation of extracellular matrix metalloproteinase inducer, which is associated with lower levels of MMP-2 and MMP-9.	puerarin	34-42	interleukin 1 beta	Rattus norvegicus	142-150
25645818-13	2015	Western blot analysis showed that puerarin (200 mg/kg) inhibited the activation of nuclear factor-kappa B p65, which is associated with lower IL-1beta and TNF-alpha production, and reduced the glycosylation of extracellular matrix metalloproteinase inducer, which is associated with lower levels of MMP-2 and MMP-9.	puerarin	34-42	tumor necrosis factor	Rattus norvegicus	155-164
25645818-13	2015	Western blot analysis showed that puerarin (200 mg/kg) inhibited the activation of nuclear factor-kappa B p65, which is associated with lower IL-1beta and TNF-alpha production, and reduced the glycosylation of extracellular matrix metalloproteinase inducer, which is associated with lower levels of MMP-2 and MMP-9.	puerarin	34-42	matrix metallopeptidase 2	Rattus norvegicus	299-304
25645818-13	2015	Western blot analysis showed that puerarin (200 mg/kg) inhibited the activation of nuclear factor-kappa B p65, which is associated with lower IL-1beta and TNF-alpha production, and reduced the glycosylation of extracellular matrix metalloproteinase inducer, which is associated with lower levels of MMP-2 and MMP-9.	puerarin	34-42	matrix metallopeptidase 9	Rattus norvegicus	309-314
25645818-14	2015	CONCLUSIONS: Puerarin reduced the alveolar bone loss and collagen destruction in rats with ligature-induced periodontitis by inhibiting the production of RANKL, IL-1beta, TNF-alpha, MMP-2 and MMP-9.	puerarin	13-21	TNF superfamily member 11	Rattus norvegicus	154-159
25645818-14	2015	CONCLUSIONS: Puerarin reduced the alveolar bone loss and collagen destruction in rats with ligature-induced periodontitis by inhibiting the production of RANKL, IL-1beta, TNF-alpha, MMP-2 and MMP-9.	puerarin	13-21	interleukin 1 beta	Rattus norvegicus	161-169
25645818-14	2015	CONCLUSIONS: Puerarin reduced the alveolar bone loss and collagen destruction in rats with ligature-induced periodontitis by inhibiting the production of RANKL, IL-1beta, TNF-alpha, MMP-2 and MMP-9.	puerarin	13-21	tumor necrosis factor	Rattus norvegicus	171-180
25645818-14	2015	CONCLUSIONS: Puerarin reduced the alveolar bone loss and collagen destruction in rats with ligature-induced periodontitis by inhibiting the production of RANKL, IL-1beta, TNF-alpha, MMP-2 and MMP-9.	puerarin	13-21	matrix metallopeptidase 2	Rattus norvegicus	182-187
25645818-14	2015	CONCLUSIONS: Puerarin reduced the alveolar bone loss and collagen destruction in rats with ligature-induced periodontitis by inhibiting the production of RANKL, IL-1beta, TNF-alpha, MMP-2 and MMP-9.	puerarin	13-21	matrix metallopeptidase 9	Rattus norvegicus	192-197
27576607-10	2016	In addition, the downregulated PI3K and phospho-Akt protein expression were restored by puerarin.	puerarin	88-96	AKT serine/threonine kinase 1	Rattus norvegicus	48-51
26885006-0	2015	Puerarin accelerate scardiac angiogenesis and improves cardiac function of myocardial infarction by upregulating VEGFA, Ang-1 and Ang-2 in rats.	puerarin	0-8	angiopoietin 1	Rattus norvegicus	120-125
26885006-0	2015	Puerarin accelerate scardiac angiogenesis and improves cardiac function of myocardial infarction by upregulating VEGFA, Ang-1 and Ang-2 in rats.	puerarin	0-8	angiogenin, ribonuclease A family, member 2	Rattus norvegicus	130-135
26885006-8	2015	Impaired angiogenesis and cardiac function were remarkably improved in puerarin treatment rats with great increase of VEGFA, Ang-1 and Ang-2.	puerarin	71-79	vascular endothelial growth factor A	Rattus norvegicus	118-123
26885006-8	2015	Impaired angiogenesis and cardiac function were remarkably improved in puerarin treatment rats with great increase of VEGFA, Ang-1 and Ang-2.	puerarin	71-79	angiopoietin 1	Rattus norvegicus	125-130
26885006-8	2015	Impaired angiogenesis and cardiac function were remarkably improved in puerarin treatment rats with great increase of VEGFA, Ang-1 and Ang-2.	puerarin	71-79	angiogenin, ribonuclease A family, member 2	Rattus norvegicus	135-140
26885006-9	2015	CONCLUSION: The above results demonstrated that puerarin could accelerate cardiac angiogenesis and improve cardiac function of myocardial infarction rats by upregulating VEGFA, Ang-1 and Ang-2.	puerarin	48-56	vascular endothelial growth factor A	Rattus norvegicus	170-175
26885006-9	2015	CONCLUSION: The above results demonstrated that puerarin could accelerate cardiac angiogenesis and improve cardiac function of myocardial infarction rats by upregulating VEGFA, Ang-1 and Ang-2.	puerarin	48-56	angiopoietin 1	Rattus norvegicus	177-182
26885006-9	2015	CONCLUSION: The above results demonstrated that puerarin could accelerate cardiac angiogenesis and improve cardiac function of myocardial infarction rats by upregulating VEGFA, Ang-1 and Ang-2.	puerarin	48-56	angiogenin, ribonuclease A family, member 2	Rattus norvegicus	187-192
26677708-7	2015	Both LY294002 and Pue can inhibit hypoxia-induced Bcl-2, up-regulation of P-AKT expression and down-regulation of Bax expression.	puerarin	18-21	BCL2, apoptosis regulator	Rattus norvegicus	50-55
26196403-12	2015	Immunofluorescence intensity measurements confirmed the expressions of the DLC2 and Dync1h1 subunits of dynein in RPE or puerarin treated hippocampal neurons were up-regulated when RPE or puerarin induced changes in neuronal cytoarchitecture.	puerarin	121-129	dynein light chain LC8-type 2	Rattus norvegicus	75-79
26196403-12	2015	Immunofluorescence intensity measurements confirmed the expressions of the DLC2 and Dync1h1 subunits of dynein in RPE or puerarin treated hippocampal neurons were up-regulated when RPE or puerarin induced changes in neuronal cytoarchitecture.	puerarin	121-129	dynein cytoplasmic 1 heavy chain 1	Rattus norvegicus	84-91
26196403-12	2015	Immunofluorescence intensity measurements confirmed the expressions of the DLC2 and Dync1h1 subunits of dynein in RPE or puerarin treated hippocampal neurons were up-regulated when RPE or puerarin induced changes in neuronal cytoarchitecture.	puerarin	188-196	dynein light chain LC8-type 2	Rattus norvegicus	75-79
26196403-12	2015	Immunofluorescence intensity measurements confirmed the expressions of the DLC2 and Dync1h1 subunits of dynein in RPE or puerarin treated hippocampal neurons were up-regulated when RPE or puerarin induced changes in neuronal cytoarchitecture.	puerarin	188-196	dynein cytoplasmic 1 heavy chain 1	Rattus norvegicus	84-91
26218281-7	2015	RESULTS: Puerarin showed significant therapeutic effects against neutrophil infiltration and tissue injury, as evidenced by histopathological findings and MPO activity.	puerarin	9-17	myeloperoxidase	Rattus norvegicus	155-158
26188094-7	2015	Further in vivo study demonstrated that puerarin significantly enabled phosphorylation of 5"-AMPK to be activated, subsequently inhibiting expression of the mammalian target of rapamycin (mTOR) target proteins S6 ribosomal protein and 4E-binding protein 1.	puerarin	40-48	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	93-97
26188094-7	2015	Further in vivo study demonstrated that puerarin significantly enabled phosphorylation of 5"-AMPK to be activated, subsequently inhibiting expression of the mammalian target of rapamycin (mTOR) target proteins S6 ribosomal protein and 4E-binding protein 1.	puerarin	40-48	mechanistic target of rapamycin kinase	Homo sapiens	157-186
26188094-7	2015	Further in vivo study demonstrated that puerarin significantly enabled phosphorylation of 5"-AMPK to be activated, subsequently inhibiting expression of the mammalian target of rapamycin (mTOR) target proteins S6 ribosomal protein and 4E-binding protein 1.	puerarin	40-48	mechanistic target of rapamycin kinase	Homo sapiens	188-192
26188094-8	2015	All these data indicate that puerarin exerts protective effects against cardiomyocyte hypertrophy and apoptosis, partly by restoration of autophagy through AMPK/mTOR-mediated signaling.	puerarin	29-37	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	156-160
26188094-8	2015	All these data indicate that puerarin exerts protective effects against cardiomyocyte hypertrophy and apoptosis, partly by restoration of autophagy through AMPK/mTOR-mediated signaling.	puerarin	29-37	mechanistic target of rapamycin kinase	Rattus norvegicus	161-165
26079885-10	2015	Western blot analysis showed that PUE enhanced phosphorylation of Akt and decreased PPAR alpha.	puerarin	34-37	thymoma viral proto-oncogene 1	Mus musculus	66-69
26079885-10	2015	Western blot analysis showed that PUE enhanced phosphorylation of Akt and decreased PPAR alpha.	puerarin	34-37	peroxisome proliferator activated receptor alpha	Mus musculus	84-94
26101183-0	2015	Puerarin attenuates glucocorticoid-induced apoptosis of hFOB1.19 cells through the JNK- and Akt-mediated mitochondrial apoptotic pathways.	puerarin	0-8	mitogen-activated protein kinase 8	Homo sapiens	83-86
26101183-0	2015	Puerarin attenuates glucocorticoid-induced apoptosis of hFOB1.19 cells through the JNK- and Akt-mediated mitochondrial apoptotic pathways.	puerarin	0-8	AKT serine/threonine kinase 1	Homo sapiens	92-95
26101183-4	2015	Puerarin attenuated the DEX-induced release of cytochrome c and cleavage of caspase-3, and treatment with puerarin inhibited the c-Jun N-terminal kinase (JNK) pathway and activated the phosphoinositide 3-kinase (PI3K)/Akt pathway in the hFOB1.19 cells.	puerarin	0-8	cytochrome c, somatic	Homo sapiens	47-59
26101183-4	2015	Puerarin attenuated the DEX-induced release of cytochrome c and cleavage of caspase-3, and treatment with puerarin inhibited the c-Jun N-terminal kinase (JNK) pathway and activated the phosphoinositide 3-kinase (PI3K)/Akt pathway in the hFOB1.19 cells.	puerarin	0-8	caspase 3	Homo sapiens	76-85
26101183-4	2015	Puerarin attenuated the DEX-induced release of cytochrome c and cleavage of caspase-3, and treatment with puerarin inhibited the c-Jun N-terminal kinase (JNK) pathway and activated the phosphoinositide 3-kinase (PI3K)/Akt pathway in the hFOB1.19 cells.	puerarin	0-8	AKT serine/threonine kinase 1	Homo sapiens	218-221
26101183-4	2015	Puerarin attenuated the DEX-induced release of cytochrome c and cleavage of caspase-3, and treatment with puerarin inhibited the c-Jun N-terminal kinase (JNK) pathway and activated the phosphoinositide 3-kinase (PI3K)/Akt pathway in the hFOB1.19 cells.	puerarin	106-114	mitogen-activated protein kinase 8	Homo sapiens	129-152
26101183-4	2015	Puerarin attenuated the DEX-induced release of cytochrome c and cleavage of caspase-3, and treatment with puerarin inhibited the c-Jun N-terminal kinase (JNK) pathway and activated the phosphoinositide 3-kinase (PI3K)/Akt pathway in the hFOB1.19 cells.	puerarin	106-114	mitogen-activated protein kinase 8	Homo sapiens	154-157
26101183-4	2015	Puerarin attenuated the DEX-induced release of cytochrome c and cleavage of caspase-3, and treatment with puerarin inhibited the c-Jun N-terminal kinase (JNK) pathway and activated the phosphoinositide 3-kinase (PI3K)/Akt pathway in the hFOB1.19 cells.	puerarin	106-114	AKT serine/threonine kinase 1	Homo sapiens	218-221
26101183-5	2015	Furthermore, the Akt inhibitor, LY294002, partly eliminated the protective effect of puerarin on DEX-induced apoptosis, and puerarin combined with the JNK inhibitor, SP600125, suppressed DEX-induced apoptosis to a lesser extent than in the cells treated with SP600125 alone.	puerarin	85-93	AKT serine/threonine kinase 1	Homo sapiens	17-20
26101183-6	2015	These results suggested that the JNK and PI3K/Akt signaling pathways mediate the inhibitory effects of puerarin on apoptosis in the hFOB1.19 cells.	puerarin	103-111	mitogen-activated protein kinase 8	Homo sapiens	33-36
26101183-6	2015	These results suggested that the JNK and PI3K/Akt signaling pathways mediate the inhibitory effects of puerarin on apoptosis in the hFOB1.19 cells.	puerarin	103-111	AKT serine/threonine kinase 1	Homo sapiens	46-49
26101183-7	2015	In conclusion, puerarin prevented DEX-induced apoptosis of hFOB1.19 cells via inhibition of the JNK pathway and activation of the PI3K/Akt signaling pathway in the cells, dependent on the mitochondrial apoptotic pathway.	puerarin	15-23	mitogen-activated protein kinase 8	Homo sapiens	96-99
26101183-7	2015	In conclusion, puerarin prevented DEX-induced apoptosis of hFOB1.19 cells via inhibition of the JNK pathway and activation of the PI3K/Akt signaling pathway in the cells, dependent on the mitochondrial apoptotic pathway.	puerarin	15-23	AKT serine/threonine kinase 1	Homo sapiens	135-138
27062829-0	2015	[Effects of combination of glycyrrhizin acid, ligustrazine and puerarin on LPS-induced cytokines expression in macrophage].	puerarin	63-71	toll-like receptor 4	Mus musculus	75-78
27062829-5	2015	The liquichip technique was used to detect the effect of different combined administration of glycyrrhizin acid, ligustrazine and puerarin on the 23 cytokines expressed in LPS-induced mouse macrophage RAW264.	puerarin	130-138	toll-like receptor 4	Mus musculus	172-175
24596333-8	2015	When genes related to cardiac development were assessed, the expression of Tbx1, Raldh2, and Bmp2b changed after exposure to the combination of TBBPA and puerarin.	puerarin	154-162	T-box transcription factor 1	Danio rerio	75-79
24596333-8	2015	When genes related to cardiac development were assessed, the expression of Tbx1, Raldh2, and Bmp2b changed after exposure to the combination of TBBPA and puerarin.	puerarin	154-162	aldehyde dehydrogenase 1 family, member A2	Danio rerio	81-87
24596333-8	2015	When genes related to cardiac development were assessed, the expression of Tbx1, Raldh2, and Bmp2b changed after exposure to the combination of TBBPA and puerarin.	puerarin	154-162	bone morphogenetic protein 2b	Danio rerio	93-98
24596333-10	2015	Therefore, puerarin regulates the expression of cardiac developmental genes, such as Tbx1, Bmp2b, and Raldh2 by inhibiting ROS production, and subsequently modulates cardiac development after the exposure of zebrafish larvae to TBBPA.	puerarin	11-19	T-box transcription factor 1	Danio rerio	85-89
24596333-10	2015	Therefore, puerarin regulates the expression of cardiac developmental genes, such as Tbx1, Bmp2b, and Raldh2 by inhibiting ROS production, and subsequently modulates cardiac development after the exposure of zebrafish larvae to TBBPA.	puerarin	11-19	bone morphogenetic protein 2b	Danio rerio	91-96
24596333-10	2015	Therefore, puerarin regulates the expression of cardiac developmental genes, such as Tbx1, Bmp2b, and Raldh2 by inhibiting ROS production, and subsequently modulates cardiac development after the exposure of zebrafish larvae to TBBPA.	puerarin	11-19	aldehyde dehydrogenase 1 family, member A2	Danio rerio	102-108
26677708-7	2015	Both LY294002 and Pue can inhibit hypoxia-induced Bcl-2, up-regulation of P-AKT expression and down-regulation of Bax expression.	puerarin	18-21	AKT serine/threonine kinase 1	Rattus norvegicus	76-79
26677708-7	2015	Both LY294002 and Pue can inhibit hypoxia-induced Bcl-2, up-regulation of P-AKT expression and down-regulation of Bax expression.	puerarin	18-21	BCL2 associated X, apoptosis regulator	Rattus norvegicus	114-117
26677708-8	2015	Compared with the hypoxia + Pue group or the hypoxia + LY294002 group, the hypoxia + Pue + LY294002 group showed more significantly changes in Bcl-2, Bax, P-AKT expressions.	puerarin	85-88	BCL2, apoptosis regulator	Rattus norvegicus	143-148
26677708-8	2015	Compared with the hypoxia + Pue group or the hypoxia + LY294002 group, the hypoxia + Pue + LY294002 group showed more significantly changes in Bcl-2, Bax, P-AKT expressions.	puerarin	85-88	BCL2 associated X, apoptosis regulator	Rattus norvegicus	150-153
26677708-8	2015	Compared with the hypoxia + Pue group or the hypoxia + LY294002 group, the hypoxia + Pue + LY294002 group showed more significantly changes in Bcl-2, Bax, P-AKT expressions.	puerarin	85-88	AKT serine/threonine kinase 1	Rattus norvegicus	157-160
26677708-9	2015	The results show that, Pue can inhibit the hypoxic-induced PASMC apoptosis, which may be regulated through PI3K/AKT pathway.	puerarin	23-26	AKT serine/threonine kinase 1	Rattus norvegicus	112-115
25199800-9	2015	The other Lactococcus sp., MRG-IF-3, could not hydrolyse the C-glycosidic linkage of puerarin, while it showed a broad substrate spectrum of O-glycosidase activity similar to the other two bacteria.	puerarin	85-93	MAS1 proto-oncogene like, G protein-coupled receptor	Homo sapiens	27-30
25892538-4	2015	Puerarin (2.5-100 microM) increased hBMSC growth in a dose-dependent manner, as indicated by an MTT assay, and stimulated osteoblastic maturation as indicated by assessment of alkaline phosphatase (ALP) activity, as well as calcium deposition into the extracellular matrix detected by alizarin red S staining.	puerarin	0-8	alkaline phosphatase, placental	Homo sapiens	176-196
25892538-4	2015	Puerarin (2.5-100 microM) increased hBMSC growth in a dose-dependent manner, as indicated by an MTT assay, and stimulated osteoblastic maturation as indicated by assessment of alkaline phosphatase (ALP) activity, as well as calcium deposition into the extracellular matrix detected by alizarin red S staining.	puerarin	0-8	alkaline phosphatase, placental	Homo sapiens	198-201
25892538-5	2015	Furthermore, polymerase chain reaction analysis showed that the expression of osteoblastic markers, including Runt-related transcription factor 2/core-binding factor alpha 1, osterix and osteocalcin, were increased in hBMSCs following incubation with puerarin.	puerarin	251-259	RUNX family transcription factor 2	Homo sapiens	110-145
25892538-5	2015	Furthermore, polymerase chain reaction analysis showed that the expression of osteoblastic markers, including Runt-related transcription factor 2/core-binding factor alpha 1, osterix and osteocalcin, were increased in hBMSCs following incubation with puerarin.	puerarin	251-259	Sp7 transcription factor	Homo sapiens	175-182
25892538-5	2015	Furthermore, polymerase chain reaction analysis showed that the expression of osteoblastic markers, including Runt-related transcription factor 2/core-binding factor alpha 1, osterix and osteocalcin, were increased in hBMSCs following incubation with puerarin.	puerarin	251-259	bone gamma-carboxyglutamate protein	Homo sapiens	187-198
26201474-0	2015	Effect of Puerarin on Expression of ICAM-1 and TNF-alpha in Kidneys of Diabetic Rats.	puerarin	10-18	intercellular adhesion molecule 1	Rattus norvegicus	36-42
26201474-0	2015	Effect of Puerarin on Expression of ICAM-1 and TNF-alpha in Kidneys of Diabetic Rats.	puerarin	10-18	tumor necrosis factor	Rattus norvegicus	47-56
26201474-10	2015	Puerarin at each dosage significantly eliminated elevations of ICAM-1 and TNF-alpha levels in model rats (p<0.05), and decreased apoptotic indexes of renal cortex cells (p<0.05).	puerarin	0-8	intercellular adhesion molecule 1	Rattus norvegicus	63-69
26201474-10	2015	Puerarin at each dosage significantly eliminated elevations of ICAM-1 and TNF-alpha levels in model rats (p<0.05), and decreased apoptotic indexes of renal cortex cells (p<0.05).	puerarin	0-8	tumor necrosis factor	Rattus norvegicus	74-83
26201474-11	2015	CONCLUSIONS: Early-stage renal damages can be significantly improved by puerarin, possibly via its suppression of ICAM-1 and TNF-alpha expression in diabetic rat kidneys.	puerarin	72-80	intercellular adhesion molecule 1	Rattus norvegicus	114-120
26201474-11	2015	CONCLUSIONS: Early-stage renal damages can be significantly improved by puerarin, possibly via its suppression of ICAM-1 and TNF-alpha expression in diabetic rat kidneys.	puerarin	72-80	tumor necrosis factor	Rattus norvegicus	125-134
26309712-10	2015	Moreover, puerarin treatment suppressed the expression of p-Akt and Bcl-2 and promoted the expression of Bax and cleaved caspase-3 in U251 cells.	puerarin	10-18	BCL2 apoptosis regulator	Homo sapiens	68-73
26309712-10	2015	Moreover, puerarin treatment suppressed the expression of p-Akt and Bcl-2 and promoted the expression of Bax and cleaved caspase-3 in U251 cells.	puerarin	10-18	BCL2 associated X, apoptosis regulator	Homo sapiens	105-108
26309712-10	2015	Moreover, puerarin treatment suppressed the expression of p-Akt and Bcl-2 and promoted the expression of Bax and cleaved caspase-3 in U251 cells.	puerarin	10-18	caspase 3	Homo sapiens	121-130
25817234-0	2015	Puerarin suppresses high glucose-induced MCP-1 expression via modulating histone methylation in cultured endothelial cells.	puerarin	0-8	C-C motif chemokine ligand 2	Homo sapiens	41-46
25831201-9	2015	In the model group, Glu and GABA levels decreased (P<0.05), and Glu/GABA, TNF-alpha, and IL-1beta increased (P<0.01) with puerarin treatment, returning to near normal levels.	puerarin	128-136	tumor necrosis factor	Mus musculus	77-86
25831201-9	2015	In the model group, Glu and GABA levels decreased (P<0.05), and Glu/GABA, TNF-alpha, and IL-1beta increased (P<0.01) with puerarin treatment, returning to near normal levels.	puerarin	128-136	interleukin 1 beta	Mus musculus	92-100
25817234-2	2015	The purpose of the present study was to investigate the epigenetic mechanism involved in the repression of monocyte chemoattractant protein-1 (MCP-1) expression by puerarin under high glucose (25mM) condition.	puerarin	164-172	C-C motif chemokine ligand 2	Homo sapiens	107-141
25817234-2	2015	The purpose of the present study was to investigate the epigenetic mechanism involved in the repression of monocyte chemoattractant protein-1 (MCP-1) expression by puerarin under high glucose (25mM) condition.	puerarin	164-172	C-C motif chemokine ligand 2	Homo sapiens	143-148
25817234-4	2015	KEY FINDINGS: Puerarin significantly inhibited high glucose-induced upregulation of H3K4 di- and tri-methylation (H3K4me2/3) on the MCP-1 gene promotor.	puerarin	14-22	C-C motif chemokine ligand 2	Homo sapiens	132-137
25817234-8	2015	SIGNIFICANCE: Our findings suggested that puerarin plays a critical role in transcriptional repression of high glucose-induced MCP-1 gene expression, at least in part due to alteration of H3K4me2/3 methylation, thus possesses a therapeutic potential in diabetes-induced vascular injuries.	puerarin	42-50	C-C motif chemokine ligand 2	Homo sapiens	127-132
25754765-5	2015	Results in lung tissues, either edaravone or puerarin treatment alone showed significant protective effects against neutrophil infiltration and tissue injury, as demonstrated by myeloperoxidase activity and histopathological analysis (all p<0.05).	puerarin	45-53	myeloperoxidase	Homo sapiens	178-193
25828059-6	2015	Puerarin, kudzu and its other phytoestrogenic components displayed preferential affinity for ERbeta, however the diverse effects of kudzu and puerarin on sperm function implicate the involvement of multiple signaling systems.	puerarin	0-8	estrogen receptor 2	Homo sapiens	93-99
26191159-17	2015	On the molecular level, Nrf2, FoxO1, FoxO3 and FoxO4 were up regulated by puerarin.	puerarin	74-82	NFE2 like bZIP transcription factor 2	Rattus norvegicus	24-28
26191159-17	2015	On the molecular level, Nrf2, FoxO1, FoxO3 and FoxO4 were up regulated by puerarin.	puerarin	74-82	forkhead box O1	Rattus norvegicus	30-35
26191159-17	2015	On the molecular level, Nrf2, FoxO1, FoxO3 and FoxO4 were up regulated by puerarin.	puerarin	74-82	forkhead box O3	Rattus norvegicus	37-42
26191159-17	2015	On the molecular level, Nrf2, FoxO1, FoxO3 and FoxO4 were up regulated by puerarin.	puerarin	74-82	forkhead box O4	Rattus norvegicus	47-52
25707518-0	2015	The Puerarin improves renal function in STZ-induced diabetic rats by attenuating eNOS expression.	puerarin	4-12	nitric oxide synthase 3	Rattus norvegicus	81-85
25707518-8	2015	It also attenuated eNOS expression in glomerular endothelial cells and tubular cells of diabetic rats with Puerarin treatment (p < 0.05).	puerarin	107-115	nitric oxide synthase 3	Rattus norvegicus	19-23
25707518-9	2015	The Puerarin had significant renal-protective effects for the diabetic nephropathy, possibly through regulating eNOS expression, and it may be used as a potential therapeutic reagent.	puerarin	4-12	nitric oxide synthase 3	Rattus norvegicus	112-116
25822741-7	2015	mRNA expression of peroxisome proliferator-activated receptor gamma 2 (PPARgamma 2) was down-regulated in liver of mice fed the 0.8% diet compared with HFD, while mRNA expression of CAT and HSL was considerably up-regulated by 0.4% and 0.8% puerarin diets.	puerarin	241-249	peroxisome proliferator activated receptor gamma	Mus musculus	19-69
28352705-8	2015	Expression levels of AKT, mTOR, P70S6K mRNAs, and phosphorylated proteins decreased significantly after action of puerarin at different concentrations.	puerarin	114-122	AKT serine/threonine kinase 1	Homo sapiens	21-24
28352705-8	2015	Expression levels of AKT, mTOR, P70S6K mRNAs, and phosphorylated proteins decreased significantly after action of puerarin at different concentrations.	puerarin	114-122	mechanistic target of rapamycin kinase	Homo sapiens	26-30
28352705-8	2015	Expression levels of AKT, mTOR, P70S6K mRNAs, and phosphorylated proteins decreased significantly after action of puerarin at different concentrations.	puerarin	114-122	ribosomal protein S6 kinase B1	Homo sapiens	32-38
28352705-9	2015	With increasing puerarin concentration, expression of cleaved-caspase-3 in JEG-3 cells increased, whereas that of Bcl-2 decreased.	puerarin	16-24	BCL2 apoptosis regulator	Homo sapiens	114-119
25822741-7	2015	mRNA expression of peroxisome proliferator-activated receptor gamma 2 (PPARgamma 2) was down-regulated in liver of mice fed the 0.8% diet compared with HFD, while mRNA expression of CAT and HSL was considerably up-regulated by 0.4% and 0.8% puerarin diets.	puerarin	241-249	peroxisome proliferator activated receptor gamma	Mus musculus	71-82
25822741-7	2015	mRNA expression of peroxisome proliferator-activated receptor gamma 2 (PPARgamma 2) was down-regulated in liver of mice fed the 0.8% diet compared with HFD, while mRNA expression of CAT and HSL was considerably up-regulated by 0.4% and 0.8% puerarin diets.	puerarin	241-249	catalase	Mus musculus	182-185
25822741-7	2015	mRNA expression of peroxisome proliferator-activated receptor gamma 2 (PPARgamma 2) was down-regulated in liver of mice fed the 0.8% diet compared with HFD, while mRNA expression of CAT and HSL was considerably up-regulated by 0.4% and 0.8% puerarin diets.	puerarin	241-249	lipase, hormone sensitive	Mus musculus	190-193
25822741-8	2015	The protein expression of PPARgamma2 in liver was decreased and those of p-AMPK, HSL and p-HSL were increased in mice fed 0.4% and 0.8% puerarin diets.	puerarin	136-144	peroxisome proliferator activated receptor gamma	Mus musculus	26-36
25822741-8	2015	The protein expression of PPARgamma2 in liver was decreased and those of p-AMPK, HSL and p-HSL were increased in mice fed 0.4% and 0.8% puerarin diets.	puerarin	136-144	lipase, hormone sensitive	Mus musculus	81-84
25822741-8	2015	The protein expression of PPARgamma2 in liver was decreased and those of p-AMPK, HSL and p-HSL were increased in mice fed 0.4% and 0.8% puerarin diets.	puerarin	136-144	lipase, hormone sensitive	Mus musculus	91-94
24510110-15	2015	CONCLUSIONS: Puerarin inhibits the formation and development of AS plaque and suppresses the migration and reproduction of vascular smooth muscle cells by decreasing PCNA and PDGF-A expressions in the rabbit.	puerarin	13-21	proliferating cell nuclear antigen	Oryctolagus cuniculus	166-170
24510110-15	2015	CONCLUSIONS: Puerarin inhibits the formation and development of AS plaque and suppresses the migration and reproduction of vascular smooth muscle cells by decreasing PCNA and PDGF-A expressions in the rabbit.	puerarin	13-21	platelet-derived growth factor subunit A	Oryctolagus cuniculus	175-181
25605057-0	2015	Puerarin ameliorates hepatic steatosis by activating the PPARalpha and AMPK signaling pathways in hepatocytes.	puerarin	0-8	peroxisome proliferator activated receptor alpha	Homo sapiens	57-66
25605057-9	2015	Furthermore, puerarin decreased the expression levels of lipogenic enzymes, such as FAS and SREBPs, and increased the expression levels of PPARalpha, which are critical regulators of hepatic lipid metabolism through the AMPK signaling pathway.	puerarin	13-21	fatty acid synthase	Homo sapiens	84-87
25605057-9	2015	Furthermore, puerarin decreased the expression levels of lipogenic enzymes, such as FAS and SREBPs, and increased the expression levels of PPARalpha, which are critical regulators of hepatic lipid metabolism through the AMPK signaling pathway.	puerarin	13-21	peroxisome proliferator activated receptor alpha	Homo sapiens	139-148
25605057-10	2015	These results indicate that puerarin has the same ability to activate AMPK, and reduce SREBP-1 and FAS expression, thus inhibiting hepatic lipogenesis and increasing hepatic antioxidant activity.	puerarin	28-36	sterol regulatory element binding transcription factor 1	Homo sapiens	87-94
25605057-10	2015	These results indicate that puerarin has the same ability to activate AMPK, and reduce SREBP-1 and FAS expression, thus inhibiting hepatic lipogenesis and increasing hepatic antioxidant activity.	puerarin	28-36	fatty acid synthase	Homo sapiens	99-102
25592416-0	2015	Puerarin alleviates noise-induced hearing loss via affecting PKCgamma and GABAB receptor expression.	puerarin	0-8	protein kinase C, gamma	Mus musculus	61-69
25592416-8	2015	Puerarin significantly attenuated the increased expression of PKCgamma but elevated the reduced expression of GABABR1 and GABABR2 after noise exposure.	puerarin	0-8	protein kinase C, gamma	Mus musculus	62-70
25592416-8	2015	Puerarin significantly attenuated the increased expression of PKCgamma but elevated the reduced expression of GABABR1 and GABABR2 after noise exposure.	puerarin	0-8	gamma-aminobutyric acid (GABA) B receptor, 1	Mus musculus	110-117
25592416-8	2015	Puerarin significantly attenuated the increased expression of PKCgamma but elevated the reduced expression of GABABR1 and GABABR2 after noise exposure.	puerarin	0-8	gamma-aminobutyric acid (GABA) B receptor, 2	Mus musculus	122-129
25592416-9	2015	Thus, we provided the first evidence that puerarin ameliorated the auditory functions of NIHL mice, and this effect may be due to its ability to regulate the expression of PKCgamma and GABABR.	puerarin	42-50	protein kinase C, gamma	Mus musculus	172-180
26576421-0	2015	Puerarin Inhibits oxLDL-Induced Macrophage Activation and Foam Cell Formation in Human THP1 Macrophage.	puerarin	0-8	GLI family zinc finger 2	Homo sapiens	87-91
25530546-0	2015	Puerarin attenuates airway inflammation by regulation of eotaxin-3.	puerarin	0-8	chemokine (C-C motif) ligand 26	Mus musculus	57-66
25530546-6	2015	Our study demonstrated that, compared with model group, puerarin inhibited OVA-induced increases in Raw and eosinophil count; interleukin (IL)-4, IL-5, IL-13 levels were recovered in bronchoalveolar lavage fluid compared; increased IFN-gamma level in bronchoalveolar lavage fluid; histological studies demonstrated that puerarin substantially inhibited OVA-induced eosinophilia in lung tissue compared with model group.	puerarin	56-64	interleukin 13	Mus musculus	152-157
25530546-6	2015	Our study demonstrated that, compared with model group, puerarin inhibited OVA-induced increases in Raw and eosinophil count; interleukin (IL)-4, IL-5, IL-13 levels were recovered in bronchoalveolar lavage fluid compared; increased IFN-gamma level in bronchoalveolar lavage fluid; histological studies demonstrated that puerarin substantially inhibited OVA-induced eosinophilia in lung tissue compared with model group.	puerarin	56-64	interferon gamma	Mus musculus	232-241
25530546-7	2015	Western blotting studies demonstrated that puerarin substantially inhibited eotaxin-3 compared with model group.	puerarin	43-51	chemokine (C-C motif) ligand 26	Mus musculus	76-85
26576421-3	2015	The present study investigated whether puerarin inhibited atherogenic lipid oxLDL-mediated macrophage activation and foam cell formation in human THP1 macrophage.	puerarin	39-47	GLI family zinc finger 2	Homo sapiens	146-150
26576421-5	2015	Puerarin dose-dependently prevented an increase in oxLDL-induced proinflammatory gene expression with downregulation of TLR4 and the ratio of phospho-IkappaBalpha/IkappaBalpha.	puerarin	0-8	toll like receptor 4	Homo sapiens	120-124
26576421-5	2015	Puerarin dose-dependently prevented an increase in oxLDL-induced proinflammatory gene expression with downregulation of TLR4 and the ratio of phospho-IkappaBalpha/IkappaBalpha.	puerarin	0-8	NFKB inhibitor alpha	Homo sapiens	150-162
26576421-5	2015	Puerarin dose-dependently prevented an increase in oxLDL-induced proinflammatory gene expression with downregulation of TLR4 and the ratio of phospho-IkappaBalpha/IkappaBalpha.	puerarin	0-8	NFKB inhibitor alpha	Homo sapiens	163-175
26576421-8	2015	Our results show that puerarin has anti-inflammatory and antiatherogenic effects in vitro; the underlying mechanisms may involve the inhibition of TLR4/NFkappaB pathway and downregulation of CD36 expression.	puerarin	22-30	toll like receptor 4	Homo sapiens	147-151
26330232-0	2015	Puerarin Suppresses the Self-Renewal of Murine Embryonic Stem Cells by Inhibition of REST-MiR-21 Regulatory Pathway.	puerarin	0-8	microRNA 21a	Mus musculus	90-96
25173778-7	2015	Expressions of PI3K and p-Akt were downregulated by puerarin.	puerarin	52-60	AKT serine/threonine kinase 1	Homo sapiens	26-29
26330232-12	2015	CONCLUSION: Inhibition of REST-miR-21 regulatory pathway may be the key mechanism of puerarin-induced suppression of mES cells self-renewal.	puerarin	85-93	microRNA 21a	Mus musculus	31-37
26677706-8	2015	Both Rotenone and Pue could inhibit the up-regulated expressions of HIF-1alpha, Cyclin A, PCNA caused by anoxia, with a synergistic effect.	puerarin	18-21	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	68-78
26677706-8	2015	Both Rotenone and Pue could inhibit the up-regulated expressions of HIF-1alpha, Cyclin A, PCNA caused by anoxia, with a synergistic effect.	puerarin	18-21	proliferating cell nuclear antigen	Rattus norvegicus	90-94
26330232-7	2015	Transfected mES cells with antagomir21 were used to confirm the role of miR-21 in the action of puerarin on cell self-renewal.	puerarin	96-104	microRNA 21a	Mus musculus	72-78
26330232-8	2015	RESULTS: Puerarin significantly decreased the percentage of the self-renewal colonies, and suppressed the transcripts of Oct4, Nanog, Sox2, c-Myc and REST.	puerarin	9-17	POU domain, class 5, transcription factor 1, related sequence 1	Mus musculus	121-125
26677708-0	2015	[Effect of puerarin on PI3K/AKT pathway-mediated apoptosis of PASMCs].	puerarin	11-19	AKT serine/threonine kinase 1	Rattus norvegicus	28-31
26330232-8	2015	RESULTS: Puerarin significantly decreased the percentage of the self-renewal colonies, and suppressed the transcripts of Oct4, Nanog, Sox2, c-Myc and REST.	puerarin	9-17	Nanog homeobox	Mus musculus	127-132
26330232-8	2015	RESULTS: Puerarin significantly decreased the percentage of the self-renewal colonies, and suppressed the transcripts of Oct4, Nanog, Sox2, c-Myc and REST.	puerarin	9-17	SRY (sex determining region Y)-box 2	Mus musculus	134-138
25310912-0	2015	Botanical drug puerarin coordinates with nerve growth factor in the regulation of neuronal survival and neuritogenesis via activating ERK1/2 and PI3K/Akt signaling pathways in the neurite extension process.	puerarin	15-23	nerve growth factor	Rattus norvegicus	41-60
26158288-0	2015	Puerarin Suppresses Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting NADPH Oxidase Activation and Oxidative Stress-Triggered AP-1 Signaling Pathways.	puerarin	0-8	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	20-34
26158288-0	2015	Puerarin Suppresses Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting NADPH Oxidase Activation and Oxidative Stress-Triggered AP-1 Signaling Pathways.	puerarin	0-8	jun proto-oncogene	Mus musculus	133-137
26158288-1	2015	PURPOSE: To examine the effects of puerarin (Pue) on angiotensin II (AngII)-induced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation and oxidative stress-related signaling pathways in the hypertrophic response of cardiomyocytes.	puerarin	35-43	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	53-67
26158288-1	2015	PURPOSE: To examine the effects of puerarin (Pue) on angiotensin II (AngII)-induced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation and oxidative stress-related signaling pathways in the hypertrophic response of cardiomyocytes.	puerarin	35-43	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	69-74
26158288-1	2015	PURPOSE: To examine the effects of puerarin (Pue) on angiotensin II (AngII)-induced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation and oxidative stress-related signaling pathways in the hypertrophic response of cardiomyocytes.	puerarin	45-48	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	53-67
26158288-1	2015	PURPOSE: To examine the effects of puerarin (Pue) on angiotensin II (AngII)-induced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation and oxidative stress-related signaling pathways in the hypertrophic response of cardiomyocytes.	puerarin	45-48	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	69-74
25593509-0	2014	The effect of puerarin against IL-1beta-mediated leukostasis and apoptosis in retinal capillary endothelial cells (TR-iBRB2).	puerarin	14-22	interleukin 1 beta	Rattus norvegicus	31-39
25593509-3	2014	This study extensively evaluated the protective effect of puerarin, a major active component extracted from the traditional herb Radix puerariae, against IL-1beta-induced cell dysfunction in TR-iBRB2 cells, a retinal capillary endothelial cell line.	puerarin	58-66	interleukin 1 beta	Rattus norvegicus	154-162
25593509-6	2014	RESULTS: Our data showed that puerarin attenuated IL-1beta-mediated leukostasis and cell apoptosis in TR-iBRB2 cells.	puerarin	30-38	interleukin 1 beta	Rattus norvegicus	50-58
25593509-7	2014	Furthermore, puerarin strikingly prevented IL-1beta-induced molecular events of the upstream and downstream signaling pathways involved in this cellular process.	puerarin	13-21	interleukin 1 beta	Rattus norvegicus	43-51
25301568-0	2015	The neuroprotective mechanism of puerarin in the treatment of acute spinal ischemia-reperfusion injury is linked to cyclin-dependent kinase 5.	puerarin	33-41	cyclin-dependent kinase 5	Rattus norvegicus	116-141
25301568-9	2015	Puerarin improved motor function associated with the decreased apoptosis number, spinal infarction volume, and Cdk5 and p25 activities.	puerarin	0-8	cyclin-dependent kinase 5	Rattus norvegicus	111-115
25301568-9	2015	Puerarin improved motor function associated with the decreased apoptosis number, spinal infarction volume, and Cdk5 and p25 activities.	puerarin	0-8	lipocalin 2	Rattus norvegicus	120-123
25301568-10	2015	The present study indicated that reduction of spinal injury was associated with inhibition of Cdk5 and p25, and that inhibition of Cdk5 and p25 was one of the neuroprotective mechanisms in the puerarin treatment of acute ischemia/reperfusion-induced spinal injury in rats.	puerarin	193-201	cyclin-dependent kinase 5	Rattus norvegicus	131-135
25301568-10	2015	The present study indicated that reduction of spinal injury was associated with inhibition of Cdk5 and p25, and that inhibition of Cdk5 and p25 was one of the neuroprotective mechanisms in the puerarin treatment of acute ischemia/reperfusion-induced spinal injury in rats.	puerarin	193-201	lipocalin 2	Rattus norvegicus	140-143
25310912-0	2015	Botanical drug puerarin coordinates with nerve growth factor in the regulation of neuronal survival and neuritogenesis via activating ERK1/2 and PI3K/Akt signaling pathways in the neurite extension process.	puerarin	15-23	mitogen activated protein kinase 3	Rattus norvegicus	134-140
25310912-0	2015	Botanical drug puerarin coordinates with nerve growth factor in the regulation of neuronal survival and neuritogenesis via activating ERK1/2 and PI3K/Akt signaling pathways in the neurite extension process.	puerarin	15-23	AKT serine/threonine kinase 1	Rattus norvegicus	150-153
25310912-2	2015	This study was designed to investigate whether botanical drug C-glucosylated isoflavone puerarin coordinates with NGF to regulate neuritogenesis via activating ERK1/2 and PI3K/Akt in neurite extension process.	puerarin	88-96	nerve growth factor	Rattus norvegicus	114-117
25310912-2	2015	This study was designed to investigate whether botanical drug C-glucosylated isoflavone puerarin coordinates with NGF to regulate neuritogenesis via activating ERK1/2 and PI3K/Akt in neurite extension process.	puerarin	88-96	mitogen activated protein kinase 3	Rattus norvegicus	160-166
25310912-2	2015	This study was designed to investigate whether botanical drug C-glucosylated isoflavone puerarin coordinates with NGF to regulate neuritogenesis via activating ERK1/2 and PI3K/Akt in neurite extension process.	puerarin	88-96	AKT serine/threonine kinase 1	Rattus norvegicus	176-179
25310912-4	2015	The effects of puerarin on ERK1/2, Akt, Nrf2, and HO-1 were assessed by Western blotting.	puerarin	15-23	mitogen activated protein kinase 3	Rattus norvegicus	27-33
25310912-4	2015	The effects of puerarin on ERK1/2, Akt, Nrf2, and HO-1 were assessed by Western blotting.	puerarin	15-23	heme oxygenase 1	Rattus norvegicus	50-54
25310912-7	2015	Puerarin potentiated the effect of NGF on neuritogenesis in PC12 cells by >10-fold.	puerarin	0-8	nerve growth factor	Rattus norvegicus	35-38
25310912-8	2015	Mechanistic studies revealed: (1) puerarin rapidly activated ERK1/2 and Akt, leading to the activation of Nrf2/heme oxygenase-1 (HO-1) pathways; (2) ERK1/2, PI3K/Akt, and HO-1 inhibitors attenuated the neuritogenic activity of puerarin.	puerarin	34-42	mitogen activated protein kinase 3	Rattus norvegicus	61-67
25310912-8	2015	Mechanistic studies revealed: (1) puerarin rapidly activated ERK1/2 and Akt, leading to the activation of Nrf2/heme oxygenase-1 (HO-1) pathways; (2) ERK1/2, PI3K/Akt, and HO-1 inhibitors attenuated the neuritogenic activity of puerarin.	puerarin	34-42	AKT serine/threonine kinase 1	Rattus norvegicus	72-75
25310912-8	2015	Mechanistic studies revealed: (1) puerarin rapidly activated ERK1/2 and Akt, leading to the activation of Nrf2/heme oxygenase-1 (HO-1) pathways; (2) ERK1/2, PI3K/Akt, and HO-1 inhibitors attenuated the neuritogenic activity of puerarin.	puerarin	34-42	heme oxygenase 1	Rattus norvegicus	106-127
25310912-8	2015	Mechanistic studies revealed: (1) puerarin rapidly activated ERK1/2 and Akt, leading to the activation of Nrf2/heme oxygenase-1 (HO-1) pathways; (2) ERK1/2, PI3K/Akt, and HO-1 inhibitors attenuated the neuritogenic activity of puerarin.	puerarin	34-42	heme oxygenase 1	Rattus norvegicus	129-133
25310912-8	2015	Mechanistic studies revealed: (1) puerarin rapidly activated ERK1/2 and Akt, leading to the activation of Nrf2/heme oxygenase-1 (HO-1) pathways; (2) ERK1/2, PI3K/Akt, and HO-1 inhibitors attenuated the neuritogenic activity of puerarin.	puerarin	34-42	AKT serine/threonine kinase 1	Rattus norvegicus	162-165
25310912-8	2015	Mechanistic studies revealed: (1) puerarin rapidly activated ERK1/2 and Akt, leading to the activation of Nrf2/heme oxygenase-1 (HO-1) pathways; (2) ERK1/2, PI3K/Akt, and HO-1 inhibitors attenuated the neuritogenic activity of puerarin.	puerarin	34-42	heme oxygenase 1	Rattus norvegicus	171-175
25310912-9	2015	Notably, puerarin enhanced NGF-induced neuritogenesis in a timing-dependent manner.	puerarin	9-17	nerve growth factor	Rattus norvegicus	27-30
25310912-10	2015	CONCLUSION: Puerarin effectively coordinated with NGF to stimulate neuritogenesis via activating ERK1/2 and PI3K/Akt pathways in neurite extension process.	puerarin	12-20	nerve growth factor	Rattus norvegicus	50-53
25310912-10	2015	CONCLUSION: Puerarin effectively coordinated with NGF to stimulate neuritogenesis via activating ERK1/2 and PI3K/Akt pathways in neurite extension process.	puerarin	12-20	mitogen activated protein kinase 3	Rattus norvegicus	97-103
25310912-10	2015	CONCLUSION: Puerarin effectively coordinated with NGF to stimulate neuritogenesis via activating ERK1/2 and PI3K/Akt pathways in neurite extension process.	puerarin	12-20	AKT serine/threonine kinase 1	Rattus norvegicus	113-116
25911789-4	2014	Results in this experiment showed that the components that peak 7 and peak 8 (baicalin) represented had poor similarity with the reference peak 2 (puerarin).	puerarin	147-155	PEAK1 related, kinase-activating pseudokinase 1	Homo sapiens	139-145
25657724-4	2014	Twenty-four hours after reperfusion, we found that puerarin significantly improved neurological deficit, reduced infarct size and brain water content, and notably diminished the expression of Toll-like receptor-4, myeloid differentiation factor 88, nuclear factor kappa B and tumor necrosis factor-alpha in the ischemic region.	puerarin	51-59	toll-like receptor 4	Rattus norvegicus	192-212
25657724-4	2014	Twenty-four hours after reperfusion, we found that puerarin significantly improved neurological deficit, reduced infarct size and brain water content, and notably diminished the expression of Toll-like receptor-4, myeloid differentiation factor 88, nuclear factor kappa B and tumor necrosis factor-alpha in the ischemic region.	puerarin	51-59	tumor necrosis factor	Rattus norvegicus	249-303
25911789-6	2014	Components that peaks represented had better similarity with the reference peak 2 (puerarin) in other medium.	puerarin	83-91	PEAK1 related, kinase-activating pseudokinase 1	Homo sapiens	75-81
24698568-0	2014	Puerarin attenuates carbon tetrachloride-induced liver oxidative stress and hyperlipidaemia in mouse by JNK/c-Jun/CYP7A1 pathway.	puerarin	0-8	mitogen-activated protein kinase 8	Mus musculus	104-107
24698568-0	2014	Puerarin attenuates carbon tetrachloride-induced liver oxidative stress and hyperlipidaemia in mouse by JNK/c-Jun/CYP7A1 pathway.	puerarin	0-8	jun proto-oncogene	Mus musculus	108-113
24698568-0	2014	Puerarin attenuates carbon tetrachloride-induced liver oxidative stress and hyperlipidaemia in mouse by JNK/c-Jun/CYP7A1 pathway.	puerarin	0-8	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	114-120
24698568-2	2014	The aim of this study was to investigate the effects of puerarin on hepatic oxidative stress and hyperlipidaemia in mice exposed to carbon tetrachloride (CCl4).	puerarin	56-64	chemokine (C-C motif) ligand 4	Mus musculus	154-158
25173404-2	2014	In this study, we investigated the protective effect of puerarin on amyloid-beta protein (Abeta)-induced cytotoxicity and its potential mechanisms in BV-2 and primary microglial cells.	puerarin	56-64	amyloid beta (A4) precursor protein	Mus musculus	90-95
24698568-4	2014	Our data showed that puerarin significantly prevented CCl4-induced hepatotoxicity, indicated by both diagnostic indicators of the liver damage (serum aminotransferase levels) and histopathological analysis.	puerarin	21-29	chemokine (C-C motif) ligand 4	Mus musculus	54-58
24698568-5	2014	Puerarin decreased the thiobarbituric acid reactive substances (TBARS) and the protein carbonyl content (PCO) in the liver of CCl4-treated mice.	puerarin	0-8	chemokine (C-C motif) ligand 4	Mus musculus	126-130
24698568-7	2014	Furthermore, the increase in serum cholesterol, triglycerides and low-density lipoproteins (LDL) induced by CCl4 was effectively suppressed by puerarin.	puerarin	143-151	chemokine (C-C motif) ligand 4	Mus musculus	108-112
24698568-8	2014	The high-density lipoprotein (HDL) level in the CCl4 treatment mice was also increased by puerarin.	puerarin	90-98	chemokine (C-C motif) ligand 4	Mus musculus	48-52
24698568-9	2014	Western blot analysis showed that puerarin remarkably inhibited hyperlipidaemia by regulating the expression of phosphorylated Jun N-terminal kinases (JNK), phosphorylated c-Jun protein and cholesterol 7a-hydroxylase (CYP7A1) in the liver of CCl4-treated mice.	puerarin	34-42	mitogen-activated protein kinase 8	Mus musculus	151-154
24698568-9	2014	Western blot analysis showed that puerarin remarkably inhibited hyperlipidaemia by regulating the expression of phosphorylated Jun N-terminal kinases (JNK), phosphorylated c-Jun protein and cholesterol 7a-hydroxylase (CYP7A1) in the liver of CCl4-treated mice.	puerarin	34-42	jun proto-oncogene	Mus musculus	172-177
24698568-9	2014	Western blot analysis showed that puerarin remarkably inhibited hyperlipidaemia by regulating the expression of phosphorylated Jun N-terminal kinases (JNK), phosphorylated c-Jun protein and cholesterol 7a-hydroxylase (CYP7A1) in the liver of CCl4-treated mice.	puerarin	34-42	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	190-216
24698568-9	2014	Western blot analysis showed that puerarin remarkably inhibited hyperlipidaemia by regulating the expression of phosphorylated Jun N-terminal kinases (JNK), phosphorylated c-Jun protein and cholesterol 7a-hydroxylase (CYP7A1) in the liver of CCl4-treated mice.	puerarin	34-42	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	218-224
24698568-9	2014	Western blot analysis showed that puerarin remarkably inhibited hyperlipidaemia by regulating the expression of phosphorylated Jun N-terminal kinases (JNK), phosphorylated c-Jun protein and cholesterol 7a-hydroxylase (CYP7A1) in the liver of CCl4-treated mice.	puerarin	34-42	chemokine (C-C motif) ligand 4	Mus musculus	242-246
24698568-10	2014	Altogether, these results suggest that puerarin could protect the CCl4-induced liver injury and hyperlipidaemia by reducing reactive oxygen species S production, renewing the total antioxidant capacity and influencing expression of hepatic lipid biosynthesis and metabolism genes.	puerarin	39-47	chemokine (C-C motif) ligand 4	Mus musculus	66-70
25151533-6	2014	Western blot analysis showed that puerarin treatment significantly decreased the expression of Bax and increased the expression of Bcl-2.	puerarin	34-42	BCL2 associated X, apoptosis regulator	Rattus norvegicus	95-98
25151533-6	2014	Western blot analysis showed that puerarin treatment significantly decreased the expression of Bax and increased the expression of Bcl-2.	puerarin	34-42	BCL2, apoptosis regulator	Rattus norvegicus	131-136
25175767-11	2014	Puerarin treatment increased caspase-3,8,9 and apoptosis-inducing factor (AIF) mRNA expression levels in SMMC-7721 cells, while the phosphorylation levels of P38, extracellular signal-regulated kinase (ERK1) and c-Jun N-terminal kinase were also increased.	puerarin	0-8	caspase 3	Homo sapiens	29-42
25175767-11	2014	Puerarin treatment increased caspase-3,8,9 and apoptosis-inducing factor (AIF) mRNA expression levels in SMMC-7721 cells, while the phosphorylation levels of P38, extracellular signal-regulated kinase (ERK1) and c-Jun N-terminal kinase were also increased.	puerarin	0-8	apoptosis inducing factor mitochondria associated 1	Homo sapiens	47-72
25175767-11	2014	Puerarin treatment increased caspase-3,8,9 and apoptosis-inducing factor (AIF) mRNA expression levels in SMMC-7721 cells, while the phosphorylation levels of P38, extracellular signal-regulated kinase (ERK1) and c-Jun N-terminal kinase were also increased.	puerarin	0-8	apoptosis inducing factor mitochondria associated 1	Homo sapiens	74-77
25175767-11	2014	Puerarin treatment increased caspase-3,8,9 and apoptosis-inducing factor (AIF) mRNA expression levels in SMMC-7721 cells, while the phosphorylation levels of P38, extracellular signal-regulated kinase (ERK1) and c-Jun N-terminal kinase were also increased.	puerarin	0-8	mitogen-activated protein kinase 1	Homo sapiens	158-161
25175767-11	2014	Puerarin treatment increased caspase-3,8,9 and apoptosis-inducing factor (AIF) mRNA expression levels in SMMC-7721 cells, while the phosphorylation levels of P38, extracellular signal-regulated kinase (ERK1) and c-Jun N-terminal kinase were also increased.	puerarin	0-8	mitogen-activated protein kinase 3	Homo sapiens	202-206
25195717-7	2014	The effects of puerarin could be partially blocked by pharmacologic inhibition of PI3K and the glycogen synthase kinase 3beta (GSK-3beta) pathways with LY294002 and LiCl, respectively.	puerarin	15-23	glycogen synthase kinase 3 beta	Rattus norvegicus	95-125
25195717-7	2014	The effects of puerarin could be partially blocked by pharmacologic inhibition of PI3K and the glycogen synthase kinase 3beta (GSK-3beta) pathways with LY294002 and LiCl, respectively.	puerarin	15-23	glycogen synthase kinase 3 beta	Rattus norvegicus	127-136
25195717-8	2014	On the other hand, puerarin treatment promoted Akt and GSK-3beta phosphorylation in PC12 cells exposed to lead acetate.	puerarin	19-27	AKT serine/threonine kinase 1	Rattus norvegicus	47-50
25195717-8	2014	On the other hand, puerarin treatment promoted Akt and GSK-3beta phosphorylation in PC12 cells exposed to lead acetate.	puerarin	19-27	glycogen synthase kinase 3 beta	Rattus norvegicus	55-64
25195717-0	2014	Puerarin induces the upregulation of glutathione levels and nuclear translocation of Nrf2 through PI3K/Akt/GSK-3beta signaling events in PC12 cells exposed to lead.	puerarin	0-8	NFE2 like bZIP transcription factor 2	Rattus norvegicus	85-89
25195717-0	2014	Puerarin induces the upregulation of glutathione levels and nuclear translocation of Nrf2 through PI3K/Akt/GSK-3beta signaling events in PC12 cells exposed to lead.	puerarin	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	103-106
25195717-0	2014	Puerarin induces the upregulation of glutathione levels and nuclear translocation of Nrf2 through PI3K/Akt/GSK-3beta signaling events in PC12 cells exposed to lead.	puerarin	0-8	glycogen synthase kinase 3 beta	Rattus norvegicus	107-116
25173404-3	2014	We found that pretreatment with puerarin afforded protection against Abeta-induced cytotoxicity through inhibiting apoptosis in BV-2 and primary microglial cells.	puerarin	32-40	amyloid beta (A4) precursor protein	Mus musculus	69-74
25173404-5	2014	Phospho-Akt and Bcl-2 expression increased after pretreatment with puerarin in BV-2 and primary microglial cells exposed to Abeta, whereas Bax expression and cytochrome c release decreased.	puerarin	67-75	thymoma viral proto-oncogene 1	Mus musculus	8-11
25173404-5	2014	Phospho-Akt and Bcl-2 expression increased after pretreatment with puerarin in BV-2 and primary microglial cells exposed to Abeta, whereas Bax expression and cytochrome c release decreased.	puerarin	67-75	B cell leukemia/lymphoma 2	Mus musculus	16-21
25173404-5	2014	Phospho-Akt and Bcl-2 expression increased after pretreatment with puerarin in BV-2 and primary microglial cells exposed to Abeta, whereas Bax expression and cytochrome c release decreased.	puerarin	67-75	amyloid beta (A4) precursor protein	Mus musculus	124-129
25173404-7	2014	Interestingly, these effects of puerarin against Abeta insult were abolished by LY294002, an inhibitor of PI3K phosphorylation.	puerarin	32-40	amyloid beta (A4) precursor protein	Mus musculus	49-54
25173404-8	2014	Taken together, these findings suggest that puerarin prevents Abeta-induced microglial apoptosis via the activation of PI3K/Akt signaling pathway, and might be a potential preventive or therapeutic agent for Alzheimer"s disease.	puerarin	44-52	amyloid beta (A4) precursor protein	Mus musculus	62-67
25173404-8	2014	Taken together, these findings suggest that puerarin prevents Abeta-induced microglial apoptosis via the activation of PI3K/Akt signaling pathway, and might be a potential preventive or therapeutic agent for Alzheimer"s disease.	puerarin	44-52	thymoma viral proto-oncogene 1	Mus musculus	124-127
25423828-3	2014	The inclusion between puerarin, borneol and catalpol was tested by measuring the inclusion concentration, DSC and X-ray diffraction.	puerarin	22-30	desmocollin 3	Homo sapiens	106-109
25195717-3	2014	Therefore, the aim of the present study was to test the hypothesis that puerarin inhibits lead acetate-induced oxidative stress in PC12 cells by interrupting phosphatidylinositol-3 kinase (PI3K)/Akt signaling through increasing glutathione (GSH) synthesis.	puerarin	72-80	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta	Rattus norvegicus	158-187
25195717-3	2014	Therefore, the aim of the present study was to test the hypothesis that puerarin inhibits lead acetate-induced oxidative stress in PC12 cells by interrupting phosphatidylinositol-3 kinase (PI3K)/Akt signaling through increasing glutathione (GSH) synthesis.	puerarin	72-80	AKT serine/threonine kinase 1	Rattus norvegicus	195-198
25195717-5	2014	Treatment with puerarin significantly up-regulates glutamate cysteine ligase catalytic subunit (GCLc) expression both at its mRNA and protein levels, but not glutamate cysteine ligase modifier (GCLm) subunit, accompanying the elevation of cellular glutathione level.	puerarin	15-23	glutamate-cysteine ligase, catalytic subunit	Rattus norvegicus	51-94
25195717-5	2014	Treatment with puerarin significantly up-regulates glutamate cysteine ligase catalytic subunit (GCLc) expression both at its mRNA and protein levels, but not glutamate cysteine ligase modifier (GCLm) subunit, accompanying the elevation of cellular glutathione level.	puerarin	15-23	glutamate-cysteine ligase, catalytic subunit	Rattus norvegicus	96-100
25195717-6	2014	The increased nuclear accumulation of nuclear factor erythroid 2-related factor 2 (Nrf2) was not because of increased transcription of Nrf2 as Nrf2 transcript levels did not change after puerarin treatment.	puerarin	187-195	NFE2 like bZIP transcription factor 2	Rattus norvegicus	38-81
25442257-6	2014	After being exposed for 48 h to 100 mug/ml PM extract, 1000 nM genistein, or 1000 nM puerarin, primary baboon osteoblasts markedly increased the rate of proliferation and mRNA levels of ALP and type I collagen without changes in Runx2, osterix, or osteocalcin expression.	puerarin	85-93	runt-related transcription factor 2	Papio anubis	229-234
24975872-0	2014	Puerarin ameliorates carbon tetrachloride-induced oxidative DNA damage and inflammation in mouse kidney through ERK/Nrf2/ARE pathway.	puerarin	0-8	mitogen-activated protein kinase 1	Mus musculus	112-115
24975872-0	2014	Puerarin ameliorates carbon tetrachloride-induced oxidative DNA damage and inflammation in mouse kidney through ERK/Nrf2/ARE pathway.	puerarin	0-8	nuclear factor, erythroid derived 2, like 2	Mus musculus	116-120
24975872-2	2014	In this study, we evaluated the effect of puerarin on oxidative stress and inflammation in kidney induced by carbon tetrachloride (CCl4) and explored the potential mechanisms underlying this effect.	puerarin	42-50	chemokine (C-C motif) ligand 4	Mus musculus	131-135
24975872-3	2014	Our results showed that puerarin administration significantly inhibited CCl4-induced kidney injury, which indicated by both diagnostic indicators and histopathological analysis.	puerarin	24-32	chemokine (C-C motif) ligand 4	Mus musculus	72-76
24975872-4	2014	One of the potential mechanisms of puerarin action was decreased the oxidative stress, as evidenced by decreasing of lipid peroxidation level, increasing of SOD, CAT and GPx activities and GSH level.	puerarin	35-43	catalase	Mus musculus	162-165
24975872-4	2014	One of the potential mechanisms of puerarin action was decreased the oxidative stress, as evidenced by decreasing of lipid peroxidation level, increasing of SOD, CAT and GPx activities and GSH level.	puerarin	35-43	peroxiredoxin 6 pseudogene 2	Mus musculus	170-173
24975872-5	2014	Puerarin also decreased 8-hydroxy-2-deoxyguanosine (one product of oxidative DNA damage) level and increased the expression levels of NQO1, GST and HO-1 in kidneys of CCl4-treated mice.	puerarin	0-8	NAD(P)H dehydrogenase, quinone 1	Mus musculus	134-138
24975872-5	2014	Puerarin also decreased 8-hydroxy-2-deoxyguanosine (one product of oxidative DNA damage) level and increased the expression levels of NQO1, GST and HO-1 in kidneys of CCl4-treated mice.	puerarin	0-8	chemokine (C-C motif) ligand 4	Mus musculus	167-171
24975872-6	2014	Moreover, western blot analysis showed that puerarin decreased production of pro-inflammatory markers including iNOS and COX-2 in CCl4-treated mouse kidney.	puerarin	44-52	cytochrome c oxidase II, mitochondrial	Mus musculus	121-126
24975872-6	2014	Moreover, western blot analysis showed that puerarin decreased production of pro-inflammatory markers including iNOS and COX-2 in CCl4-treated mouse kidney.	puerarin	44-52	chemokine (C-C motif) ligand 4	Mus musculus	130-134
24975872-7	2014	We found that puerarin significantly inhibited the ERK phosphorylation and increased the translocation of Nrf2 from the cytosol to the nuclear fraction, which in turn inactivated NF-kappaB and the inflammatory cytokines in kidneys of the CCl4-treated mice.	puerarin	14-22	mitogen-activated protein kinase 1	Mus musculus	51-54
24975872-7	2014	We found that puerarin significantly inhibited the ERK phosphorylation and increased the translocation of Nrf2 from the cytosol to the nuclear fraction, which in turn inactivated NF-kappaB and the inflammatory cytokines in kidneys of the CCl4-treated mice.	puerarin	14-22	nuclear factor, erythroid derived 2, like 2	Mus musculus	106-110
24975872-7	2014	We found that puerarin significantly inhibited the ERK phosphorylation and increased the translocation of Nrf2 from the cytosol to the nuclear fraction, which in turn inactivated NF-kappaB and the inflammatory cytokines in kidneys of the CCl4-treated mice.	puerarin	14-22	chemokine (C-C motif) ligand 4	Mus musculus	238-242
24975872-8	2014	Altogether, these results suggest that puerarin could protect the CCl4-induced oxidative stress and inflammation by ERK/Nrf2/ARE pathway.	puerarin	39-47	chemokine (C-C motif) ligand 4	Mus musculus	66-70
24975872-8	2014	Altogether, these results suggest that puerarin could protect the CCl4-induced oxidative stress and inflammation by ERK/Nrf2/ARE pathway.	puerarin	39-47	mitogen-activated protein kinase 1	Mus musculus	116-119
24975872-8	2014	Altogether, these results suggest that puerarin could protect the CCl4-induced oxidative stress and inflammation by ERK/Nrf2/ARE pathway.	puerarin	39-47	nuclear factor, erythroid derived 2, like 2	Mus musculus	120-124
24827001-0	2014	Puerarin protects pancreatic beta-cell survival via PI3K/Akt signaling pathway.	puerarin	0-8	thymoma viral proto-oncogene 1	Mus musculus	57-60
24827001-9	2014	Puerarin protection of beta-cell survival involved the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway.	puerarin	0-8	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	55-80
24827001-9	2014	Puerarin protection of beta-cell survival involved the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway.	puerarin	0-8	thymoma viral proto-oncogene 1	Mus musculus	88-91
24827001-10	2014	In conclusion, puerarin protects pancreatic beta-cell function and survival via direct effects on beta-cells, and its protection of beta-cell survival is mediated by the PI3K/Akt pathway.	puerarin	15-23	thymoma viral proto-oncogene 1	Mus musculus	175-178
24339367-7	2014	The beneficial effects of puerarin on the various medicinal purposes may be due to its wide spectrum of pharmacological properties such as vasodilation, cardioprotection, neuroprotection, antioxidant, anticancer, antiinflammation, alleviating pain, promoting bone formation, inhibiting alcohol intake, and attenuating insulin resistance.	puerarin	26-34	insulin	Homo sapiens	318-325
24710899-3	2014	The in vitro cytochrome P450 inhibitory effect of puerarin in human and rat liver microsomes was evaluated using the following model cytochrome P450 substrates: phenacetin for CYP1A, diclofenac for CYP2C, dextromethorphan for CYP2D, and testosterone for CYP3A.	puerarin	50-58	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	198-203
24786236-6	2014	Among the 63 phytochemicals screened, 6 compounds, including coptisine sulfate, bilobalide, schizandrin B, luteolin, schizandrin A and puerarin, at 100 mumol/L inhibited CYP2D6(*)1- and CYP2D6(*)10-mediated O-demethylation of a coumarin compound AMMC by more than 50%.	puerarin	135-143	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	170-176
24786236-6	2014	Among the 63 phytochemicals screened, 6 compounds, including coptisine sulfate, bilobalide, schizandrin B, luteolin, schizandrin A and puerarin, at 100 mumol/L inhibited CYP2D6(*)1- and CYP2D6(*)10-mediated O-demethylation of a coumarin compound AMMC by more than 50%.	puerarin	135-143	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	186-192
24595557-0	2014	Effects of puerarin in STZ-induced diabetic rats by oxidative stress and the TGF-beta1/Smad2 pathway.	puerarin	11-19	transforming growth factor, beta 1	Rattus norvegicus	77-86
24595557-0	2014	Effects of puerarin in STZ-induced diabetic rats by oxidative stress and the TGF-beta1/Smad2 pathway.	puerarin	11-19	SMAD family member 2	Rattus norvegicus	87-92
24595557-5	2014	In contrast, the puerarin treatment dose-dependently significantly decreased the kidney index, blood glucose, TG, TC, MDA, IFN-gamma, and IFN-gamma/IL-4 levels, increased the body weight, FPI, IL-4, SOD, CAT, GSH-Px and NO levels and improved the renal function (lower BUN, SCr, UP levels and glomerular extracellular matrix (relative area)) in puerarin treatment groups (p < 0.05).	puerarin	17-25	interferon gamma	Rattus norvegicus	123-132
24595557-5	2014	In contrast, the puerarin treatment dose-dependently significantly decreased the kidney index, blood glucose, TG, TC, MDA, IFN-gamma, and IFN-gamma/IL-4 levels, increased the body weight, FPI, IL-4, SOD, CAT, GSH-Px and NO levels and improved the renal function (lower BUN, SCr, UP levels and glomerular extracellular matrix (relative area)) in puerarin treatment groups (p < 0.05).	puerarin	17-25	interferon gamma	Rattus norvegicus	138-147
24595557-5	2014	In contrast, the puerarin treatment dose-dependently significantly decreased the kidney index, blood glucose, TG, TC, MDA, IFN-gamma, and IFN-gamma/IL-4 levels, increased the body weight, FPI, IL-4, SOD, CAT, GSH-Px and NO levels and improved the renal function (lower BUN, SCr, UP levels and glomerular extracellular matrix (relative area)) in puerarin treatment groups (p < 0.05).	puerarin	17-25	interleukin 4	Rattus norvegicus	148-152
24595557-5	2014	In contrast, the puerarin treatment dose-dependently significantly decreased the kidney index, blood glucose, TG, TC, MDA, IFN-gamma, and IFN-gamma/IL-4 levels, increased the body weight, FPI, IL-4, SOD, CAT, GSH-Px and NO levels and improved the renal function (lower BUN, SCr, UP levels and glomerular extracellular matrix (relative area)) in puerarin treatment groups (p < 0.05).	puerarin	17-25	interleukin 4	Rattus norvegicus	193-197
24595557-5	2014	In contrast, the puerarin treatment dose-dependently significantly decreased the kidney index, blood glucose, TG, TC, MDA, IFN-gamma, and IFN-gamma/IL-4 levels, increased the body weight, FPI, IL-4, SOD, CAT, GSH-Px and NO levels and improved the renal function (lower BUN, SCr, UP levels and glomerular extracellular matrix (relative area)) in puerarin treatment groups (p < 0.05).	puerarin	17-25	catalase	Rattus norvegicus	204-207
24595557-7	2014	It can be concluded that puerarin exerted its anti-diabetic effect on the STZ-treated rats through the inhibition of the TGF-beta1/Smad2 pathway.	puerarin	25-33	transforming growth factor, beta 1	Rattus norvegicus	121-130
24595557-7	2014	It can be concluded that puerarin exerted its anti-diabetic effect on the STZ-treated rats through the inhibition of the TGF-beta1/Smad2 pathway.	puerarin	25-33	SMAD family member 2	Rattus norvegicus	131-136
24657446-0	2014	Puerarin alleviates aggravated sympathoexcitatory response induced by myocardial ischemia via regulating P2X3 receptor in rat superior cervical ganglia.	puerarin	0-8	purinergic receptor P2X 3	Rattus norvegicus	105-109
24657446-4	2014	Our study was aimed to explore the effect of puerarin on sympathoexcitatory response induced by myocardial ischemic injury and possible relationship with P2X3 receptor.	puerarin	45-53	purinergic receptor P2X 3	Rattus norvegicus	154-158
24657446-5	2014	Our results showed that puerarin alleviated systolic blood pressure and heart rate, and decreased the up-regulated of P2X3 mRNA and protein in SCG of myocardial ischemic rats.	puerarin	24-32	purinergic receptor P2X 3	Rattus norvegicus	118-122
24657446-8	2014	Puerarin also significantly inhibited ATP-activated currents in HEK293 cells transfected with P2X3 receptor.	puerarin	0-8	purinergic receptor P2X 3	Rattus norvegicus	94-98
24657446-9	2014	These results suggest that puerarin can depress up-sympathoexcitatory response induced by myocardial ischemia via acting on P2X3 receptor in rat SCG to protect myocardium.	puerarin	27-35	purinergic receptor P2X 3	Rattus norvegicus	124-128
24855829-0	2014	In vivo inhibitory effects of puerarin on selected rat cytochrome P450 isoenzymes.	puerarin	30-38	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	55-70
24855829-2	2014	The purpose of this study was to find out whether puerarin influences the effect on rat cytochrome P450 (CYP) enzymes (CYP2B6, CYP2C9 and CYP3A4) by using cocktail probe drugs in vivo.	puerarin	50-58	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	88-103
24855829-2	2014	The purpose of this study was to find out whether puerarin influences the effect on rat cytochrome P450 (CYP) enzymes (CYP2B6, CYP2C9 and CYP3A4) by using cocktail probe drugs in vivo.	puerarin	50-58	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	105-108
24855829-2	2014	The purpose of this study was to find out whether puerarin influences the effect on rat cytochrome P450 (CYP) enzymes (CYP2B6, CYP2C9 and CYP3A4) by using cocktail probe drugs in vivo.	puerarin	50-58	cytochrome P450, family 2, subfamily b, polypeptide 3	Rattus norvegicus	119-125
24855829-5	2014	The results showed that treatment with multiple doses of puerarin had inhibitory effects on rat CYP2B6, CYP2C9 and CYP3A4 enzyme activities.	puerarin	57-65	cytochrome P450, family 2, subfamily b, polypeptide 3	Rattus norvegicus	96-102
24854571-0	2014	Puerarin concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-kappaB ligand (RANKL) and interleukin-6 production in human osteoblastic MG-63 cells.	puerarin	0-8	TNF receptor superfamily member 11b	Homo sapiens	33-48
24854571-0	2014	Puerarin concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-kappaB ligand (RANKL) and interleukin-6 production in human osteoblastic MG-63 cells.	puerarin	0-8	TNF superfamily member 11	Homo sapiens	102-107
24854571-0	2014	Puerarin concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-kappaB ligand (RANKL) and interleukin-6 production in human osteoblastic MG-63 cells.	puerarin	0-8	interleukin 6	Homo sapiens	113-126
24854571-6	2014	Here we show that puerarin concurrently stimulates osteoprotegerin (OPG) and inhibits receptor activator of nuclear factor-kappaB ligand (RANKL) and Interleukin-6 (IL-6) production by human osteoblastic MG-63 cells containing two estrogen receptor (ER) isotypes.	puerarin	18-26	TNF receptor superfamily member 11b	Homo sapiens	51-66
24854571-6	2014	Here we show that puerarin concurrently stimulates osteoprotegerin (OPG) and inhibits receptor activator of nuclear factor-kappaB ligand (RANKL) and Interleukin-6 (IL-6) production by human osteoblastic MG-63 cells containing two estrogen receptor (ER) isotypes.	puerarin	18-26	TNF receptor superfamily member 11b	Homo sapiens	68-71
24854571-6	2014	Here we show that puerarin concurrently stimulates osteoprotegerin (OPG) and inhibits receptor activator of nuclear factor-kappaB ligand (RANKL) and Interleukin-6 (IL-6) production by human osteoblastic MG-63 cells containing two estrogen receptor (ER) isotypes.	puerarin	18-26	TNF superfamily member 11	Homo sapiens	86-136
24854571-6	2014	Here we show that puerarin concurrently stimulates osteoprotegerin (OPG) and inhibits receptor activator of nuclear factor-kappaB ligand (RANKL) and Interleukin-6 (IL-6) production by human osteoblastic MG-63 cells containing two estrogen receptor (ER) isotypes.	puerarin	18-26	TNF superfamily member 11	Homo sapiens	138-143
24854571-6	2014	Here we show that puerarin concurrently stimulates osteoprotegerin (OPG) and inhibits receptor activator of nuclear factor-kappaB ligand (RANKL) and Interleukin-6 (IL-6) production by human osteoblastic MG-63 cells containing two estrogen receptor (ER) isotypes.	puerarin	18-26	interleukin 6	Homo sapiens	149-162
24854571-6	2014	Here we show that puerarin concurrently stimulates osteoprotegerin (OPG) and inhibits receptor activator of nuclear factor-kappaB ligand (RANKL) and Interleukin-6 (IL-6) production by human osteoblastic MG-63 cells containing two estrogen receptor (ER) isotypes.	puerarin	18-26	interleukin 6	Homo sapiens	164-168
24854571-8	2014	Using small interfering double-stranded RNAs technology, we further demonstrate that the effects of puerarin on OPG and RANKL expression are mediated by both ERalpha and ERbeta but those on IL-6 production primarily by ERalpha.	puerarin	100-108	TNF receptor superfamily member 11b	Homo sapiens	112-115
24854571-8	2014	Using small interfering double-stranded RNAs technology, we further demonstrate that the effects of puerarin on OPG and RANKL expression are mediated by both ERalpha and ERbeta but those on IL-6 production primarily by ERalpha.	puerarin	100-108	TNF superfamily member 11	Homo sapiens	120-125
24854571-8	2014	Using small interfering double-stranded RNAs technology, we further demonstrate that the effects of puerarin on OPG and RANKL expression are mediated by both ERalpha and ERbeta but those on IL-6 production primarily by ERalpha.	puerarin	100-108	estrogen receptor 1	Homo sapiens	158-165
24854571-8	2014	Using small interfering double-stranded RNAs technology, we further demonstrate that the effects of puerarin on OPG and RANKL expression are mediated by both ERalpha and ERbeta but those on IL-6 production primarily by ERalpha.	puerarin	100-108	estrogen receptor 2	Homo sapiens	170-176
24854571-9	2014	Moreover, we demonstrate that puerarin may promote activation of the classic estrogen response element (ERE) pathway through increasing ERalpha, ERbeta and steroid hormone receptor coactivator (SRC)-1 expression.	puerarin	30-38	estrogen receptor 1	Homo sapiens	136-143
24854571-9	2014	Moreover, we demonstrate that puerarin may promote activation of the classic estrogen response element (ERE) pathway through increasing ERalpha, ERbeta and steroid hormone receptor coactivator (SRC)-1 expression.	puerarin	30-38	estrogen receptor 2	Homo sapiens	145-151
24854571-9	2014	Moreover, we demonstrate that puerarin may promote activation of the classic estrogen response element (ERE) pathway through increasing ERalpha, ERbeta and steroid hormone receptor coactivator (SRC)-1 expression.	puerarin	30-38	nuclear receptor coactivator 1	Homo sapiens	156-200
24690262-7	2014	The present study suggests that puerarin exerts its protective action probably through reduction of NADPH oxidase-derived reactive oxygen species overproduction and activation of the PI3K/Akt/eNOS pathways.	puerarin	32-40	AKT serine/threonine kinase 1	Homo sapiens	188-191
24496955-0	2014	The protective effects of puerarin in cardiomyocytes from anoxia/reoxygenation injury are mediated by PKCepsilon.	puerarin	26-34	protein kinase C, epsilon	Rattus norvegicus	102-112
24496955-3	2014	On the basis of previous findings, we hypothesized that puerarin protects cardiomyocytes from ischemia-reperfusion injury via the protein kinase C epsilon (PKCepsilon) (a critical cardioprotective protein) signalling pathway.	puerarin	56-64	protein kinase C, epsilon	Rattus norvegicus	130-154
24496955-3	2014	On the basis of previous findings, we hypothesized that puerarin protects cardiomyocytes from ischemia-reperfusion injury via the protein kinase C epsilon (PKCepsilon) (a critical cardioprotective protein) signalling pathway.	puerarin	56-64	protein kinase C, epsilon	Rattus norvegicus	156-166
24496955-5	2014	Western blot analysis showed that expression and activity of PKCepsilon protein in puerarin preconditioned group were both increased compared with the control or A/R group.	puerarin	83-91	protein kinase C, epsilon	Rattus norvegicus	61-71
24496955-8	2014	Thus, for the first time, we revealed the protective effects of puerarin in cardiomocytes from anoxia/reoxygenation injury are mediated by PKCepsilon.	puerarin	64-72	protein kinase C, epsilon	Rattus norvegicus	139-149
24122632-0	2014	Induction of adhesion molecule expression in co-culture of human bronchial epithelial cells and neutrophils suppressed by puerarin via down-regulating p38 mitogen-activated protein kinase and nuclear factor kappaB pathways.	puerarin	122-130	mitogen-activated protein kinase 14	Homo sapiens	151-187
24122632-1	2014	OBJECTIVE: In this study, we aimed to investigate the expressions of adhesion molecules on human bronchial epithelial cells and neutrophils in co-culture system, assess the effects of puerarin on suppressing these adhesion molecules expressions, and explore the roles of two crucial signal-transduction elements p38 mitogen-activated protein kinase (p38 MAPK) and nuclear factor kappa B (NF-kappaB) in modulating adhesion molecules expressions.	puerarin	184-192	mitogen-activated protein kinase 14	Homo sapiens	312-348
24122632-1	2014	OBJECTIVE: In this study, we aimed to investigate the expressions of adhesion molecules on human bronchial epithelial cells and neutrophils in co-culture system, assess the effects of puerarin on suppressing these adhesion molecules expressions, and explore the roles of two crucial signal-transduction elements p38 mitogen-activated protein kinase (p38 MAPK) and nuclear factor kappa B (NF-kappaB) in modulating adhesion molecules expressions.	puerarin	184-192	mitogen-activated protein kinase 14	Homo sapiens	350-358
24122632-1	2014	OBJECTIVE: In this study, we aimed to investigate the expressions of adhesion molecules on human bronchial epithelial cells and neutrophils in co-culture system, assess the effects of puerarin on suppressing these adhesion molecules expressions, and explore the roles of two crucial signal-transduction elements p38 mitogen-activated protein kinase (p38 MAPK) and nuclear factor kappa B (NF-kappaB) in modulating adhesion molecules expressions.	puerarin	184-192	nuclear factor kappa B subunit 1	Homo sapiens	364-386
24122632-1	2014	OBJECTIVE: In this study, we aimed to investigate the expressions of adhesion molecules on human bronchial epithelial cells and neutrophils in co-culture system, assess the effects of puerarin on suppressing these adhesion molecules expressions, and explore the roles of two crucial signal-transduction elements p38 mitogen-activated protein kinase (p38 MAPK) and nuclear factor kappa B (NF-kappaB) in modulating adhesion molecules expressions.	puerarin	184-192	nuclear factor kappa B subunit 1	Homo sapiens	388-397
24242937-0	2014	MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate.	puerarin	61-69	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-4
24242937-0	2014	MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate.	puerarin	61-69	solute carrier family 22 member 6	Rattus norvegicus	9-13
24242937-0	2014	MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate.	puerarin	61-69	solute carrier family 22 member 8	Rattus norvegicus	14-18
24710899-3	2014	The in vitro cytochrome P450 inhibitory effect of puerarin in human and rat liver microsomes was evaluated using the following model cytochrome P450 substrates: phenacetin for CYP1A, diclofenac for CYP2C, dextromethorphan for CYP2D, and testosterone for CYP3A.	puerarin	50-58	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	254-259
24710899-8	2014	Therefore, results of the in vitro microsomal and in vivo pharmacokinetic studies suggest the possible inhibition of hepatic CYP3A-mediated drug metabolism by puerarin administration, potentially leading to metabolism-mediated herb-drug interactions with clinical significance.	puerarin	159-167	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	125-130
24743933-3	2014	The interaction between puerarin and CYPs (CYP1A2 and CYP2D6) was investigated by fluorescence, UV-Vis and circular dichroism spectroscopies, as well as molecular docking, to explore the underlying mechanism under simulated physiological conditions.	puerarin	24-32	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	43-49
24743933-3	2014	The interaction between puerarin and CYPs (CYP1A2 and CYP2D6) was investigated by fluorescence, UV-Vis and circular dichroism spectroscopies, as well as molecular docking, to explore the underlying mechanism under simulated physiological conditions.	puerarin	24-32	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
24743933-7	2014	At the same temperature, puerarin bound to CYP1A2 more weakly than it did to CYP2D6.	puerarin	25-33	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	43-49
24743933-7	2014	At the same temperature, puerarin bound to CYP1A2 more weakly than it did to CYP2D6.	puerarin	25-33	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	77-83
24333675-8	2014	In our in vitro study, we have found that puerarin inhibited the pro-apoptosis factor and upregulated the BDNF secret of astrocytes after OGD-R.	puerarin	42-50	brain-derived neurotrophic factor	Rattus norvegicus	106-110
24608673-0	2014	Puerarin inhibits angiotensin II-induced cardiac hypertrophy via the redox-sensitive ERK1/2, p38 and NF-kappaB pathways.	puerarin	0-8	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	18-32
24608673-0	2014	Puerarin inhibits angiotensin II-induced cardiac hypertrophy via the redox-sensitive ERK1/2, p38 and NF-kappaB pathways.	puerarin	0-8	mitogen-activated protein kinase 3	Mus musculus	85-91
24608673-0	2014	Puerarin inhibits angiotensin II-induced cardiac hypertrophy via the redox-sensitive ERK1/2, p38 and NF-kappaB pathways.	puerarin	0-8	mitogen-activated protein kinase 14	Mus musculus	93-96
24608673-0	2014	Puerarin inhibits angiotensin II-induced cardiac hypertrophy via the redox-sensitive ERK1/2, p38 and NF-kappaB pathways.	puerarin	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	101-110
24608673-1	2014	AIM: To investigate the effects of puerarin (Pue), an isoflavone derived from Kudzu roots, on angiotensin II (Ang II)-induced hypertrophy of cardiomyocytes in vivo and in vitro.	puerarin	35-43	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	94-108
24608673-1	2014	AIM: To investigate the effects of puerarin (Pue), an isoflavone derived from Kudzu roots, on angiotensin II (Ang II)-induced hypertrophy of cardiomyocytes in vivo and in vitro.	puerarin	35-43	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	110-116
24345484-0	2014	Puerarin alleviates cognitive impairment and oxidative stress in APP/PS1 transgenic mice.	puerarin	0-8	presenilin 1	Mus musculus	69-72
24345484-4	2014	Therefore, the aim of the present study was to determine whether puerarin improves cognitive function and reduces oxidative stress in amyloid precursor protein/presenilin-1 (APP/PS1) mice, a well established AD mouse model, and explore its potential mechanism.	puerarin	65-73	amyloid beta (A4) precursor protein	Mus musculus	134-159
24345484-4	2014	Therefore, the aim of the present study was to determine whether puerarin improves cognitive function and reduces oxidative stress in amyloid precursor protein/presenilin-1 (APP/PS1) mice, a well established AD mouse model, and explore its potential mechanism.	puerarin	65-73	presenilin 1	Mus musculus	160-172
24345484-5	2014	Our results show that oral administration of puerarin significantly ameliorates cognitive impairment in APP/PS1 mice assessed by the Morris water maze (MWM) test.	puerarin	45-53	presenilin 1	Mus musculus	108-111
24608673-1	2014	AIM: To investigate the effects of puerarin (Pue), an isoflavone derived from Kudzu roots, on angiotensin II (Ang II)-induced hypertrophy of cardiomyocytes in vivo and in vitro.	puerarin	45-48	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	94-108
24608673-1	2014	AIM: To investigate the effects of puerarin (Pue), an isoflavone derived from Kudzu roots, on angiotensin II (Ang II)-induced hypertrophy of cardiomyocytes in vivo and in vitro.	puerarin	45-48	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	110-116
24708212-0	2014	Puerarin protects endothelial cells from oxidized low density lipoprotein induced injuries via the suppression of LOX-1 and induction of eNOS.	puerarin	0-8	oxidized low density lipoprotein receptor 1	Homo sapiens	114-119
24708212-10	2014	These results suggest that puerarin inhibits oxLDL-induced endothelial cell injuries, at least in part, via inhibition of the LOX-1-mediated p38MAPK-NF-kappaB inflammatory and the PKB-eNOS signaling pathways.	puerarin	27-35	oxidized low density lipoprotein receptor 1	Homo sapiens	126-131
24708212-10	2014	These results suggest that puerarin inhibits oxLDL-induced endothelial cell injuries, at least in part, via inhibition of the LOX-1-mediated p38MAPK-NF-kappaB inflammatory and the PKB-eNOS signaling pathways.	puerarin	27-35	nuclear factor kappa B subunit 1	Homo sapiens	149-158
24707866-7	2014	Our results showed puerarin could inhibit ALP activity, osteocalcin secretion and Runx2 expression in CVSMCs.	puerarin	19-27	bone gamma-carboxyglutamate protein 2	Mus musculus	56-67
25206860-4	2014	Puerarin at the middle and high doses significantly up-regulated the expression of growth-associated protein 43 in the L4-6 segments of the spinal cord from mice at 1, 2, and 4 weeks after modeling, and reduced the atrophy of the triceps surae on the affected side and promoted the regeneration of nerve fibers of the damaged spinal cord at 8 weeks after injury.	puerarin	0-8	growth associated protein 43	Mus musculus	83-111
25206860-5	2014	We conclude that puerarin exerts an ongoing role to activate growth-associated protein 43 in the corresponding segment of the spinal cord after sciatic nerve injury, thus contributing to neural regeneration after sciatic nerve injuries.	puerarin	17-25	growth associated protein 43	Mus musculus	61-89
24520264-6	2014	Briefly, curcumin and puerarin significantly downregulated the levels of tumor necrosis factor-alpha in the blood serum of mice (P<0.01, versus the MCD group).	puerarin	22-30	tumor necrosis factor	Mus musculus	73-100
24520264-9	2014	Curcumin and puerarin significantly increased the levels of peroxisome proliferator-activated receptor-gamma (PPARgamma; P<0.05, versus the MCD group).	puerarin	13-21	peroxisome proliferator activated receptor gamma	Mus musculus	60-108
24520264-9	2014	Curcumin and puerarin significantly increased the levels of peroxisome proliferator-activated receptor-gamma (PPARgamma; P<0.05, versus the MCD group).	puerarin	13-21	peroxisome proliferator activated receptor gamma	Mus musculus	110-119
24447636-0	2014	Puerarin blocks the signaling transmission mediated by P2X3 in SG and DRG to relieve myocardial ischemic damage.	puerarin	0-8	purinergic receptor P2X 3	Homo sapiens	55-59
24447636-3	2014	The present study is aimed to observe the effects of puerarin on the signaling transmission mediated by P2X3 receptor in SG and DRG after myocardial ischemic damage.	puerarin	53-61	purinergic receptor P2X 3	Homo sapiens	104-108
24447636-5	2014	Puerarin reduced systolic blood pressure and heart rate, relieved pain and decreased up-regulated expression of P2X3 mRNA and protein in SG and DRG after myocardial ischemia.	puerarin	0-8	purinergic receptor P2X 3	Homo sapiens	112-116
24447636-7	2014	Thus, puerarin can relieve myocardial ischemic damage through blocking the P2X3 signaling transmission and then depressed the aggravated sympathoexcitatory reflex.	puerarin	6-14	purinergic receptor P2X 3	Homo sapiens	75-79
23512787-6	2014	Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	puerarin	0-8	glial cell line derived neurotrophic factor	Mus musculus	61-104
23512787-6	2014	Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	puerarin	0-8	glial cell line derived neurotrophic factor	Mus musculus	106-110
23512787-6	2014	Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	puerarin	0-8	thymoma viral proto-oncogene 1	Mus musculus	132-135
23512787-7	2014	In addition to the effect on ROS, puerarin ameliorated MPTP-reduced lysosome-associated membrane protein type 2A (Lamp 2A) expression.	puerarin	34-42	lysosomal-associated membrane protein 2	Mus musculus	68-112
23512787-7	2014	In addition to the effect on ROS, puerarin ameliorated MPTP-reduced lysosome-associated membrane protein type 2A (Lamp 2A) expression.	puerarin	34-42	lysosomal-associated membrane protein 2	Mus musculus	114-121
24454919-0	2014	Puerarin attenuated early diabetic kidney injury through down-regulation of matrix metalloproteinase 9 in streptozotocin-induced diabetic rats.	puerarin	0-8	matrix metallopeptidase 9	Rattus norvegicus	76-102
24454919-6	2014	In addition, both puerarin and losartan increased expression of podocyte slit diaphragm proteins such as nephrin and podocin.	puerarin	18-26	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	105-112
24454919-6	2014	In addition, both puerarin and losartan increased expression of podocyte slit diaphragm proteins such as nephrin and podocin.	puerarin	18-26	NPHS2 stomatin family member, podocin	Rattus norvegicus	117-124
24454919-8	2014	Furthermore, we found that matrix metalloproteinase-9 (MMP-9), which is known to be activated by oxidative stress and S-nitrosylation of proteins, was also suppressed more extensively by puerarin than losartan.	puerarin	187-195	matrix metallopeptidase 9	Rattus norvegicus	27-53
24454919-8	2014	Furthermore, we found that matrix metalloproteinase-9 (MMP-9), which is known to be activated by oxidative stress and S-nitrosylation of proteins, was also suppressed more extensively by puerarin than losartan.	puerarin	187-195	matrix metallopeptidase 9	Rattus norvegicus	55-60
24707866-7	2014	Our results showed puerarin could inhibit ALP activity, osteocalcin secretion and Runx2 expression in CVSMCs.	puerarin	19-27	runt related transcription factor 2	Mus musculus	82-87
24707866-8	2014	Puerarin could induce the activation of Akt.	puerarin	0-8	thymoma viral proto-oncogene 1	Mus musculus	40-43
23907019-0	2013	Puerarin suppresses proliferation of endometriotic stromal cells in part via differential recruitment of nuclear receptor coregulators to estrogen receptor-alpha.	puerarin	0-8	estrogen receptor 1	Homo sapiens	138-161
23906530-9	2014	In addition, the inhibitory effect of puerarin (1 muM, 5 muM, 10 muM, 20 muM, 40 muM) on mRNA expression of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in Ang II (1 muM)-stimulated H9c2 cells was investigated using quantitative real-time reverse transcription-polymerase chain reaction.	puerarin	38-46	natriuretic peptide A	Rattus norvegicus	108-134
23906530-9	2014	In addition, the inhibitory effect of puerarin (1 muM, 5 muM, 10 muM, 20 muM, 40 muM) on mRNA expression of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in Ang II (1 muM)-stimulated H9c2 cells was investigated using quantitative real-time reverse transcription-polymerase chain reaction.	puerarin	38-46	natriuretic peptide B	Rattus norvegicus	145-171
25089076-6	2014	Puerarin also reduced the upregulated levels of nuclear factor-kappaB (NF-kappaB) and other proinflammatory cytokines, such as IL-6, IL-1beta, and TNF-alpha, in the spinal cord.	puerarin	0-8	nuclear factor kappa B subunit 1	Homo sapiens	48-69
25089076-6	2014	Puerarin also reduced the upregulated levels of nuclear factor-kappaB (NF-kappaB) and other proinflammatory cytokines, such as IL-6, IL-1beta, and TNF-alpha, in the spinal cord.	puerarin	0-8	nuclear factor kappa B subunit 1	Homo sapiens	71-80
25089076-6	2014	Puerarin also reduced the upregulated levels of nuclear factor-kappaB (NF-kappaB) and other proinflammatory cytokines, such as IL-6, IL-1beta, and TNF-alpha, in the spinal cord.	puerarin	0-8	interleukin 6	Homo sapiens	127-131
25089076-6	2014	Puerarin also reduced the upregulated levels of nuclear factor-kappaB (NF-kappaB) and other proinflammatory cytokines, such as IL-6, IL-1beta, and TNF-alpha, in the spinal cord.	puerarin	0-8	interleukin 1 beta	Homo sapiens	133-141
25089076-6	2014	Puerarin also reduced the upregulated levels of nuclear factor-kappaB (NF-kappaB) and other proinflammatory cytokines, such as IL-6, IL-1beta, and TNF-alpha, in the spinal cord.	puerarin	0-8	tumor necrosis factor	Homo sapiens	147-156
25089076-8	2014	The anti-inflammation effect of puerarin might be related to the suppression of spinal NF-kappaB activation and/or cytokines upregulation.	puerarin	32-40	nuclear factor kappa B subunit 1	Homo sapiens	87-96
25590084-10	2014	Puerarin increased energy to ultimate load, plasma osteocalcin and ALP (p<0.01).	puerarin	0-8	bone gamma-carboxyglutamate protein	Rattus norvegicus	51-62
25059232-8	2014	The transcript levels of caveolin-3, amphiphysin-2 and junctophinlin-2, which are crucial for the formation and development of t-tubules, were significantly upregulated by puerarin treatment.	puerarin	172-180	caveolin 3	Mus musculus	25-35
25059232-8	2014	The transcript levels of caveolin-3, amphiphysin-2 and junctophinlin-2, which are crucial for the formation and development of t-tubules, were significantly upregulated by puerarin treatment.	puerarin	172-180	bridging integrator 1	Mus musculus	37-50
25059232-9	2014	Furthermore, puerarin repressed the expression of miR-22, which targets to caveolin-3.	puerarin	13-21	microRNA 22	Mus musculus	50-56
25059232-9	2014	Furthermore, puerarin repressed the expression of miR-22, which targets to caveolin-3.	puerarin	13-21	caveolin 3	Mus musculus	75-85
25059232-11	2014	This might be related to the repression of miR-22 by puerarin and upregulation of Cav3, Bin1 and JP2 transcripts.	puerarin	53-61	microRNA 22	Mus musculus	43-49
24715930-14	2014	Puerarin-treated MECs showed greater proliferation and p42/44 MAPKs activities than vehicle treatment.	puerarin	0-8	mitogen activated protein kinase 3	Rattus norvegicus	55-67
24715930-16	2014	Puerarin possesses effects of antihypertension and stroke prevention by improved microcirculation in SHRs, which results from the increase in cerebral blood perfusion both by arteriole relaxation and p42/44 MAPKs-mediated angiogenesis.	puerarin	0-8	mitogen activated protein kinase 3	Rattus norvegicus	200-212
24523826-9	2014	At the same time, the release of IL-4, IL-10, and IFN- gamma in serum and the expression of mRNAs in lung tissue homogenate were changed by puerarin.	puerarin	140-148	interleukin 4	Rattus norvegicus	33-37
24523826-9	2014	At the same time, the release of IL-4, IL-10, and IFN- gamma in serum and the expression of mRNAs in lung tissue homogenate were changed by puerarin.	puerarin	140-148	interleukin 10	Rattus norvegicus	39-44
24523826-9	2014	At the same time, the release of IL-4, IL-10, and IFN- gamma in serum and the expression of mRNAs in lung tissue homogenate were changed by puerarin.	puerarin	140-148	interleukin 18	Rattus norvegicus	50-60
23906530-9	2014	In addition, the inhibitory effect of puerarin (1 muM, 5 muM, 10 muM, 20 muM, 40 muM) on mRNA expression of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in Ang II (1 muM)-stimulated H9c2 cells was investigated using quantitative real-time reverse transcription-polymerase chain reaction.	puerarin	38-46	natriuretic peptide B	Rattus norvegicus	173-176
23906530-9	2014	In addition, the inhibitory effect of puerarin (1 muM, 5 muM, 10 muM, 20 muM, 40 muM) on mRNA expression of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in Ang II (1 muM)-stimulated H9c2 cells was investigated using quantitative real-time reverse transcription-polymerase chain reaction.	puerarin	38-46	angiogenin	Rattus norvegicus	181-184
23906530-13	2014	Further studies showed that pressure overload significantly induced the activation of phosphoinositide 3-kinase (PI3K)/Akt signaling and c-Jun N-terminal kinase (JNK) signaling, which was blocked by puerarin treatment.	puerarin	199-207	thymoma viral proto-oncogene 1	Mus musculus	119-122
23906530-13	2014	Further studies showed that pressure overload significantly induced the activation of phosphoinositide 3-kinase (PI3K)/Akt signaling and c-Jun N-terminal kinase (JNK) signaling, which was blocked by puerarin treatment.	puerarin	199-207	mitogen-activated protein kinase 8	Mus musculus	137-160
23906530-13	2014	Further studies showed that pressure overload significantly induced the activation of phosphoinositide 3-kinase (PI3K)/Akt signaling and c-Jun N-terminal kinase (JNK) signaling, which was blocked by puerarin treatment.	puerarin	199-207	mitogen-activated protein kinase 8	Mus musculus	162-165
23906530-14	2014	Cardiomyocyte apoptosis and induction of Bax in response to AB were suppressed by puerarin.	puerarin	82-90	BCL2-associated X protein	Mus musculus	41-44
23906530-15	2014	Furthermore, the increased mRNA expression of ANP and BNP induced by Ang II (1 muM) was restrained to a different extent by different concentrations of puerarin.	puerarin	152-160	natriuretic peptide type B	Mus musculus	54-57
23906530-15	2014	Furthermore, the increased mRNA expression of ANP and BNP induced by Ang II (1 muM) was restrained to a different extent by different concentrations of puerarin.	puerarin	152-160	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	69-72
23906530-16	2014	CONCLUSION: Puerarin may have an ability to retard the progression of cardiac hypertrophy and apoptosis which is probably mediated by the blockade of PI3K/Akt and JNK signaling pathways.	puerarin	12-20	thymoma viral proto-oncogene 1	Mus musculus	155-158
23906530-16	2014	CONCLUSION: Puerarin may have an ability to retard the progression of cardiac hypertrophy and apoptosis which is probably mediated by the blockade of PI3K/Akt and JNK signaling pathways.	puerarin	12-20	mitogen-activated protein kinase 8	Mus musculus	163-166
25206641-5	2013	Results showed that puerarin pretreatment (intravenous injection) reduced the ischemic infarct volume, improved neurological deficit after cerebral ischemia/reperfusion and decreased the levels of interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha in brain tissue.	puerarin	20-28	interleukin 1 beta	Rattus norvegicus	197-214
25206641-5	2013	Results showed that puerarin pretreatment (intravenous injection) reduced the ischemic infarct volume, improved neurological deficit after cerebral ischemia/reperfusion and decreased the levels of interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha in brain tissue.	puerarin	20-28	interleukin 6	Rattus norvegicus	216-261
25206641-6	2013	Pretreatment with puerarin (intravenous injection) attenuated the inflammatory response in rats, which was accompanied by janus-activated kinase 2 (JAK2) and signal transducers and activators of transcription 3 (STAT3) activation and nuclear factor kappa B (NF-kappaB) inhibition.	puerarin	18-26	Janus kinase 2	Rattus norvegicus	122-146
25206641-6	2013	Pretreatment with puerarin (intravenous injection) attenuated the inflammatory response in rats, which was accompanied by janus-activated kinase 2 (JAK2) and signal transducers and activators of transcription 3 (STAT3) activation and nuclear factor kappa B (NF-kappaB) inhibition.	puerarin	18-26	Janus kinase 2	Rattus norvegicus	148-152
25206641-6	2013	Pretreatment with puerarin (intravenous injection) attenuated the inflammatory response in rats, which was accompanied by janus-activated kinase 2 (JAK2) and signal transducers and activators of transcription 3 (STAT3) activation and nuclear factor kappa B (NF-kappaB) inhibition.	puerarin	18-26	signal transducer and activator of transcription 3	Rattus norvegicus	158-210
25206641-6	2013	Pretreatment with puerarin (intravenous injection) attenuated the inflammatory response in rats, which was accompanied by janus-activated kinase 2 (JAK2) and signal transducers and activators of transcription 3 (STAT3) activation and nuclear factor kappa B (NF-kappaB) inhibition.	puerarin	18-26	signal transducer and activator of transcription 3	Rattus norvegicus	212-217
23907019-8	2013	We found that puerarin can suppress estrogen-stimulated proliferation partly through down-regulating the transcription of cyclin D1 and cdc25A by promoting the recruitment of corepressors to estrogen receptor-alpha as well as limiting that of coactivators in ESCs.	puerarin	14-22	cyclin D1	Homo sapiens	122-131
23907019-8	2013	We found that puerarin can suppress estrogen-stimulated proliferation partly through down-regulating the transcription of cyclin D1 and cdc25A by promoting the recruitment of corepressors to estrogen receptor-alpha as well as limiting that of coactivators in ESCs.	puerarin	14-22	cell division cycle 25A	Homo sapiens	136-142
23907019-8	2013	We found that puerarin can suppress estrogen-stimulated proliferation partly through down-regulating the transcription of cyclin D1 and cdc25A by promoting the recruitment of corepressors to estrogen receptor-alpha as well as limiting that of coactivators in ESCs.	puerarin	14-22	estrogen receptor 1	Homo sapiens	191-214
23764356-1	2013	The protective effects of puerarin on liver damage were evaluated by carbon tetrachloride (CCl4)-induced hepatotoxicity in rats.	puerarin	26-34	C-C motif chemokine ligand 4	Rattus norvegicus	91-95
23668913-6	2013	Puerarin treatment could suppress the increase of acetylcholinesterase expression and activity to the levels of the intact group, although they were not significantly different from those of the ovariectomized animals.	puerarin	0-8	acetylcholinesterase	Cavia porcellus	50-70
24660593-0	2013	Effect of puerarin on matrix metalloproteinase-2 in human fetal scleral fibroblasts treated with low frequency electromagnetic fields.	puerarin	10-18	matrix metallopeptidase 2	Homo sapiens	22-48
24660593-1	2013	OBJECTIVE: To study the effect of puerarin on matrix metalloproteinase-2 (MMP-2) gene and protein expression in human fetal scleral fibroblasts (HFSFs) exposed to extremely low frequency electromagnetic fields (ELF-EMF).	puerarin	34-42	matrix metallopeptidase 2	Homo sapiens	46-72
24660593-1	2013	OBJECTIVE: To study the effect of puerarin on matrix metalloproteinase-2 (MMP-2) gene and protein expression in human fetal scleral fibroblasts (HFSFs) exposed to extremely low frequency electromagnetic fields (ELF-EMF).	puerarin	34-42	matrix metallopeptidase 2	Homo sapiens	74-79
24660593-4	2013	RESULTS: MMP-2 mRNA and protein expression increased by 0.793 and 1.130 folds respectively under the exposure of ELF-EMFs at 0.2 mT flux density for 24 h. Puerarin at the concentration of 0.1 microM reversed this effect by 8.53% in mRNA and by 17.97% in protein expression (P < 0.05).	puerarin	155-163	matrix metallopeptidase 2	Homo sapiens	9-14
23764356-6	2013	Liver histopathology also showed that puerarin reduced the incidence of liver lesions induced by CCl4.	puerarin	38-46	C-C motif chemokine ligand 4	Rattus norvegicus	97-101
23764356-7	2013	The results suggest that puerarin exhibits potent hepatoprotective effects on CCl4-induced liver damages in rats, and that the hepatoprotective effects of puerarin may be due to both the inhibition of lipid peroxidation and to increase of antioxidant enzymes activity.	puerarin	25-33	C-C motif chemokine ligand 4	Rattus norvegicus	78-82
23764356-3	2013	Our results showed that puerarin at doses of 50, 100, and 200 mg/kg b. w. significantly reduced the elevated activities of serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and lactate dehydrogenase at least 15%, 17%, 14% and 18%, respectively.	puerarin	24-32	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	155-181
23764356-4	2013	In addition, puerarin at different doses significantly decreased (p<0.05) the level of hepatic thiobarbituric acid reactive substances compared to the CCl4-treated group.	puerarin	13-21	C-C motif chemokine ligand 4	Rattus norvegicus	154-158
23764356-5	2013	Furthermore, the treatment of puerarin was also found to significantly increase the activities of superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase, and glutathione content at least 40%, 12%, 25%, 52%, 17% and 44% in the liver of CCl4-treated rats, respectively.	puerarin	30-38	catalase	Rattus norvegicus	120-128
23764356-5	2013	Furthermore, the treatment of puerarin was also found to significantly increase the activities of superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase, and glutathione content at least 40%, 12%, 25%, 52%, 17% and 44% in the liver of CCl4-treated rats, respectively.	puerarin	30-38	glutathione-disulfide reductase	Rattus norvegicus	154-175
23764356-5	2013	Furthermore, the treatment of puerarin was also found to significantly increase the activities of superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase, and glutathione content at least 40%, 12%, 25%, 52%, 17% and 44% in the liver of CCl4-treated rats, respectively.	puerarin	30-38	hematopoietic prostaglandin D synthase	Rattus norvegicus	177-202
23764356-5	2013	Furthermore, the treatment of puerarin was also found to significantly increase the activities of superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase, and glutathione content at least 40%, 12%, 25%, 52%, 17% and 44% in the liver of CCl4-treated rats, respectively.	puerarin	30-38	C-C motif chemokine ligand 4	Rattus norvegicus	285-289
23146695-0	2013	Puerarin mediates hepatoprotection against CCl4-induced hepatic fibrosis rats through attenuation of inflammation response and amelioration of metabolic function.	puerarin	0-8	C-C motif chemokine ligand 4	Rattus norvegicus	43-47
23965299-8	2013	Puerarin (20 muM) promoted osteocalcin secretion (P = 0.004) and the protein expression of both osteopontin (P = 0.001) and osteoprotegerin (P = 0.003).	puerarin	0-8	bone gamma-carboxyglutamate protein 2	Mus musculus	27-38
23965299-8	2013	Puerarin (20 muM) promoted osteocalcin secretion (P = 0.004) and the protein expression of both osteopontin (P = 0.001) and osteoprotegerin (P = 0.003).	puerarin	0-8	secreted phosphoprotein 1	Mus musculus	96-107
23965299-8	2013	Puerarin (20 muM) promoted osteocalcin secretion (P = 0.004) and the protein expression of both osteopontin (P = 0.001) and osteoprotegerin (P = 0.003).	puerarin	0-8	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	124-139
23965299-10	2013	In addition, puerarin (20 muM) decreased the mRNA and protein levels of CCAAT/enhancer binding protein alpha (P = 0.001, P = 0.002), proliferator-activated receptor gamma (P = 0.005, P = 0.003), and adipocyte lipid-binding protein 4 (P = 0.001, P = 0.001).	puerarin	13-21	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	72-108
23965299-11	2013	Moreover, phosphorylation of AKT1-Ser437 (10 muM, P = 0.003; 20 muM, P = 0.007) and GSK-Ser9 (10 muM, P = 0.005; 20 muM, P = 0.003), and the nuclear translocation of beta-catenin (10 muM, P = 0.006; 10 muM, P = 0.002) were increased in 3T3-L1 cells treated by puerarin.	puerarin	260-268	thymoma viral proto-oncogene 1	Mus musculus	29-33
23747813-0	2013	Puerarin attenuates neuronal degeneration in the substantia nigra of 6-OHDA-lesioned rats through regulating BDNF expression and activating the Nrf2/ARE signaling pathway.	puerarin	0-8	brain-derived neurotrophic factor	Rattus norvegicus	109-113
23747813-0	2013	Puerarin attenuates neuronal degeneration in the substantia nigra of 6-OHDA-lesioned rats through regulating BDNF expression and activating the Nrf2/ARE signaling pathway.	puerarin	0-8	NFE2 like bZIP transcription factor 2	Rattus norvegicus	144-148
23747813-9	2013	Our findings indicated that puerarin effectively protects against 6-OHDA-mediated oxidative stress injury in SN neurons, in which the underlying mechanisms are involved in modulating BDNF expression and activating the Nrf2/ARE signaling pathway.	puerarin	28-36	brain-derived neurotrophic factor	Rattus norvegicus	183-187
23747813-9	2013	Our findings indicated that puerarin effectively protects against 6-OHDA-mediated oxidative stress injury in SN neurons, in which the underlying mechanisms are involved in modulating BDNF expression and activating the Nrf2/ARE signaling pathway.	puerarin	28-36	NFE2 like bZIP transcription factor 2	Rattus norvegicus	218-222
23639192-9	2013	Using small interfering double-stranded RNA technology, we further demonstrate that the effects of puerarin on proliferation, differentiation and survival are mediated by both ERalpha and ERbeta.	puerarin	99-107	estrogen receptor 1	Homo sapiens	176-183
23639192-9	2013	Using small interfering double-stranded RNA technology, we further demonstrate that the effects of puerarin on proliferation, differentiation and survival are mediated by both ERalpha and ERbeta.	puerarin	99-107	estrogen receptor 2	Homo sapiens	188-194
23639192-10	2013	Moreover, we also demonstrate that puerarin functions at least partially through activation of MEK/ERK and PI3K/Akt signaling.	puerarin	35-43	mitogen-activated protein kinase kinase 7	Homo sapiens	95-98
23639192-10	2013	Moreover, we also demonstrate that puerarin functions at least partially through activation of MEK/ERK and PI3K/Akt signaling.	puerarin	35-43	mitogen-activated protein kinase 1	Homo sapiens	99-102
23639192-10	2013	Moreover, we also demonstrate that puerarin functions at least partially through activation of MEK/ERK and PI3K/Akt signaling.	puerarin	35-43	AKT serine/threonine kinase 1	Homo sapiens	112-115
23523569-1	2013	This study aimed to investigate the effect of combination of felodipine+puerarin on ACE2-Ang (1-7)-Mas axis, and to explore the protective effect of the combination against kidney in renovascular hypertensive rats.	puerarin	72-80	angiotensin I converting enzyme 2	Rattus norvegicus	84-88
23523569-1	2013	This study aimed to investigate the effect of combination of felodipine+puerarin on ACE2-Ang (1-7)-Mas axis, and to explore the protective effect of the combination against kidney in renovascular hypertensive rats.	puerarin	72-80	angiogenin	Rattus norvegicus	89-92
23500774-0	2013	Anti-fibrotic effects of puerarin on CCl4-induced hepatic fibrosis in rats possibly through the regulation of PPAR-gamma expression and inhibition of PI3K/Akt pathway.	puerarin	25-33	C-C motif chemokine ligand 4	Rattus norvegicus	37-41
23500774-0	2013	Anti-fibrotic effects of puerarin on CCl4-induced hepatic fibrosis in rats possibly through the regulation of PPAR-gamma expression and inhibition of PI3K/Akt pathway.	puerarin	25-33	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	110-120
23500774-0	2013	Anti-fibrotic effects of puerarin on CCl4-induced hepatic fibrosis in rats possibly through the regulation of PPAR-gamma expression and inhibition of PI3K/Akt pathway.	puerarin	25-33	AKT serine/threonine kinase 1	Rattus norvegicus	155-158
23500774-2	2013	In this study, we aimed to investigate the therapeutic effects of puerarin (PR), an active ingredient from kudzu root, on CCl4-induced HF rats.	puerarin	66-74	C-C motif chemokine ligand 4	Rattus norvegicus	122-126
23277536-9	2013	These hepatic pathologic changes were significantly inhibited in puerarin-treated animals as were the endotoxin levels and hepatic CD68 and endotoxin receptors.	puerarin	65-73	Cd68 molecule	Rattus norvegicus	131-135
23639192-0	2013	Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/Akt activation.	puerarin	0-8	mitogen-activated protein kinase kinase 7	Homo sapiens	137-140
23639192-0	2013	Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/Akt activation.	puerarin	0-8	mitogen-activated protein kinase 1	Homo sapiens	141-144
23639192-0	2013	Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/Akt activation.	puerarin	0-8	AKT serine/threonine kinase 1	Homo sapiens	154-157
23639192-7	2013	Puerarin promotes proliferation by altering cell cycle distribution whereas puerarin-mediated survival may be associated with up-regulation of Bcl-xL expression.	puerarin	76-84	BCL2 like 1	Homo sapiens	143-149
23501611-9	2013	Western blot analysis showed that puerarin dramatically increased the expression levels of nNOS, eNOS and phosphor-Akt in brains of Pb-treated mice.	puerarin	34-42	nitric oxide synthase 1, neuronal	Mus musculus	91-95
23501611-9	2013	Western blot analysis showed that puerarin dramatically increased the expression levels of nNOS, eNOS and phosphor-Akt in brains of Pb-treated mice.	puerarin	34-42	thymoma viral proto-oncogene 1	Mus musculus	115-118
23501611-10	2013	In conclusion, these results suggested that puerarin can inhibit Pb-induced neurotoxicity, at least in part, by suppressing oxidative stress, reversing the Pb-induced alterations in transmitters and enzymes and modulating the PKA/Akt/NOS signaling pathway.	puerarin	44-52	thymoma viral proto-oncogene 1	Mus musculus	230-233
23146695-8	2013	These findings demonstrate that puerarin successfully reverses hepatotoxicity in CCl(4)-induced HF rats via the underlying mechanisms of regulating serum enzymes and attenuating TNF-alpha/NF-kappaB pathway for anti-inflammation response, as well as improving metabolic function in liver tissue.	puerarin	32-40	tumor necrosis factor	Rattus norvegicus	178-187
23668014-0	2013	[Effect of puerarin combined with felodipine on mRNA and protein expression of apelin and APJ in renovascular hypertensive rat].	puerarin	11-19	apelin	Rattus norvegicus	79-85
23668014-0	2013	[Effect of puerarin combined with felodipine on mRNA and protein expression of apelin and APJ in renovascular hypertensive rat].	puerarin	11-19	apelin receptor	Rattus norvegicus	90-93
23089583-5	2013	Annexin V-FITC/PI staining method was conducted to determine the influences of the puerarin nanosuspensions on cell cycle and apoptosis.	puerarin	83-91	annexin A5	Homo sapiens	0-9
23668014-1	2013	OBJECTIVE: To explore the effect of puerarin combined with felodipine on the mRNA and protein expression of apelin and APJ in renal tissue of renovascular hypertensive rat.	puerarin	36-44	apelin	Rattus norvegicus	108-114
23668014-1	2013	OBJECTIVE: To explore the effect of puerarin combined with felodipine on the mRNA and protein expression of apelin and APJ in renal tissue of renovascular hypertensive rat.	puerarin	36-44	apelin receptor	Rattus norvegicus	119-122
23668014-10	2013	Compared with felodipine group, the expression of apelin mRNA and protein in ischemic and non-ischemic kidneys was decreased (P < 0.01 or P < 0.05) in the group treated with both puerarin and felodipine; and the expression of APJ mRNA and protein in ischemic kidneys did not reach significant level, however, that was upregulated in non-ischemic kidneys (P < 0.01 or P < 0.05).	puerarin	185-193	apelin	Rattus norvegicus	50-56
23668014-10	2013	Compared with felodipine group, the expression of apelin mRNA and protein in ischemic and non-ischemic kidneys was decreased (P < 0.01 or P < 0.05) in the group treated with both puerarin and felodipine; and the expression of APJ mRNA and protein in ischemic kidneys did not reach significant level, however, that was upregulated in non-ischemic kidneys (P < 0.01 or P < 0.05).	puerarin	185-193	apelin receptor	Rattus norvegicus	232-235
23668014-11	2013	CONCLUSION: Puerarin downregulates the expression of apelin mRNA and protein in ischemic and non-ischemic kidneys, and upregulates that of APJ mRNA and protein in non-ischemic kidneys.	puerarin	12-20	apelin	Rattus norvegicus	53-59
23668014-11	2013	CONCLUSION: Puerarin downregulates the expression of apelin mRNA and protein in ischemic and non-ischemic kidneys, and upregulates that of APJ mRNA and protein in non-ischemic kidneys.	puerarin	12-20	apelin receptor	Rattus norvegicus	139-142
23668014-13	2013	The results suggest that puerarin regulates blood pressure and protects target organ through apelin/APJ pathway and that puerarin has synergetic effects with CCB.	puerarin	25-33	apelin	Rattus norvegicus	93-99
23668014-13	2013	The results suggest that puerarin regulates blood pressure and protects target organ through apelin/APJ pathway and that puerarin has synergetic effects with CCB.	puerarin	25-33	apelin receptor	Rattus norvegicus	100-103
23088308-3	2013	The central hypothesis guiding this study is that puerarin will prevent or at least markedly attenuate Abeta(25-35)-induced excess production of reactive oxygen species (ROS) by interrupting glycogen synthase kinase-3beta (GSK-3beta) signaling.	puerarin	50-58	glycogen synthase kinase 3 beta	Rattus norvegicus	191-221
24080853-7	2013	Puerarin treatment shifted the cardiac phenotype from pacemaker-like cells to ventricular-like cells, which were Mlc2v-positive and present typical ventricular-like AP.	puerarin	0-8	myosin, light polypeptide 2, regulatory, cardiac, slow	Mus musculus	113-118
23088308-5	2013	Puerarin induced expression of nuclear Nrf2 protein, but not in the Nrf2 mRNA level, and increased heme oxygenase-1 (HO-1) levels at levels of transcription and translation.	puerarin	0-8	NFE2 like bZIP transcription factor 2	Rattus norvegicus	39-43
23088308-5	2013	Puerarin induced expression of nuclear Nrf2 protein, but not in the Nrf2 mRNA level, and increased heme oxygenase-1 (HO-1) levels at levels of transcription and translation.	puerarin	0-8	heme oxygenase 1	Rattus norvegicus	99-115
23088308-3	2013	The central hypothesis guiding this study is that puerarin will prevent or at least markedly attenuate Abeta(25-35)-induced excess production of reactive oxygen species (ROS) by interrupting glycogen synthase kinase-3beta (GSK-3beta) signaling.	puerarin	50-58	glycogen synthase kinase 3 beta	Rattus norvegicus	223-232
23085309-12	2012	The Papp of puerarin transported on Caco-2 cell monolayer model was significantly changed when the specified inhibitors of P-gp were added to the model and the PDR decreased from 1.74 to 0.43.	puerarin	12-20	phosphoglycolate phosphatase	Homo sapiens	123-127
23088308-6	2013	Puerarin-induced Serine 9 phosphorylation of GSK-3beta was blocked by lithium chloride treatment in primary hippocampal neurons, indicating the participation of the GSK-3beta inactivation.	puerarin	0-8	glycogen synthase kinase 3 beta	Rattus norvegicus	45-54
23088308-6	2013	Puerarin-induced Serine 9 phosphorylation of GSK-3beta was blocked by lithium chloride treatment in primary hippocampal neurons, indicating the participation of the GSK-3beta inactivation.	puerarin	0-8	glycogen synthase kinase 3 beta	Rattus norvegicus	165-174
23843790-0	2013	Puerarin Suppress Apoptosis of Human Osteoblasts via ERK Signaling Pathway.	puerarin	0-8	mitogen-activated protein kinase 1	Homo sapiens	53-56
23843790-3	2013	However, the effect of puerarin on the process of human osteoblasts (hOBs) apoptosis is still unclear.	puerarin	23-31	leptin	Homo sapiens	69-73
23843790-4	2013	In this study, we detected the function of puerarin on serum-free-induced cell apoptosis using ELISA and TUNEL arrays and then found that the mortality of hOBs was significantly decreased after exposure to 10(-10)-10(-6) M puerarin and reached the maximal antiapoptotic effect at the concentration of 10(-8) M. In addition, compared with the control group, puerarin notably increased the Bcl-2 protein levels while it decreased the Bax protein levels in the hOBs in a dose-dependent way.	puerarin	43-51	leptin	Homo sapiens	155-159
23843790-4	2013	In this study, we detected the function of puerarin on serum-free-induced cell apoptosis using ELISA and TUNEL arrays and then found that the mortality of hOBs was significantly decreased after exposure to 10(-10)-10(-6) M puerarin and reached the maximal antiapoptotic effect at the concentration of 10(-8) M. In addition, compared with the control group, puerarin notably increased the Bcl-2 protein levels while it decreased the Bax protein levels in the hOBs in a dose-dependent way.	puerarin	43-51	BCL2 apoptosis regulator	Homo sapiens	388-393
23843790-4	2013	In this study, we detected the function of puerarin on serum-free-induced cell apoptosis using ELISA and TUNEL arrays and then found that the mortality of hOBs was significantly decreased after exposure to 10(-10)-10(-6) M puerarin and reached the maximal antiapoptotic effect at the concentration of 10(-8) M. In addition, compared with the control group, puerarin notably increased the Bcl-2 protein levels while it decreased the Bax protein levels in the hOBs in a dose-dependent way.	puerarin	43-51	BCL2 associated X, apoptosis regulator	Homo sapiens	432-435
23843790-4	2013	In this study, we detected the function of puerarin on serum-free-induced cell apoptosis using ELISA and TUNEL arrays and then found that the mortality of hOBs was significantly decreased after exposure to 10(-10)-10(-6) M puerarin and reached the maximal antiapoptotic effect at the concentration of 10(-8) M. In addition, compared with the control group, puerarin notably increased the Bcl-2 protein levels while it decreased the Bax protein levels in the hOBs in a dose-dependent way.	puerarin	43-51	leptin	Homo sapiens	458-462
23843790-4	2013	In this study, we detected the function of puerarin on serum-free-induced cell apoptosis using ELISA and TUNEL arrays and then found that the mortality of hOBs was significantly decreased after exposure to 10(-10)-10(-6) M puerarin and reached the maximal antiapoptotic effect at the concentration of 10(-8) M. In addition, compared with the control group, puerarin notably increased the Bcl-2 protein levels while it decreased the Bax protein levels in the hOBs in a dose-dependent way.	puerarin	223-231	leptin	Homo sapiens	155-159
23843790-4	2013	In this study, we detected the function of puerarin on serum-free-induced cell apoptosis using ELISA and TUNEL arrays and then found that the mortality of hOBs was significantly decreased after exposure to 10(-10)-10(-6) M puerarin and reached the maximal antiapoptotic effect at the concentration of 10(-8) M. In addition, compared with the control group, puerarin notably increased the Bcl-2 protein levels while it decreased the Bax protein levels in the hOBs in a dose-dependent way.	puerarin	223-231	leptin	Homo sapiens	155-159
23843790-5	2013	10(-7) M puerarin decreased the Bax/Bcl-2 ratio with a maximal decrease to 0.08.	puerarin	9-17	BCL2 associated X, apoptosis regulator	Homo sapiens	32-35
23843790-5	2013	10(-7) M puerarin decreased the Bax/Bcl-2 ratio with a maximal decrease to 0.08.	puerarin	9-17	BCL2 apoptosis regulator	Homo sapiens	36-41
23843790-6	2013	Moreover, puerarin activated ERK signaling pathways in hOBs, and the antiapoptotic effect induced by puerarin was abolished by incubation of ERK inhibitor PD98059.	puerarin	10-18	mitogen-activated protein kinase 1	Homo sapiens	29-32
23843790-6	2013	Moreover, puerarin activated ERK signaling pathways in hOBs, and the antiapoptotic effect induced by puerarin was abolished by incubation of ERK inhibitor PD98059.	puerarin	10-18	leptin	Homo sapiens	55-59
23843790-6	2013	Moreover, puerarin activated ERK signaling pathways in hOBs, and the antiapoptotic effect induced by puerarin was abolished by incubation of ERK inhibitor PD98059.	puerarin	10-18	mitogen-activated protein kinase 1	Homo sapiens	141-144
23843790-6	2013	Moreover, puerarin activated ERK signaling pathways in hOBs, and the antiapoptotic effect induced by puerarin was abolished by incubation of ERK inhibitor PD98059.	puerarin	101-109	leptin	Homo sapiens	55-59
23843790-6	2013	Moreover, puerarin activated ERK signaling pathways in hOBs, and the antiapoptotic effect induced by puerarin was abolished by incubation of ERK inhibitor PD98059.	puerarin	101-109	mitogen-activated protein kinase 1	Homo sapiens	141-144
23843790-7	2013	Similarly, the estrogen receptor antagonist ICI182780 also suppressed the inhibitory effect of puerarin on hOBs apoptosis.	puerarin	95-103	leptin	Homo sapiens	107-111
23843790-8	2013	In conclusion, puerarin could prevent hOBs apoptosis via ERK signaling pathway, which might be effective in providing protection against bone loss and bone remolding associated with osteoporosis.	puerarin	15-23	leptin	Homo sapiens	38-42
23843790-8	2013	In conclusion, puerarin could prevent hOBs apoptosis via ERK signaling pathway, which might be effective in providing protection against bone loss and bone remolding associated with osteoporosis.	puerarin	15-23	mitogen-activated protein kinase 1	Homo sapiens	57-60
23085309-14	2012	The intestinal absorption of puerarin is by passive diffusion as the dominating process and active transportation was mediated by P-gp and MRP transporter in Caco-2 cell monolayer model, and Radix Angelicae Dahuricae could enhance the intestinal absorption of puerarin.	puerarin	29-37	phosphoglycolate phosphatase	Homo sapiens	130-134
23085309-14	2012	The intestinal absorption of puerarin is by passive diffusion as the dominating process and active transportation was mediated by P-gp and MRP transporter in Caco-2 cell monolayer model, and Radix Angelicae Dahuricae could enhance the intestinal absorption of puerarin.	puerarin	29-37	ATP binding cassette subfamily C member 1	Homo sapiens	139-142
23146804-0	2012	Puerarin enhances superoxide dismutase activity and inhibits RAGE and VEGF expression in retinas of STZ-induced early diabetic rats.	puerarin	0-8	advanced glycosylation end product-specific receptor	Rattus norvegicus	61-65
25368634-8	2012	Furthermore, puerarin treatment downregulated Bax expression, upregulated bcl-2 expression and attenuated the activation of caspase-3 and -9.	puerarin	13-21	BCL2 associated X, apoptosis regulator	Homo sapiens	46-49
25368634-8	2012	Furthermore, puerarin treatment downregulated Bax expression, upregulated bcl-2 expression and attenuated the activation of caspase-3 and -9.	puerarin	13-21	BCL2 apoptosis regulator	Homo sapiens	74-79
25368634-8	2012	Furthermore, puerarin treatment downregulated Bax expression, upregulated bcl-2 expression and attenuated the activation of caspase-3 and -9.	puerarin	13-21	caspase 3	Homo sapiens	124-140
22648071-0	2012	UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for puerarin metabolism in human liver microsomes.	puerarin	72-80	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-31
23146804-0	2012	Puerarin enhances superoxide dismutase activity and inhibits RAGE and VEGF expression in retinas of STZ-induced early diabetic rats.	puerarin	0-8	vascular endothelial growth factor A	Rattus norvegicus	70-74
23146804-8	2012	mRNA and protein expression levels of RAGE and VEGF in the DM group were significantly higher than those of the other groups (P<0.05), and decreased after puerarin treatment (P<0.05).	puerarin	158-166	advanced glycosylation end product-specific receptor	Rattus norvegicus	38-42
23146804-8	2012	mRNA and protein expression levels of RAGE and VEGF in the DM group were significantly higher than those of the other groups (P<0.05), and decreased after puerarin treatment (P<0.05).	puerarin	158-166	vascular endothelial growth factor A	Rattus norvegicus	47-51
23146804-9	2012	CONCLUSIONS: Puerarin is able to enhance SOD activity, and inhibit RAGE and VEGF expressions in retinas of STZ-induced early diabetic rats.	puerarin	13-21	advanced glycosylation end product-specific receptor	Rattus norvegicus	67-71
23146804-9	2012	CONCLUSIONS: Puerarin is able to enhance SOD activity, and inhibit RAGE and VEGF expressions in retinas of STZ-induced early diabetic rats.	puerarin	13-21	vascular endothelial growth factor A	Rattus norvegicus	76-80
22609359-3	2012	In the present study, we determined the efficacy and possible mechanism of puerarin on the advanced glycation end product (AGE)-modified bovine serum albumin (BSA)-induced apoptosis of cultured bovine retinal pericytes and rat retinal pericytes in intravitreally AGE-modified rat serum albumin (RSA)-injected eyes.	puerarin	75-83	albumin	Bos taurus	144-157
21146379-6	2012	Puerarin markedly restored Cu/Zn-SOD, CAT and GPx activities and the GSH/GSSG ratio in the liver of lead-treated rat.	puerarin	0-8	superoxide dismutase 1	Rattus norvegicus	27-36
21146379-6	2012	Puerarin markedly restored Cu/Zn-SOD, CAT and GPx activities and the GSH/GSSG ratio in the liver of lead-treated rat.	puerarin	0-8	catalase	Rattus norvegicus	38-41
21146379-8	2012	The enhanced caspase-3 activity in the rat liver induced by lead was also inhibited by puerarin.	puerarin	87-95	caspase 3	Rattus norvegicus	13-22
22079205-0	2012	Puerarin prevents isoprenaline-induced myocardial fibrosis in mice by reduction of myocardial TGF-beta1 expression.	puerarin	0-8	transforming growth factor, beta 1	Mus musculus	94-103
22079205-5	2012	The results from reverse transcription polymerase chain reaction indicated that the messenger RNA (mRNA) expression of transforming growth factor-beta1 in myocardial tissue was decreased, while the mRNA expressions of peroxisome proliferator-activated receptor alpha/gamma were increased, in the puerarin groups as compared with the model group.	puerarin	296-304	transforming growth factor, beta 1	Mus musculus	119-151
22079205-5	2012	The results from reverse transcription polymerase chain reaction indicated that the messenger RNA (mRNA) expression of transforming growth factor-beta1 in myocardial tissue was decreased, while the mRNA expressions of peroxisome proliferator-activated receptor alpha/gamma were increased, in the puerarin groups as compared with the model group.	puerarin	296-304	peroxisome proliferator activated receptor alpha	Mus musculus	218-266
22079205-6	2012	Importantly, puerarin could significantly decrease the protein expressions of transforming growth factor-beta1 and nuclear factor-kappaB in myocardial tissue.	puerarin	13-21	transforming growth factor, beta 1	Mus musculus	78-110
22079205-7	2012	These results suggested that puerarin could prevent isoprenaline-induced myocardial fibrosis in mice, and its mechanisms might be related to reduction of transforming growth factor-beta1 expression via activation of peroxisome proliferator-activated receptor alpha/gamma and subsequent inhibition of nuclear factor-kappaB in myocardial tissue.	puerarin	29-37	transforming growth factor, beta 1	Mus musculus	154-186
22079205-7	2012	These results suggested that puerarin could prevent isoprenaline-induced myocardial fibrosis in mice, and its mechanisms might be related to reduction of transforming growth factor-beta1 expression via activation of peroxisome proliferator-activated receptor alpha/gamma and subsequent inhibition of nuclear factor-kappaB in myocardial tissue.	puerarin	29-37	peroxisome proliferator activated receptor alpha	Mus musculus	216-264
22951392-5	2012	Quantitative real-time PCR revealed that P. mirifica extract and puerarin significantly increased the mRNA expression of alkaline phosphatase (ALP) and osteoprotegerin, but not Runx2, osterix or osteocalcin.	puerarin	65-73	TNF receptor superfamily member 11B	Rattus norvegicus	152-167
22951392-5	2012	Quantitative real-time PCR revealed that P. mirifica extract and puerarin significantly increased the mRNA expression of alkaline phosphatase (ALP) and osteoprotegerin, but not Runx2, osterix or osteocalcin.	puerarin	65-73	Sp7 transcription factor	Rattus norvegicus	184-191
22951392-5	2012	Quantitative real-time PCR revealed that P. mirifica extract and puerarin significantly increased the mRNA expression of alkaline phosphatase (ALP) and osteoprotegerin, but not Runx2, osterix or osteocalcin.	puerarin	65-73	bone gamma-carboxyglutamate protein	Rattus norvegicus	195-206
23075718-0	2012	Stimulatory effect of puerarin on bone formation through co-activation of nitric oxide and bone morphogenetic protein-2/mitogen-activated protein kinases pathways in mice.	puerarin	22-30	bone morphogenetic protein 2	Mus musculus	91-119
23075718-10	2012	With 10(-8) mol/L puerarin treatment, BMP-2, SMAD4, Cbfa1/Runx2, and OPG gene expression were up-regulated, while the RANKL gene expression is down-regulated.	puerarin	18-26	bone morphogenetic protein 2	Mus musculus	38-43
23075718-10	2012	With 10(-8) mol/L puerarin treatment, BMP-2, SMAD4, Cbfa1/Runx2, and OPG gene expression were up-regulated, while the RANKL gene expression is down-regulated.	puerarin	18-26	SMAD family member 4	Mus musculus	45-50
23075718-10	2012	With 10(-8) mol/L puerarin treatment, BMP-2, SMAD4, Cbfa1/Runx2, and OPG gene expression were up-regulated, while the RANKL gene expression is down-regulated.	puerarin	18-26	runt related transcription factor 2	Mus musculus	52-57
23075718-10	2012	With 10(-8) mol/L puerarin treatment, BMP-2, SMAD4, Cbfa1/Runx2, and OPG gene expression were up-regulated, while the RANKL gene expression is down-regulated.	puerarin	18-26	runt related transcription factor 2	Mus musculus	58-63
23075718-10	2012	With 10(-8) mol/L puerarin treatment, BMP-2, SMAD4, Cbfa1/Runx2, and OPG gene expression were up-regulated, while the RANKL gene expression is down-regulated.	puerarin	18-26	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	69-72
23075718-10	2012	With 10(-8) mol/L puerarin treatment, BMP-2, SMAD4, Cbfa1/Runx2, and OPG gene expression were up-regulated, while the RANKL gene expression is down-regulated.	puerarin	18-26	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	118-123
23075718-12	2012	CONCLUSIONS: In this in vitro study, we demonstrate that puerarin is a bone anabolic agent that exerts its osteogenic effects through the induction of BMP-2 and NO synthesis, subsequently regulating Cbfa1/Runx2, OPG, and RANKL gene expression.	puerarin	57-65	bone morphogenetic protein 2	Mus musculus	151-156
23075718-12	2012	CONCLUSIONS: In this in vitro study, we demonstrate that puerarin is a bone anabolic agent that exerts its osteogenic effects through the induction of BMP-2 and NO synthesis, subsequently regulating Cbfa1/Runx2, OPG, and RANKL gene expression.	puerarin	57-65	runt related transcription factor 2	Mus musculus	199-204
23075718-12	2012	CONCLUSIONS: In this in vitro study, we demonstrate that puerarin is a bone anabolic agent that exerts its osteogenic effects through the induction of BMP-2 and NO synthesis, subsequently regulating Cbfa1/Runx2, OPG, and RANKL gene expression.	puerarin	57-65	runt related transcription factor 2	Mus musculus	205-210
23075718-12	2012	CONCLUSIONS: In this in vitro study, we demonstrate that puerarin is a bone anabolic agent that exerts its osteogenic effects through the induction of BMP-2 and NO synthesis, subsequently regulating Cbfa1/Runx2, OPG, and RANKL gene expression.	puerarin	57-65	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	212-215
23075718-12	2012	CONCLUSIONS: In this in vitro study, we demonstrate that puerarin is a bone anabolic agent that exerts its osteogenic effects through the induction of BMP-2 and NO synthesis, subsequently regulating Cbfa1/Runx2, OPG, and RANKL gene expression.	puerarin	57-65	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	221-226
23311164-13	2012	The pretreatment with puerarin could inhibit the expression of TNF-alpha and MIP-2 in cell supernatant and NF-kappaB p65 mRNA in cells (P < 0.05).	puerarin	22-30	tumor necrosis factor	Mus musculus	63-72
23311164-13	2012	The pretreatment with puerarin could inhibit the expression of TNF-alpha and MIP-2 in cell supernatant and NF-kappaB p65 mRNA in cells (P < 0.05).	puerarin	22-30	chemokine (C-X-C motif) ligand 2	Mus musculus	77-82
23311164-13	2012	The pretreatment with puerarin could inhibit the expression of TNF-alpha and MIP-2 in cell supernatant and NF-kappaB p65 mRNA in cells (P < 0.05).	puerarin	22-30	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	107-116
23311164-13	2012	The pretreatment with puerarin could inhibit the expression of TNF-alpha and MIP-2 in cell supernatant and NF-kappaB p65 mRNA in cells (P < 0.05).	puerarin	22-30	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	117-120
23311164-15	2012	CONCLUSION: As a safe and effective natural anti-inflammatory drug, puerarin can significantly reduce the expression of inflammatory cytokines (TNF-alpha, MIP-2).	puerarin	68-76	tumor necrosis factor	Mus musculus	144-153
23311164-15	2012	CONCLUSION: As a safe and effective natural anti-inflammatory drug, puerarin can significantly reduce the expression of inflammatory cytokines (TNF-alpha, MIP-2).	puerarin	68-76	chemokine (C-X-C motif) ligand 2	Mus musculus	155-160
22609359-3	2012	In the present study, we determined the efficacy and possible mechanism of puerarin on the advanced glycation end product (AGE)-modified bovine serum albumin (BSA)-induced apoptosis of cultured bovine retinal pericytes and rat retinal pericytes in intravitreally AGE-modified rat serum albumin (RSA)-injected eyes.	puerarin	75-83	albumin	Rattus norvegicus	280-293
22609359-4	2012	Puerarin significantly inhibited pericyte apoptosis, the generation of reactive oxygen species (ROS), and NADPH oxidase activity by inhibiting the phosphorylation of p47phox and Rac1 which were induced by the AGE-BSA treatment.	puerarin	0-8	neutrophil cytosolic factor 1	Rattus norvegicus	166-173
22609359-4	2012	Puerarin significantly inhibited pericyte apoptosis, the generation of reactive oxygen species (ROS), and NADPH oxidase activity by inhibiting the phosphorylation of p47phox and Rac1 which were induced by the AGE-BSA treatment.	puerarin	0-8	Rac family small GTPase 1	Rattus norvegicus	178-182
22401764-10	2012	The in vitro data showed that puerarin inhibited the production of IL-1beta, TNF-alpha, IL-6, PGE(2) and NO; moreover, the RT-PCR analysis and the western blot analysis indicated that puerarin regulated the transcriptional level via suppression of NF-kappaB activation and blockade of MAPK signal pathway.	puerarin	30-38	interleukin 1 beta	Rattus norvegicus	67-75
21352351-0	2012	Puerarin protects human umbilical vein endothelial cells against high glucose-induced apoptosis by upregulating heme oxygenase-1 and inhibiting calpain activation.	puerarin	0-8	heme oxygenase 1	Homo sapiens	112-128
21352351-5	2012	Compared with the NG group, exposure of HUVECs to HG for 48 h resulted in significant increases in calpain and caspase-3 activity as well as apoptosis, which were prevented by co-incubation with puerarin (1-100 mum) in a concentration-dependent manner.	puerarin	195-203	caspase 3	Homo sapiens	111-120
21352351-6	2012	HO-1 mRNA expression and HO activity were decreased in HUVECs treated with HG for 48 h. Compared with the group exposed to HG alone, co-incubation of HUVECs with puerarin and HG induced increases in HO-1 mRNA expression and HO activity.	puerarin	162-170	heme oxygenase 1	Homo sapiens	0-4
21352351-6	2012	HO-1 mRNA expression and HO activity were decreased in HUVECs treated with HG for 48 h. Compared with the group exposed to HG alone, co-incubation of HUVECs with puerarin and HG induced increases in HO-1 mRNA expression and HO activity.	puerarin	162-170	heme oxygenase 1	Homo sapiens	199-203
21352351-7	2012	The HO-1 inhibitor protoporphyrin IX zinc (II) abolished the inhibitory effect of puerarin on HG-induced calpain and caspase-3 activation, as well as apoptosis.	puerarin	82-90	heme oxygenase 1	Homo sapiens	4-8
21352351-7	2012	The HO-1 inhibitor protoporphyrin IX zinc (II) abolished the inhibitory effect of puerarin on HG-induced calpain and caspase-3 activation, as well as apoptosis.	puerarin	82-90	caspase 3	Homo sapiens	117-126
21352351-8	2012	The data show that puerarin protects against HG-induced endothelial cell apoptosis by a mechanism involving upregulation of HO-1 expression and inhibition of calpain activity.	puerarin	19-27	heme oxygenase 1	Homo sapiens	124-128
22470138-0	2012	Puerarin inhibits caspase-3 expression in osteoblasts of diabetic rats.	puerarin	0-8	caspase 3	Rattus norvegicus	18-27
22470138-1	2012	The aim of this study was to investigate the protective effect of puerarin on attenuating caspase-3 expression in osteoblasts of streptozotocin-induced diabetic rats and the possible mechanisms involved.	puerarin	66-74	caspase 3	Rattus norvegicus	90-99
22470138-6	2012	These pathological changes were improved and caspase-3 expression decreased in the puerarin-treated rats compared to the diabetic rats (P<0.01).	puerarin	83-91	caspase 3	Rattus norvegicus	45-54
22470138-8	2012	Puerarin may play a protective role in diabetic osteoporosis via the reduction of caspase-3 expression.	puerarin	0-8	caspase 3	Rattus norvegicus	82-91
22314193-0	2012	Puerarin attenuates endothelial insulin resistance through inhibition of inflammatory response in an IKKbeta/IRS-1-dependent manner.	puerarin	0-8	inhibitor of nuclear factor kappa B kinase subunit beta	Rattus norvegicus	101-108
22314193-0	2012	Puerarin attenuates endothelial insulin resistance through inhibition of inflammatory response in an IKKbeta/IRS-1-dependent manner.	puerarin	0-8	insulin receptor substrate 1	Rattus norvegicus	109-114
22314193-7	2012	Puerarin inhibited IKKbeta/NF-kappaB activation and decreased TNF-alpha and IL-6 production with the downregulation of relative gene overexpression.	puerarin	0-8	inhibitor of nuclear factor kappa B kinase subunit beta	Rattus norvegicus	19-26
22314193-7	2012	Puerarin inhibited IKKbeta/NF-kappaB activation and decreased TNF-alpha and IL-6 production with the downregulation of relative gene overexpression.	puerarin	0-8	tumor necrosis factor	Rattus norvegicus	62-71
22314193-7	2012	Puerarin inhibited IKKbeta/NF-kappaB activation and decreased TNF-alpha and IL-6 production with the downregulation of relative gene overexpression.	puerarin	0-8	interleukin 6	Rattus norvegicus	76-80
22314193-9	2012	Puerarin attenuated PA-induced phosphorylation of insulin receptor substrate-1 (IRS-1) at S307 and effectively ameliorated insulin-mediated tyrosine phosphorylation of IRS-1.	puerarin	0-8	insulin receptor substrate 1	Rattus norvegicus	50-78
22314193-9	2012	Puerarin attenuated PA-induced phosphorylation of insulin receptor substrate-1 (IRS-1) at S307 and effectively ameliorated insulin-mediated tyrosine phosphorylation of IRS-1.	puerarin	0-8	insulin receptor substrate 1	Rattus norvegicus	80-85
22314193-9	2012	Puerarin attenuated PA-induced phosphorylation of insulin receptor substrate-1 (IRS-1) at S307 and effectively ameliorated insulin-mediated tyrosine phosphorylation of IRS-1.	puerarin	0-8	insulin receptor substrate 1	Rattus norvegicus	168-173
22314193-11	2012	These results suggest that puerarin inhibits inflammation and attenuates endothelial insulin resistance in an IKKbeta/IRS-1-dependent manner.	puerarin	27-35	inhibitor of nuclear factor kappa B kinase subunit beta	Rattus norvegicus	110-117
22314193-11	2012	These results suggest that puerarin inhibits inflammation and attenuates endothelial insulin resistance in an IKKbeta/IRS-1-dependent manner.	puerarin	27-35	insulin receptor substrate 1	Rattus norvegicus	118-123
22401764-10	2012	The in vitro data showed that puerarin inhibited the production of IL-1beta, TNF-alpha, IL-6, PGE(2) and NO; moreover, the RT-PCR analysis and the western blot analysis indicated that puerarin regulated the transcriptional level via suppression of NF-kappaB activation and blockade of MAPK signal pathway.	puerarin	30-38	interleukin 6	Rattus norvegicus	88-92
22401764-10	2012	The in vitro data showed that puerarin inhibited the production of IL-1beta, TNF-alpha, IL-6, PGE(2) and NO; moreover, the RT-PCR analysis and the western blot analysis indicated that puerarin regulated the transcriptional level via suppression of NF-kappaB activation and blockade of MAPK signal pathway.	puerarin	30-38	tumor necrosis factor	Rattus norvegicus	77-86
22246431-6	2012	We also observed that the enhanced phosphorylation of p38, JNK and ERK1/2             in N9 cells induced by LPS were inhibited by puerarin, otherwise the down-regulation             of O-GlcNAcylation level of protein in N9 cell induced by LPS was up-regulated             by pretreatment with puerarin.	puerarin	131-139	mitogen-activated protein kinase 1	Homo sapiens	54-57
22246431-0	2012	Puerarin suppresses production of nitric oxide and inducible nitric             oxide synthase in lipopolysaccharide-induced N9 microglial cells through regulating             MAPK phosphorylation, O-GlcNAcylation and NF-kappaB translocation.	puerarin	0-8	mitogen-activated protein kinase 3	Homo sapiens	176-180
22246431-0	2012	Puerarin suppresses production of nitric oxide and inducible nitric             oxide synthase in lipopolysaccharide-induced N9 microglial cells through regulating             MAPK phosphorylation, O-GlcNAcylation and NF-kappaB translocation.	puerarin	0-8	nuclear factor kappa B subunit 1	Homo sapiens	218-227
22246431-6	2012	We also observed that the enhanced phosphorylation of p38, JNK and ERK1/2             in N9 cells induced by LPS were inhibited by puerarin, otherwise the down-regulation             of O-GlcNAcylation level of protein in N9 cell induced by LPS was up-regulated             by pretreatment with puerarin.	puerarin	131-139	mitogen-activated protein kinase 8	Homo sapiens	59-62
22246431-6	2012	We also observed that the enhanced phosphorylation of p38, JNK and ERK1/2             in N9 cells induced by LPS were inhibited by puerarin, otherwise the down-regulation             of O-GlcNAcylation level of protein in N9 cell induced by LPS was up-regulated             by pretreatment with puerarin.	puerarin	131-139	mitogen-activated protein kinase 3	Homo sapiens	67-73
22246431-5	2012	Furthermore, treatment with puerarin on N9 cells suppressed the over-expression             of inducible nitric oxide synthase (iNOS) induced by LPS which is implicated in             intracellular O-linked beta-N-acetylglucosamine (O-GlcNAc) level, phosphorylation             of mitogen-activated protein kinase (MAPK) and nuclear factor kappaB (NF-kappaB) signaling             pathway.	puerarin	28-36	nitric oxide synthase 2	Homo sapiens	95-126
22246431-5	2012	Furthermore, treatment with puerarin on N9 cells suppressed the over-expression             of inducible nitric oxide synthase (iNOS) induced by LPS which is implicated in             intracellular O-linked beta-N-acetylglucosamine (O-GlcNAc) level, phosphorylation             of mitogen-activated protein kinase (MAPK) and nuclear factor kappaB (NF-kappaB) signaling             pathway.	puerarin	28-36	nitric oxide synthase 2	Homo sapiens	128-132
22246431-5	2012	Furthermore, treatment with puerarin on N9 cells suppressed the over-expression             of inducible nitric oxide synthase (iNOS) induced by LPS which is implicated in             intracellular O-linked beta-N-acetylglucosamine (O-GlcNAc) level, phosphorylation             of mitogen-activated protein kinase (MAPK) and nuclear factor kappaB (NF-kappaB) signaling             pathway.	puerarin	28-36	mitogen-activated protein kinase 3	Homo sapiens	315-319
22246431-5	2012	Furthermore, treatment with puerarin on N9 cells suppressed the over-expression             of inducible nitric oxide synthase (iNOS) induced by LPS which is implicated in             intracellular O-linked beta-N-acetylglucosamine (O-GlcNAc) level, phosphorylation             of mitogen-activated protein kinase (MAPK) and nuclear factor kappaB (NF-kappaB) signaling             pathway.	puerarin	28-36	nuclear factor kappa B subunit 1	Homo sapiens	340-346
22246431-5	2012	Furthermore, treatment with puerarin on N9 cells suppressed the over-expression             of inducible nitric oxide synthase (iNOS) induced by LPS which is implicated in             intracellular O-linked beta-N-acetylglucosamine (O-GlcNAc) level, phosphorylation             of mitogen-activated protein kinase (MAPK) and nuclear factor kappaB (NF-kappaB) signaling             pathway.	puerarin	28-36	nuclear factor kappa B subunit 1	Homo sapiens	348-357
22246431-6	2012	We also observed that the enhanced phosphorylation of p38, JNK and ERK1/2             in N9 cells induced by LPS were inhibited by puerarin, otherwise the down-regulation             of O-GlcNAcylation level of protein in N9 cell induced by LPS was up-regulated             by pretreatment with puerarin.	puerarin	295-303	mitogen-activated protein kinase 1	Homo sapiens	54-57
22246431-7	2012	These results indicate that puerarin effectively             inhibits microglia activation induced by LPS through inhibiting expression of             iNOS, production of NO and ROS which was mediated via regulating O-GlcNAcylation,             phosphorylation of MAPK and NF-kappaB translocation.	puerarin	28-36	nitric oxide synthase 2	Homo sapiens	151-155
22246431-7	2012	These results indicate that puerarin effectively             inhibits microglia activation induced by LPS through inhibiting expression of             iNOS, production of NO and ROS which was mediated via regulating O-GlcNAcylation,             phosphorylation of MAPK and NF-kappaB translocation.	puerarin	28-36	mitogen-activated protein kinase 3	Homo sapiens	264-268
22246431-7	2012	These results indicate that puerarin effectively             inhibits microglia activation induced by LPS through inhibiting expression of             iNOS, production of NO and ROS which was mediated via regulating O-GlcNAcylation,             phosphorylation of MAPK and NF-kappaB translocation.	puerarin	28-36	nuclear factor kappa B subunit 1	Homo sapiens	273-282
22457139-0	2012	Effect of puerarin on the release of interleukin-8 in co-culture of human bronchial epithelial cells and neutrophils.	puerarin	10-18	C-X-C motif chemokine ligand 8	Homo sapiens	37-50
22278629-5	2012	Preincubation of the cells with puerarin prior to Abeta25-35 exposure increased cell survival and GSH-Px and CAT activities and decreased ROS production.	puerarin	32-40	catalase	Rattus norvegicus	109-112
22278629-7	2012	In this study, Abeta25-35 treatment is found to increase GSK-3beta activity and pretreatment with puerarin preventesAbeta-induced activation of GSK-3beta based on Western blot analysis.	puerarin	98-106	glycogen synthase kinase 3 beta	Rattus norvegicus	144-153
22278629-8	2012	In addition, puerarin is shown to activate protein kinase B (PKB)/Akt, an important upstream kinase of GSK-3beta, possibly promoting subsequent GSK-3beta inhibition.	puerarin	13-21	AKT serine/threonine kinase 1	Rattus norvegicus	61-64
22278629-8	2012	In addition, puerarin is shown to activate protein kinase B (PKB)/Akt, an important upstream kinase of GSK-3beta, possibly promoting subsequent GSK-3beta inhibition.	puerarin	13-21	AKT serine/threonine kinase 1	Rattus norvegicus	66-69
22278629-8	2012	In addition, puerarin is shown to activate protein kinase B (PKB)/Akt, an important upstream kinase of GSK-3beta, possibly promoting subsequent GSK-3beta inhibition.	puerarin	13-21	glycogen synthase kinase 3 beta	Rattus norvegicus	103-112
22278629-8	2012	In addition, puerarin is shown to activate protein kinase B (PKB)/Akt, an important upstream kinase of GSK-3beta, possibly promoting subsequent GSK-3beta inhibition.	puerarin	13-21	glycogen synthase kinase 3 beta	Rattus norvegicus	144-153
22812004-6	2012	Puerarin restrains the ceramide accumulation to block downstream p38 MAPK pathway and calcium ion rising, therefore reduces DNA damage in HaCaT cells induced by UVB.	puerarin	0-8	mitogen-activated protein kinase 14	Homo sapiens	65-68
22513471-0	2012	Puerarin decreases apoptosis of retinal pigment epithelial cells in diabetic rats by reducing peroxynitrite level and iNOS expression.	puerarin	0-8	nitric oxide synthase 2	Rattus norvegicus	118-122
22513471-10	2012	Puerarin relieved apoptosis of RPE cells and decreased NT, iNOS mRNA, Fas/FasL protein expressions in puerarin group 20 or 40 d after STZ injection, compared with STZ group.	puerarin	0-8	nitric oxide synthase 2	Rattus norvegicus	59-63
22513471-10	2012	Puerarin relieved apoptosis of RPE cells and decreased NT, iNOS mRNA, Fas/FasL protein expressions in puerarin group 20 or 40 d after STZ injection, compared with STZ group.	puerarin	0-8	Fas ligand	Rattus norvegicus	74-78
22513471-11	2012	These results suggest puerarin can decrease RPE cells apoptosis in diabetic rats by reducing peroxynitrite level and iNOS expression, thus being a potential therapeutic agent in controlling of diabetic retinopathy.	puerarin	22-30	nitric oxide synthase 2	Rattus norvegicus	117-121
22457139-7	2012	Treatment with puerarin could significantly down-regulate the expression of IL-8 mRNA in BEAS-2B cells and IL-8 release in the supernatant of the co-culture of BEAS-2B cells and neutrophils (P<0.01).	puerarin	15-23	C-X-C motif chemokine ligand 8	Homo sapiens	76-80
22457139-7	2012	Treatment with puerarin could significantly down-regulate the expression of IL-8 mRNA in BEAS-2B cells and IL-8 release in the supernatant of the co-culture of BEAS-2B cells and neutrophils (P<0.01).	puerarin	15-23	C-X-C motif chemokine ligand 8	Homo sapiens	107-111
22457139-8	2012	CONCLUSION: Puerarin could exhibit anti-inflammatory activity by suppressing IL-8 production from the co-culture of human bronchial epithelial cells and neutrophils.	puerarin	12-20	C-X-C motif chemokine ligand 8	Homo sapiens	77-81
22457141-0	2012	Puerarin improve insulin resistance of adipocyte through activating Cb1 binding protein path.	puerarin	0-8	insulin	Homo sapiens	17-24
22457141-0	2012	Puerarin improve insulin resistance of adipocyte through activating Cb1 binding protein path.	puerarin	0-8	cannabinoid receptor 1	Homo sapiens	68-71
22457141-1	2012	OBJECTIVE: To explore the molecular mechanism of puerarin (Pue) in improving insulin resistance through observing its effect on the insulin resistance of 3T3-Li lipocyte induced by free fatty acid (FFA).	puerarin	49-57	insulin	Homo sapiens	77-84
22457141-1	2012	OBJECTIVE: To explore the molecular mechanism of puerarin (Pue) in improving insulin resistance through observing its effect on the insulin resistance of 3T3-Li lipocyte induced by free fatty acid (FFA).	puerarin	49-57	insulin	Homo sapiens	132-139
22457141-1	2012	OBJECTIVE: To explore the molecular mechanism of puerarin (Pue) in improving insulin resistance through observing its effect on the insulin resistance of 3T3-Li lipocyte induced by free fatty acid (FFA).	puerarin	59-62	insulin	Homo sapiens	77-84
22457141-1	2012	OBJECTIVE: To explore the molecular mechanism of puerarin (Pue) in improving insulin resistance through observing its effect on the insulin resistance of 3T3-Li lipocyte induced by free fatty acid (FFA).	puerarin	59-62	insulin	Homo sapiens	132-139
22457141-7	2012	In addition, the CAP mRNA expression and membranous distribution of Glut-4 were higher in the two Pue treated groups than those in the model group, respectively.	puerarin	98-101	solute carrier family 2 member 4	Homo sapiens	68-74
22265823-0	2012	Involvement of activation of PI3K/Akt pathway in the protective effects of puerarin against MPP+-induced human neuroblastoma SH-SY5Y cell death.	puerarin	75-83	AKT serine/threonine kinase 1	Homo sapiens	34-37
25745461-5	2012	Puerarin reversed these changes, and results demonstrated that puerarin inhibited Fas/FasL expression and alleviated peroxyntrite injury to retinal pigment epithelial cells.	puerarin	63-71	Fas ligand	Rattus norvegicus	86-90
22265823-3	2012	The presence of PI3K inhibitor LY294002 completely blocked puerarin-induced activation of Akt phosphorylation.	puerarin	59-67	AKT serine/threonine kinase 1	Homo sapiens	90-93
22265823-4	2012	Moreover, puerarin decreased MPP(+)-induced cell death, which was blocked by phosphoinositide 3-kinase (PI3K) inhibitor LY294002.	puerarin	10-18	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	77-102
22265823-5	2012	We further demonstrated that puerarin protected against MPP(+)-induced p53 nuclear accumulation, Puma (p53-upregulated mediator of apoptosis) and Bax expression and caspase-3-dependent programmed cell death (PCD).	puerarin	29-37	tumor protein p53	Homo sapiens	71-74
22265823-5	2012	We further demonstrated that puerarin protected against MPP(+)-induced p53 nuclear accumulation, Puma (p53-upregulated mediator of apoptosis) and Bax expression and caspase-3-dependent programmed cell death (PCD).	puerarin	29-37	tumor protein p53	Homo sapiens	103-106
22265823-5	2012	We further demonstrated that puerarin protected against MPP(+)-induced p53 nuclear accumulation, Puma (p53-upregulated mediator of apoptosis) and Bax expression and caspase-3-dependent programmed cell death (PCD).	puerarin	29-37	caspase 3	Homo sapiens	165-174
22265823-8	2012	Collectively, these data suggest that the activation of PI3K/Akt pathway is involved in the protective effect of puerarin against MPP(+)-induced neuroblastoma SH-SY5Y cell death through inhibiting nuclear p53 accumulation and subsequently caspase-3-dependent PCD.	puerarin	113-121	AKT serine/threonine kinase 1	Homo sapiens	61-64
22265823-8	2012	Collectively, these data suggest that the activation of PI3K/Akt pathway is involved in the protective effect of puerarin against MPP(+)-induced neuroblastoma SH-SY5Y cell death through inhibiting nuclear p53 accumulation and subsequently caspase-3-dependent PCD.	puerarin	113-121	tumor protein p53	Homo sapiens	205-208
22265823-8	2012	Collectively, these data suggest that the activation of PI3K/Akt pathway is involved in the protective effect of puerarin against MPP(+)-induced neuroblastoma SH-SY5Y cell death through inhibiting nuclear p53 accumulation and subsequently caspase-3-dependent PCD.	puerarin	113-121	caspase 3	Homo sapiens	239-248
22686089-12	2012	Compared with the model group, the levels of serum FSH, Inhibin beta, and the expression of Inhibin beta mRNA were significantly improved in the low and high dose puerarin groups (P<0.05), more obviously in the high dose puerarin group (P<0.01, P<0.05).	puerarin	163-171	follicle stimulating hormone beta	Mus musculus	51-54
22574584-8	2012	RESULTS: Compared with the control group, the plasma levels of NO, ET-1, and 6-K-PGF1alpha increased in the puerarin group (P < 0.	puerarin	108-116	endothelin 1	Homo sapiens	67-71
25774183-0	2012	Puerarin decreases hypoxia inducible factor-1 alpha in the hippocampus of vascular dementia rats.	puerarin	0-8	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	19-51
25774183-5	2012	Our experimental findings indicate that puerarin can significantly improve learning and memory in a vascular dementia model, and that the underlying mechanism may be associated with the regulation of the expression of hypoxia inducible factor-1 alpha.	puerarin	40-48	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	218-250
22172631-0	2012	Puerarin protects rat kidney from lead-induced apoptosis by modulating the PI3K/Akt/eNOS pathway.	puerarin	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	80-83
22172631-8	2012	In exploring the underlying mechanisms of puerarin action, we found that activities of caspase-3 were markedly inhibited by the treatment of puerarin in the kidney of Pb-treated rats.	puerarin	42-50	caspase 3	Rattus norvegicus	87-96
22172631-8	2012	In exploring the underlying mechanisms of puerarin action, we found that activities of caspase-3 were markedly inhibited by the treatment of puerarin in the kidney of Pb-treated rats.	puerarin	141-149	caspase 3	Rattus norvegicus	87-96
22172631-9	2012	Puerarin increased phosphorylated Akt, phosphorylated eNOS and NO levels in kidney, which in turn inactivated pro-apoptotic signaling events including inhibition of mitochondria cytochrome c release and restoration of the balance between pro- and anti-apoptotic Bcl-2 proteins in kidney of Pb-treated rats.	puerarin	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	34-37
22172631-9	2012	Puerarin increased phosphorylated Akt, phosphorylated eNOS and NO levels in kidney, which in turn inactivated pro-apoptotic signaling events including inhibition of mitochondria cytochrome c release and restoration of the balance between pro- and anti-apoptotic Bcl-2 proteins in kidney of Pb-treated rats.	puerarin	0-8	BCL2, apoptosis regulator	Rattus norvegicus	262-267
22172631-10	2012	In conclusion, these results suggested that the inhibition of Pb-induced apoptosis by puerarin is due at least in part to its antioxidant activity and its ability to modulate the PI3K/Akt/eNOS signaling pathway.	puerarin	86-94	AKT serine/threonine kinase 1	Rattus norvegicus	184-187
23029074-0	2012	Puerarin suppresses proliferation of endometriotic stromal cells partly via the MAPK signaling pathway induced by 17ss-estradiol-BSA.	puerarin	0-8	mitogen-activated protein kinase 3	Homo sapiens	80-84
22044944-4	2012	The present research investigated the role of puerarin in the signalling of chronic neuropathic pain mediated by P2X(3) receptors of rat dorsal root ganglion neurons.	puerarin	46-54	purinergic receptor P2X 3	Rattus norvegicus	113-119
22044944-12	2012	Therefore, puerarin may alleviate neuropathic pain mediated by P2X(3) receptors in dorsal root ganglion neurons.	puerarin	11-19	purinergic receptor P2X 3	Rattus norvegicus	63-69
22917468-0	2012	Puerarin stimulates osteoblasts differentiation and bone formation through estrogen receptor, p38 MAPK, and Wnt/beta-catenin pathways.	puerarin	0-8	estrogen receptor 1	Rattus norvegicus	75-92
22917468-0	2012	Puerarin stimulates osteoblasts differentiation and bone formation through estrogen receptor, p38 MAPK, and Wnt/beta-catenin pathways.	puerarin	0-8	mitogen activated protein kinase 14	Rattus norvegicus	94-97
22917468-0	2012	Puerarin stimulates osteoblasts differentiation and bone formation through estrogen receptor, p38 MAPK, and Wnt/beta-catenin pathways.	puerarin	0-8	Wnt family member 2	Rattus norvegicus	108-111
22917468-0	2012	Puerarin stimulates osteoblasts differentiation and bone formation through estrogen receptor, p38 MAPK, and Wnt/beta-catenin pathways.	puerarin	0-8	catenin beta 1	Rattus norvegicus	112-124
22917468-3	2012	Whereas the estrogen receptor (ER) antagonist ICI 182780 was able to reduce the increase in ALP activity and Col I secretion induced by puerarin.	puerarin	136-144	estrogen receptor 1	Rattus norvegicus	12-29
22917468-3	2012	Whereas the estrogen receptor (ER) antagonist ICI 182780 was able to reduce the increase in ALP activity and Col I secretion induced by puerarin.	puerarin	136-144	estrogen receptor 1	Rattus norvegicus	31-33
22917468-4	2012	Furthermore, puerarin was shown to elevate levels of phospho-p38 mitogen-activated protein kinase (MAPK) and beta-catenin proteins in a time-dependent manner.	puerarin	13-21	mitogen activated protein kinase 14	Rattus norvegicus	61-64
22917468-4	2012	Furthermore, puerarin was shown to elevate levels of phospho-p38 mitogen-activated protein kinase (MAPK) and beta-catenin proteins in a time-dependent manner.	puerarin	13-21	catenin beta 1	Rattus norvegicus	109-121
22917468-7	2012	Taken together, ER, p38 MAPK, and Wnt/beta-catenin pathways were involved in puerarin-stimulated osteoblasts differentiation and bone formation.	puerarin	77-85	estrogen receptor 1	Rattus norvegicus	16-18
22917468-7	2012	Taken together, ER, p38 MAPK, and Wnt/beta-catenin pathways were involved in puerarin-stimulated osteoblasts differentiation and bone formation.	puerarin	77-85	mitogen activated protein kinase 14	Rattus norvegicus	20-23
22917468-7	2012	Taken together, ER, p38 MAPK, and Wnt/beta-catenin pathways were involved in puerarin-stimulated osteoblasts differentiation and bone formation.	puerarin	77-85	Wnt family member 2	Rattus norvegicus	34-37
22917468-7	2012	Taken together, ER, p38 MAPK, and Wnt/beta-catenin pathways were involved in puerarin-stimulated osteoblasts differentiation and bone formation.	puerarin	77-85	catenin beta 1	Rattus norvegicus	38-50
22878391-3	2012	Since the bone absorption marker, serum tartarate-resistant acid phosphatase (TRAP) activity of puerarin-fed mice decreased but the bone formation marker, osteocalcin level, did not alter, the puerarin diet was proved to specifically depress the bone absorption, but not the overall bone metabolism.	puerarin	96-104	acid phosphatase 5, tartrate resistant	Mus musculus	40-76
22878391-3	2012	Since the bone absorption marker, serum tartarate-resistant acid phosphatase (TRAP) activity of puerarin-fed mice decreased but the bone formation marker, osteocalcin level, did not alter, the puerarin diet was proved to specifically depress the bone absorption, but not the overall bone metabolism.	puerarin	96-104	acid phosphatase 5, tartrate resistant	Mus musculus	78-82
22878391-3	2012	Since the bone absorption marker, serum tartarate-resistant acid phosphatase (TRAP) activity of puerarin-fed mice decreased but the bone formation marker, osteocalcin level, did not alter, the puerarin diet was proved to specifically depress the bone absorption, but not the overall bone metabolism.	puerarin	193-201	acid phosphatase 5, tartrate resistant	Mus musculus	40-76
22878391-3	2012	Since the bone absorption marker, serum tartarate-resistant acid phosphatase (TRAP) activity of puerarin-fed mice decreased but the bone formation marker, osteocalcin level, did not alter, the puerarin diet was proved to specifically depress the bone absorption, but not the overall bone metabolism.	puerarin	193-201	acid phosphatase 5, tartrate resistant	Mus musculus	78-82
22878391-5	2012	The atrophied uterine due to low estrogen (E2) level after ovariectomy was not restored by the puerarin diet, suggesting that puerarin exerted the anti-osteoporotic action through a non estrogen receptor (ER) mediated-pathway, in vivo.	puerarin	126-134	estrogen receptor 1 (alpha)	Mus musculus	205-207
23029074-14	2012	Treating ESCs with puerarin abrogated the phosphorylation of ERK and significantly decreased cell proliferation, as well as related gene expression levels enhanced by E(2)-BSA.	puerarin	19-27	mitogen-activated protein kinase 1	Homo sapiens	61-64
23029074-15	2012	CONCLUSIONS/SIGNIFICANCE: Puerarin suppresses proliferation of ESCs induced by E(2)-BSA partly via impeding a rapid, non-genomic, membrane-initiated ERK pathway, and down-regulation of Cyclin D1, Cox-2 and Cyp19 are involved in the process.	puerarin	26-34	mitogen-activated protein kinase 1	Homo sapiens	149-152
23029074-15	2012	CONCLUSIONS/SIGNIFICANCE: Puerarin suppresses proliferation of ESCs induced by E(2)-BSA partly via impeding a rapid, non-genomic, membrane-initiated ERK pathway, and down-regulation of Cyclin D1, Cox-2 and Cyp19 are involved in the process.	puerarin	26-34	cyclin D1	Homo sapiens	185-194
23029074-15	2012	CONCLUSIONS/SIGNIFICANCE: Puerarin suppresses proliferation of ESCs induced by E(2)-BSA partly via impeding a rapid, non-genomic, membrane-initiated ERK pathway, and down-regulation of Cyclin D1, Cox-2 and Cyp19 are involved in the process.	puerarin	26-34	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	196-201
23029074-15	2012	CONCLUSIONS/SIGNIFICANCE: Puerarin suppresses proliferation of ESCs induced by E(2)-BSA partly via impeding a rapid, non-genomic, membrane-initiated ERK pathway, and down-regulation of Cyclin D1, Cox-2 and Cyp19 are involved in the process.	puerarin	26-34	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	206-211
22027447-0	2011	Effects of puerarin on expression of cardiac Smad3 and Smad7 mRNA in spontaneously hypertensive rat.	puerarin	11-19	SMAD family member 3	Rattus norvegicus	45-50
22457823-9	2012	Puerarin-induced apoptosis in hypoxic HPASMCs was accompanied by reduced mitochondrial membrane potential, cytochrome c release from the mitochondria, caspase-9 activation, and Bcl-2 down-regulation with concurrent Bax up-regulation.	puerarin	0-8	cytochrome c, somatic	Homo sapiens	107-119
22457823-9	2012	Puerarin-induced apoptosis in hypoxic HPASMCs was accompanied by reduced mitochondrial membrane potential, cytochrome c release from the mitochondria, caspase-9 activation, and Bcl-2 down-regulation with concurrent Bax up-regulation.	puerarin	0-8	caspase 9	Homo sapiens	151-160
22457823-9	2012	Puerarin-induced apoptosis in hypoxic HPASMCs was accompanied by reduced mitochondrial membrane potential, cytochrome c release from the mitochondria, caspase-9 activation, and Bcl-2 down-regulation with concurrent Bax up-regulation.	puerarin	0-8	BCL2 apoptosis regulator	Homo sapiens	177-182
22457823-9	2012	Puerarin-induced apoptosis in hypoxic HPASMCs was accompanied by reduced mitochondrial membrane potential, cytochrome c release from the mitochondria, caspase-9 activation, and Bcl-2 down-regulation with concurrent Bax up-regulation.	puerarin	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	215-218
22027447-0	2011	Effects of puerarin on expression of cardiac Smad3 and Smad7 mRNA in spontaneously hypertensive rat.	puerarin	11-19	SMAD family member 7	Rattus norvegicus	55-60
22027447-4	2011	This study was to observe effects of puerarin on expression of cardiac transforming growth factor beta(1) (TGF-beta(1)), Smad3 and Smad7 mRNA in the spontaneously hypertensive rat (SHR), and to explore its possible mechanism of myocardial protection.	puerarin	37-45	transforming growth factor, beta 1	Rattus norvegicus	71-105
22027447-4	2011	This study was to observe effects of puerarin on expression of cardiac transforming growth factor beta(1) (TGF-beta(1)), Smad3 and Smad7 mRNA in the spontaneously hypertensive rat (SHR), and to explore its possible mechanism of myocardial protection.	puerarin	37-45	transforming growth factor, beta 1	Rattus norvegicus	107-118
22027447-4	2011	This study was to observe effects of puerarin on expression of cardiac transforming growth factor beta(1) (TGF-beta(1)), Smad3 and Smad7 mRNA in the spontaneously hypertensive rat (SHR), and to explore its possible mechanism of myocardial protection.	puerarin	37-45	SMAD family member 3	Rattus norvegicus	121-126
22027447-4	2011	This study was to observe effects of puerarin on expression of cardiac transforming growth factor beta(1) (TGF-beta(1)), Smad3 and Smad7 mRNA in the spontaneously hypertensive rat (SHR), and to explore its possible mechanism of myocardial protection.	puerarin	37-45	SMAD family member 7	Rattus norvegicus	131-136
22027447-14	2011	High- and middle-dose puerarin decreased the expression of TGF-beta(1) and Smad3 mRNA (p<0.01) and increased the expression of Smad7 mRNA (p<0.05).	puerarin	22-30	transforming growth factor, beta 1	Rattus norvegicus	59-70
22027447-14	2011	High- and middle-dose puerarin decreased the expression of TGF-beta(1) and Smad3 mRNA (p<0.01) and increased the expression of Smad7 mRNA (p<0.05).	puerarin	22-30	SMAD family member 3	Rattus norvegicus	75-80
22027447-14	2011	High- and middle-dose puerarin decreased the expression of TGF-beta(1) and Smad3 mRNA (p<0.01) and increased the expression of Smad7 mRNA (p<0.05).	puerarin	22-30	SMAD family member 7	Rattus norvegicus	130-135
22027447-15	2011	CONCLUSION: Puerarin reduces expression of TGF-beta(1) and Smad3 mRNA and increases that of Smad7 mRNA in SHR myocardium.	puerarin	12-20	transforming growth factor, beta 1	Rattus norvegicus	43-54
22027447-15	2011	CONCLUSION: Puerarin reduces expression of TGF-beta(1) and Smad3 mRNA and increases that of Smad7 mRNA in SHR myocardium.	puerarin	12-20	SMAD family member 3	Rattus norvegicus	59-64
22027447-15	2011	CONCLUSION: Puerarin reduces expression of TGF-beta(1) and Smad3 mRNA and increases that of Smad7 mRNA in SHR myocardium.	puerarin	12-20	SMAD family member 7	Rattus norvegicus	92-97
22001170-7	2011	Western blot analysis showed that puerarin remarkably inhibited hyperlipidemia by regulating the expression of cholesterol 7a-hydroxylase (CYP7A1), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) and low-density lipoprotein receptor (LDL-R) in liver of lead treated rats.	puerarin	34-42	cytochrome P450 family 7 subfamily A member 1	Rattus norvegicus	139-145
22001170-7	2011	Western blot analysis showed that puerarin remarkably inhibited hyperlipidemia by regulating the expression of cholesterol 7a-hydroxylase (CYP7A1), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) and low-density lipoprotein receptor (LDL-R) in liver of lead treated rats.	puerarin	34-42	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	148-188
22001170-7	2011	Western blot analysis showed that puerarin remarkably inhibited hyperlipidemia by regulating the expression of cholesterol 7a-hydroxylase (CYP7A1), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) and low-density lipoprotein receptor (LDL-R) in liver of lead treated rats.	puerarin	34-42	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	190-194
22001170-7	2011	Western blot analysis showed that puerarin remarkably inhibited hyperlipidemia by regulating the expression of cholesterol 7a-hydroxylase (CYP7A1), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) and low-density lipoprotein receptor (LDL-R) in liver of lead treated rats.	puerarin	34-42	low density lipoprotein receptor	Rattus norvegicus	200-232
22001170-7	2011	Western blot analysis showed that puerarin remarkably inhibited hyperlipidemia by regulating the expression of cholesterol 7a-hydroxylase (CYP7A1), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) and low-density lipoprotein receptor (LDL-R) in liver of lead treated rats.	puerarin	34-42	low density lipoprotein receptor	Rattus norvegicus	234-239
21833698-0	2011	Puerarin alleviates burn-related procedural pain mediated by P2X(3) receptors.	puerarin	0-8	purinergic receptor P2X 3	Homo sapiens	61-67
21833698-5	2011	Puerarin is extracted from a traditional Chinese medicine and may act on P2X(3) receptor mechanisms.	puerarin	0-8	purinergic receptor P2X 3	Homo sapiens	73-79
21833698-12	2011	The blood glucose, insulin, and cortisol levels in the puerarin-treated group at post-dressing changes were significantly decreased in comparison with those in NS group.	puerarin	55-63	insulin	Homo sapiens	19-26
21833698-13	2011	The expression levels of P2X(3) protein and mRNA in PBMCs of burn patients in NS group were significantly increased in comparison with those in the puerarin-treated group.	puerarin	148-156	purinergic receptor P2X 3	Homo sapiens	25-31
21833698-14	2011	Puerarin can antagonize inflammatory factors (such as ATP) and decrease the upregulated expressions of P2X(3) protein and mRNA in PBMCs after burns to decrease VAS.	puerarin	0-8	purinergic receptor P2X 3	Homo sapiens	103-109
21833698-15	2011	Thus, puerarin had an analgesic effect on procedural pain in dressing changes of burn patients related to P2X(3) receptors.	puerarin	6-14	purinergic receptor P2X 3	Homo sapiens	106-112
22088587-13	2011	CONCLUSION: Flavonoids of puerarin can restrain the increase of IL-6 after acute ischemic stroke, and depress the LDH raised by reperfusion after cerebral ischemia.	puerarin	26-34	interleukin 6	Homo sapiens	64-68
21884717-0	2011	Puerarin activates endothelial nitric oxide synthase through estrogen receptor-dependent PI3-kinase and calcium-dependent AMP-activated protein kinase.	puerarin	0-8	nitric oxide synthase 3	Homo sapiens	19-52
21884717-0	2011	Puerarin activates endothelial nitric oxide synthase through estrogen receptor-dependent PI3-kinase and calcium-dependent AMP-activated protein kinase.	puerarin	0-8	estrogen receptor 1	Homo sapiens	61-78
21884717-1	2011	The cardioprotective properties of puerarin, a natural product, have been attributed to the endothelial nitric oxide synthase (eNOS)-mediated production of nitric oxide (NO) in EA.hy926 endothelial cells.	puerarin	35-43	nitric oxide synthase 3	Homo sapiens	92-125
21884717-5	2011	Puerarin-induced eNOS phosphorylation required estrogen receptor (ER)-mediated phosphatidylinositol 3-kinase (PI3K)/Akt signaling and was reversed by AMP-activated protein kinase (AMPK) and calcium/calmodulin-dependent kinase II (CaMKII) inhibition.	puerarin	0-8	estrogen receptor 1	Homo sapiens	47-64
21884717-5	2011	Puerarin-induced eNOS phosphorylation required estrogen receptor (ER)-mediated phosphatidylinositol 3-kinase (PI3K)/Akt signaling and was reversed by AMP-activated protein kinase (AMPK) and calcium/calmodulin-dependent kinase II (CaMKII) inhibition.	puerarin	0-8	estrogen receptor 1	Homo sapiens	66-68
21884717-5	2011	Puerarin-induced eNOS phosphorylation required estrogen receptor (ER)-mediated phosphatidylinositol 3-kinase (PI3K)/Akt signaling and was reversed by AMP-activated protein kinase (AMPK) and calcium/calmodulin-dependent kinase II (CaMKII) inhibition.	puerarin	0-8	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	230-236
21884717-6	2011	Importantly, puerarin inhibited the adhesion of tumor necrosis factor (TNF)-alpha-stimulated monocytes to endothelial cells and suppressed the TNF-alpha induced expression of intercellular cell adhesion molecule-1.	puerarin	13-21	tumor necrosis factor	Homo sapiens	48-81
21884717-6	2011	Importantly, puerarin inhibited the adhesion of tumor necrosis factor (TNF)-alpha-stimulated monocytes to endothelial cells and suppressed the TNF-alpha induced expression of intercellular cell adhesion molecule-1.	puerarin	13-21	tumor necrosis factor	Homo sapiens	143-152
21884717-7	2011	Puerarin also inhibited the TNF-alpha-induced nuclear factor-kappaB activation, which was attenuated by pretreatment with N(G)-nitro-L-arginine methyl ester, a NOS inhibitor.	puerarin	0-8	tumor necrosis factor	Homo sapiens	28-37
21884717-8	2011	These results indicate that puerarin stimulates eNOS phosphorylation and NO production via activation of an estrogen receptor-mediated PI3K/Akt- and CaMKII/AMPK-dependent pathway.	puerarin	28-36	estrogen receptor 1	Homo sapiens	108-125
21884717-8	2011	These results indicate that puerarin stimulates eNOS phosphorylation and NO production via activation of an estrogen receptor-mediated PI3K/Akt- and CaMKII/AMPK-dependent pathway.	puerarin	28-36	AKT serine/threonine kinase 1	Homo sapiens	140-155
21945127-0	2011	Analysis of binding interaction between pegylated puerarin and bovine serum albumin by spectroscopic methods and dynamic light scattering.	puerarin	50-58	albumin	Homo sapiens	70-83
21945127-1	2011	The interaction between bovine serum albumin (BSA) and pegylated puerarin (Pur) in aqueous solution was investigated by UV-Vis spectroscopy, fluorescence spectroscopy and circular dichroism spectra (CD), as well as dynamic light scattering (DLS).	puerarin	65-73	albumin	Homo sapiens	31-44
21673282-8	2011	Low-dose Puerarin inhibited P450arom expression and significantly reduced estrogen levels in endometriotic tissue (P < .01).	puerarin	9-17	cytochrome P450, family 19, subfamily a, polypeptide 1	Rattus norvegicus	28-36
21964292-6	2011	The effect of puerarin on mammalian targets of rapamycin (mTOR), a key regulator of autophagy, was examined in ethanol-treated hepatocytes.	puerarin	14-22	mechanistic target of rapamycin kinase	Homo sapiens	58-62
21964292-8	2011	These data suggest that puerarin restored the viability of cells and reduced lipid accumulation in ethanol-treated hepatocytes by activating autophagy via AMPK/mTOR-mediated signaling.	puerarin	24-32	mechanistic target of rapamycin kinase	Homo sapiens	160-164
22357486-0	2011	[Effects of puerarin on proliferation, apoptosis and Kv1.5 gene expression of pulmonary artery smooth muscle cells induced by hypoxia].	puerarin	12-20	potassium voltage-gated channel subfamily A member 5	Rattus norvegicus	53-58
22357486-1	2011	OBJECTIVE: To study the effects of puerarin on proliferation, apoptosis and Kv1.5 gene expression of rat pulmonary artery smooth muscle cells (PASMCs) induced by hypoxia.	puerarin	35-43	potassium voltage-gated channel subfamily A member 5	Rattus norvegicus	76-81
22357486-6	2011	CONCLUSION: Puerarin could decrease the proliferation and increase the apoptosis induced by hypoxia in rat PASMCs, and the up-regulated expression of Kv1.5 gene may be the mechanism of puerarin effects.	puerarin	185-193	potassium voltage-gated channel subfamily A member 5	Rattus norvegicus	150-155
21964292-5	2011	The reduced expression of LC3 was restored by puerarin in a dose-dependent manner in ethanol-treated cells.	puerarin	46-54	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	26-29
21651907-0	2011	Anti-oxidative and TNF-alpha suppressive activities of puerarin derivative (4AC) in RAW264.7 cells and collagen-induced arthritic rats.	puerarin	55-63	tumor necrosis factor	Mus musculus	19-28
21327545-0	2011	Puerarin: a novel antagonist to inward rectifier potassium channel (IK1).	puerarin	0-8	potassium calcium-activated channel subfamily N member 4	Rattus norvegicus	68-71
21933599-14	2011	Similarly, the expressions of iNOS mRNA and iNOS protein in ONOO(-)group were up-regulated in ONOO(-) group, but down-regulated in puerarin group (P < 0.001).	puerarin	131-139	nitric oxide synthase 2, inducible	Mus musculus	30-34
21933599-14	2011	Similarly, the expressions of iNOS mRNA and iNOS protein in ONOO(-)group were up-regulated in ONOO(-) group, but down-regulated in puerarin group (P < 0.001).	puerarin	131-139	nitric oxide synthase 2, inducible	Mus musculus	44-48
21933599-18	2011	The antagonizing mechanism of puerarin may be related to its inhibitory to the expression of iNOS mRNA, and therefore decrease ONOO(-) formation as well as directly antagonize the effect of ONOO(-).	puerarin	30-38	nitric oxide synthase 2, inducible	Mus musculus	93-97
22097342-6	2011	Puerarin can enhance the expression of Caspase-9 and Bax protein, decrease the expression of Bcl-2 protein.	puerarin	0-8	caspase 9	Rattus norvegicus	39-48
22097342-6	2011	Puerarin can enhance the expression of Caspase-9 and Bax protein, decrease the expression of Bcl-2 protein.	puerarin	0-8	BCL2 associated X, apoptosis regulator	Rattus norvegicus	53-56
22097342-6	2011	Puerarin can enhance the expression of Caspase-9 and Bax protein, decrease the expression of Bcl-2 protein.	puerarin	0-8	BCL2, apoptosis regulator	Rattus norvegicus	93-98
21933599-0	2011	Inducible nitric oxide synthase and Fas/FasL with C3 expression of mouse retinal pigment epithelial cells in response to stimulation by peroxynitrite and antagonism of puerarin.	puerarin	168-176	nitric oxide synthase 2, inducible	Mus musculus	0-31
21933599-0	2011	Inducible nitric oxide synthase and Fas/FasL with C3 expression of mouse retinal pigment epithelial cells in response to stimulation by peroxynitrite and antagonism of puerarin.	puerarin	168-176	Fas ligand (TNF superfamily, member 6)	Mus musculus	40-44
21933599-0	2011	Inducible nitric oxide synthase and Fas/FasL with C3 expression of mouse retinal pigment epithelial cells in response to stimulation by peroxynitrite and antagonism of puerarin.	puerarin	168-176	complement component 3	Mus musculus	50-52
21933599-13	2011	Compared to control group, the expression of Fas/FasL was up-regulated in ONOO(-) group, but was down-regulated in puerarin group (P < 0.001).	puerarin	115-123	Fas ligand (TNF superfamily, member 6)	Mus musculus	49-53
21473901-3	2011	The aim of the present study was to assess the neuroprotective effects of puerarin, a phytoestrogen isolated from Pueraria lobata, against the toxicity of beta-amyloid (Abeta) in relation to the mitochondria-mediated cell death process, and to elucidate the role the activation of Akt and modulation of the pro- and antiapoptotic proteins in puerarin-induced neuroprotection.	puerarin	74-82	amyloid beta precursor protein	Rattus norvegicus	155-175
21882538-6	2011	On 7th day, ALP expression of puerarin group was higher than that of control group.	puerarin	30-38	ATHS	Homo sapiens	12-15
21882538-7	2011	On 14th day, ALP staining showed that the positive rate of puerarin group was higher than that of control group.	puerarin	59-67	ATHS	Homo sapiens	13-16
21473901-3	2011	The aim of the present study was to assess the neuroprotective effects of puerarin, a phytoestrogen isolated from Pueraria lobata, against the toxicity of beta-amyloid (Abeta) in relation to the mitochondria-mediated cell death process, and to elucidate the role the activation of Akt and modulation of the pro- and antiapoptotic proteins in puerarin-induced neuroprotection.	puerarin	74-82	AKT serine/threonine kinase 1	Rattus norvegicus	281-284
21473901-3	2011	The aim of the present study was to assess the neuroprotective effects of puerarin, a phytoestrogen isolated from Pueraria lobata, against the toxicity of beta-amyloid (Abeta) in relation to the mitochondria-mediated cell death process, and to elucidate the role the activation of Akt and modulation of the pro- and antiapoptotic proteins in puerarin-induced neuroprotection.	puerarin	342-350	amyloid beta precursor protein	Rattus norvegicus	155-175
21473901-6	2011	P-Akt, Bcl-2 and p-Bad expression increased after pretreatment with puerarin in PC12 cells exposed to Abeta(25-35), whereas Bax expression and cytochrome c release decreased.	puerarin	68-76	AKT serine/threonine kinase 1	Rattus norvegicus	2-5
21473901-6	2011	P-Akt, Bcl-2 and p-Bad expression increased after pretreatment with puerarin in PC12 cells exposed to Abeta(25-35), whereas Bax expression and cytochrome c release decreased.	puerarin	68-76	BCL2, apoptosis regulator	Rattus norvegicus	7-12
21842654-8	2011	Both ELISA and Western blotting showed that puerarin prevented the release of cytochrome c from the mitochondrial interior to the cystol elicited by MPP+.	puerarin	44-52	cytochrome c, somatic	Homo sapiens	78-90
21842654-12	2011	Taken together, puerarin can modulate mitochondrial membrane potential and inhibit the cytochrome c releasing-caspase cascade to pre vent MPP+ -induced cell injury.	puerarin	16-24	cytochrome c, somatic	Homo sapiens	87-99
21296138-6	2011	Ischemia-reperfusion injury resulted in a decrease in the expression of thioredoxin, while puerarin administration elevated the expression of thioredoxin-1/thioredoxin-2 mRNA.	puerarin	91-99	thioredoxin 1	Rattus norvegicus	142-155
21296138-6	2011	Ischemia-reperfusion injury resulted in a decrease in the expression of thioredoxin, while puerarin administration elevated the expression of thioredoxin-1/thioredoxin-2 mRNA.	puerarin	91-99	thioredoxin 2	Rattus norvegicus	156-169
21296138-8	2011	CONCLUSIONS: We conclude that administration of puerarin within 4h of spinal ischemia-reperfusion injury reduces ischemic reperfusion damage, and that the neuroprotective effect of puerarin involves an increase in the transcription of thioredoxin and a reduction of apoptosis.	puerarin	48-56	thioredoxin 1	Rattus norvegicus	235-246
21296138-8	2011	CONCLUSIONS: We conclude that administration of puerarin within 4h of spinal ischemia-reperfusion injury reduces ischemic reperfusion damage, and that the neuroprotective effect of puerarin involves an increase in the transcription of thioredoxin and a reduction of apoptosis.	puerarin	181-189	thioredoxin 1	Rattus norvegicus	235-246
20934486-3	2011	PC12 cells exposed to MPP(+) (500 muM) significantly decreased the viability of PC12 cells when examined by MTT assay, DNA ELISA assay, and Annexin V assays, which was prevented by puerarin in a dose-dependent manner.	puerarin	181-189	annexin A5	Rattus norvegicus	140-149
21560344-7	2011	(3) After incubation with puerarin for 4 h, the HO-1 activity of thoracic aorta increased; ZnPP, an inhibitor of HO-1, abrogated the protection effect of puerarin.	puerarin	26-34	heme oxygenase 1	Rattus norvegicus	48-52
21560344-7	2011	(3) After incubation with puerarin for 4 h, the HO-1 activity of thoracic aorta increased; ZnPP, an inhibitor of HO-1, abrogated the protection effect of puerarin.	puerarin	26-34	heme oxygenase 1	Rattus norvegicus	113-117
21560344-7	2011	(3) After incubation with puerarin for 4 h, the HO-1 activity of thoracic aorta increased; ZnPP, an inhibitor of HO-1, abrogated the protection effect of puerarin.	puerarin	154-162	heme oxygenase 1	Rattus norvegicus	48-52
21560344-7	2011	(3) After incubation with puerarin for 4 h, the HO-1 activity of thoracic aorta increased; ZnPP, an inhibitor of HO-1, abrogated the protection effect of puerarin.	puerarin	154-162	heme oxygenase 1	Rattus norvegicus	113-117
20934486-4	2011	PC12 cells exposed to MPP(+) (500 muM) elicited phosphorylation of MKK7, c-Jun-NH(2)-terminal kinase (JNK), and c-Jun which followed by the increase in cytochrome c levels, and which was prevented by puerarin.	puerarin	200-208	mitogen activated protein kinase kinase 7	Rattus norvegicus	67-71
20934486-5	2011	Moreover, puerarin inhibited the activation of caspase-9 and caspase-3 in MPP(+)-exposed PC12 cells.	puerarin	10-18	caspase 9	Rattus norvegicus	47-56
20934486-5	2011	Moreover, puerarin inhibited the activation of caspase-9 and caspase-3 in MPP(+)-exposed PC12 cells.	puerarin	10-18	caspase 3	Rattus norvegicus	61-70
20934486-6	2011	Whereas, the neuroprotective effect of puerarin against MPP(+) insults can be blocked by SP600125 (inhibitor of JNK).	puerarin	39-47	mitogen-activated protein kinase 8	Rattus norvegicus	112-115
20934486-7	2011	Taken together, these results suggest that puerarin protected PC12 cells against MPP(+)-induced neurotoxicity through the inhibition of the JNK signaling pathways.	puerarin	43-51	mitogen-activated protein kinase 8	Rattus norvegicus	140-143
21548369-5	2010	RESULTS: After 24 h ischemia and reperfusion in gerbils, the level of Bcl-2 and HSP70 expressions in puerarin solid lipid nanoparticle group increased (P < 0.01) compared with the ischemic-reperfusion model group, and the level of Caspase-3 expression decreased (P < 0.01).	puerarin	101-109	BCL2 apoptosis regulator	Homo sapiens	70-75
20933077-6	2011	These results suggest that expression of SAD mitochondrial genes in cybrids activates oxidative-stress-related signaling pathways and reduces viability, and that the protective effects of puerarin inhibit oxidative-stress-induced apoptosis through down-regulation of Bax/Bcl-2 ratio, which blocks the activation of JNK, p38 and caspase-3.	puerarin	188-196	BCL2 associated X, apoptosis regulator	Homo sapiens	267-270
20933077-6	2011	These results suggest that expression of SAD mitochondrial genes in cybrids activates oxidative-stress-related signaling pathways and reduces viability, and that the protective effects of puerarin inhibit oxidative-stress-induced apoptosis through down-regulation of Bax/Bcl-2 ratio, which blocks the activation of JNK, p38 and caspase-3.	puerarin	188-196	BCL2 apoptosis regulator	Homo sapiens	271-276
20933077-6	2011	These results suggest that expression of SAD mitochondrial genes in cybrids activates oxidative-stress-related signaling pathways and reduces viability, and that the protective effects of puerarin inhibit oxidative-stress-induced apoptosis through down-regulation of Bax/Bcl-2 ratio, which blocks the activation of JNK, p38 and caspase-3.	puerarin	188-196	mitogen-activated protein kinase 8	Homo sapiens	315-318
20933077-6	2011	These results suggest that expression of SAD mitochondrial genes in cybrids activates oxidative-stress-related signaling pathways and reduces viability, and that the protective effects of puerarin inhibit oxidative-stress-induced apoptosis through down-regulation of Bax/Bcl-2 ratio, which blocks the activation of JNK, p38 and caspase-3.	puerarin	188-196	mitogen-activated protein kinase 14	Homo sapiens	320-323
20933077-6	2011	These results suggest that expression of SAD mitochondrial genes in cybrids activates oxidative-stress-related signaling pathways and reduces viability, and that the protective effects of puerarin inhibit oxidative-stress-induced apoptosis through down-regulation of Bax/Bcl-2 ratio, which blocks the activation of JNK, p38 and caspase-3.	puerarin	188-196	caspase 3	Homo sapiens	328-337
21857089-0	2011	Puerarin inhibits iNOS, COX-2 and CRP expression via suppression of NF-kappaB activation in LPS-induced RAW264.7 macrophage cells.	puerarin	0-8	nitric oxide synthase 2, inducible	Mus musculus	18-22
21857089-0	2011	Puerarin inhibits iNOS, COX-2 and CRP expression via suppression of NF-kappaB activation in LPS-induced RAW264.7 macrophage cells.	puerarin	0-8	prostaglandin-endoperoxide synthase 2	Mus musculus	24-29
21857089-0	2011	Puerarin inhibits iNOS, COX-2 and CRP expression via suppression of NF-kappaB activation in LPS-induced RAW264.7 macrophage cells.	puerarin	0-8	C-reactive protein, pentraxin-related	Mus musculus	34-37
21857089-2	2011	In the present study, the ability of the puerarin to modulate inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and C reactive protein (CRP) expression and induce changes in the nuclear factor kappaB (NF-kappaB) pathway in RAW264.7 macrophage cells was examined.	puerarin	41-49	nitric oxide synthase 2, inducible	Mus musculus	62-93
21857089-2	2011	In the present study, the ability of the puerarin to modulate inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and C reactive protein (CRP) expression and induce changes in the nuclear factor kappaB (NF-kappaB) pathway in RAW264.7 macrophage cells was examined.	puerarin	41-49	nitric oxide synthase 2, inducible	Mus musculus	95-99
21857089-2	2011	In the present study, the ability of the puerarin to modulate inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and C reactive protein (CRP) expression and induce changes in the nuclear factor kappaB (NF-kappaB) pathway in RAW264.7 macrophage cells was examined.	puerarin	41-49	prostaglandin-endoperoxide synthase 2	Mus musculus	102-118
21857089-2	2011	In the present study, the ability of the puerarin to modulate inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and C reactive protein (CRP) expression and induce changes in the nuclear factor kappaB (NF-kappaB) pathway in RAW264.7 macrophage cells was examined.	puerarin	41-49	prostaglandin-endoperoxide synthase 2	Mus musculus	120-125
21857089-2	2011	In the present study, the ability of the puerarin to modulate inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and C reactive protein (CRP) expression and induce changes in the nuclear factor kappaB (NF-kappaB) pathway in RAW264.7 macrophage cells was examined.	puerarin	41-49	C-reactive protein, pentraxin-related	Mus musculus	131-149
21857089-2	2011	In the present study, the ability of the puerarin to modulate inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and C reactive protein (CRP) expression and induce changes in the nuclear factor kappaB (NF-kappaB) pathway in RAW264.7 macrophage cells was examined.	puerarin	41-49	C-reactive protein, pentraxin-related	Mus musculus	151-154
21857089-5	2011	The results indicated that puerarin inhibited the expression of LPS-induced iNOS, COX-2 and CRP proteins and also suppressed their mRNAs from RT-PCR experiments in RAW264.7 cells.	puerarin	27-35	nitric oxide synthase 2, inducible	Mus musculus	76-80
21857089-5	2011	The results indicated that puerarin inhibited the expression of LPS-induced iNOS, COX-2 and CRP proteins and also suppressed their mRNAs from RT-PCR experiments in RAW264.7 cells.	puerarin	27-35	prostaglandin-endoperoxide synthase 2	Mus musculus	82-87
21857089-5	2011	The results indicated that puerarin inhibited the expression of LPS-induced iNOS, COX-2 and CRP proteins and also suppressed their mRNAs from RT-PCR experiments in RAW264.7 cells.	puerarin	27-35	C-reactive protein, pentraxin-related	Mus musculus	92-95
21857089-7	2011	These data suggested that the effect of puerarin-mediated inhibition of LPS-induced iNOS, COX-2 and CRP expression is attributed to suppressed NF-kappaB activation at the transcriptional level.	puerarin	40-48	nitric oxide synthase 2, inducible	Mus musculus	84-88
21857089-7	2011	These data suggested that the effect of puerarin-mediated inhibition of LPS-induced iNOS, COX-2 and CRP expression is attributed to suppressed NF-kappaB activation at the transcriptional level.	puerarin	40-48	prostaglandin-endoperoxide synthase 2	Mus musculus	90-95
21857089-7	2011	These data suggested that the effect of puerarin-mediated inhibition of LPS-induced iNOS, COX-2 and CRP expression is attributed to suppressed NF-kappaB activation at the transcriptional level.	puerarin	40-48	C-reactive protein, pentraxin-related	Mus musculus	100-103
21355301-0	2011	[Effect of puerarin on the expression of NMDA receptor in the hippocampus CA1 region after focal cerebral ischemia in rats].	puerarin	11-19	carbonic anhydrase 1	Rattus norvegicus	74-77
20863868-9	2010	Chinese traditional medicine, i.e., tetramethylpyrazine (TMP), sodium ferulate (SF) and puerarin can antagonize the nociceptive or pain transmission mediated by P2X(3) and/or P2X(2/3) receptors in primary afferent neurons.	puerarin	88-96	purinergic receptor P2X 3	Rattus norvegicus	161-167
20863868-9	2010	Chinese traditional medicine, i.e., tetramethylpyrazine (TMP), sodium ferulate (SF) and puerarin can antagonize the nociceptive or pain transmission mediated by P2X(3) and/or P2X(2/3) receptors in primary afferent neurons.	puerarin	88-96	purinergic receptor P2X 3	Rattus norvegicus	175-182
20863868-10	2010	P2X(3) and/or P2X(2/3) receptors are the pharmacological targets of TMP, SF and puerarin for the therapeutic treatment of pain.	puerarin	80-88	purinergic receptor P2X 3	Rattus norvegicus	0-6
20863868-10	2010	P2X(3) and/or P2X(2/3) receptors are the pharmacological targets of TMP, SF and puerarin for the therapeutic treatment of pain.	puerarin	80-88	purinergic receptor P2X 3	Rattus norvegicus	14-21
20868658-3	2010	In this study, we investigated the effects of puerarin, a phytoestrogen isolated from Pueraria lobata, on cognitive function and neuronal apoptosis in the intrahippocampal injection of Abeta rats and its mechanism of action.	puerarin	46-54	amyloid beta precursor protein	Rattus norvegicus	185-190
21548369-5	2010	RESULTS: After 24 h ischemia and reperfusion in gerbils, the level of Bcl-2 and HSP70 expressions in puerarin solid lipid nanoparticle group increased (P < 0.01) compared with the ischemic-reperfusion model group, and the level of Caspase-3 expression decreased (P < 0.01).	puerarin	101-109	heat shock protein family A (Hsp70) member 4	Homo sapiens	80-85
21548369-5	2010	RESULTS: After 24 h ischemia and reperfusion in gerbils, the level of Bcl-2 and HSP70 expressions in puerarin solid lipid nanoparticle group increased (P < 0.01) compared with the ischemic-reperfusion model group, and the level of Caspase-3 expression decreased (P < 0.01).	puerarin	101-109	caspase 3	Homo sapiens	234-243
21548369-7	2010	CONCLUSIONS: Puerarin solid lipid nanoparticle group can protect the cerebral ischemia-reperfusion injury in gerbils, which may be related to the upregulation of Bcl-2 and HSP70 expression and downregulation of Caspase-3 expression.	puerarin	13-21	BCL2 apoptosis regulator	Homo sapiens	162-167
21548369-7	2010	CONCLUSIONS: Puerarin solid lipid nanoparticle group can protect the cerebral ischemia-reperfusion injury in gerbils, which may be related to the upregulation of Bcl-2 and HSP70 expression and downregulation of Caspase-3 expression.	puerarin	13-21	heat shock protein family A (Hsp70) member 4	Homo sapiens	172-177
21548369-7	2010	CONCLUSIONS: Puerarin solid lipid nanoparticle group can protect the cerebral ischemia-reperfusion injury in gerbils, which may be related to the upregulation of Bcl-2 and HSP70 expression and downregulation of Caspase-3 expression.	puerarin	13-21	caspase 3	Homo sapiens	211-220
20509103-0	2010	Puerarin protects dopaminergic neurons against 6-hydroxydopamine neurotoxicity via inhibiting apoptosis and upregulating glial cell line-derived neurotrophic factor in a rat model of Parkinson"s disease.	puerarin	0-8	glial cell derived neurotrophic factor	Rattus norvegicus	121-164
20806284-0	2010	Puerarin enhances adipocyte differentiation, adiponectin expression, and antioxidant response in 3T3-L1 cells.	puerarin	0-8	adiponectin, C1Q and collagen domain containing	Mus musculus	45-56
20806284-4	2010	At a molecular level, puerarin upregulated mRNA expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and its target genes, an adipocyte-specific fatty acid binding protein (aP2) and GLUT4.	puerarin	22-30	peroxisome proliferator activated receptor gamma	Mus musculus	62-110
20806284-4	2010	At a molecular level, puerarin upregulated mRNA expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and its target genes, an adipocyte-specific fatty acid binding protein (aP2) and GLUT4.	puerarin	22-30	peroxisome proliferator activated receptor gamma	Mus musculus	112-121
20806284-4	2010	At a molecular level, puerarin upregulated mRNA expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and its target genes, an adipocyte-specific fatty acid binding protein (aP2) and GLUT4.	puerarin	22-30	fatty acid binding protein 4, adipocyte	Mus musculus	195-198
20806284-4	2010	At a molecular level, puerarin upregulated mRNA expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and its target genes, an adipocyte-specific fatty acid binding protein (aP2) and GLUT4.	puerarin	22-30	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	204-209
20806284-5	2010	Puerarin also caused a significant increase in mRNA level of adiponectin, an important insulin-sensitizing adipocytokine that is downregulated in insulin-resistant and diabetic states.	puerarin	0-8	adiponectin, C1Q and collagen domain containing	Mus musculus	61-72
20806284-6	2010	In addition, treatment with puerarin was found to upregulate mRNA levels of G6PDH, glutathione reductase, and catalase, all of which are important for endogenous antioxidant responses.	puerarin	28-36	glutathione reductase	Mus musculus	83-104
20806284-6	2010	In addition, treatment with puerarin was found to upregulate mRNA levels of G6PDH, glutathione reductase, and catalase, all of which are important for endogenous antioxidant responses.	puerarin	28-36	catalase	Mus musculus	110-118
20806284-7	2010	These data suggest that the hypoglycemic effects of puerarin can be attributed to the upregulation of PPARgamma and its downstream target genes, GLUT4 and adiponectin expression, leading to increased glucose utilization.	puerarin	52-60	peroxisome proliferator activated receptor gamma	Mus musculus	102-111
20806284-7	2010	These data suggest that the hypoglycemic effects of puerarin can be attributed to the upregulation of PPARgamma and its downstream target genes, GLUT4 and adiponectin expression, leading to increased glucose utilization.	puerarin	52-60	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	145-150
20806284-7	2010	These data suggest that the hypoglycemic effects of puerarin can be attributed to the upregulation of PPARgamma and its downstream target genes, GLUT4 and adiponectin expression, leading to increased glucose utilization.	puerarin	52-60	adiponectin, C1Q and collagen domain containing	Mus musculus	155-166
20974012-9	2010	Puerarin increased expression of gama-aminobutyric acid type A receptor alpha1 subunit and decreased expression of alpha4 subunit.	puerarin	0-8	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2	Mus musculus	33-71
20974012-10	2010	In chronic alcoholic mice, puerarin pretreatment significantly increased body weight and liver ADH activity in a dose-dependent manner.	puerarin	27-35	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	95-98
20974012-11	2010	Puerarin pretreatment, but not post-treatment, can reverse the changes of gama-aminobutyric acid type A receptor subunit expression and increase ADH activity in alcoholism models.	puerarin	0-8	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2	Mus musculus	74-112
20974012-11	2010	Puerarin pretreatment, but not post-treatment, can reverse the changes of gama-aminobutyric acid type A receptor subunit expression and increase ADH activity in alcoholism models.	puerarin	0-8	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	145-148
20509103-11	2010	These results suggest that puerarin develops its neuroprotective effect against 6-hydroxydopamine-induced neurotoxicity in the substantia nigra through the inhibition of apoptotic signaling pathways and upregulation of glial cell line-derived neurotrophic factor expression in the striatum.	puerarin	27-35	glial cell derived neurotrophic factor	Rattus norvegicus	219-262
20605096-3	2010	An isoflavone C-glucoside, puerarin (1), is known to enhance glucose uptake into the insulin sensitive cell and is thought to be a candidate for treatment of diabetes mellitus.	puerarin	27-35	insulin	Homo sapiens	85-92
20214329-7	2009	CONCLUSION: Injecting puerarin before CPB could effectively suppress the pro-inflammatory cytokines like TNF-alpha, IL-6 and IL-8; and enhance the expression of anti-inflammatory cytokines like IL-10, thus to alleviate the inflammatory reaction induced by CPB.	puerarin	22-30	tumor necrosis factor	Homo sapiens	105-114
20060010-5	2010	Induction of HO-1 expression by puerarin was suppressed by GF109203X, a general inhibitor of PKC, and by rottlerin, a specific inhibitor of PKC delta.	puerarin	32-40	protein kinase C, alpha	Mus musculus	93-96
20060010-5	2010	Induction of HO-1 expression by puerarin was suppressed by GF109203X, a general inhibitor of PKC, and by rottlerin, a specific inhibitor of PKC delta.	puerarin	32-40	protein kinase C, delta	Mus musculus	140-149
20060010-9	2010	Mutation of the ARE sequence abolished puerarin-induced HO-1 expression.	puerarin	39-47	heme oxygenase 1	Mus musculus	56-60
20060010-10	2010	Furthermore, puerarin treatments resulted in a marked increase in NF-E2 related factor-2 (Nrf-2) translocation, leading to up-regulation of HO-1 expression.	puerarin	13-21	nuclear factor, erythroid derived 2, like 2	Mus musculus	66-88
20060010-10	2010	Furthermore, puerarin treatments resulted in a marked increase in NF-E2 related factor-2 (Nrf-2) translocation, leading to up-regulation of HO-1 expression.	puerarin	13-21	nuclear factor, erythroid derived 2, like 2	Mus musculus	90-95
20060010-10	2010	Furthermore, puerarin treatments resulted in a marked increase in NF-E2 related factor-2 (Nrf-2) translocation, leading to up-regulation of HO-1 expression.	puerarin	13-21	heme oxygenase 1	Mus musculus	140-144
20060010-12	2010	Pretreatment with puerarin inhibited the expressions of COX-2, MMP-2 and MMP-9.	puerarin	18-26	cytochrome c oxidase II, mitochondrial	Mus musculus	56-61
20060010-12	2010	Pretreatment with puerarin inhibited the expressions of COX-2, MMP-2 and MMP-9.	puerarin	18-26	matrix metallopeptidase 2	Mus musculus	63-68
20060010-12	2010	Pretreatment with puerarin inhibited the expressions of COX-2, MMP-2 and MMP-9.	puerarin	18-26	matrix metallopeptidase 9	Mus musculus	73-78
20060010-14	2010	Taken together, our results demonstrate that puerarin-induced expression of HO-1 is mediated by the PKC delta-Nrf-2-HO-1 pathway and inhibits N-carboxymethyllysine (CML)-induced inflammation in mouse mesangial cells.	puerarin	45-53	heme oxygenase 1	Mus musculus	76-80
20060010-14	2010	Taken together, our results demonstrate that puerarin-induced expression of HO-1 is mediated by the PKC delta-Nrf-2-HO-1 pathway and inhibits N-carboxymethyllysine (CML)-induced inflammation in mouse mesangial cells.	puerarin	45-53	protein kinase C, delta	Mus musculus	100-109
20060010-14	2010	Taken together, our results demonstrate that puerarin-induced expression of HO-1 is mediated by the PKC delta-Nrf-2-HO-1 pathway and inhibits N-carboxymethyllysine (CML)-induced inflammation in mouse mesangial cells.	puerarin	45-53	nuclear factor, erythroid derived 2, like 2	Mus musculus	110-115
20060010-14	2010	Taken together, our results demonstrate that puerarin-induced expression of HO-1 is mediated by the PKC delta-Nrf-2-HO-1 pathway and inhibits N-carboxymethyllysine (CML)-induced inflammation in mouse mesangial cells.	puerarin	45-53	heme oxygenase 1	Mus musculus	116-120
19854265-0	2010	Puerarin attenuates high-glucose-and diabetes-induced vascular smooth muscle cell proliferation by blocking PKCbeta2/Rac1-dependent signaling.	puerarin	0-8	Rac family small GTPase 1	Rattus norvegicus	117-121
19854265-5	2010	Puerarin treatment remarkably disrupted the phosphorylation and membrane translocation of PKCbeta2 as well as Rac1, p47phox, and p67phox subunits.	puerarin	0-8	Rac family small GTPase 1	Rattus norvegicus	110-114
19854265-5	2010	Puerarin treatment remarkably disrupted the phosphorylation and membrane translocation of PKCbeta2 as well as Rac1, p47phox, and p67phox subunits.	puerarin	0-8	neutrophil cytosolic factor 1	Rattus norvegicus	116-123
19854265-8	2010	These results demonstrate that puerarin may exert inhibitory effects on HG-induced VSMC proliferation via interfering with PKCbeta2/Rac1-dependent ROS pathways, thus resulting in the attenuation of neointimal formation in the context of hyperglycemia in diabetes mellitus.	puerarin	31-39	Rac family small GTPase 1	Rattus norvegicus	132-136
20353015-0	2009	[Effects of puerarin on expression of apelin and its receptor of 2K1C renal hypertension rats].	puerarin	12-20	apelin	Rattus norvegicus	38-69
20353015-1	2009	OBJECTIVE: To examine the change of puerarin on the expression of apelin and its receptor of the two-kidney, one-clip (2K1C) rats.	puerarin	36-44	apelin	Rattus norvegicus	66-72
20353015-15	2009	CONCLUSION: Through regulating apelin/APJ system puerarin has protective effect on the development of left ventricular hypertrophy by renal hypertension.	puerarin	49-57	apelin	Rattus norvegicus	31-37
20353015-15	2009	CONCLUSION: Through regulating apelin/APJ system puerarin has protective effect on the development of left ventricular hypertrophy by renal hypertension.	puerarin	49-57	apelin receptor	Rattus norvegicus	38-41
20346059-0	2010	Puerarin inhibits C-reactive protein expression via suppression of nuclear factor kappaB activation in lipopolysaccharide-induced peripheral blood mononuclear cells of patients with stable angina pectoris.	puerarin	0-8	C-reactive protein	Homo sapiens	18-36
20346059-2	2010	In this report, we examined the ability of puerarin to modulate C-reactive protein (CRP) expression and key molecules in the nuclear factor kappa B (NF-kappaB) pathway to determine its molecular target.	puerarin	43-51	C-reactive protein	Homo sapiens	64-82
20346059-2	2010	In this report, we examined the ability of puerarin to modulate C-reactive protein (CRP) expression and key molecules in the nuclear factor kappa B (NF-kappaB) pathway to determine its molecular target.	puerarin	43-51	C-reactive protein	Homo sapiens	84-87
20346059-5	2010	The results indicated that puerarin inhibited the expression of the protein and mRNA levels of CRP in LPS-induced peripheral blood mononuclear cells.	puerarin	27-35	C-reactive protein	Homo sapiens	95-98
20346059-7	2010	We conclude that puerarin acts as an anti-inflammatory agent by blocking NF-kappaB signalling, and may possibly be developed as a useful agent for the chemoprevention of atherosclerosis.	puerarin	17-25	nuclear factor kappa B subunit 1	Homo sapiens	73-82
20077420-0	2010	Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-kappaB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells.	puerarin	46-54	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
20077420-0	2010	Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-kappaB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells.	puerarin	46-54	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	178-206
20077420-2	2010	In the present study, we investigated that puerarin, a natural isoflavonoid from Pueraria lobata, down-regulated MDR1 expression in MCF-7/adriamycin (MCF-7/adr), a human breast MDR cancer cell line.	puerarin	43-51	ATP binding cassette subfamily B member 1	Homo sapiens	113-117
20077420-3	2010	Puerarin treatment significantly inhibited MDR1 expression, MDR1 mRNA and MDR1 promoter activity in MCF-7/adr cells.	puerarin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	43-47
20077420-3	2010	Puerarin treatment significantly inhibited MDR1 expression, MDR1 mRNA and MDR1 promoter activity in MCF-7/adr cells.	puerarin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
20077420-3	2010	Puerarin treatment significantly inhibited MDR1 expression, MDR1 mRNA and MDR1 promoter activity in MCF-7/adr cells.	puerarin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
20077420-4	2010	The suppression of MDR1 was accompanied by partial recovery of intracellular drug accumulation, leading to increased toxicity of adriamycin and fluorescence of rhodamine 123, indicating that puerarin reversed the MDR phenotype by inhibiting the drug efflux function of MDR1.	puerarin	191-199	ATP binding cassette subfamily B member 1	Homo sapiens	19-23
20077420-4	2010	The suppression of MDR1 was accompanied by partial recovery of intracellular drug accumulation, leading to increased toxicity of adriamycin and fluorescence of rhodamine 123, indicating that puerarin reversed the MDR phenotype by inhibiting the drug efflux function of MDR1.	puerarin	191-199	ATP binding cassette subfamily B member 1	Homo sapiens	269-273
20077420-6	2010	Puerarin stimulated AMP-activated protein kinase (AMPK), acetyl-CoA carboxylase and glycogen synthase kinase-3beta phosphorylation, but puerarin decreased cAMP-responsive element-binding protein phosphorylation.	puerarin	0-8	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	20-48
20077420-6	2010	Puerarin stimulated AMP-activated protein kinase (AMPK), acetyl-CoA carboxylase and glycogen synthase kinase-3beta phosphorylation, but puerarin decreased cAMP-responsive element-binding protein phosphorylation.	puerarin	0-8	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	50-54
20077420-6	2010	Puerarin stimulated AMP-activated protein kinase (AMPK), acetyl-CoA carboxylase and glycogen synthase kinase-3beta phosphorylation, but puerarin decreased cAMP-responsive element-binding protein phosphorylation.	puerarin	0-8	glycogen synthase kinase 3 beta	Homo sapiens	84-114
20077420-7	2010	The puerarin-induced suppression of MDR1 expression was reduced by AMPK inhibitor (compound C).	puerarin	4-12	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
20077420-7	2010	The puerarin-induced suppression of MDR1 expression was reduced by AMPK inhibitor (compound C).	puerarin	4-12	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	67-71
20077420-9	2010	Taken together, our results suggested that puerarin down-regulated MDR1 expression via nuclear factor kappa-B and CRE transcriptional activity-dependent up-regulation of AMPK in MCF-7/adr cells.	puerarin	43-51	ATP binding cassette subfamily B member 1	Homo sapiens	67-71
20077420-9	2010	Taken together, our results suggested that puerarin down-regulated MDR1 expression via nuclear factor kappa-B and CRE transcriptional activity-dependent up-regulation of AMPK in MCF-7/adr cells.	puerarin	43-51	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	170-174
20060010-0	2010	Puerarin suppresses AGEs-induced inflammation in mouse mesangial cells: a possible pathway through the induction of heme oxygenase-1 expression.	puerarin	0-8	heme oxygenase 1	Mus musculus	116-132
20060010-3	2010	Puerarin acts by inducing the expression of heme oxygenase-1 (HO-1) in a dose- and time-dependent manner.	puerarin	0-8	heme oxygenase 1	Mus musculus	44-60
20060010-3	2010	Puerarin acts by inducing the expression of heme oxygenase-1 (HO-1) in a dose- and time-dependent manner.	puerarin	0-8	heme oxygenase 1	Mus musculus	62-66
20060010-4	2010	Puerarin was able to enhance phosphorylation of protein kinase C (PKC) delta, but not PKC alpha/beta II, in a time-dependent manner.	puerarin	0-8	protein kinase C, delta	Mus musculus	48-76
20060010-5	2010	Induction of HO-1 expression by puerarin was suppressed by GF109203X, a general inhibitor of PKC, and by rottlerin, a specific inhibitor of PKC delta.	puerarin	32-40	heme oxygenase 1	Mus musculus	13-17
20195825-0	2010	The effects of puerarin on CYP2D6 and CYP1A2 activities in vivo.	puerarin	15-23	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	27-33
20195825-0	2010	The effects of puerarin on CYP2D6 and CYP1A2 activities in vivo.	puerarin	15-23	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	38-44
20195825-7	2010	The logarithm value of metabolic rate decrease from -0.0055 +/- 0.1887 to -0.1754 +/- 0.2411 implied puerarin inhibited activity of CYP2D6.	puerarin	101-109	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	132-138
20195825-9	2010	The paraxanthin/caffeine ratio in the plasma sample at 6th hour was increased by 30 +/- 47% (p = 0.003), implied puerarin induced the activity of CYP1A2.	puerarin	113-121	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	146-152
20225658-0	2010	The effects of genistein and puerarin on the activation of nuclear factor-kappaB and the production of tumor necrosis factor-alpha in asthma patients.	puerarin	29-37	nuclear factor kappa B subunit 1	Homo sapiens	59-80
20225658-0	2010	The effects of genistein and puerarin on the activation of nuclear factor-kappaB and the production of tumor necrosis factor-alpha in asthma patients.	puerarin	29-37	tumor necrosis factor	Homo sapiens	103-130
20225658-2	2010	The aim of the present study was to investigate the effect of antioxidants genistein and puerarin on the activation of nuclear factor-kappaB (NF-kappaB) and the production of tumor necrosis factor-alpha (TNF-alpha) in peripheral blood mononuclear cells (PBMCs) in asthma patients.	puerarin	89-97	nuclear factor kappa B subunit 1	Homo sapiens	119-140
20225658-2	2010	The aim of the present study was to investigate the effect of antioxidants genistein and puerarin on the activation of nuclear factor-kappaB (NF-kappaB) and the production of tumor necrosis factor-alpha (TNF-alpha) in peripheral blood mononuclear cells (PBMCs) in asthma patients.	puerarin	89-97	nuclear factor kappa B subunit 1	Homo sapiens	142-151
20225658-2	2010	The aim of the present study was to investigate the effect of antioxidants genistein and puerarin on the activation of nuclear factor-kappaB (NF-kappaB) and the production of tumor necrosis factor-alpha (TNF-alpha) in peripheral blood mononuclear cells (PBMCs) in asthma patients.	puerarin	89-97	tumor necrosis factor	Homo sapiens	175-202
20225658-2	2010	The aim of the present study was to investigate the effect of antioxidants genistein and puerarin on the activation of nuclear factor-kappaB (NF-kappaB) and the production of tumor necrosis factor-alpha (TNF-alpha) in peripheral blood mononuclear cells (PBMCs) in asthma patients.	puerarin	89-97	tumor necrosis factor	Homo sapiens	204-213
20225658-8	2010	The percentages of NF-kappaB positive cells in PBMCs were significantly decreased in the genistein group 15.2 +/- 5.4% and in the puerarin group 16.2 +/- 5.1% than those in control groups 23.1 +/- 6.7% in asthma patients (p respectively < 0.01, < 0.05).	puerarin	130-138	nuclear factor kappa B subunit 1	Homo sapiens	19-28
20225658-9	2010	The levels of TNF-alpha in PBMCs supernatants were remarkably decreased in genistein group 1.08 +/- 0.40 microg/L and in puerarin group 1.24 +/- 0.29 microg/L than those in control group 2.10 +/- 0.38 microg/L in asthma patients (p all < 0.01).	puerarin	121-129	tumor necrosis factor	Homo sapiens	14-23
20225658-10	2010	There were positive correlations between the percentages of NF-kappaB positive cells and the levels of TNF-alpha in genistein group (r = 0.579, p < 0.01) and in puerarin group (r = 0.665, p < 0.01) in asthma patients.	puerarin	164-172	nuclear factor kappa B subunit 1	Homo sapiens	60-69
20225658-12	2010	Genistein, and puerarin could inhibit the pathway of NF-kappaB and TNF-alpha in asthma patients, so it was implicated that asthma patients will benefit from the antioxidants genistein and puerarin.	puerarin	15-23	nuclear factor kappa B subunit 1	Homo sapiens	53-62
20225658-12	2010	Genistein, and puerarin could inhibit the pathway of NF-kappaB and TNF-alpha in asthma patients, so it was implicated that asthma patients will benefit from the antioxidants genistein and puerarin.	puerarin	15-23	tumor necrosis factor	Homo sapiens	67-76
20225658-12	2010	Genistein, and puerarin could inhibit the pathway of NF-kappaB and TNF-alpha in asthma patients, so it was implicated that asthma patients will benefit from the antioxidants genistein and puerarin.	puerarin	188-196	nuclear factor kappa B subunit 1	Homo sapiens	53-62
20225658-12	2010	Genistein, and puerarin could inhibit the pathway of NF-kappaB and TNF-alpha in asthma patients, so it was implicated that asthma patients will benefit from the antioxidants genistein and puerarin.	puerarin	188-196	tumor necrosis factor	Homo sapiens	67-76
22553574-0	2010	Effect of puerarin on retinal pigment epithelial cells apoptosis induced partly by peroxynitrite via Fas/FasL pathway.	puerarin	10-18	Fas ligand	Rattus norvegicus	105-109
22553574-1	2010	AIM: To evaluate the peroxynitrite (ONOO(-)) of puerarin on retinal pigment epithelial (RPE) cells apoptosis induced partly by peroxynitrite via Fas/FasL.	puerarin	48-56	Fas ligand	Rattus norvegicus	149-153
22553574-6	2010	RESULTS: Both RPE cells in ONOO(-) and puerarin group developed apoptosis and expressed NT, C3, iNOS mRNA and Fas/FasL.	puerarin	39-47	complement C3	Rattus norvegicus	92-94
22553574-6	2010	RESULTS: Both RPE cells in ONOO(-) and puerarin group developed apoptosis and expressed NT, C3, iNOS mRNA and Fas/FasL.	puerarin	39-47	nitric oxide synthase 2	Rattus norvegicus	96-100
22553574-6	2010	RESULTS: Both RPE cells in ONOO(-) and puerarin group developed apoptosis and expressed NT, C3, iNOS mRNA and Fas/FasL.	puerarin	39-47	Fas ligand	Rattus norvegicus	114-118
20016245-0	2010	Puerarin inhibits adhesion molecule expression in tnf-alpha-stimulated human endothelial cells via modulation of the nuclear factor kappaB pathway.	puerarin	0-8	tumor necrosis factor	Homo sapiens	50-59
20016245-2	2010	In this report, the ability of puerarin to modulate intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and endothelial leukocyte adhesion molecule 1 (E-selectin), and to induce changes in the nuclear factor kappaB (NF-kappaB) pathway in human umbilical vein endothelial cells (HUVECs) was examined.	puerarin	31-39	intercellular adhesion molecule 1	Homo sapiens	52-85
20016245-2	2010	In this report, the ability of puerarin to modulate intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and endothelial leukocyte adhesion molecule 1 (E-selectin), and to induce changes in the nuclear factor kappaB (NF-kappaB) pathway in human umbilical vein endothelial cells (HUVECs) was examined.	puerarin	31-39	intercellular adhesion molecule 1	Homo sapiens	87-93
20016245-2	2010	In this report, the ability of puerarin to modulate intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and endothelial leukocyte adhesion molecule 1 (E-selectin), and to induce changes in the nuclear factor kappaB (NF-kappaB) pathway in human umbilical vein endothelial cells (HUVECs) was examined.	puerarin	31-39	vascular cell adhesion molecule 1	Homo sapiens	96-129
20016245-2	2010	In this report, the ability of puerarin to modulate intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and endothelial leukocyte adhesion molecule 1 (E-selectin), and to induce changes in the nuclear factor kappaB (NF-kappaB) pathway in human umbilical vein endothelial cells (HUVECs) was examined.	puerarin	31-39	vascular cell adhesion molecule 1	Homo sapiens	131-137
20016245-2	2010	In this report, the ability of puerarin to modulate intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and endothelial leukocyte adhesion molecule 1 (E-selectin), and to induce changes in the nuclear factor kappaB (NF-kappaB) pathway in human umbilical vein endothelial cells (HUVECs) was examined.	puerarin	31-39	selectin E	Homo sapiens	143-184
20016245-2	2010	In this report, the ability of puerarin to modulate intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and endothelial leukocyte adhesion molecule 1 (E-selectin), and to induce changes in the nuclear factor kappaB (NF-kappaB) pathway in human umbilical vein endothelial cells (HUVECs) was examined.	puerarin	31-39	selectin E	Homo sapiens	186-196
20016245-2	2010	In this report, the ability of puerarin to modulate intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and endothelial leukocyte adhesion molecule 1 (E-selectin), and to induce changes in the nuclear factor kappaB (NF-kappaB) pathway in human umbilical vein endothelial cells (HUVECs) was examined.	puerarin	31-39	nuclear factor kappa B subunit 1	Homo sapiens	251-260
20016245-5	2010	RESULTS: Puerarin inhibited the expression of TNF-alpha-induced ICAM-1, VCAM-1 and E-selectin proteins and mRNAs in HUVECs.	puerarin	9-17	tumor necrosis factor	Homo sapiens	46-55
20016245-5	2010	RESULTS: Puerarin inhibited the expression of TNF-alpha-induced ICAM-1, VCAM-1 and E-selectin proteins and mRNAs in HUVECs.	puerarin	9-17	intercellular adhesion molecule 1	Homo sapiens	64-70
20016245-5	2010	RESULTS: Puerarin inhibited the expression of TNF-alpha-induced ICAM-1, VCAM-1 and E-selectin proteins and mRNAs in HUVECs.	puerarin	9-17	vascular cell adhesion molecule 1	Homo sapiens	72-78
20016245-5	2010	RESULTS: Puerarin inhibited the expression of TNF-alpha-induced ICAM-1, VCAM-1 and E-selectin proteins and mRNAs in HUVECs.	puerarin	9-17	selectin E	Homo sapiens	83-93
20016245-7	2010	CONCLUSION: These data suggested that the effect of puerarin-mediated inhibition of TNF-alpha-induced ICAM-1, VCAM-1 and E-selectin expression is attributed to suppressed NF-kappaB activation on the transcriptional level.	puerarin	52-60	tumor necrosis factor	Homo sapiens	84-93
20016245-7	2010	CONCLUSION: These data suggested that the effect of puerarin-mediated inhibition of TNF-alpha-induced ICAM-1, VCAM-1 and E-selectin expression is attributed to suppressed NF-kappaB activation on the transcriptional level.	puerarin	52-60	intercellular adhesion molecule 1	Homo sapiens	102-108
20016245-7	2010	CONCLUSION: These data suggested that the effect of puerarin-mediated inhibition of TNF-alpha-induced ICAM-1, VCAM-1 and E-selectin expression is attributed to suppressed NF-kappaB activation on the transcriptional level.	puerarin	52-60	vascular cell adhesion molecule 1	Homo sapiens	110-116
20016245-7	2010	CONCLUSION: These data suggested that the effect of puerarin-mediated inhibition of TNF-alpha-induced ICAM-1, VCAM-1 and E-selectin expression is attributed to suppressed NF-kappaB activation on the transcriptional level.	puerarin	52-60	selectin E	Homo sapiens	121-131
20016245-7	2010	CONCLUSION: These data suggested that the effect of puerarin-mediated inhibition of TNF-alpha-induced ICAM-1, VCAM-1 and E-selectin expression is attributed to suppressed NF-kappaB activation on the transcriptional level.	puerarin	52-60	nuclear factor kappa B subunit 1	Homo sapiens	171-180
19744545-1	2009	The study investigated the effects of puerarin on P2X(3) receptor involved in hyperalgesia after burn injury in the rat.	puerarin	38-46	purinergic receptor P2X 3	Rattus norvegicus	50-56
19744545-7	2009	At day 3 post-burn, the expressions of P2X(3) protein and mRNA in DRG neurons in untreated superficial second degree back burn group were increased significantly compared with sham back burn group, puerarin-treated back unburned control group, blank back control group, while in puerarin-treated superficial second degree back burn group, the P2X(3) protein and mRNA expressions were decreased markedly.	puerarin	198-206	purinergic receptor P2X 3	Rattus norvegicus	39-45
19744545-7	2009	At day 3 post-burn, the expressions of P2X(3) protein and mRNA in DRG neurons in untreated superficial second degree back burn group were increased significantly compared with sham back burn group, puerarin-treated back unburned control group, blank back control group, while in puerarin-treated superficial second degree back burn group, the P2X(3) protein and mRNA expressions were decreased markedly.	puerarin	198-206	purinergic receptor P2X 3	Rattus norvegicus	343-349
19744545-7	2009	At day 3 post-burn, the expressions of P2X(3) protein and mRNA in DRG neurons in untreated superficial second degree back burn group were increased significantly compared with sham back burn group, puerarin-treated back unburned control group, blank back control group, while in puerarin-treated superficial second degree back burn group, the P2X(3) protein and mRNA expressions were decreased markedly.	puerarin	279-287	purinergic receptor P2X 3	Rattus norvegicus	39-45
19744545-9	2009	Therefore, puerarin may reduce the nociceptive transmission of burn injury pain mediated by P2X(3) receptor and alleviate P2X(3) receptor involved in hyperalgesia after burn injury in the rats.	puerarin	11-19	purinergic receptor P2X 3	Rattus norvegicus	92-98
19744545-9	2009	Therefore, puerarin may reduce the nociceptive transmission of burn injury pain mediated by P2X(3) receptor and alleviate P2X(3) receptor involved in hyperalgesia after burn injury in the rats.	puerarin	11-19	purinergic receptor P2X 3	Rattus norvegicus	122-128
20214329-7	2009	CONCLUSION: Injecting puerarin before CPB could effectively suppress the pro-inflammatory cytokines like TNF-alpha, IL-6 and IL-8; and enhance the expression of anti-inflammatory cytokines like IL-10, thus to alleviate the inflammatory reaction induced by CPB.	puerarin	22-30	interleukin 6	Homo sapiens	116-120
20214329-7	2009	CONCLUSION: Injecting puerarin before CPB could effectively suppress the pro-inflammatory cytokines like TNF-alpha, IL-6 and IL-8; and enhance the expression of anti-inflammatory cytokines like IL-10, thus to alleviate the inflammatory reaction induced by CPB.	puerarin	22-30	C-X-C motif chemokine ligand 8	Homo sapiens	125-129
20214329-7	2009	CONCLUSION: Injecting puerarin before CPB could effectively suppress the pro-inflammatory cytokines like TNF-alpha, IL-6 and IL-8; and enhance the expression of anti-inflammatory cytokines like IL-10, thus to alleviate the inflammatory reaction induced by CPB.	puerarin	22-30	interleukin 10	Homo sapiens	194-199
18587665-6	2009	Puerarin regulates expressions of VEGF and HIF-1alpha stimulated by STZ.	puerarin	0-8	vascular endothelial growth factor A	Rattus norvegicus	34-38
19125353-1	2009	To explore the effects of puerarin on mRNA expression of advanced glycation end products (AGE) specIfic cellular receptor (RAGE) in renal cortex of diabetic rats induced by streptozotocin (STZ).	puerarin	26-34	advanced glycosylation end product-specific receptor	Rattus norvegicus	123-127
19125353-9	2009	Puerarin can protect the renal tissue from the impairment of hyperglycemia and AGE by decreasing AGEs contents and inhibiting of the expression of RAGE mRNA in the kidney.	puerarin	0-8	advanced glycosylation end product-specific receptor	Rattus norvegicus	147-151
19848202-9	2009	Puerarin shows a protective effect on the T2DM caused oxidative damage by way of up-regulating bcl-2 to inhibit oxidative stress, and improving the energy metabolic dysfunction in liver of mice.	puerarin	0-8	B cell leukemia/lymphoma 2	Mus musculus	95-100
19852296-0	2009	[Of berberine and puerarin on dexamethasone-induced insulin resistance in porcine ovarian thecal cells].	puerarin	18-26	insulin	Homo sapiens	52-59
18587665-6	2009	Puerarin regulates expressions of VEGF and HIF-1alpha stimulated by STZ.	puerarin	0-8	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	43-53
19565720-3	2009	CONCLUSIONS: Puerarin can increase the activity of SOD, reduce the content of MDA, promote the expession of Bcl-2 and restrain the expression of Bax in the early spinal cord injury.	puerarin	13-21	BCL2, apoptosis regulator	Rattus norvegicus	108-113
19508827-10	2009	The erythropoietin activity was higher in puerarin treated group compared with the vehicle group.	puerarin	42-50	erythropoietin	Rattus norvegicus	4-18
19508827-11	2009	DISCUSSION: Puerarin has neuroprotection effects in rats at doses of 200 and 400 mg/kg, administered intraperitoneally after transient middle cerebral artery occlusion which may be partly due to activation of erythropoietin activity.	puerarin	12-20	erythropoietin	Rattus norvegicus	209-223
19537197-8	2009	A significant decrease of TSP-1 expression was observed in the puerarin treated rats" myocardium compared to the diabetic rats (P<0.01).	puerarin	63-71	thrombospondin 1	Rattus norvegicus	26-31
19537197-10	2009	Altogether puerarin could improve the left ventricular function of diabetic rats and showed protective effects of myocardium by decreasing the TSP-1 expression in myocardium of diabetic rats.	puerarin	11-19	thrombospondin 1	Rattus norvegicus	143-148
19073281-0	2009	Puerarin protects against high glucose-induced acute vascular dysfunction: role of heme oxygenase-1 in rat thoracic aorta.	puerarin	0-8	heme oxygenase 1	Rattus norvegicus	83-99
19073281-6	2009	ZnPP (an inhibitor of heme oxygenase-1) offset the protective effect of puerarin.	puerarin	72-80	heme oxygenase 1	Rattus norvegicus	22-38
19073281-8	2009	HO-1 activity was proposed as a mechanism to account for the protection of vascular responses by puerarin.	puerarin	97-105	heme oxygenase 1	Rattus norvegicus	0-4
19565720-3	2009	CONCLUSIONS: Puerarin can increase the activity of SOD, reduce the content of MDA, promote the expession of Bcl-2 and restrain the expression of Bax in the early spinal cord injury.	puerarin	13-21	BCL2 associated X, apoptosis regulator	Rattus norvegicus	145-148
19271171-10	2009	Compared with the reperfusion group, the expression of Bcl-2 in the puerarin group was up-regulated at the respective time points after ischemia reperfusion (P<0.01), reaching the peak on day 1.	puerarin	68-76	BCL2, apoptosis regulator	Rattus norvegicus	55-60
19022306-6	2009	Meanwhile, caspase-3 activity was remarkably attenuated by Puerarin.	puerarin	59-67	caspase 3	Homo sapiens	11-20
19222113-0	2009	Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways.	puerarin	22-30	Janus kinase 2	Rattus norvegicus	112-116
19222113-0	2009	Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways.	puerarin	22-30	signal transducer and activator of transcription 3	Rattus norvegicus	117-122
19222113-5	2009	The results showed that puerarin significantly decreased the TG, TC content in liver of the non-alcoholic fatty disease rats, ameliorated steatosis in liver, lowered liver inflammatory reaction, decreased leptin level in serum, and enhanced the expression of leptin receptor mRNA and P-JAK2/P-STAT3 level.	puerarin	24-32	leptin receptor	Rattus norvegicus	259-274
19222113-5	2009	The results showed that puerarin significantly decreased the TG, TC content in liver of the non-alcoholic fatty disease rats, ameliorated steatosis in liver, lowered liver inflammatory reaction, decreased leptin level in serum, and enhanced the expression of leptin receptor mRNA and P-JAK2/P-STAT3 level.	puerarin	24-32	Janus kinase 2	Rattus norvegicus	286-290
19222113-5	2009	The results showed that puerarin significantly decreased the TG, TC content in liver of the non-alcoholic fatty disease rats, ameliorated steatosis in liver, lowered liver inflammatory reaction, decreased leptin level in serum, and enhanced the expression of leptin receptor mRNA and P-JAK2/P-STAT3 level.	puerarin	24-32	signal transducer and activator of transcription 3	Rattus norvegicus	293-298
19222113-6	2009	All the results demonstrated that puerarin can exhibit therapeutic effect on non-alcoholic fatty liver disease by improving leptin signal transduction through JAK2/STAT3 pathways.	puerarin	34-42	Janus kinase 2	Rattus norvegicus	159-163
19222113-6	2009	All the results demonstrated that puerarin can exhibit therapeutic effect on non-alcoholic fatty liver disease by improving leptin signal transduction through JAK2/STAT3 pathways.	puerarin	34-42	signal transducer and activator of transcription 3	Rattus norvegicus	164-169
18845176-7	2008	Moreover, puerarin induced Nrf2 nuclear translocation, which is upstream of puerarin-induced HO-1 expression, and PI3K activation, a pathway that is involved in induced Nrf2 nuclear translocation, HO-1 expression and cytoprotection.	puerarin	10-18	heme oxygenase 1	Homo sapiens	93-97
19134456-7	2009	Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA.	puerarin	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	100-103
19134456-7	2009	Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA.	puerarin	0-8	caspase 8	Homo sapiens	105-110
19134456-7	2009	Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA.	puerarin	0-8	caspase 9	Homo sapiens	112-117
19134456-7	2009	Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA.	puerarin	0-8	Fas cell surface death receptor	Homo sapiens	119-126
19134456-7	2009	Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA.	puerarin	0-8	cyclin dependent kinase inhibitor 1B	Homo sapiens	128-134
19134456-7	2009	Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA.	puerarin	0-8	cyclin dependent kinase inhibitor 2A	Homo sapiens	136-142
19134456-7	2009	Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA.	puerarin	0-8	interferon alpha 1	Homo sapiens	144-149
19134456-7	2009	Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA.	puerarin	0-8	interferon beta 1	Homo sapiens	154-159
19134456-7	2009	Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA.	puerarin	0-8	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	197-200
19134456-7	2009	Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA.	puerarin	0-8	checkpoint kinase 2	Homo sapiens	202-207
19134456-7	2009	Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA.	puerarin	0-8	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	209-212
19134456-7	2009	Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA.	puerarin	0-8	integrin subunit beta 5	Homo sapiens	214-219
19134456-7	2009	Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA.	puerarin	0-8	matrix metallopeptidase 9	Homo sapiens	221-225
19134456-7	2009	Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA.	puerarin	0-8	platelet derived growth factor subunit A	Homo sapiens	227-232
19134456-7	2009	Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA.	puerarin	0-8	NFKB inhibitor alpha	Homo sapiens	237-243
18845176-4	2008	In this study, we demonstrate that the phytoestrogen puerarin inhibits tert-butyl hydroperoxide (t-BHP)-induced oxidative injury via an ER-dependent Gbeta1/PI3K/Akt and heme oxygenase-1 (HO-1) pathway.	puerarin	53-61	estrogen receptor 1	Homo sapiens	136-138
18845176-4	2008	In this study, we demonstrate that the phytoestrogen puerarin inhibits tert-butyl hydroperoxide (t-BHP)-induced oxidative injury via an ER-dependent Gbeta1/PI3K/Akt and heme oxygenase-1 (HO-1) pathway.	puerarin	53-61	AKT serine/threonine kinase 1	Homo sapiens	161-164
18845176-4	2008	In this study, we demonstrate that the phytoestrogen puerarin inhibits tert-butyl hydroperoxide (t-BHP)-induced oxidative injury via an ER-dependent Gbeta1/PI3K/Akt and heme oxygenase-1 (HO-1) pathway.	puerarin	53-61	heme oxygenase 1	Homo sapiens	169-185
18845176-4	2008	In this study, we demonstrate that the phytoestrogen puerarin inhibits tert-butyl hydroperoxide (t-BHP)-induced oxidative injury via an ER-dependent Gbeta1/PI3K/Akt and heme oxygenase-1 (HO-1) pathway.	puerarin	53-61	heme oxygenase 1	Homo sapiens	187-191
18845176-5	2008	Pretreatment of Hepa1c1c7 and HepG2 cells with puerarin significantly reduced t-BHP-induced caspase-3 activation and subsequent cell death.	puerarin	47-55	caspase 3	Homo sapiens	92-101
18845176-7	2008	Moreover, puerarin induced Nrf2 nuclear translocation, which is upstream of puerarin-induced HO-1 expression, and PI3K activation, a pathway that is involved in induced Nrf2 nuclear translocation, HO-1 expression and cytoprotection.	puerarin	10-18	NFE2 like bZIP transcription factor 2	Homo sapiens	27-31
18845176-7	2008	Moreover, puerarin induced Nrf2 nuclear translocation, which is upstream of puerarin-induced HO-1 expression, and PI3K activation, a pathway that is involved in induced Nrf2 nuclear translocation, HO-1 expression and cytoprotection.	puerarin	10-18	NFE2 like bZIP transcription factor 2	Homo sapiens	169-173
18845176-7	2008	Moreover, puerarin induced Nrf2 nuclear translocation, which is upstream of puerarin-induced HO-1 expression, and PI3K activation, a pathway that is involved in induced Nrf2 nuclear translocation, HO-1 expression and cytoprotection.	puerarin	10-18	heme oxygenase 1	Homo sapiens	197-201
18845176-7	2008	Moreover, puerarin induced Nrf2 nuclear translocation, which is upstream of puerarin-induced HO-1 expression, and PI3K activation, a pathway that is involved in induced Nrf2 nuclear translocation, HO-1 expression and cytoprotection.	puerarin	76-84	NFE2 like bZIP transcription factor 2	Homo sapiens	27-31
18845176-7	2008	Moreover, puerarin induced Nrf2 nuclear translocation, which is upstream of puerarin-induced HO-1 expression, and PI3K activation, a pathway that is involved in induced Nrf2 nuclear translocation, HO-1 expression and cytoprotection.	puerarin	76-84	heme oxygenase 1	Homo sapiens	93-97
18845176-8	2008	Puerarin-induced up-regulation of HO-1 and cytoprotection against t-BHP were abolished by silencing Nrf2 expression with specific siRNA.	puerarin	0-8	heme oxygenase 1	Homo sapiens	34-38
18845176-8	2008	Puerarin-induced up-regulation of HO-1 and cytoprotection against t-BHP were abolished by silencing Nrf2 expression with specific siRNA.	puerarin	0-8	NFE2 like bZIP transcription factor 2	Homo sapiens	100-104
18845176-9	2008	Also, puerarin-mediated increases in PI3K activation and HO-1 induction were reversed by co-treatment with ICI 182,780 and pertussis toxin.	puerarin	6-14	heme oxygenase 1	Homo sapiens	57-61
18845176-10	2008	Taken together, these results suggest that puerarin augments cellular antioxidant defense capacity through ER-dependent HO-1 induction via the Gbeta1/PI3K/Akt-Nrf2 signaling pathway, thereby protecting cells from oxidative stress.	puerarin	43-51	estrogen receptor 1	Homo sapiens	107-109
18845176-10	2008	Taken together, these results suggest that puerarin augments cellular antioxidant defense capacity through ER-dependent HO-1 induction via the Gbeta1/PI3K/Akt-Nrf2 signaling pathway, thereby protecting cells from oxidative stress.	puerarin	43-51	heme oxygenase 1	Homo sapiens	120-124
18845176-10	2008	Taken together, these results suggest that puerarin augments cellular antioxidant defense capacity through ER-dependent HO-1 induction via the Gbeta1/PI3K/Akt-Nrf2 signaling pathway, thereby protecting cells from oxidative stress.	puerarin	43-51	AKT serine/threonine kinase 1	Homo sapiens	155-158
18845176-10	2008	Taken together, these results suggest that puerarin augments cellular antioxidant defense capacity through ER-dependent HO-1 induction via the Gbeta1/PI3K/Akt-Nrf2 signaling pathway, thereby protecting cells from oxidative stress.	puerarin	43-51	NFE2 like bZIP transcription factor 2	Homo sapiens	159-163
19260323-6	2008	After 14 days treatment, the level of serum vWF and NIHSS score were obviously decreased in patients treated with puerarin and aspirin, not in basic treated patients.	puerarin	114-122	von Willebrand factor	Homo sapiens	44-47
18848966-0	2008	Decreased expression of aromatase in the Ishikawa and RL95-2 cells by the isoflavone, puerarin, is associated with inhibition of c-jun expression and AP-1 activity.	puerarin	86-94	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	129-134
18848966-0	2008	Decreased expression of aromatase in the Ishikawa and RL95-2 cells by the isoflavone, puerarin, is associated with inhibition of c-jun expression and AP-1 activity.	puerarin	86-94	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	150-154
18848966-6	2008	Our data have demonstrated a significant decrease of P450(arom) expression at both mRNA and protein levels by low dose puerarin treatment in both cell lines.	puerarin	119-127	PARP1 binding protein	Homo sapiens	53-63
18848966-8	2008	We also found that puerarin exerted a time-course effect on the inhibition of c-jun mRNA, which parallelled that of P450(arom).	puerarin	19-27	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	78-83
18848966-8	2008	We also found that puerarin exerted a time-course effect on the inhibition of c-jun mRNA, which parallelled that of P450(arom).	puerarin	19-27	PARP1 binding protein	Homo sapiens	116-126
18848966-9	2008	To further confirm if c-jun is responsible for the P450(arom) regulation by puerarin, we knocked down c-jun expression using siRNA and it indicates that c-jun acts as a considerable transcription factor in regulating P450(arom) expression and activity.	puerarin	76-84	PARP1 binding protein	Homo sapiens	51-61
18848966-9	2008	To further confirm if c-jun is responsible for the P450(arom) regulation by puerarin, we knocked down c-jun expression using siRNA and it indicates that c-jun acts as a considerable transcription factor in regulating P450(arom) expression and activity.	puerarin	76-84	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	22-27
18848966-9	2008	To further confirm if c-jun is responsible for the P450(arom) regulation by puerarin, we knocked down c-jun expression using siRNA and it indicates that c-jun acts as a considerable transcription factor in regulating P450(arom) expression and activity.	puerarin	76-84	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	102-107
18848966-9	2008	To further confirm if c-jun is responsible for the P450(arom) regulation by puerarin, we knocked down c-jun expression using siRNA and it indicates that c-jun acts as a considerable transcription factor in regulating P450(arom) expression and activity.	puerarin	76-84	PARP1 binding protein	Homo sapiens	217-227
18848966-10	2008	Accordingly, the suppression of P450(arom) expression and activity by puerarin treatment may associate with the downregulation of transcription factor AP-1 or c-jun.	puerarin	70-78	PARP1 binding protein	Homo sapiens	32-42
18848966-10	2008	Accordingly, the suppression of P450(arom) expression and activity by puerarin treatment may associate with the downregulation of transcription factor AP-1 or c-jun.	puerarin	70-78	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	151-155
18848966-10	2008	Accordingly, the suppression of P450(arom) expression and activity by puerarin treatment may associate with the downregulation of transcription factor AP-1 or c-jun.	puerarin	70-78	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	159-164
19260323-8	2008	CONCLUSION: Patients with ACI cotreated with puerarin and aspirin improved the neurological function, decreased the levels of serum vWF and sTM, indicating puerarin with aspirin had the protective effects on the damaged vascular endothelial cells.	puerarin	156-164	von Willebrand factor	Homo sapiens	132-135
19260323-8	2008	CONCLUSION: Patients with ACI cotreated with puerarin and aspirin improved the neurological function, decreased the levels of serum vWF and sTM, indicating puerarin with aspirin had the protective effects on the damaged vascular endothelial cells.	puerarin	156-164	sulfotransferase family 1A member 3	Homo sapiens	140-143
19260323-7	2008	The level of sTM was increased in patients after 14 d, while puerarin treated patient has lower sTM level than patients with basic treatment (P < 0.05).	puerarin	61-69	sulfotransferase family 1A member 3	Homo sapiens	96-99
19260323-8	2008	CONCLUSION: Patients with ACI cotreated with puerarin and aspirin improved the neurological function, decreased the levels of serum vWF and sTM, indicating puerarin with aspirin had the protective effects on the damaged vascular endothelial cells.	puerarin	45-53	von Willebrand factor	Homo sapiens	132-135
19260323-8	2008	CONCLUSION: Patients with ACI cotreated with puerarin and aspirin improved the neurological function, decreased the levels of serum vWF and sTM, indicating puerarin with aspirin had the protective effects on the damaged vascular endothelial cells.	puerarin	45-53	sulfotransferase family 1A member 3	Homo sapiens	140-143
18981705-7	2008	The results indicated that puerarin can limit the tissue injury caused by local cerebral ischemia injury through improving expression of HSP70, and limit the tissue injury caused by local cerebral ischemia-reperfusion through decreasing the Fas expression and improving expression of HSP70.	puerarin	27-35	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	137-142
18981705-7	2008	The results indicated that puerarin can limit the tissue injury caused by local cerebral ischemia injury through improving expression of HSP70, and limit the tissue injury caused by local cerebral ischemia-reperfusion through decreasing the Fas expression and improving expression of HSP70.	puerarin	27-35	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	284-289
18847535-2	2008	METHODS: The effects of puerarin on the P450(arom) mRNA expression were determined by real-time polymerase chain reaction (RT-PCR).	puerarin	24-32	PARP1 binding protein	Homo sapiens	40-50
18675923-2	2008	In this study, the protective effect of puerarin, an isoflavone purified from the radix of the Chinese herb Pueraria lobata, on Abeta-induced rat pheochromocytoma (PC12) cultures was investigated.	puerarin	40-48	amyloid beta precursor protein	Rattus norvegicus	128-133
18847535-8	2008	RESULTS: The data demonstrated that low-dose puerarin treatment could decrease P450(arom) expression at mRNA level compared to dimethyl sulphoxide (DMSO) treatment (P<0.01), and puerarin (10(-7)mol/L) had a time-course effect on P450(arom) mRNA expression, which reached the bottom at 12h (P<0.01).	puerarin	45-53	PARP1 binding protein	Homo sapiens	79-89
18847535-8	2008	RESULTS: The data demonstrated that low-dose puerarin treatment could decrease P450(arom) expression at mRNA level compared to dimethyl sulphoxide (DMSO) treatment (P<0.01), and puerarin (10(-7)mol/L) had a time-course effect on P450(arom) mRNA expression, which reached the bottom at 12h (P<0.01).	puerarin	45-53	PARP1 binding protein	Homo sapiens	232-242
18847535-11	2008	The activity of exogenous AP-1 was reduced after 12 hours of puerarin treatment (P<0.05).	puerarin	61-69	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	26-30
18847535-13	2008	The protein level of c-jun was also down-regulated by puerarin (10(-7)mol/L) treatment at 12h.	puerarin	54-62	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	21-26
18692596-9	2008	To get further insights into the underlying mechanisms of these effects induced by puerarin, we measured telomerase activity and determined the phosphorylation of serine/threonine protein kinase Akt by using western blot.	puerarin	83-91	AKT serine/threonine kinase 1	Homo sapiens	195-198
19166018-0	2008	[Effect of puerarin on levels of TGF-beta1 and alpha-SMA in rats with alcoholic injury liver].	puerarin	11-19	transforming growth factor, beta 1	Rattus norvegicus	33-42
19166018-0	2008	[Effect of puerarin on levels of TGF-beta1 and alpha-SMA in rats with alcoholic injury liver].	puerarin	11-19	actin gamma 2, smooth muscle	Rattus norvegicus	47-56
19166018-1	2008	OBJECTIVE: To investigate the regulatory effects of puerarin on the levels of transforming growth beta1 (TGF-beta1) and alpha-smooth muscle actin (alpha-SMA) in rats with alcoholic injury liver, and to probe into the prevention and cure mechanism of puerarin on alcoholic liver injury.	puerarin	52-60	transforming growth factor, beta 1	Rattus norvegicus	105-114
19166018-1	2008	OBJECTIVE: To investigate the regulatory effects of puerarin on the levels of transforming growth beta1 (TGF-beta1) and alpha-smooth muscle actin (alpha-SMA) in rats with alcoholic injury liver, and to probe into the prevention and cure mechanism of puerarin on alcoholic liver injury.	puerarin	52-60	actin gamma 2, smooth muscle	Rattus norvegicus	120-145
19166018-1	2008	OBJECTIVE: To investigate the regulatory effects of puerarin on the levels of transforming growth beta1 (TGF-beta1) and alpha-smooth muscle actin (alpha-SMA) in rats with alcoholic injury liver, and to probe into the prevention and cure mechanism of puerarin on alcoholic liver injury.	puerarin	52-60	actin gamma 2, smooth muscle	Rattus norvegicus	147-156
19166018-8	2008	Meanwhile the level of TGF-beta1 and alpha-SMA in both high and low dose puerarin groups were significantly decreased compared with model group (P<0.01).	puerarin	73-81	transforming growth factor, beta 1	Rattus norvegicus	23-32
19166018-8	2008	Meanwhile the level of TGF-beta1 and alpha-SMA in both high and low dose puerarin groups were significantly decreased compared with model group (P<0.01).	puerarin	73-81	actin gamma 2, smooth muscle	Rattus norvegicus	37-46
19166018-9	2008	Furthermore the level of alpha-SMA of puerarin high dose group were significantly decreased compared with control group (P<0.05), whereas there was no significant difference between puerarin low dose group and model group.	puerarin	38-46	actin gamma 2, smooth muscle	Rattus norvegicus	25-34
19166018-10	2008	CONCLUSION: There was an ascend in the level of TGF-beta1 and alpha-SMA expression in rats with alcoholic injury liver, and puerarin has regulatory effects on the expression of TGF-beta1 and alpha-SMA.	puerarin	124-132	transforming growth factor, beta 1	Rattus norvegicus	48-57
19166018-10	2008	CONCLUSION: There was an ascend in the level of TGF-beta1 and alpha-SMA expression in rats with alcoholic injury liver, and puerarin has regulatory effects on the expression of TGF-beta1 and alpha-SMA.	puerarin	124-132	transforming growth factor, beta 1	Rattus norvegicus	177-186
19166018-10	2008	CONCLUSION: There was an ascend in the level of TGF-beta1 and alpha-SMA expression in rats with alcoholic injury liver, and puerarin has regulatory effects on the expression of TGF-beta1 and alpha-SMA.	puerarin	124-132	actin gamma 2, smooth muscle	Rattus norvegicus	191-200
19065898-0	2008	[Effect of puerarin injection on the mRNA expressions of AT1 and ACE2 in spontaneous hypertension rats].	puerarin	11-19	angiotensin II receptor, type 1b	Rattus norvegicus	57-60
19065898-0	2008	[Effect of puerarin injection on the mRNA expressions of AT1 and ACE2 in spontaneous hypertension rats].	puerarin	11-19	angiotensin I converting enzyme 2	Rattus norvegicus	65-69
19065898-1	2008	OBJECTIVE: To study the effect of puerarin on angiotensin II type 1 receptor (AT1) and angiotensin-converting enzyme 2 (ACE2) in spontaneous hypertension rat (SHR).	puerarin	34-42	angiotensin II receptor, type 1b	Rattus norvegicus	46-76
19065898-1	2008	OBJECTIVE: To study the effect of puerarin on angiotensin II type 1 receptor (AT1) and angiotensin-converting enzyme 2 (ACE2) in spontaneous hypertension rat (SHR).	puerarin	34-42	angiotensin II receptor, type 1b	Rattus norvegicus	78-81
19065898-1	2008	OBJECTIVE: To study the effect of puerarin on angiotensin II type 1 receptor (AT1) and angiotensin-converting enzyme 2 (ACE2) in spontaneous hypertension rat (SHR).	puerarin	34-42	angiotensin I converting enzyme 2	Rattus norvegicus	87-118
19065898-1	2008	OBJECTIVE: To study the effect of puerarin on angiotensin II type 1 receptor (AT1) and angiotensin-converting enzyme 2 (ACE2) in spontaneous hypertension rat (SHR).	puerarin	34-42	angiotensin I converting enzyme 2	Rattus norvegicus	120-124
19065898-6	2008	CONCLUSION: High dose puerarin could increase the mRNA expressions of AT1 and ACE2 in kidney, while low dose puerarin could decrease them in heart; there might be a feed back correlation between AT1 and ACE2.	puerarin	22-30	angiotensin II receptor, type 1b	Rattus norvegicus	70-73
19065898-6	2008	CONCLUSION: High dose puerarin could increase the mRNA expressions of AT1 and ACE2 in kidney, while low dose puerarin could decrease them in heart; there might be a feed back correlation between AT1 and ACE2.	puerarin	22-30	angiotensin I converting enzyme 2	Rattus norvegicus	78-82
19065898-6	2008	CONCLUSION: High dose puerarin could increase the mRNA expressions of AT1 and ACE2 in kidney, while low dose puerarin could decrease them in heart; there might be a feed back correlation between AT1 and ACE2.	puerarin	22-30	angiotensin II receptor, type 1b	Rattus norvegicus	195-198
19065898-6	2008	CONCLUSION: High dose puerarin could increase the mRNA expressions of AT1 and ACE2 in kidney, while low dose puerarin could decrease them in heart; there might be a feed back correlation between AT1 and ACE2.	puerarin	22-30	angiotensin I converting enzyme 2	Rattus norvegicus	203-207
19065898-6	2008	CONCLUSION: High dose puerarin could increase the mRNA expressions of AT1 and ACE2 in kidney, while low dose puerarin could decrease them in heart; there might be a feed back correlation between AT1 and ACE2.	puerarin	109-117	angiotensin II receptor, type 1b	Rattus norvegicus	195-198
19065898-6	2008	CONCLUSION: High dose puerarin could increase the mRNA expressions of AT1 and ACE2 in kidney, while low dose puerarin could decrease them in heart; there might be a feed back correlation between AT1 and ACE2.	puerarin	109-117	angiotensin I converting enzyme 2	Rattus norvegicus	203-207
19086646-0	2008	[Effects of puerarin on ADRP gene expression in fatty tissue of type 2 diabetes mellitus rats].	puerarin	12-20	perilipin 2	Rattus norvegicus	24-28
18782535-0	2008	[Effects of puerarin on expressions of leptin receptor mRNA, phosphorylated Janus kinase 2/phosphorylated signal transducers and activators of transcription 3 proteins in the liver of rats with non-alcoholic fatty liver].	puerarin	12-20	leptin receptor	Rattus norvegicus	39-54
18782535-1	2008	OBJECTIVE: To observe the effects of puerarin on the expressions of leptin receptor mRNA and phosphorylated Janus kinase 2 / phosphorylated signal transducers and activators of transcription 3 (P-JAK2/P-STAT3) proteins in the liver of rats with non-alcoholic fatty liver (NAFLD).	puerarin	37-45	leptin receptor	Rattus norvegicus	68-83
18782535-1	2008	OBJECTIVE: To observe the effects of puerarin on the expressions of leptin receptor mRNA and phosphorylated Janus kinase 2 / phosphorylated signal transducers and activators of transcription 3 (P-JAK2/P-STAT3) proteins in the liver of rats with non-alcoholic fatty liver (NAFLD).	puerarin	37-45	Janus kinase 2	Rattus norvegicus	108-122
18782535-9	2008	The serum leptin level was increased and the expressions of leptin receptor mRNA and P-JAK2/P-STAT3 proteins were up-regulated in puerarin-treated group.	puerarin	130-138	leptin	Rattus norvegicus	10-16
18782535-9	2008	The serum leptin level was increased and the expressions of leptin receptor mRNA and P-JAK2/P-STAT3 proteins were up-regulated in puerarin-treated group.	puerarin	130-138	leptin receptor	Rattus norvegicus	60-75
18782535-10	2008	CONCLUSION: Puerarin can effectively attenuate liver lipid disorder and inflammation by improving the leptin resistance and enhancing the expressions of leptin receptor mRNA and P-JAK2/P-STAT3 proteins.	puerarin	12-20	leptin	Rattus norvegicus	102-108
18782535-10	2008	CONCLUSION: Puerarin can effectively attenuate liver lipid disorder and inflammation by improving the leptin resistance and enhancing the expressions of leptin receptor mRNA and P-JAK2/P-STAT3 proteins.	puerarin	12-20	leptin receptor	Rattus norvegicus	153-168
18937077-6	2008	Among the flavonoids, kaempferol activated ERE-reporter activity, whereas puerarin inhibited ERE-reporter transcription in cells overexpressing ERbeta.	puerarin	74-82	estrogen receptor 2	Homo sapiens	144-150
18692596-10	2008	Puerarin significantly increased telomerase activity and phosphorylation of Akt, a downstream effector of phosphoinositide 3-kinase (PI-3K).	puerarin	0-8	AKT serine/threonine kinase 1	Homo sapiens	76-79
18692596-10	2008	Puerarin significantly increased telomerase activity and phosphorylation of Akt, a downstream effector of phosphoinositide 3-kinase (PI-3K).	puerarin	0-8	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	106-131
19086646-1	2008	OBJECTIVE: To observe the effects of puerarin on ADRP gene mRNA expression in fatty tissue of type 2 diabetes mellitus rats (T2DM).	puerarin	37-45	perilipin 2	Rattus norvegicus	49-53
18692596-12	2008	Taken together, the results of the present study indicated that puerarin delayed the onset of EPCs senescence, which may be related to the activation of telomerase through the PI-3K/Akt pathway.	puerarin	64-72	AKT serine/threonine kinase 1	Homo sapiens	182-185
18533503-6	2008	Ligustrazine together with puerarin group has remarkably decreased MDA and LDH level and increased SOD level, compared with ligustrazine group and puerarin group (P < 0.05).	puerarin	27-35	superoxide dismutase 1	Homo sapiens	99-102
19086646-6	2008	RESULT: Compared with model control group, high and middle dosage of puerarin can decreased ADRP gene mRNA expression in fatty tissue obviously, FBG, IR level in each puerarin group and FINS in high and middle dosage puerarin groups decreased obviously.	puerarin	69-77	perilipin 2	Rattus norvegicus	92-96
19086646-6	2008	RESULT: Compared with model control group, high and middle dosage of puerarin can decreased ADRP gene mRNA expression in fatty tissue obviously, FBG, IR level in each puerarin group and FINS in high and middle dosage puerarin groups decreased obviously.	puerarin	167-175	perilipin 2	Rattus norvegicus	92-96
19086646-6	2008	RESULT: Compared with model control group, high and middle dosage of puerarin can decreased ADRP gene mRNA expression in fatty tissue obviously, FBG, IR level in each puerarin group and FINS in high and middle dosage puerarin groups decreased obviously.	puerarin	167-175	perilipin 2	Rattus norvegicus	92-96
19086646-7	2008	CONCLUSION: Puerarin can decrease the blood glucose level of T2DM by downregulating ADRP mRNA expression and depressing the insulin resistance.	puerarin	12-20	perilipin 2	Rattus norvegicus	84-88
18763636-8	2008	CONCLUSION: The compound Puerarin might have some functions on preventing ren by inhibiting expression of type IV collagen.	puerarin	25-33	renin	Rattus norvegicus	74-77
18058205-0	2008	Binding of puerarin to human serum albumin: a spectroscopic analysis and molecular docking.	puerarin	11-19	albumin	Homo sapiens	29-42
18058205-2	2008	Binding of puerarin to human serum albumin (HSA) was investigated by ultraviolet absorbance, fluorescence, circular dichroism and molecular docking.	puerarin	11-19	albumin	Homo sapiens	29-42
18382055-8	2008	The NF-kappaB activity of K562/AO2 intervened by puerarin was lower than that unintervened by puerarin.The p-gp and survivin expression of K562/AO2 was significantly higher than K562.	puerarin	49-57	phosphoglycolate phosphatase	Homo sapiens	107-111
18382055-8	2008	The NF-kappaB activity of K562/AO2 intervened by puerarin was lower than that unintervened by puerarin.The p-gp and survivin expression of K562/AO2 was significantly higher than K562.	puerarin	94-102	phosphoglycolate phosphatase	Homo sapiens	107-111
18382055-10	2008	But the p-gp and survivin expression of K562 which was pretreated by puerarin and then treated by ADR was much lower than that not pretreated by puerarin.The p-gp and survivin expression of K562/AO2 intervened by puerarin was lower than that unintervened by puerarin.	puerarin	69-77	phosphoglycolate phosphatase	Homo sapiens	8-12
18382055-10	2008	But the p-gp and survivin expression of K562 which was pretreated by puerarin and then treated by ADR was much lower than that not pretreated by puerarin.The p-gp and survivin expression of K562/AO2 intervened by puerarin was lower than that unintervened by puerarin.	puerarin	69-77	phosphoglycolate phosphatase	Homo sapiens	158-162
18382055-10	2008	But the p-gp and survivin expression of K562 which was pretreated by puerarin and then treated by ADR was much lower than that not pretreated by puerarin.The p-gp and survivin expression of K562/AO2 intervened by puerarin was lower than that unintervened by puerarin.	puerarin	145-153	phosphoglycolate phosphatase	Homo sapiens	158-162
18382055-10	2008	But the p-gp and survivin expression of K562 which was pretreated by puerarin and then treated by ADR was much lower than that not pretreated by puerarin.The p-gp and survivin expression of K562/AO2 intervened by puerarin was lower than that unintervened by puerarin.	puerarin	145-153	phosphoglycolate phosphatase	Homo sapiens	158-162
18382055-10	2008	But the p-gp and survivin expression of K562 which was pretreated by puerarin and then treated by ADR was much lower than that not pretreated by puerarin.The p-gp and survivin expression of K562/AO2 intervened by puerarin was lower than that unintervened by puerarin.	puerarin	145-153	phosphoglycolate phosphatase	Homo sapiens	158-162
18382055-14	2008	Puerarin can prevent and stop the multi-drug resistance in K562 and reverse the multi-drug resistance of K562/AO2 to ADR by inhibiting the activity of NF-kappaB and the expression of p-gp and survivin.	puerarin	0-8	phosphoglycolate phosphatase	Homo sapiens	183-187
18278451-8	2008	In rats treated with puerarin, the percentage of CMA/IAPA and cell proliferation was reduced, whereas PASMC apoptosis was increased; The expression levels of PKC-alpha mRNA and protein were lower than in smoke exposure rats.	puerarin	21-29	protein kinase C, alpha	Rattus norvegicus	158-167
18278451-11	2008	Puerarin appears to be able to reduce cell proliferation and vascular remodeling possibly through PKC signaling transduction pathway.	puerarin	0-8	protein kinase C, alpha	Rattus norvegicus	98-101
18348063-9	2008	The increased expression of eNOS and the Akt/PKB pathway may be the underlying mechanism by which puerarin stimulates NO production.	puerarin	98-106	nitric oxide synthase 3	Rattus norvegicus	28-32
18348063-9	2008	The increased expression of eNOS and the Akt/PKB pathway may be the underlying mechanism by which puerarin stimulates NO production.	puerarin	98-106	AKT serine/threonine kinase 1	Rattus norvegicus	41-48
17942262-0	2007	Analysis of binding interaction between puerarin and bovine serum albumin by multi-spectroscopic method.	puerarin	40-48	albumin	Homo sapiens	60-73
17942262-1	2007	The interaction of puerarin and bovine serum albumin (BSA) was investigated by means of fluorescence spectroscopy, resonance light-scattering spectroscopy, infrared spectroscopy, and synchronous fluorescence spectra.	puerarin	19-27	albumin	Homo sapiens	39-52
18038910-2	2007	The purpose of this study was to investigate the protective effects of puerarin against hepatotoxicity induced by carbon tetrachloride (CCl4) and the mechanism of its hepatoprotective effect.	puerarin	71-79	chemokine (C-C motif) ligand 4	Mus musculus	136-140
18330247-0	2007	[Effects of puerarin on expression of nuclear factor kappaB after cerebral ischemia/reperfusion in rats].	puerarin	12-20	RELA proto-oncogene, NF-kB subunit	Rattus norvegicus	38-59
18330251-4	2007	RESULT: There is a good linear relationship for puerarin in the range 0.025-3.2 microg x mL-1, RSD < 10%, and the average recovery is 97.6%.	puerarin	48-56	L1 cell adhesion molecule	Mus musculus	89-93
18038910-3	2007	In mice, pretreatment with puerarin prior to the administration of CCl4 significantly prevented the increased serum enzymatic activity of alanine aspartate aminotransferase and hepatic malondialdehyde formation in a dose-dependent manner.	puerarin	27-35	chemokine (C-C motif) ligand 4	Mus musculus	67-71
18038910-4	2007	In addition, pretreatment with puerarin significantly prevented both the depletion of reduced glutathione (GSH) content and the decrease in glutathione S-transferase (GST) activity in the liver of CCl4-intoxicated mice.	puerarin	31-39	hematopoietic prostaglandin D synthase	Mus musculus	140-165
18038910-4	2007	In addition, pretreatment with puerarin significantly prevented both the depletion of reduced glutathione (GSH) content and the decrease in glutathione S-transferase (GST) activity in the liver of CCl4-intoxicated mice.	puerarin	31-39	hematopoietic prostaglandin D synthase	Mus musculus	167-170
18038910-4	2007	In addition, pretreatment with puerarin significantly prevented both the depletion of reduced glutathione (GSH) content and the decrease in glutathione S-transferase (GST) activity in the liver of CCl4-intoxicated mice.	puerarin	31-39	chemokine (C-C motif) ligand 4	Mus musculus	197-201
18038910-5	2007	Hepatic GSH levels and GST activity were increased by treatment with puerarin alone.	puerarin	69-77	hematopoietic prostaglandin D synthase	Mus musculus	23-26
18038910-7	2007	The effects of puerarin on cytochrome P450 (CYP) 2E1, the major isozyme involved in CCl4 bioactivation, were also investigated.	puerarin	15-23	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	27-52
18038910-8	2007	Treatment of the mice with puerarin resulted in a significant decrease in the CYP2E1-dependent aniline hydroxylation in a dose-dependent manner.	puerarin	27-35	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	78-84
18038910-11	2007	These results suggest that the protective effects of puerarin against the CCl4-induced hepatotoxicity possibly involve mechanisms related to its ability to block CYP-mediated CCl4 bioactivation, induction of GST activity and free radical scavenging effects.	puerarin	53-61	chemokine (C-C motif) ligand 4	Mus musculus	74-78
18038910-11	2007	These results suggest that the protective effects of puerarin against the CCl4-induced hepatotoxicity possibly involve mechanisms related to its ability to block CYP-mediated CCl4 bioactivation, induction of GST activity and free radical scavenging effects.	puerarin	53-61	chemokine (C-C motif) ligand 4	Mus musculus	175-179
18038910-11	2007	These results suggest that the protective effects of puerarin against the CCl4-induced hepatotoxicity possibly involve mechanisms related to its ability to block CYP-mediated CCl4 bioactivation, induction of GST activity and free radical scavenging effects.	puerarin	53-61	hematopoietic prostaglandin D synthase	Mus musculus	208-211
17652634-5	2007	Puerarin activated BK-alpha+beta1 currents with a half-maximal concentration (EC50) of 0.8 nM and a Hill coefficient of 1.11 at 10 microM Ca2+ and with an EC50 of 12.6 nM and a Hill coefficient of 1.08 at 0 microM Ca2+.	puerarin	0-8	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Rattus norvegicus	19-33
17652634-6	2007	Puerarin (1 nM) induced a 16-mV leftward shift in the conductance-voltage curve for BK-alpha+beta1 currents at 10 microM Ca2+ and at 100 nM induced a 26-mV leftward shift at 0 microM Ca2+.	puerarin	0-8	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Rattus norvegicus	84-98
17652634-7	2007	Puerarin mainly increased the BK-alpha+beta1 channel open probability without changing the unitary conductance.	puerarin	0-8	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Rattus norvegicus	30-44
17652634-12	2007	This is the first study demonstrating that puerarin activates BK(Ca) channels, especially BK-alpha+beta1 channels.	puerarin	43-51	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Rattus norvegicus	90-104
17258874-9	2007	Uterine IGF-1 gene expression was only upregulated in puerarin high group.	puerarin	54-62	insulin-like growth factor 1	Rattus norvegicus	8-13
18051529-0	2007	[Studies on the interaction between puerarin and bovine serum albumin].	puerarin	36-44	albumin	Homo sapiens	56-69
18051529-1	2007	The interaction of puerarin and bovine serum albumin (BSA) under physiological condition was studied by fluorospectrophotometry.	puerarin	19-27	albumin	Homo sapiens	39-52
18095572-0	2007	[Study of regulation of Puerarin on blood P-selectin and the expression of aorta VCAM mRNA in diabetes].	puerarin	24-32	selectin P	Rattus norvegicus	42-52
18095572-1	2007	OBJECTIVE: To observe the regulation of Puerarin on blood P-selectin and expression of aorta vascular cell adhesion molecule (VCAM) in diabetic rats induced by Streptozotocin.	puerarin	40-48	selectin P	Rattus norvegicus	58-68
18095572-8	2007	(2) Puerarin could decrease the levels of cholesterol (P < 0.05), low density lipoprotein (P < 0.05), P-selectin (P < 0.05), oxidative low density lipoprotein, and glycosylated low density (P < 0.05), lipoprotein increase high density lipoprotein (P < 0.05).	puerarin	4-12	selectin P	Rattus norvegicus	108-118
17666819-7	2007	In addition, quercetin, morin, myricetin, kaempferol and puerarin exhibited significant inhibition on the liver xanthine oxidase (XOD) activities.	puerarin	57-65	xanthine dehydrogenase	Mus musculus	112-128
17666819-7	2007	In addition, quercetin, morin, myricetin, kaempferol and puerarin exhibited significant inhibition on the liver xanthine oxidase (XOD) activities.	puerarin	57-65	xanthine dehydrogenase	Mus musculus	130-133
17610871-12	2007	However, U-73122, the inhibitor of phospholipase C (PLC) had no effect, indicating that the cyclic AMP/PKA signaling pathway was involved in the activation of CICR by puerarin.	puerarin	167-175	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	103-106
17173194-22	2006	In STZ + puerarin group, mild expression of iNOS was observed on day 20, significantly increased on day 40, but markedly decreased on day 60.	puerarin	9-17	nitric oxide synthase 2	Rattus norvegicus	44-48
17443435-0	2007	Stimulatory effect of puerarin on bone formation through activation of PI3K/Akt pathway in rat calvaria osteoblasts.	puerarin	22-30	AKT serine/threonine kinase 1	Rattus norvegicus	76-79
17443435-6	2007	This functional improvement by puerarin was accompanied by activation and nuclear translocation of Akt.	puerarin	31-39	AKT serine/threonine kinase 1	Rattus norvegicus	99-102
17443435-7	2007	Furthermore, puerarin-stimulated osteoblastic growth, Akt activation and redistribution were significantly blocked by the specific PI3K inhibitor, LY294002.	puerarin	13-21	AKT serine/threonine kinase 1	Rattus norvegicus	54-57
17443435-8	2007	These results strongly suggested that puerarin stimulated osteoblastic proliferation and Akt activation in a PI3K-dependent manner.	puerarin	38-46	AKT serine/threonine kinase 1	Rattus norvegicus	89-92
17048591-5	2006	RESULT: High dose and middle dose of puerarin can decrease the activity of aldose reductase in red blood cells (P < 0.01), and inhibit the formation of glycation products significantly in model rats induced by D-galactose (P < 0.01).	puerarin	37-45	aldo-keto reductase family 1 member B1	Rattus norvegicus	75-91
17205823-7	2006	Puerarin could promote ADMA metabolism through increasing DDAH activity, and improve NOS activity, thus to reduce the impairing of OFR on endothelial function.	puerarin	0-8	dimethylarginine dimethylaminohydrolase 1	Homo sapiens	58-62
16055262-5	2006	We then investigated effects of puerarin on expression of apoptosis-associated genes and the results revealed an increase of bax and decreases of c-myc and bcl-2.	puerarin	32-40	BCL2 associated X, apoptosis regulator	Homo sapiens	125-128
16055262-5	2006	We then investigated effects of puerarin on expression of apoptosis-associated genes and the results revealed an increase of bax and decreases of c-myc and bcl-2.	puerarin	32-40	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	146-151
16055262-5	2006	We then investigated effects of puerarin on expression of apoptosis-associated genes and the results revealed an increase of bax and decreases of c-myc and bcl-2.	puerarin	32-40	BCL2 apoptosis regulator	Homo sapiens	156-161
16055262-6	2006	Finally, puerarin treatment significantly increased the activation of caspase-3, a key executioner of apoptosis.	puerarin	9-17	caspase 3	Homo sapiens	70-79
16426832-9	2006	Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as indexes of hepatic cell disruption, were reduced with puerarin treatment, whereas no significant effect was discovered in the levels of alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT) activities.	puerarin	132-140	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	41-67
16426832-9	2006	Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as indexes of hepatic cell disruption, were reduced with puerarin treatment, whereas no significant effect was discovered in the levels of alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT) activities.	puerarin	132-140	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	69-72
16426832-9	2006	Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as indexes of hepatic cell disruption, were reduced with puerarin treatment, whereas no significant effect was discovered in the levels of alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT) activities.	puerarin	132-140	gamma-glutamyltransferase 1	Rattus norvegicus	245-270
16426832-9	2006	Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as indexes of hepatic cell disruption, were reduced with puerarin treatment, whereas no significant effect was discovered in the levels of alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT) activities.	puerarin	132-140	gamma-glutamyltransferase 1	Rattus norvegicus	272-275
16426832-11	2006	And the expression of bcl-2 mRNA was down-regulated after puerarin administration.	puerarin	58-66	BCL2, apoptosis regulator	Rattus norvegicus	22-27
17205823-0	2006	[Effect of puerarin on ADMA-DDAH system in human umbilical vein endothelial cells cultured with oxidized free radical].	puerarin	11-19	dimethylarginine dimethylaminohydrolase 1	Homo sapiens	23-32
17205823-1	2006	OBJECTIVE: To observe the effects of puerarin on activity of dimethylarginine dimethylaminohydrolase (DDAH) in human umbilical vein endothelial cells (HUVECs) cultured with oxidized free radical (OFR), to explore the effect of puerarin on metabolic mechanism of asymmetric dimethylarginine (ADMA).	puerarin	37-45	dimethylarginine dimethylaminohydrolase 1	Homo sapiens	61-100
17205823-1	2006	OBJECTIVE: To observe the effects of puerarin on activity of dimethylarginine dimethylaminohydrolase (DDAH) in human umbilical vein endothelial cells (HUVECs) cultured with oxidized free radical (OFR), to explore the effect of puerarin on metabolic mechanism of asymmetric dimethylarginine (ADMA).	puerarin	37-45	dimethylarginine dimethylaminohydrolase 1	Homo sapiens	102-106
17205823-1	2006	OBJECTIVE: To observe the effects of puerarin on activity of dimethylarginine dimethylaminohydrolase (DDAH) in human umbilical vein endothelial cells (HUVECs) cultured with oxidized free radical (OFR), to explore the effect of puerarin on metabolic mechanism of asymmetric dimethylarginine (ADMA).	puerarin	227-235	dimethylarginine dimethylaminohydrolase 1	Homo sapiens	61-100
17205823-1	2006	OBJECTIVE: To observe the effects of puerarin on activity of dimethylarginine dimethylaminohydrolase (DDAH) in human umbilical vein endothelial cells (HUVECs) cultured with oxidized free radical (OFR), to explore the effect of puerarin on metabolic mechanism of asymmetric dimethylarginine (ADMA).	puerarin	227-235	dimethylarginine dimethylaminohydrolase 1	Homo sapiens	102-106
16472823-0	2006	Puerarin decreases serum total cholesterol and enhances thoracic aorta endothelial nitric oxide synthase expression in diet-induced hypercholesterolemic rats.	puerarin	0-8	nitric oxide synthase 3	Rattus norvegicus	71-104
16472823-10	2006	Animals administered with puerarin suppressed the hypercholesterolemic diet induced impairment of eNOS expression, whereas there was no significant difference in the endothelium-dependent vasorelaxation among various groups of animals.	puerarin	26-34	nitric oxide synthase 3	Rattus norvegicus	98-102
17569333-0	2006	[Protective effect of puerarin on endothelial dysfunction of heat shock protein 60 induced specific immunity in apolipoprotein E-null mice].	puerarin	22-30	heat shock protein 1 (chaperonin)	Mus musculus	61-82
17569333-0	2006	[Protective effect of puerarin on endothelial dysfunction of heat shock protein 60 induced specific immunity in apolipoprotein E-null mice].	puerarin	22-30	apolipoprotein E	Mus musculus	112-128
17569333-11	2006	CONCLUSION: Hsp60 could activate DCs in vitro and in vivo, Puerarin could significantly inhibit specific immunity induced by HSP60 and improve vascular endothelium-dependent dilation.	puerarin	59-67	heat shock protein 1 (chaperonin)	Mus musculus	125-130
16494032-4	2005	RESULT: It was found that puerarin had the effect on stimulating cell proliferation, activity of ALP and the number of mineral node of cultured osteoblasts (P < 0.01 or P < 0.05).	puerarin	26-34	PDZ and LIM domain 3	Rattus norvegicus	97-100
16651724-8	2006	The gene expression or activation of vascular endothelial growth factor (VEGF), hypoxia-inducible factor 1alpha (HIF-1alpha) and endothelial nitric oxide synthase (eNOS) that correlated with angiogenesis were also induced by puerarin.	puerarin	225-233	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	80-111
16651724-10	2006	The mechanism may be that puerarin can induce VEGF and eNOS expression.	puerarin	26-34	vascular endothelial growth factor A	Rattus norvegicus	46-50
16722382-0	2006	[Puerarin suppresses the proliferation of vscular smooth muscule cells and c-fos and bcl-2 protein expression].	puerarin	1-9	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	75-80
16722382-1	2006	OBJECTIVE: To observe the role of puerarin on the proliferation of vascular smooth muscle cells(VSMC) induced by thrombin (T) and the effect of puerarin on the c-fos and bcl-2 protein expression.	puerarin	34-42	coagulation factor II, thrombin	Homo sapiens	113-121
16722382-1	2006	OBJECTIVE: To observe the role of puerarin on the proliferation of vascular smooth muscle cells(VSMC) induced by thrombin (T) and the effect of puerarin on the c-fos and bcl-2 protein expression.	puerarin	144-152	BCL2 apoptosis regulator	Homo sapiens	170-175
16722382-3	2006	Western blot was used to indicate the changes of c-fos and bcl-2 protein after 24 h of treatment of T and puerarin.	puerarin	106-114	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	49-54
16722382-3	2006	Western blot was used to indicate the changes of c-fos and bcl-2 protein after 24 h of treatment of T and puerarin.	puerarin	106-114	BCL2 apoptosis regulator	Homo sapiens	59-64
16722382-4	2006	RESULT: 1.5 x 10(-5) - 1.5 x 10(-3) mol x L(-1) puerarin could significantly suppress this stimulation of VSMC proliferation and DNA synthesis induced by T. Western blot demonstrated that after 24 hour of treatment with T and puerarin, T could significantly increase c-fos and bcl-2 protein and 1.5 x 10(-5) - 1.5 x 10(-3) mol x L(-1) puerain could significantly suppress this increase.	puerarin	48-56	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	267-272
16722382-4	2006	RESULT: 1.5 x 10(-5) - 1.5 x 10(-3) mol x L(-1) puerarin could significantly suppress this stimulation of VSMC proliferation and DNA synthesis induced by T. Western blot demonstrated that after 24 hour of treatment with T and puerarin, T could significantly increase c-fos and bcl-2 protein and 1.5 x 10(-5) - 1.5 x 10(-3) mol x L(-1) puerain could significantly suppress this increase.	puerarin	48-56	BCL2 apoptosis regulator	Homo sapiens	277-282
16722382-5	2006	CONCLUSION: puerarin can suppress the proliferation and DNA synthesis of VSMC promoted by T. This inhibitory effects of puerarin are closely related with the suppression of c-fos and bcl-2 protein.	puerarin	12-20	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	173-178
16722382-5	2006	CONCLUSION: puerarin can suppress the proliferation and DNA synthesis of VSMC promoted by T. This inhibitory effects of puerarin are closely related with the suppression of c-fos and bcl-2 protein.	puerarin	12-20	BCL2 apoptosis regulator	Homo sapiens	183-188
16722382-5	2006	CONCLUSION: puerarin can suppress the proliferation and DNA synthesis of VSMC promoted by T. This inhibitory effects of puerarin are closely related with the suppression of c-fos and bcl-2 protein.	puerarin	120-128	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	173-178
16722382-5	2006	CONCLUSION: puerarin can suppress the proliferation and DNA synthesis of VSMC promoted by T. This inhibitory effects of puerarin are closely related with the suppression of c-fos and bcl-2 protein.	puerarin	120-128	BCL2 apoptosis regulator	Homo sapiens	183-188
16677576-0	2006	[Effects of puerarin on proliferation of vascular smooth muscle cells induced by thrombin].	puerarin	12-20	coagulation factor II	Rattus norvegicus	81-89
16677576-1	2006	OBJECTIVE: To investigate the effects of puerarin on the proliferation of vascular smooth muscle cells (VSMC) induced by thrombin and the mechanism thereof.	puerarin	41-49	coagulation factor II	Rattus norvegicus	121-129
16677576-7	2006	The c-fos protein expression of the VSMCs after thrombin stimulation for 24 h increased by 156.0% +/- 11.3% (P < 0.05), and the bcl-2 protein expression of the VSMCs pretreated with puerarin of the concentrations of 1.5 x 10(-5), 1.5 x 10(-4), and 1.5 x 10(-3) mol/L, and then stimulated by thrombin was significantly lower than that of the VSMCs only stimulated by thrombin with the suppression rates of 20.7% +/- 2.1%, 31.6% +/- 5.2%, and 44.5% +/- 7.5% respectively (all P < 0.05).	puerarin	185-193	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	4-9
16677576-8	2006	The bcl-2 protein expression of the VSMCs after thrombin stimulation for 24 h increased by 96.7% +/- 8.3% (P < 0.05), and the bcl-2 protein expression of the VSMCs pretreated with puerarin of the concentrations of 1.5 x 10(-5), 1.5 x 10(-4), and 1.5 x 10(-3) mol/L, and then stimulated by thrombin was significantly lower than that of the VSMCs only stimulated by thrombin with the suppression rates of 7.1% +/- 0.8%, 18.8% +/- 1.2%, and 39.6% +/- 6.4% respectively (all P < 0.05).	puerarin	183-191	BCL2, apoptosis regulator	Rattus norvegicus	4-9
16677576-8	2006	The bcl-2 protein expression of the VSMCs after thrombin stimulation for 24 h increased by 96.7% +/- 8.3% (P < 0.05), and the bcl-2 protein expression of the VSMCs pretreated with puerarin of the concentrations of 1.5 x 10(-5), 1.5 x 10(-4), and 1.5 x 10(-3) mol/L, and then stimulated by thrombin was significantly lower than that of the VSMCs only stimulated by thrombin with the suppression rates of 7.1% +/- 0.8%, 18.8% +/- 1.2%, and 39.6% +/- 6.4% respectively (all P < 0.05).	puerarin	183-191	coagulation factor II	Rattus norvegicus	48-56
16677576-8	2006	The bcl-2 protein expression of the VSMCs after thrombin stimulation for 24 h increased by 96.7% +/- 8.3% (P < 0.05), and the bcl-2 protein expression of the VSMCs pretreated with puerarin of the concentrations of 1.5 x 10(-5), 1.5 x 10(-4), and 1.5 x 10(-3) mol/L, and then stimulated by thrombin was significantly lower than that of the VSMCs only stimulated by thrombin with the suppression rates of 7.1% +/- 0.8%, 18.8% +/- 1.2%, and 39.6% +/- 6.4% respectively (all P < 0.05).	puerarin	183-191	BCL2, apoptosis regulator	Rattus norvegicus	129-134
16677576-10	2006	The puerarin of the concentrations of 1.5 x 10(-5) mol/L and 1.5 x 10(-4) mol/L decreased the increase of TR mRNA expression induced by thrombin, however, without significant differences (both P > 0.05), and puerarin of the concentration of 1.5 x 10(-3) mol/L significantly suppressed the increase of TR mRNA expression induced by thrombin by 17.6% +/- 1.7% (P < 0.05).	puerarin	4-12	coagulation factor II	Rattus norvegicus	136-144
16677576-10	2006	The puerarin of the concentrations of 1.5 x 10(-5) mol/L and 1.5 x 10(-4) mol/L decreased the increase of TR mRNA expression induced by thrombin, however, without significant differences (both P > 0.05), and puerarin of the concentration of 1.5 x 10(-3) mol/L significantly suppressed the increase of TR mRNA expression induced by thrombin by 17.6% +/- 1.7% (P < 0.05).	puerarin	4-12	coagulation factor II	Rattus norvegicus	334-342
16677576-11	2006	CONCLUSION: Puerarin suppresses the proliferation and DNA synthesis of VSMC induced by thrombin.	puerarin	12-20	coagulation factor II	Rattus norvegicus	87-95
16677576-12	2006	The inhibitory effect of puerarin is closely related with the suppression of the protein expression of c-fos and bcl-2n, and partly related with the suppression of the TR mRNA expression.	puerarin	25-33	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	103-108
16677576-12	2006	The inhibitory effect of puerarin is closely related with the suppression of the protein expression of c-fos and bcl-2n, and partly related with the suppression of the TR mRNA expression.	puerarin	25-33	BCL2, apoptosis regulator	Rattus norvegicus	113-118
16466908-2	2006	The puerarin-loaded HBP-CMCHS micellar system was prepared by physical entrapped method.	puerarin	4-12	heme binding protein 1	Homo sapiens	20-23
16466908-3	2006	Result showed that when adding the same amount of puerarin, the solubilizing capacity was enhanced by increasing the concentration of HBP-CMCHS and temperature.	puerarin	50-58	heme binding protein 1	Homo sapiens	134-137
16466908-4	2006	Puerarin-loaded micellar system of HBP-CMCHS was characterized by TEM and DLS.	puerarin	0-8	heme binding protein 1	Homo sapiens	35-38
16321378-6	2006	Puerarin was also found to inhibit the free radicals production induced by H(2)O(2) and to increase catalase and superoxide dismutase (SOD) activities in the isolated pancreatic islets.	puerarin	0-8	catalase	Rattus norvegicus	100-108
16005472-7	2005	Results of present study showed that puerarin could potentiate insulin-induced preadipocyte differentiation, promote glucose-uptake of adipocytes that have been induced insulin resistance by high glucose, and prevent TNF-a-induced apoptosis and viability loss of endothelial cells.	puerarin	37-45	insulin	Homo sapiens	63-70
16005472-7	2005	Results of present study showed that puerarin could potentiate insulin-induced preadipocyte differentiation, promote glucose-uptake of adipocytes that have been induced insulin resistance by high glucose, and prevent TNF-a-induced apoptosis and viability loss of endothelial cells.	puerarin	37-45	insulin	Homo sapiens	169-176
16005472-7	2005	Results of present study showed that puerarin could potentiate insulin-induced preadipocyte differentiation, promote glucose-uptake of adipocytes that have been induced insulin resistance by high glucose, and prevent TNF-a-induced apoptosis and viability loss of endothelial cells.	puerarin	37-45	tumor necrosis factor	Homo sapiens	217-222
16324368-1	2005	OBJECTIVE: To study if the Pueraria crude extreact (CP) and standard preparation of pure puerarin (SP) possess the same neuroprotective effects on the expression of heat shock protein (HSP) 70 in the embryonic mouse hippocampal cells.	puerarin	89-97	heat shock protein 1B	Mus musculus	165-192
16335816-4	2005	Flavonoid compounds and their derivates from traditional medicinal herbs are active inhibitors to aldose reductase, such as quercetin, silymarin, puerarin, baicalim, berberine and so on.	puerarin	146-154	aldo-keto reductase family 1 member B	Homo sapiens	98-114
16011103-0	2005	[Effect of puerarin on the expression of Hsp70 in the rats with cerebral injury induced by acute local ischemia].	puerarin	11-19	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	41-46
16038632-0	2005	Puerarin reduces increased c-fos, c-jun, and type IV collagen expression caused by high glucose in glomerular mesangial cells.	puerarin	0-8	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	27-32
16038632-4	2005	The aim of this study is to investigate the effect of puerarin on c-fos, c-jun and CoIV expression in GMC cultured in medium containing 5.6 or 27.8 mmol/L glucose.	puerarin	54-62	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	66-71
16038632-8	2005	RESULTS: Puerarin (10(-5) mmol/L) significantly ameliorated the high-glucose effect on c-fos, c-jun and CoIV expression.	puerarin	9-17	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	87-92
16038632-10	2005	CONCLUSION: Our results suggest that reduced PKC activity and expression of c-fos and c-jun in GMC might participate in the mechanisms underlying the therapeutic effect of puerarin on diabetic nephropathy.	puerarin	172-180	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	76-81
16112764-0	2005	Protection by puerarin against MPP+-induced neurotoxicity in PC12 cells mediated by inhibiting mitochondrial dysfunction and caspase-3-like activation.	puerarin	14-22	caspase-3-like	Rattus norvegicus	125-139
16112764-7	2005	In addition, puerarin also reduced MPP+-induced caspase-3-like activation.	puerarin	13-21	caspase-3-like	Rattus norvegicus	48-62
16011103-5	2005	CONCLUSION: Puerarin can enhance the level of Hsp70 expression in the rats with cerebral injury induced by acute local ischemia.	puerarin	12-20	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	46-51
16011103-1	2005	OBJECTIVE: To study the effect of puerarin on the expression of Hsp (heat shock protein) 70 in the rats with cerebral injury induced by acute local ischemia.	puerarin	34-42	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	69-91
15842138-2	2005	METHODS: Seventy-nine patients with anterior AMI were randomly divided into three groups, they were treated with conventional Western medical treatment, but to the puerarin group (PG) and the G-CSF group (GCG) puerarin and G-CSF was given additionally, respectively.	puerarin	210-218	colony stimulating factor 3	Homo sapiens	192-197
15493832-1	2004	AIM: To investigate the effect of puerarin on expressions of MMP-2 and TIMP-2 in the kidney of diabetic rats.	puerarin	34-42	matrix metallopeptidase 2	Rattus norvegicus	61-66
15493832-1	2004	AIM: To investigate the effect of puerarin on expressions of MMP-2 and TIMP-2 in the kidney of diabetic rats.	puerarin	34-42	TIMP metallopeptidase inhibitor 2	Rattus norvegicus	71-77
15493832-6	2004	The level of MMP-2 expression was advanced, while expression of TIMP-2 was reduced by puerarin treatment (P < 0.05).	puerarin	86-94	TIMP metallopeptidase inhibitor 2	Rattus norvegicus	64-70
15493832-7	2004	CONCLUSION: Puerarin showed some renal protective effect on diabetic nephropathy, partly through inhibition of excessive deposition of glomeruli extracellular matrix by up-regulating MMP-2 and down-regulating TIMP-2 expressions besides reducing the blood glucose.	puerarin	12-20	matrix metallopeptidase 2	Rattus norvegicus	183-188
15493832-7	2004	CONCLUSION: Puerarin showed some renal protective effect on diabetic nephropathy, partly through inhibition of excessive deposition of glomeruli extracellular matrix by up-regulating MMP-2 and down-regulating TIMP-2 expressions besides reducing the blood glucose.	puerarin	12-20	TIMP metallopeptidase inhibitor 2	Rattus norvegicus	209-215
15002057-10	2004	Therefore, we suggest that the HPS and puerarin act either on GH secretagogue receptors or on GHRH receptor of somatotrophin as possible agonists or an inhibitor on somatostatin receptor to release rGH, respectively.	puerarin	39-47	growth hormone releasing hormone receptor	Rattus norvegicus	94-107
12828463-6	2003	Moreover, the mRNA and protein levels of the subtype 4 form of glucose transporter (GLUT4) in soleus muscle were increased after repeated intravenous administration of puerarin in STZ-diabetic rats for 3 days.	puerarin	168-176	solute carrier family 2 member 4	Rattus norvegicus	84-89
15719689-0	2004	[Effects of puerarin on plasma membrane GLUT4 content in skeletal muscle from insulin-resistant Sprague-Dawley rats under insulin stimulation].	puerarin	12-20	solute carrier family 2 member 4	Rattus norvegicus	40-45
15719689-1	2004	OBJECTIVE: To explore the effect of puerarin injection on the amount of GLUT4 protein at the plasma membrane in insulin-resistant rat skeletal muscle.	puerarin	36-44	solute carrier family 2 member 4	Rattus norvegicus	72-77
15719689-11	2004	Puerarin Injection partly corrected fasting blood glucose (from 6.17 +/- 0.67 mmol x L(-1) to 5.54 +/- 0.35 mmol x L(-1)) and fasting serum insulin levels (from 17.09 +/- 2.02 mU x L(-1) to 11.86 +/- 1.35 mU x L(-1)) and increased the GLUT4 content at the plasma membrane by 1.18-fold in insulin-resistant rats skeletal muscle.	puerarin	0-8	solute carrier family 2 member 4	Rattus norvegicus	235-240
15719689-12	2004	CONCLUSION: Puerarin Injection can ameliorate IR, and the mechanism may be involved in increasing cell-surface level of GLUT4 through decreasing fasting blood glucose and fasting serum insulin levels, improving GLUT4 trafficking and intracellular insulin signaling.	puerarin	12-20	solute carrier family 2 member 4	Rattus norvegicus	120-125
15719689-12	2004	CONCLUSION: Puerarin Injection can ameliorate IR, and the mechanism may be involved in increasing cell-surface level of GLUT4 through decreasing fasting blood glucose and fasting serum insulin levels, improving GLUT4 trafficking and intracellular insulin signaling.	puerarin	12-20	solute carrier family 2 member 4	Rattus norvegicus	211-216
12778743-7	2003	Puerarin (0.5-3 mmol.L-1) was found to inhibit endothelial cell apoptosis effectively, and reduce the expression of Caspase-3 significantly.	puerarin	0-8	caspase 3	Bos taurus	116-125
12895679-0	2003	NPI-031G (puerarin) reduces anxiogenic effects of alcohol withdrawal or benzodiazepine inverse or 5-HT2C agonists.	puerarin	10-18	5-hydroxytryptamine receptor 2C	Rattus norvegicus	98-104
12778743-8	2003	CONCLUSION: Puerarin can protect apoptotic endothelial cells induced by chemical hypoxia-ischemia markedly and the effect was performed partly by decreasing Caspase-3 expression.	puerarin	12-20	caspase 3	Bos taurus	157-166
12451490-5	2002	An activation of alpha 1A -AR seems responsible for the action of puerarin in C 2 C 12 cells.	puerarin	66-74	calcium channel, voltage-dependent, P/Q type, alpha 1A subunit	Mus musculus	17-25
12723760-6	2003	However, daidzein, which is produced from puerarin by human intestinal bacteria, potently inhibited beta-glucuronidase.	puerarin	42-50	glucuronidase beta	Homo sapiens	100-118
14642535-6	2003	Puerarin also reduced the H(2)O(2)-induced elevation of caspase-3 activation.	puerarin	0-8	caspase 3	Rattus norvegicus	56-65
12451490-0	2002	Stimulatory effect of puerarin on alpha1A-adrenoceptor to increase glucose uptake into cultured C2C12 cells of mice.	puerarin	22-30	adrenergic receptor, alpha 1a	Mus musculus	34-54
12451490-9	2002	The obtained data suggest that an activation of alpha 1A -AR by puerarin in C 2 C 12 cells may increase the glucose uptake via the PLC-PKC pathway.	puerarin	64-72	calcium channel, voltage-dependent, P/Q type, alpha 1A subunit	Mus musculus	48-56
12451490-4	2002	The stimulatory action of puerarin on glucose uptake was also reduced in C 2 C 12 cells pre-incubated with the antagonists, both WB 4101 and RS 17 056, at concentrations sufficient to block alpha 1A -adrenoceptor (alpha 1A -AR).	puerarin	26-34	adrenergic receptor, alpha 1a	Mus musculus	190-212
12451490-4	2002	The stimulatory action of puerarin on glucose uptake was also reduced in C 2 C 12 cells pre-incubated with the antagonists, both WB 4101 and RS 17 056, at concentrations sufficient to block alpha 1A -adrenoceptor (alpha 1A -AR).	puerarin	26-34	calcium channel, voltage-dependent, P/Q type, alpha 1A subunit	Mus musculus	190-198
12599693-9	2002	These results suggested that puerarin and TIP possessed property of partial agonist of estrogen receptor.	puerarin	29-37	estrogen receptor 1 (alpha)	Mus musculus	87-104
12392089-6	2002	To evaluate the antiallergic activity of puerarin, daidzin, and daidzein, their inhibitory effects on the release of beta-hexosaminidase from RBL 2H3 cells and on the passive cutaneous anaphylaxis (PCA) reaction in mice were examined.	puerarin	41-49	O-GlcNAcase	Rattus norvegicus	117-136
12585165-0	2002	[Study on interventing effect of puerarin on insulin resistance in patients with coronary heart disease].	puerarin	33-41	insulin	Homo sapiens	45-52
12585165-1	2002	OBJECTIVE: To explore the effect of puerarin in improving the insulin resistance (IR) and its closely related abnormal lipid and fibrinolytic activity in patients with coronary heart disease (CHD).	puerarin	36-44	insulin	Homo sapiens	62-69
12585165-9	2002	After puerarin treatment, FINS level lowered and ISI increased significantly (P < 0.01), while comparing with the routine group, TC, TG, LDL-C and PAI-1 were lower but HDL-C and tPA activity before and during VOT were higher in the puerarin group (P < 0.05, P < 0.01).	puerarin	6-14	serpin family E member 1	Homo sapiens	150-155
7742802-4	1995	The bile of rats administered puerarin orally contained puerarin and two major metabolites, which were identified as puerarin 4"-O-sulfate (PB1) and puerarin 7-O-beta-D-glucuronide (PB2) on the basis of chemical and spectroscopic data.	puerarin	30-38	cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1	Rattus norvegicus	140-143
12545446-5	2001	The calibration curve was linear in the range of 2 mg/L-20 mg/L puerarin (r = 0.9999).	puerarin	64-72	immunoglobulin kappa variable 3D-11	Homo sapiens	54-58
11783153-5	1999	RESULTS: After the treatment with puerarin, SOD activity was increased, LPO reduced, while without any changes in the control group.	puerarin	34-42	superoxide dismutase 1	Homo sapiens	44-47
11783153-8	1999	CONCLUSION: Puerarin can increase the SOD activity, decrease LPO level and enhance the activity of fibrinolysis.	puerarin	12-20	superoxide dismutase 1	Homo sapiens	38-41
11742573-0	2001	Puerarin blocks transient outward K+ current and delayed rectifier K+ current in mice hippocampal CA1 neurons.	puerarin	0-8	carbonic anhydrase 1	Mus musculus	98-101
9863126-0	1997	[Effect of puerarin on plasma endothelin, renin activity and angiotensin II in patients with acute myocardial infarction].	puerarin	11-19	renin	Homo sapiens	42-47
9863126-0	1997	[Effect of puerarin on plasma endothelin, renin activity and angiotensin II in patients with acute myocardial infarction].	puerarin	11-19	angiotensinogen	Homo sapiens	61-75
9863126-6	1997	After treatment with puerarin, plasma levels of ET, RA and AT-II were recovered to normal in 3 days, but these data recovered to nearly normal until 7-14 days in group with GIK treatment.	puerarin	21-29	angiotensinogen	Homo sapiens	59-64
9863126-7	1997	CONCLUSION: Puerarin might play an important role in regulating the imbalance of ET, RA and AT-II of patients with AMI.	puerarin	12-20	angiotensinogen	Homo sapiens	92-97
33824083-11	2021	Furthermore, puerarin treatment attenuated dexamethasone-induced inhibition on the viability, osteoblastic differentiation, and the expressions of ALP, RUNX2, COL1A1 and miR-34a in the osteoblasts.	puerarin	13-21	runt-related transcription factor 2	Oryctolagus cuniculus	152-157
33824083-11	2021	Furthermore, puerarin treatment attenuated dexamethasone-induced inhibition on the viability, osteoblastic differentiation, and the expressions of ALP, RUNX2, COL1A1 and miR-34a in the osteoblasts.	puerarin	13-21	collagen alpha-1(I) chain	Oryctolagus cuniculus	159-165
33761593-0	2021	Puerarin suppresses the hepatic gluconeogenesis via activation of PI3K/Akt signaling pathway in diabetic rats and HepG2 cells.	puerarin	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	71-74
33768740-0	2021	Puerarin pretreatment inhibits myocardial apoptosis and improves cardiac function in rats after acute myocardial infarction through the PI3K/Akt signaling pathway.	puerarin	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	141-144
34863080-11	2021	Further studies showed that the inhibitory effects of puerarin on PCCs were abolished by a mTOR activator, indicating a crucial role of mTOR in anti-tumor effects of puerarin in PDAC.	puerarin	54-62	mechanistic target of rapamycin kinase	Mus musculus	91-95
34748867-14	2022	The results of PLSR and CCA revealed that the contents of puerarin, daidzin, salvianolic acid B and ginsenoside Rb1 were inversely correlated with the expression of VEGF and HIF-1alpha.	puerarin	58-66	vascular endothelial growth factor A	Rattus norvegicus	165-169
34748867-14	2022	The results of PLSR and CCA revealed that the contents of puerarin, daidzin, salvianolic acid B and ginsenoside Rb1 were inversely correlated with the expression of VEGF and HIF-1alpha.	puerarin	58-66	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	174-184
34748867-16	2022	The results of intervention on primary culture retinal Muller cells showed that puerarin, daidzin, salvianolic acid B, and ginsenoside Rb1 can significantly inhibit the expression of VEGF and HIF-1alpha.	puerarin	80-88	vascular endothelial growth factor A	Rattus norvegicus	183-187
34748867-16	2022	The results of intervention on primary culture retinal Muller cells showed that puerarin, daidzin, salvianolic acid B, and ginsenoside Rb1 can significantly inhibit the expression of VEGF and HIF-1alpha.	puerarin	80-88	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	192-202
34928145-7	2021	In our study, we found that puerarin and tryptophan showed different effects on TRPM5 and VAMP8, respectively.	puerarin	28-36	transient receptor potential cation channel, subfamily M, member 5	Rattus norvegicus	80-85
34928145-7	2021	In our study, we found that puerarin and tryptophan showed different effects on TRPM5 and VAMP8, respectively.	puerarin	28-36	vesicle-associated membrane protein 8	Rattus norvegicus	90-95
34928145-8	2021	Puerarin enhances the expression of TRPM5, and tryptophan inhibits the expression of TRPM5; however, puerarin and tryptophan have no significant effect on the expression of VAMP8.	puerarin	0-8	transient receptor potential cation channel, subfamily M, member 5	Rattus norvegicus	36-41
34975477-0	2021	Puerarin Alleviates Depression-Like Behavior Induced by High-Fat Diet Combined With Chronic Unpredictable Mild Stress via Repairing TLR4-Induced Inflammatory Damages and Phospholipid Metabolism Disorders.	puerarin	0-8	toll-like receptor 4	Rattus norvegicus	132-136
34975477-6	2021	The antidepressive effects of puerarin were associated with decreased pro-inflammatory cytokine production, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), and increased anti-inflammatory cytokine levels (IL-10) in rat hippocampal tissues and plasma.	puerarin	30-38	interleukin 6	Rattus norvegicus	118-131
34975477-6	2021	The antidepressive effects of puerarin were associated with decreased pro-inflammatory cytokine production, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), and increased anti-inflammatory cytokine levels (IL-10) in rat hippocampal tissues and plasma.	puerarin	30-38	interleukin 6	Rattus norvegicus	133-137
34975477-6	2021	The antidepressive effects of puerarin were associated with decreased pro-inflammatory cytokine production, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), and increased anti-inflammatory cytokine levels (IL-10) in rat hippocampal tissues and plasma.	puerarin	30-38	tumor necrosis factor	Rattus norvegicus	143-170
34975477-6	2021	The antidepressive effects of puerarin were associated with decreased pro-inflammatory cytokine production, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), and increased anti-inflammatory cytokine levels (IL-10) in rat hippocampal tissues and plasma.	puerarin	30-38	tumor necrosis factor	Rattus norvegicus	172-181
34975477-6	2021	The antidepressive effects of puerarin were associated with decreased pro-inflammatory cytokine production, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), and increased anti-inflammatory cytokine levels (IL-10) in rat hippocampal tissues and plasma.	puerarin	30-38	interleukin 10	Rattus norvegicus	233-238
34975477-11	2021	In vivo, puerarin treatment decreased the enzyme activities of cPLA2 and COX-2, resulting in lower production of prostaglandin E2 (PGE2) in hippocampal and intestinal tissues.	puerarin	9-17	phospholipase A2 group IVA	Rattus norvegicus	63-68
34979308-0	2021	Puerarin alleviates cadmium-induced mitochondrial mass decrease by inhibiting PINK1-Parkin and Nix-mediated mitophagy in rat cortical neurons.	puerarin	0-8	PTEN induced kinase 1	Rattus norvegicus	78-83
34979308-0	2021	Puerarin alleviates cadmium-induced mitochondrial mass decrease by inhibiting PINK1-Parkin and Nix-mediated mitophagy in rat cortical neurons.	puerarin	0-8	BCL2 interacting protein 3 like	Rattus norvegicus	95-98
34979308-6	2021	Puerarin improved the Cd-induced decrease in mitochondrial membrane potential (MMP) in vitro, and blocked PINK1-Parkin and Nix-mediated mitophagy, inhibiting Cd-induced mitochondrial mass decrease in rat cortical neurons in vitro and in vivo.	puerarin	0-8	PTEN induced kinase 1	Rattus norvegicus	106-111
34979308-6	2021	Puerarin improved the Cd-induced decrease in mitochondrial membrane potential (MMP) in vitro, and blocked PINK1-Parkin and Nix-mediated mitophagy, inhibiting Cd-induced mitochondrial mass decrease in rat cortical neurons in vitro and in vivo.	puerarin	0-8	BCL2 interacting protein 3 like	Rattus norvegicus	123-126
34975477-11	2021	In vivo, puerarin treatment decreased the enzyme activities of cPLA2 and COX-2, resulting in lower production of prostaglandin E2 (PGE2) in hippocampal and intestinal tissues.	puerarin	9-17	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	73-78
34975477-12	2021	In conclusion, puerarin treatment reverses HFD/CUMS-induced depression-like behavior by inhibiting TLR4-mediated intestine mucus barrier dysfunction and neuro-inflammatory damages via the TLR4/cPLA2/COX-2 pathway.	puerarin	15-23	toll-like receptor 4	Rattus norvegicus	99-103
34975477-12	2021	In conclusion, puerarin treatment reverses HFD/CUMS-induced depression-like behavior by inhibiting TLR4-mediated intestine mucus barrier dysfunction and neuro-inflammatory damages via the TLR4/cPLA2/COX-2 pathway.	puerarin	15-23	toll-like receptor 4	Rattus norvegicus	188-192
34975477-12	2021	In conclusion, puerarin treatment reverses HFD/CUMS-induced depression-like behavior by inhibiting TLR4-mediated intestine mucus barrier dysfunction and neuro-inflammatory damages via the TLR4/cPLA2/COX-2 pathway.	puerarin	15-23	phospholipase A2 group IVA	Rattus norvegicus	193-198
34975477-12	2021	In conclusion, puerarin treatment reverses HFD/CUMS-induced depression-like behavior by inhibiting TLR4-mediated intestine mucus barrier dysfunction and neuro-inflammatory damages via the TLR4/cPLA2/COX-2 pathway.	puerarin	15-23	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	199-204
34863080-0	2021	The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism.	puerarin	15-23	mechanistic target of rapamycin kinase	Mus musculus	102-106
34863080-6	2021	Puerarin induced the mitochondrial-dependent apoptosis of PCCs by causing a Bcl-2/Bax imbalance.	puerarin	0-8	B cell leukemia/lymphoma 2	Mus musculus	76-81
34863080-6	2021	Puerarin induced the mitochondrial-dependent apoptosis of PCCs by causing a Bcl-2/Bax imbalance.	puerarin	0-8	BCL2-associated X protein	Mus musculus	82-85
34863080-11	2021	Further studies showed that the inhibitory effects of puerarin on PCCs were abolished by a mTOR activator, indicating a crucial role of mTOR in anti-tumor effects of puerarin in PDAC.	puerarin	54-62	mechanistic target of rapamycin kinase	Mus musculus	136-140
34863080-12	2021	As a result, puerarin hindered glucose uptake and metabolism by downregulating the oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) dependent upon HIF-1alpha and glucose transporter GLUT1.	puerarin	13-21	hypoxia inducible factor 1, alpha subunit	Mus musculus	176-186
34863080-12	2021	As a result, puerarin hindered glucose uptake and metabolism by downregulating the oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) dependent upon HIF-1alpha and glucose transporter GLUT1.	puerarin	13-21	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	211-216
34863080-13	2021	Therefore, these findings indicated that puerarin has therapeutic potential for the treatment of PDAC by suppressing glucose uptake and metabolism via Akt/mTOR activity.	puerarin	41-49	thymoma viral proto-oncogene 1	Mus musculus	151-154
34863080-13	2021	Therefore, these findings indicated that puerarin has therapeutic potential for the treatment of PDAC by suppressing glucose uptake and metabolism via Akt/mTOR activity.	puerarin	41-49	mechanistic target of rapamycin kinase	Mus musculus	155-159
34350508-5	2021	Docking results showed that rutin, puerarin, baicalin, luteolin and quercetin are the most potent TXNIP inhibitors, and among them, rutin as the most effective flavonoid.	puerarin	35-43	thioredoxin interacting protein	Homo sapiens	98-103
33356808-0	2021	Puerarin induces apoptosis in prostate cancer cells via inactivation of the Keap1/Nrf2/ARE signaling pathway.	puerarin	0-8	kelch like ECH associated protein 1	Homo sapiens	76-81
33356808-0	2021	Puerarin induces apoptosis in prostate cancer cells via inactivation of the Keap1/Nrf2/ARE signaling pathway.	puerarin	0-8	NFE2 like bZIP transcription factor 2	Homo sapiens	82-86
34371290-6	2021	Puerarin enhanced the viability and osteogenic differentiation, and increased the activities of ALP, NO, and cGMP and the expressions of Collagen I, OC, OPN, RUNX2, SGC, and PKG-1 in rDFCs.	puerarin	0-8	bone gamma-carboxyglutamate protein	Rattus norvegicus	149-151
34371290-6	2021	Puerarin enhanced the viability and osteogenic differentiation, and increased the activities of ALP, NO, and cGMP and the expressions of Collagen I, OC, OPN, RUNX2, SGC, and PKG-1 in rDFCs.	puerarin	0-8	secreted phosphoprotein 1	Rattus norvegicus	153-156
34371290-6	2021	Puerarin enhanced the viability and osteogenic differentiation, and increased the activities of ALP, NO, and cGMP and the expressions of Collagen I, OC, OPN, RUNX2, SGC, and PKG-1 in rDFCs.	puerarin	0-8	RUNX family transcription factor 2	Rattus norvegicus	158-163
34371290-6	2021	Puerarin enhanced the viability and osteogenic differentiation, and increased the activities of ALP, NO, and cGMP and the expressions of Collagen I, OC, OPN, RUNX2, SGC, and PKG-1 in rDFCs.	puerarin	0-8	guanylate cyclase 1 soluble subunit beta 2	Rattus norvegicus	165-168
34371290-7	2021	After the co-treatment with puerarin and L-NMMA (NO synthase inhibitor), the promotive effects of Puerarin on cell viability, osteogenic differentiation, and the expressions of collagen I, OC, OPN, RUNX2, SGC, and PKG-1 in rDFCs were reversed by L-NMMA.	puerarin	28-36	bone gamma-carboxyglutamate protein	Rattus norvegicus	189-191
34371290-7	2021	After the co-treatment with puerarin and L-NMMA (NO synthase inhibitor), the promotive effects of Puerarin on cell viability, osteogenic differentiation, and the expressions of collagen I, OC, OPN, RUNX2, SGC, and PKG-1 in rDFCs were reversed by L-NMMA.	puerarin	28-36	secreted phosphoprotein 1	Rattus norvegicus	193-196
34371290-7	2021	After the co-treatment with puerarin and L-NMMA (NO synthase inhibitor), the promotive effects of Puerarin on cell viability, osteogenic differentiation, and the expressions of collagen I, OC, OPN, RUNX2, SGC, and PKG-1 in rDFCs were reversed by L-NMMA.	puerarin	28-36	RUNX family transcription factor 2	Rattus norvegicus	198-203
34371290-7	2021	After the co-treatment with puerarin and L-NMMA (NO synthase inhibitor), the promotive effects of Puerarin on cell viability, osteogenic differentiation, and the expressions of collagen I, OC, OPN, RUNX2, SGC, and PKG-1 in rDFCs were reversed by L-NMMA.	puerarin	28-36	guanylate cyclase 1 soluble subunit beta 2	Rattus norvegicus	205-208
34590923-0	2021	Puerarin induces platinum-resistant epithelial ovarian cancer cell apoptosis by targeting SIRT1.	puerarin	0-8	sirtuin 1	Homo sapiens	90-95
34588985-12	2021	ER, ERK and SUMO2 inhibitors attenuated the cardioprotective effects of puerarin.	puerarin	72-80	estrogen receptor 1 (alpha)	Mus musculus	0-2
34588985-12	2021	ER, ERK and SUMO2 inhibitors attenuated the cardioprotective effects of puerarin.	puerarin	72-80	mitogen-activated protein kinase 1	Mus musculus	4-7
34588985-12	2021	ER, ERK and SUMO2 inhibitors attenuated the cardioprotective effects of puerarin.	puerarin	72-80	small ubiquitin-like modifier 2	Mus musculus	12-17
34539968-15	2021	Puerarin was the active ingredient derived from Puerariae Radix which exhibited the antidepression effect by improving the viability of cell, reducing cell apoptosis, regulating ROS production, increasing protein expressions of AKT1 and FOS, and reducing protein expressions of CASP3, STAT3, and TNF-alpha.	puerarin	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	228-232
34539968-15	2021	Puerarin was the active ingredient derived from Puerariae Radix which exhibited the antidepression effect by improving the viability of cell, reducing cell apoptosis, regulating ROS production, increasing protein expressions of AKT1 and FOS, and reducing protein expressions of CASP3, STAT3, and TNF-alpha.	puerarin	0-8	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	237-240
34539968-15	2021	Puerarin was the active ingredient derived from Puerariae Radix which exhibited the antidepression effect by improving the viability of cell, reducing cell apoptosis, regulating ROS production, increasing protein expressions of AKT1 and FOS, and reducing protein expressions of CASP3, STAT3, and TNF-alpha.	puerarin	0-8	caspase 3	Rattus norvegicus	278-283
34539968-15	2021	Puerarin was the active ingredient derived from Puerariae Radix which exhibited the antidepression effect by improving the viability of cell, reducing cell apoptosis, regulating ROS production, increasing protein expressions of AKT1 and FOS, and reducing protein expressions of CASP3, STAT3, and TNF-alpha.	puerarin	0-8	signal transducer and activator of transcription 3	Rattus norvegicus	285-290
34539968-15	2021	Puerarin was the active ingredient derived from Puerariae Radix which exhibited the antidepression effect by improving the viability of cell, reducing cell apoptosis, regulating ROS production, increasing protein expressions of AKT1 and FOS, and reducing protein expressions of CASP3, STAT3, and TNF-alpha.	puerarin	0-8	tumor necrosis factor	Rattus norvegicus	296-305
34171769-7	2021	Moreover, Cd-decreased antioxidative indices superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and catalase (CAT) as well as glutathione (GSH) in hepatic tissues were significantly attenuated by PU administration, while Cd-elevated hepatic malondialdehyde (MDA) and reactive oxygen species (ROS) levels were markedly down-regulated by PU treatment, demonstrating the antioxidant effect of PU against Cd exposure.	puerarin	345-347	catalase	Mus musculus	109-117
34171769-7	2021	Moreover, Cd-decreased antioxidative indices superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and catalase (CAT) as well as glutathione (GSH) in hepatic tissues were significantly attenuated by PU administration, while Cd-elevated hepatic malondialdehyde (MDA) and reactive oxygen species (ROS) levels were markedly down-regulated by PU treatment, demonstrating the antioxidant effect of PU against Cd exposure.	puerarin	345-347	catalase	Mus musculus	119-122
34171769-7	2021	Moreover, Cd-decreased antioxidative indices superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and catalase (CAT) as well as glutathione (GSH) in hepatic tissues were significantly attenuated by PU administration, while Cd-elevated hepatic malondialdehyde (MDA) and reactive oxygen species (ROS) levels were markedly down-regulated by PU treatment, demonstrating the antioxidant effect of PU against Cd exposure.	puerarin	399-401	catalase	Mus musculus	109-117
34590923-7	2021	Puerarin treatment decreased SIRT1 expression, which attenuated the nuclear accumulation of beta-catenin to inhibit Wnt/beta-catenin signaling.	puerarin	0-8	catenin beta 1	Homo sapiens	92-104
34590923-7	2021	Puerarin treatment decreased SIRT1 expression, which attenuated the nuclear accumulation of beta-catenin to inhibit Wnt/beta-catenin signaling.	puerarin	0-8	catenin beta 1	Homo sapiens	120-132
34590923-8	2021	In addition, SIRT1 overexpression diminished the effects of puerarin treatment on cisplatin-resistant ovarian cancer cells.	puerarin	60-68	sirtuin 1	Homo sapiens	13-18
34171769-7	2021	Moreover, Cd-decreased antioxidative indices superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and catalase (CAT) as well as glutathione (GSH) in hepatic tissues were significantly attenuated by PU administration, while Cd-elevated hepatic malondialdehyde (MDA) and reactive oxygen species (ROS) levels were markedly down-regulated by PU treatment, demonstrating the antioxidant effect of PU against Cd exposure.	puerarin	205-207	catalase	Mus musculus	109-117
34171769-7	2021	Moreover, Cd-decreased antioxidative indices superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and catalase (CAT) as well as glutathione (GSH) in hepatic tissues were significantly attenuated by PU administration, while Cd-elevated hepatic malondialdehyde (MDA) and reactive oxygen species (ROS) levels were markedly down-regulated by PU treatment, demonstrating the antioxidant effect of PU against Cd exposure.	puerarin	205-207	catalase	Mus musculus	119-122
34590923-7	2021	Puerarin treatment decreased SIRT1 expression, which attenuated the nuclear accumulation of beta-catenin to inhibit Wnt/beta-catenin signaling.	puerarin	0-8	sirtuin 1	Homo sapiens	29-34
34465981-0	2021	Puerarin Alleviates UUO-Induced Inflammation and Fibrosis by Regulating the NF-kappaB P65/STAT3 and TGFbeta1/Smads Signaling Pathways.	puerarin	0-8	signal transducer and activator of transcription 3	Mus musculus	90-95
34465981-0	2021	Puerarin Alleviates UUO-Induced Inflammation and Fibrosis by Regulating the NF-kappaB P65/STAT3 and TGFbeta1/Smads Signaling Pathways.	puerarin	0-8	transforming growth factor, beta 1	Mus musculus	100-108
34421312-0	2021	Puerarin Attenuates Complete Freund"s Adjuvant-Induced Trigeminal Neuralgia and Inflammation in a Mouse Model via Sirt1-Mediated TGF-beta1/Smad3 Inhibition.	puerarin	0-8	sirtuin 1	Mus musculus	114-119
34180143-0	2021	Kakonein restores diabetes-induced endothelial junction dysfunction via promoting autophagy-mediated NLRP3 inflammasome degradation.	puerarin	0-8	NLR family, pyrin domain containing 3	Mus musculus	101-106
34421621-0	2021	Puerarin Prevents Acute Liver Injury via Inhibiting Inflammatory Responses and ZEB2 Expression.	puerarin	0-8	zinc finger E-box binding homeobox 2	Homo sapiens	79-83
34421621-5	2021	We found that puerarin inhibited liver injury and inflammatory cell infiltration in lipopolysaccharide (LPS)/D-galactose (D-Gal)-induced acute liver failure and the liver pro-inflammatory cytokines interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha) in liver tissues with ALI and LPS-induced L-02 cells but upregulated the expression level of zinc finger E-box-binding homeobox 2 (ZEB2).	puerarin	14-22	interleukin 1 alpha	Homo sapiens	198-220
34421621-5	2021	We found that puerarin inhibited liver injury and inflammatory cell infiltration in lipopolysaccharide (LPS)/D-galactose (D-Gal)-induced acute liver failure and the liver pro-inflammatory cytokines interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha) in liver tissues with ALI and LPS-induced L-02 cells but upregulated the expression level of zinc finger E-box-binding homeobox 2 (ZEB2).	puerarin	14-22	interleukin 6	Homo sapiens	222-226
34421621-5	2021	We found that puerarin inhibited liver injury and inflammatory cell infiltration in lipopolysaccharide (LPS)/D-galactose (D-Gal)-induced acute liver failure and the liver pro-inflammatory cytokines interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha) in liver tissues with ALI and LPS-induced L-02 cells but upregulated the expression level of zinc finger E-box-binding homeobox 2 (ZEB2).	puerarin	14-22	tumor necrosis factor	Homo sapiens	232-259
34421621-5	2021	We found that puerarin inhibited liver injury and inflammatory cell infiltration in lipopolysaccharide (LPS)/D-galactose (D-Gal)-induced acute liver failure and the liver pro-inflammatory cytokines interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha) in liver tissues with ALI and LPS-induced L-02 cells but upregulated the expression level of zinc finger E-box-binding homeobox 2 (ZEB2).	puerarin	14-22	tumor necrosis factor	Homo sapiens	261-270
34421621-5	2021	We found that puerarin inhibited liver injury and inflammatory cell infiltration in lipopolysaccharide (LPS)/D-galactose (D-Gal)-induced acute liver failure and the liver pro-inflammatory cytokines interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha) in liver tissues with ALI and LPS-induced L-02 cells but upregulated the expression level of zinc finger E-box-binding homeobox 2 (ZEB2).	puerarin	14-22	zinc finger E-box binding homeobox 2	Homo sapiens	365-401
34421621-5	2021	We found that puerarin inhibited liver injury and inflammatory cell infiltration in lipopolysaccharide (LPS)/D-galactose (D-Gal)-induced acute liver failure and the liver pro-inflammatory cytokines interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha) in liver tissues with ALI and LPS-induced L-02 cells but upregulated the expression level of zinc finger E-box-binding homeobox 2 (ZEB2).	puerarin	14-22	zinc finger E-box binding homeobox 2	Homo sapiens	403-407
34093765-10	2021	Furthermore, puerarin treatment significantly decreased the levels of Ang II, AT1-R and ACE, which were increased following smoke inhalation.	puerarin	13-21	angiogenin	Rattus norvegicus	70-73
34093765-10	2021	Furthermore, puerarin treatment significantly decreased the levels of Ang II, AT1-R and ACE, which were increased following smoke inhalation.	puerarin	13-21	angiotensin II receptor, type 1a	Rattus norvegicus	78-83
34093765-10	2021	Furthermore, puerarin treatment significantly decreased the levels of Ang II, AT1-R and ACE, which were increased following smoke inhalation.	puerarin	13-21	angiotensin I converting enzyme	Rattus norvegicus	88-91
34093765-11	2021	Conversely, puerarin treatment upregulated the expression of ACE2, which was downregulated following smoke inhalation.	puerarin	12-20	angiotensin I converting enzyme 2	Rattus norvegicus	61-65
34421312-0	2021	Puerarin Attenuates Complete Freund"s Adjuvant-Induced Trigeminal Neuralgia and Inflammation in a Mouse Model via Sirt1-Mediated TGF-beta1/Smad3 Inhibition.	puerarin	0-8	transforming growth factor, beta 1	Mus musculus	129-138
34421312-0	2021	Puerarin Attenuates Complete Freund"s Adjuvant-Induced Trigeminal Neuralgia and Inflammation in a Mouse Model via Sirt1-Mediated TGF-beta1/Smad3 Inhibition.	puerarin	0-8	SMAD family member 3	Mus musculus	139-144
34180121-0	2021	Puerarin attenuates intracerebral hemorrhage-induced early brain injury possibly by PI3K/Akt signal activation-mediated suppression of NF-kappaB pathway.	puerarin	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	89-92
34180121-3	2021	Puerarin (PUE) possesses excellent neuroprotective effects by suppressing the NF-kappaB pathway and activating the PI3K/Akt signal, but its role and related mechanisms in ICH-induced early brain injury (EBI) remain unclear.	puerarin	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	120-123
34180143-5	2021	The protective effect of kakonein on cardiovascular endothelial junctions and NLRP3 inflammasome activation was verified through immunofluorescence and ELISA assay.	puerarin	25-33	NLR family, pyrin domain containing 3	Mus musculus	78-83
34180143-7	2021	Results showed that kakonein restored the function of endothelial junctions and inhibited the assembly and activation of the NLRP3 inflammasome.	puerarin	20-28	NLR family, pyrin domain containing 3	Mus musculus	125-130
34180143-10	2021	In addition, kakonein inhibited both hyperglycaemia-induced cardiovascular endothelial junction dysfunction and NLRP3 inflammasome activation, similar to autophagy agonist.	puerarin	13-21	NLR family, pyrin domain containing 3	Mus musculus	112-117
34180143-11	2021	Our findings indicated that kakonein exerts a protective effect on hyperglycaemia-induced chronic vascular disease by regulating the NLRP3 inflammasome through autophagy.	puerarin	28-36	NLR family, pyrin domain containing 3	Mus musculus	133-138
34488550-9	2021	Puerarin inhibited the phosphorylation of PERK, subsequently suppressed the phosphorylation of eukaryotic initiation factor 2(Formula: see text) (eIF2(Formula: see text), then decreased the activating transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP) expression, ultimately attenuating ER stress to prevent MIN6 cells from apoptosis.	puerarin	0-8	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	42-46
34238735-9	2021	Puerarin dose-dependently inhibited the mRNA and protein expressions of fetuin B and ACC, increased AMPK mRNA and protein expressions of AMPKalpha1, P-AMPKalphaT183/ T172, and P-ACC S79, and lowered fetuin B content in the liver of diabetic mice (P < 0.01).	puerarin	0-8	fetuin beta	Mus musculus	72-80
34238735-9	2021	Puerarin dose-dependently inhibited the mRNA and protein expressions of fetuin B and ACC, increased AMPK mRNA and protein expressions of AMPKalpha1, P-AMPKalphaT183/ T172, and P-ACC S79, and lowered fetuin B content in the liver of diabetic mice (P < 0.01).	puerarin	0-8	anterior capsular cataract	Mus musculus	85-88
34238735-9	2021	Puerarin dose-dependently inhibited the mRNA and protein expressions of fetuin B and ACC, increased AMPK mRNA and protein expressions of AMPKalpha1, P-AMPKalphaT183/ T172, and P-ACC S79, and lowered fetuin B content in the liver of diabetic mice (P < 0.01).	puerarin	0-8	protein kinase, AMP-activated, alpha 1 catalytic subunit	Mus musculus	137-147
34238735-9	2021	Puerarin dose-dependently inhibited the mRNA and protein expressions of fetuin B and ACC, increased AMPK mRNA and protein expressions of AMPKalpha1, P-AMPKalphaT183/ T172, and P-ACC S79, and lowered fetuin B content in the liver of diabetic mice (P < 0.01).	puerarin	0-8	anterior capsular cataract	Mus musculus	178-181
34238735-9	2021	Puerarin dose-dependently inhibited the mRNA and protein expressions of fetuin B and ACC, increased AMPK mRNA and protein expressions of AMPKalpha1, P-AMPKalphaT183/ T172, and P-ACC S79, and lowered fetuin B content in the liver of diabetic mice (P < 0.01).	puerarin	0-8	fetuin beta	Mus musculus	199-207
34100379-9	2021	Moreover, CASP1 expression was determined after miR-16-5p silencing in HG-stimulated HRECs with puerarin exposure.	puerarin	96-104	caspase 1	Homo sapiens	10-15
34100379-14	2021	Taken together, puerarin alleviates oxidative stress and pyroptosis in HG-stimulated HRECs through regulating the miR- 16-5p/CASP1 axis.	puerarin	16-24	caspase 1	Homo sapiens	125-130
34360871-8	2021	In silico analysis showed that the main constituents, puerarin and daidzin, had excellent binding affinities for human tyrosinase.	puerarin	54-62	tyrosinase	Homo sapiens	119-129
34488550-9	2021	Puerarin inhibited the phosphorylation of PERK, subsequently suppressed the phosphorylation of eukaryotic initiation factor 2(Formula: see text) (eIF2(Formula: see text), then decreased the activating transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP) expression, ultimately attenuating ER stress to prevent MIN6 cells from apoptosis.	puerarin	0-8	eukaryotic translation initiation factor 2, subunit 2 (beta)	Mus musculus	146-150
34488550-9	2021	Puerarin inhibited the phosphorylation of PERK, subsequently suppressed the phosphorylation of eukaryotic initiation factor 2(Formula: see text) (eIF2(Formula: see text), then decreased the activating transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP) expression, ultimately attenuating ER stress to prevent MIN6 cells from apoptosis.	puerarin	0-8	activating transcription factor 4	Mus musculus	190-223
34488550-9	2021	Puerarin inhibited the phosphorylation of PERK, subsequently suppressed the phosphorylation of eukaryotic initiation factor 2(Formula: see text) (eIF2(Formula: see text), then decreased the activating transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP) expression, ultimately attenuating ER stress to prevent MIN6 cells from apoptosis.	puerarin	0-8	activating transcription factor 4	Mus musculus	225-229
34488550-9	2021	Puerarin inhibited the phosphorylation of PERK, subsequently suppressed the phosphorylation of eukaryotic initiation factor 2(Formula: see text) (eIF2(Formula: see text), then decreased the activating transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP) expression, ultimately attenuating ER stress to prevent MIN6 cells from apoptosis.	puerarin	0-8	DNA-damage inducible transcript 3	Mus musculus	235-259
34488550-9	2021	Puerarin inhibited the phosphorylation of PERK, subsequently suppressed the phosphorylation of eukaryotic initiation factor 2(Formula: see text) (eIF2(Formula: see text), then decreased the activating transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP) expression, ultimately attenuating ER stress to prevent MIN6 cells from apoptosis.	puerarin	0-8	DNA-damage inducible transcript 3	Mus musculus	261-265
35331853-7	2022	Puerarin ameliorated LPS-induced cytotoxicity and apoptosis, while repressing LPS-stimulated NLRP3 inflammasome-mediated pyroptosis in GES-1 cells, as evidenced by significantly decreased expression of NLRP3, ASC, cleaved caspase-1, IL-1beta and IL-18.	puerarin	0-8	PYD and CARD domain containing	Homo sapiens	209-212
35331853-7	2022	Puerarin ameliorated LPS-induced cytotoxicity and apoptosis, while repressing LPS-stimulated NLRP3 inflammasome-mediated pyroptosis in GES-1 cells, as evidenced by significantly decreased expression of NLRP3, ASC, cleaved caspase-1, IL-1beta and IL-18.	puerarin	0-8	NLR family pyrin domain containing 3	Homo sapiens	93-98
35331853-7	2022	Puerarin ameliorated LPS-induced cytotoxicity and apoptosis, while repressing LPS-stimulated NLRP3 inflammasome-mediated pyroptosis in GES-1 cells, as evidenced by significantly decreased expression of NLRP3, ASC, cleaved caspase-1, IL-1beta and IL-18.	puerarin	0-8	caspase 1	Homo sapiens	222-231
35331853-7	2022	Puerarin ameliorated LPS-induced cytotoxicity and apoptosis, while repressing LPS-stimulated NLRP3 inflammasome-mediated pyroptosis in GES-1 cells, as evidenced by significantly decreased expression of NLRP3, ASC, cleaved caspase-1, IL-1beta and IL-18.	puerarin	0-8	NLR family pyrin domain containing 3	Homo sapiens	202-207
35331853-7	2022	Puerarin ameliorated LPS-induced cytotoxicity and apoptosis, while repressing LPS-stimulated NLRP3 inflammasome-mediated pyroptosis in GES-1 cells, as evidenced by significantly decreased expression of NLRP3, ASC, cleaved caspase-1, IL-1beta and IL-18.	puerarin	0-8	interleukin 1 alpha	Homo sapiens	233-241
35331853-7	2022	Puerarin ameliorated LPS-induced cytotoxicity and apoptosis, while repressing LPS-stimulated NLRP3 inflammasome-mediated pyroptosis in GES-1 cells, as evidenced by significantly decreased expression of NLRP3, ASC, cleaved caspase-1, IL-1beta and IL-18.	puerarin	0-8	interleukin 18	Homo sapiens	246-251
35331853-9	2022	Puerarin activated the AMPK/SIRT1 pathway in LPS-treated GES-1 cells, and knockdown of both AMPK and SIRT1 reversed the protective effects of puerarin against LPS-induced inflammatory damage.	puerarin	0-8	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	23-27
35331853-9	2022	Puerarin activated the AMPK/SIRT1 pathway in LPS-treated GES-1 cells, and knockdown of both AMPK and SIRT1 reversed the protective effects of puerarin against LPS-induced inflammatory damage.	puerarin	0-8	sirtuin 1	Homo sapiens	28-33
35331853-9	2022	Puerarin activated the AMPK/SIRT1 pathway in LPS-treated GES-1 cells, and knockdown of both AMPK and SIRT1 reversed the protective effects of puerarin against LPS-induced inflammatory damage.	puerarin	142-150	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	23-27
35331853-9	2022	Puerarin activated the AMPK/SIRT1 pathway in LPS-treated GES-1 cells, and knockdown of both AMPK and SIRT1 reversed the protective effects of puerarin against LPS-induced inflammatory damage.	puerarin	142-150	sirtuin 1	Homo sapiens	28-33
35331853-9	2022	Puerarin activated the AMPK/SIRT1 pathway in LPS-treated GES-1 cells, and knockdown of both AMPK and SIRT1 reversed the protective effects of puerarin against LPS-induced inflammatory damage.	puerarin	142-150	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	92-96
35331853-9	2022	Puerarin activated the AMPK/SIRT1 pathway in LPS-treated GES-1 cells, and knockdown of both AMPK and SIRT1 reversed the protective effects of puerarin against LPS-induced inflammatory damage.	puerarin	142-150	sirtuin 1	Homo sapiens	101-106
35224772-0	2022	Kakonein restores hyperglycemia-induced macrophage digestion dysfunction through regulation of cathepsin B-dependent NLRP3 inflammasome activation.	puerarin	0-8	cathepsin B	Mus musculus	95-106
35509629-15	2022	Among these components, puerarin, berberine, and liquiritin appear to have a better effect on activating Nrf2 in vitro.	puerarin	24-32	NFE2 like bZIP transcription factor 2	Homo sapiens	105-109
35510332-0	2022	Puerarin suppresses hypoxia-induced vascular endothelial growth factor upregulation in human retinal pigmented epithelial cells by blocking JAK2/STAT3 pathway.	puerarin	0-8	vascular endothelial growth factor A	Homo sapiens	36-70
35510332-0	2022	Puerarin suppresses hypoxia-induced vascular endothelial growth factor upregulation in human retinal pigmented epithelial cells by blocking JAK2/STAT3 pathway.	puerarin	0-8	Janus kinase 2	Homo sapiens	140-144
35510332-0	2022	Puerarin suppresses hypoxia-induced vascular endothelial growth factor upregulation in human retinal pigmented epithelial cells by blocking JAK2/STAT3 pathway.	puerarin	0-8	signal transducer and activator of transcription 3	Homo sapiens	145-150
35510332-5	2022	We found puerarin inhibited hypoxia-induced upregulation of VEGF at both the mRNA and protein level via decreasing HIF-1alpha expression in RPE cells.	puerarin	9-17	vascular endothelial growth factor A	Rattus norvegicus	60-64
35510332-5	2022	We found puerarin inhibited hypoxia-induced upregulation of VEGF at both the mRNA and protein level via decreasing HIF-1alpha expression in RPE cells.	puerarin	9-17	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	115-125
35482440-0	2022	Puerarin protects against sepsis-induced myocardial injury through AMPK-mediated ferroptosis signaling.	puerarin	0-8	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	67-71
35482440-3	2022	In this study, our objective is to investigate the role of Puerarin-induced AMPK-mediated ferroptosis signaling in protecting myocardial injury.	puerarin	59-67	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	76-80
35482440-14	2022	CONCLUSIONS: Puerarin protected against sepsis-induced myocardial injury, and AMPK-mediated ferroptosis signaling played a crucial role in its cardioprotective effect.	puerarin	13-21	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	78-82
35368752-10	2022	Puerarin and paeoniflorin exerted anti-inflammatory effects by decreasing production of MDC/CCL22 and IL-6 in TI-treated HaCaT cells and VEGF production in SP/CRH-stimulated HMC-1 cells.	puerarin	0-8	C-C motif chemokine ligand 22	Homo sapiens	88-91
35368752-10	2022	Puerarin and paeoniflorin exerted anti-inflammatory effects by decreasing production of MDC/CCL22 and IL-6 in TI-treated HaCaT cells and VEGF production in SP/CRH-stimulated HMC-1 cells.	puerarin	0-8	C-C motif chemokine ligand 22	Homo sapiens	92-97
35368752-10	2022	Puerarin and paeoniflorin exerted anti-inflammatory effects by decreasing production of MDC/CCL22 and IL-6 in TI-treated HaCaT cells and VEGF production in SP/CRH-stimulated HMC-1 cells.	puerarin	0-8	interleukin 6	Homo sapiens	102-106
35368752-10	2022	Puerarin and paeoniflorin exerted anti-inflammatory effects by decreasing production of MDC/CCL22 and IL-6 in TI-treated HaCaT cells and VEGF production in SP/CRH-stimulated HMC-1 cells.	puerarin	0-8	vascular endothelial growth factor A	Homo sapiens	137-141
35387191-3	2022	The results showed that Puerarin treatment enhanced the concentration of crude fat, fatty acid (C14:1 and C17:1), and the activity of fatty acid synthase in Longissimus thoracis (LT), but decreased the levels of blood leptin (P < 0.05).	puerarin	24-32	fatty acid synthase	Bos taurus	134-153
35387191-3	2022	The results showed that Puerarin treatment enhanced the concentration of crude fat, fatty acid (C14:1 and C17:1), and the activity of fatty acid synthase in Longissimus thoracis (LT), but decreased the levels of blood leptin (P < 0.05).	puerarin	24-32	leptin	Bos taurus	218-224
35224772-0	2022	Kakonein restores hyperglycemia-induced macrophage digestion dysfunction through regulation of cathepsin B-dependent NLRP3 inflammasome activation.	puerarin	0-8	NLR family, pyrin domain containing 3	Mus musculus	117-122
35224772-6	2022	Meanwhile, kakonein could decrease NLRP3 inflammasome products expression and NLRP3/ASC or NLRP3/Casp1 colocalization in macrophage.	puerarin	11-19	NLR family, pyrin domain containing 3	Mus musculus	35-40
35224772-6	2022	Meanwhile, kakonein could decrease NLRP3 inflammasome products expression and NLRP3/ASC or NLRP3/Casp1 colocalization in macrophage.	puerarin	11-19	NLR family, pyrin domain containing 3	Mus musculus	78-83
35224772-6	2022	Meanwhile, kakonein could decrease NLRP3 inflammasome products expression and NLRP3/ASC or NLRP3/Casp1 colocalization in macrophage.	puerarin	11-19	steroid sulfatase	Mus musculus	84-87
35224772-6	2022	Meanwhile, kakonein could decrease NLRP3 inflammasome products expression and NLRP3/ASC or NLRP3/Casp1 colocalization in macrophage.	puerarin	11-19	NLR family, pyrin domain containing 3	Mus musculus	91-96
35224772-6	2022	Meanwhile, kakonein could decrease NLRP3 inflammasome products expression and NLRP3/ASC or NLRP3/Casp1 colocalization in macrophage.	puerarin	11-19	caspase 1	Mus musculus	97-102
35228997-12	2022	Conclusions: Collectively, puerarin prevented the bone loss in OVX rat through suppression of osteoclast activation and bone resorption, by inhibiting integrin-beta3-Pyk2/Cbl/Src signaling pathway, without affecting osteoclasts formation or apoptosis.	puerarin	27-35	Cbl proto-oncogene	Rattus norvegicus	171-174
35228997-12	2022	Conclusions: Collectively, puerarin prevented the bone loss in OVX rat through suppression of osteoclast activation and bone resorption, by inhibiting integrin-beta3-Pyk2/Cbl/Src signaling pathway, without affecting osteoclasts formation or apoptosis.	puerarin	27-35	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	175-178
35228997-12	2022	Conclusions: Collectively, puerarin prevented the bone loss in OVX rat through suppression of osteoclast activation and bone resorption, by inhibiting integrin-beta3-Pyk2/Cbl/Src signaling pathway, without affecting osteoclasts formation or apoptosis.	puerarin	27-35	integrin subunit beta 3	Rattus norvegicus	151-165
35228997-12	2022	Conclusions: Collectively, puerarin prevented the bone loss in OVX rat through suppression of osteoclast activation and bone resorption, by inhibiting integrin-beta3-Pyk2/Cbl/Src signaling pathway, without affecting osteoclasts formation or apoptosis.	puerarin	27-35	protein tyrosine kinase 2 beta	Rattus norvegicus	166-170
35134750-3	2022	Therefore, we hypothesized that puerarin may be involved in COPD progression via regulating FUNDC1 mediated mitophagy.	puerarin	32-40	FUN14 domain containing 1	Homo sapiens	92-98
35134750-4	2022	We found that the viability of cigarette smoke extract (CSE)-stimulated human bronchial epithelial cells (HBECs) was enhanced and apoptosis was reduced after treatment with different concentrations of puerarin.	puerarin	201-209	choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity)	Homo sapiens	56-59
35134750-5	2022	Puerarin reversed mitochondrial membrane potential (MMP) levels and ATP content, and decreased reactive oxygen species (ROS) content in CSE stimulated HBECs.	puerarin	0-8	choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity)	Homo sapiens	136-139
35300770-2	2022	Methods A549 cells were cultured and treated with different concentrations of puerarin.The inhibition rate (IR) on cell proliferation was detected by CCK-8,and qRT-PCR was performed to detect the mRNA levels of miR-490 and denticleless E3 ubiquitin protein ligase(DTL).Double luciferase reporter assay was employed to identify the targets of miR-490 and DTL based on the establishment of NC mimic group,miR-490 mimic group,NC inhibitor group,and miR-490 inhibitor group.The cells treated by 20 mumol/L puerarin were classified into six groups:DMSO,puerarin,puerarin+NC inhibitor,puerarin+miR-490 inhibitor,puerarin+miR-490 inhibitor+Si-NC,and puerarin+miR-490 inhibitor+Si-DTL.Transwell was used to detect cell migration and invasion.Western blotting was performed to detect the protein levels of epithelial-mesenchymal transition-related markers E-cadherin,N-cadherin,and Vimentin.	puerarin	78-86	microRNA 490	Homo sapiens	211-218
35300770-2	2022	Methods A549 cells were cultured and treated with different concentrations of puerarin.The inhibition rate (IR) on cell proliferation was detected by CCK-8,and qRT-PCR was performed to detect the mRNA levels of miR-490 and denticleless E3 ubiquitin protein ligase(DTL).Double luciferase reporter assay was employed to identify the targets of miR-490 and DTL based on the establishment of NC mimic group,miR-490 mimic group,NC inhibitor group,and miR-490 inhibitor group.The cells treated by 20 mumol/L puerarin were classified into six groups:DMSO,puerarin,puerarin+NC inhibitor,puerarin+miR-490 inhibitor,puerarin+miR-490 inhibitor+Si-NC,and puerarin+miR-490 inhibitor+Si-DTL.Transwell was used to detect cell migration and invasion.Western blotting was performed to detect the protein levels of epithelial-mesenchymal transition-related markers E-cadherin,N-cadherin,and Vimentin.	puerarin	78-86	denticleless E3 ubiquitin protein ligase homolog	Homo sapiens	264-267
35300770-2	2022	Methods A549 cells were cultured and treated with different concentrations of puerarin.The inhibition rate (IR) on cell proliferation was detected by CCK-8,and qRT-PCR was performed to detect the mRNA levels of miR-490 and denticleless E3 ubiquitin protein ligase(DTL).Double luciferase reporter assay was employed to identify the targets of miR-490 and DTL based on the establishment of NC mimic group,miR-490 mimic group,NC inhibitor group,and miR-490 inhibitor group.The cells treated by 20 mumol/L puerarin were classified into six groups:DMSO,puerarin,puerarin+NC inhibitor,puerarin+miR-490 inhibitor,puerarin+miR-490 inhibitor+Si-NC,and puerarin+miR-490 inhibitor+Si-DTL.Transwell was used to detect cell migration and invasion.Western blotting was performed to detect the protein levels of epithelial-mesenchymal transition-related markers E-cadherin,N-cadherin,and Vimentin.	puerarin	78-86	microRNA 490	Homo sapiens	342-349
35300770-2	2022	Methods A549 cells were cultured and treated with different concentrations of puerarin.The inhibition rate (IR) on cell proliferation was detected by CCK-8,and qRT-PCR was performed to detect the mRNA levels of miR-490 and denticleless E3 ubiquitin protein ligase(DTL).Double luciferase reporter assay was employed to identify the targets of miR-490 and DTL based on the establishment of NC mimic group,miR-490 mimic group,NC inhibitor group,and miR-490 inhibitor group.The cells treated by 20 mumol/L puerarin were classified into six groups:DMSO,puerarin,puerarin+NC inhibitor,puerarin+miR-490 inhibitor,puerarin+miR-490 inhibitor+Si-NC,and puerarin+miR-490 inhibitor+Si-DTL.Transwell was used to detect cell migration and invasion.Western blotting was performed to detect the protein levels of epithelial-mesenchymal transition-related markers E-cadherin,N-cadherin,and Vimentin.	puerarin	78-86	denticleless E3 ubiquitin protein ligase homolog	Homo sapiens	354-357
35300770-2	2022	Methods A549 cells were cultured and treated with different concentrations of puerarin.The inhibition rate (IR) on cell proliferation was detected by CCK-8,and qRT-PCR was performed to detect the mRNA levels of miR-490 and denticleless E3 ubiquitin protein ligase(DTL).Double luciferase reporter assay was employed to identify the targets of miR-490 and DTL based on the establishment of NC mimic group,miR-490 mimic group,NC inhibitor group,and miR-490 inhibitor group.The cells treated by 20 mumol/L puerarin were classified into six groups:DMSO,puerarin,puerarin+NC inhibitor,puerarin+miR-490 inhibitor,puerarin+miR-490 inhibitor+Si-NC,and puerarin+miR-490 inhibitor+Si-DTL.Transwell was used to detect cell migration and invasion.Western blotting was performed to detect the protein levels of epithelial-mesenchymal transition-related markers E-cadherin,N-cadherin,and Vimentin.	puerarin	78-86	microRNA 490	Homo sapiens	403-410
35300770-2	2022	Methods A549 cells were cultured and treated with different concentrations of puerarin.The inhibition rate (IR) on cell proliferation was detected by CCK-8,and qRT-PCR was performed to detect the mRNA levels of miR-490 and denticleless E3 ubiquitin protein ligase(DTL).Double luciferase reporter assay was employed to identify the targets of miR-490 and DTL based on the establishment of NC mimic group,miR-490 mimic group,NC inhibitor group,and miR-490 inhibitor group.The cells treated by 20 mumol/L puerarin were classified into six groups:DMSO,puerarin,puerarin+NC inhibitor,puerarin+miR-490 inhibitor,puerarin+miR-490 inhibitor+Si-NC,and puerarin+miR-490 inhibitor+Si-DTL.Transwell was used to detect cell migration and invasion.Western blotting was performed to detect the protein levels of epithelial-mesenchymal transition-related markers E-cadherin,N-cadherin,and Vimentin.	puerarin	78-86	microRNA 490	Homo sapiens	446-453
35300770-2	2022	Methods A549 cells were cultured and treated with different concentrations of puerarin.The inhibition rate (IR) on cell proliferation was detected by CCK-8,and qRT-PCR was performed to detect the mRNA levels of miR-490 and denticleless E3 ubiquitin protein ligase(DTL).Double luciferase reporter assay was employed to identify the targets of miR-490 and DTL based on the establishment of NC mimic group,miR-490 mimic group,NC inhibitor group,and miR-490 inhibitor group.The cells treated by 20 mumol/L puerarin were classified into six groups:DMSO,puerarin,puerarin+NC inhibitor,puerarin+miR-490 inhibitor,puerarin+miR-490 inhibitor+Si-NC,and puerarin+miR-490 inhibitor+Si-DTL.Transwell was used to detect cell migration and invasion.Western blotting was performed to detect the protein levels of epithelial-mesenchymal transition-related markers E-cadherin,N-cadherin,and Vimentin.	puerarin	78-86	microRNA 490	Homo sapiens	588-595
35300770-2	2022	Methods A549 cells were cultured and treated with different concentrations of puerarin.The inhibition rate (IR) on cell proliferation was detected by CCK-8,and qRT-PCR was performed to detect the mRNA levels of miR-490 and denticleless E3 ubiquitin protein ligase(DTL).Double luciferase reporter assay was employed to identify the targets of miR-490 and DTL based on the establishment of NC mimic group,miR-490 mimic group,NC inhibitor group,and miR-490 inhibitor group.The cells treated by 20 mumol/L puerarin were classified into six groups:DMSO,puerarin,puerarin+NC inhibitor,puerarin+miR-490 inhibitor,puerarin+miR-490 inhibitor+Si-NC,and puerarin+miR-490 inhibitor+Si-DTL.Transwell was used to detect cell migration and invasion.Western blotting was performed to detect the protein levels of epithelial-mesenchymal transition-related markers E-cadherin,N-cadherin,and Vimentin.	puerarin	78-86	microRNA 490	Homo sapiens	615-622
35300770-2	2022	Methods A549 cells were cultured and treated with different concentrations of puerarin.The inhibition rate (IR) on cell proliferation was detected by CCK-8,and qRT-PCR was performed to detect the mRNA levels of miR-490 and denticleless E3 ubiquitin protein ligase(DTL).Double luciferase reporter assay was employed to identify the targets of miR-490 and DTL based on the establishment of NC mimic group,miR-490 mimic group,NC inhibitor group,and miR-490 inhibitor group.The cells treated by 20 mumol/L puerarin were classified into six groups:DMSO,puerarin,puerarin+NC inhibitor,puerarin+miR-490 inhibitor,puerarin+miR-490 inhibitor+Si-NC,and puerarin+miR-490 inhibitor+Si-DTL.Transwell was used to detect cell migration and invasion.Western blotting was performed to detect the protein levels of epithelial-mesenchymal transition-related markers E-cadherin,N-cadherin,and Vimentin.	puerarin	78-86	microRNA 490	Homo sapiens	652-659
35300770-2	2022	Methods A549 cells were cultured and treated with different concentrations of puerarin.The inhibition rate (IR) on cell proliferation was detected by CCK-8,and qRT-PCR was performed to detect the mRNA levels of miR-490 and denticleless E3 ubiquitin protein ligase(DTL).Double luciferase reporter assay was employed to identify the targets of miR-490 and DTL based on the establishment of NC mimic group,miR-490 mimic group,NC inhibitor group,and miR-490 inhibitor group.The cells treated by 20 mumol/L puerarin were classified into six groups:DMSO,puerarin,puerarin+NC inhibitor,puerarin+miR-490 inhibitor,puerarin+miR-490 inhibitor+Si-NC,and puerarin+miR-490 inhibitor+Si-DTL.Transwell was used to detect cell migration and invasion.Western blotting was performed to detect the protein levels of epithelial-mesenchymal transition-related markers E-cadherin,N-cadherin,and Vimentin.	puerarin	78-86	denticleless E3 ubiquitin protein ligase homolog	Homo sapiens	673-676
35300770-2	2022	Methods A549 cells were cultured and treated with different concentrations of puerarin.The inhibition rate (IR) on cell proliferation was detected by CCK-8,and qRT-PCR was performed to detect the mRNA levels of miR-490 and denticleless E3 ubiquitin protein ligase(DTL).Double luciferase reporter assay was employed to identify the targets of miR-490 and DTL based on the establishment of NC mimic group,miR-490 mimic group,NC inhibitor group,and miR-490 inhibitor group.The cells treated by 20 mumol/L puerarin were classified into six groups:DMSO,puerarin,puerarin+NC inhibitor,puerarin+miR-490 inhibitor,puerarin+miR-490 inhibitor+Si-NC,and puerarin+miR-490 inhibitor+Si-DTL.Transwell was used to detect cell migration and invasion.Western blotting was performed to detect the protein levels of epithelial-mesenchymal transition-related markers E-cadherin,N-cadherin,and Vimentin.	puerarin	78-86	cadherin 1	Homo sapiens	847-857
35300770-2	2022	Methods A549 cells were cultured and treated with different concentrations of puerarin.The inhibition rate (IR) on cell proliferation was detected by CCK-8,and qRT-PCR was performed to detect the mRNA levels of miR-490 and denticleless E3 ubiquitin protein ligase(DTL).Double luciferase reporter assay was employed to identify the targets of miR-490 and DTL based on the establishment of NC mimic group,miR-490 mimic group,NC inhibitor group,and miR-490 inhibitor group.The cells treated by 20 mumol/L puerarin were classified into six groups:DMSO,puerarin,puerarin+NC inhibitor,puerarin+miR-490 inhibitor,puerarin+miR-490 inhibitor+Si-NC,and puerarin+miR-490 inhibitor+Si-DTL.Transwell was used to detect cell migration and invasion.Western blotting was performed to detect the protein levels of epithelial-mesenchymal transition-related markers E-cadherin,N-cadherin,and Vimentin.	puerarin	78-86	cadherin 2	Homo sapiens	858-868
35300770-2	2022	Methods A549 cells were cultured and treated with different concentrations of puerarin.The inhibition rate (IR) on cell proliferation was detected by CCK-8,and qRT-PCR was performed to detect the mRNA levels of miR-490 and denticleless E3 ubiquitin protein ligase(DTL).Double luciferase reporter assay was employed to identify the targets of miR-490 and DTL based on the establishment of NC mimic group,miR-490 mimic group,NC inhibitor group,and miR-490 inhibitor group.The cells treated by 20 mumol/L puerarin were classified into six groups:DMSO,puerarin,puerarin+NC inhibitor,puerarin+miR-490 inhibitor,puerarin+miR-490 inhibitor+Si-NC,and puerarin+miR-490 inhibitor+Si-DTL.Transwell was used to detect cell migration and invasion.Western blotting was performed to detect the protein levels of epithelial-mesenchymal transition-related markers E-cadherin,N-cadherin,and Vimentin.	puerarin	78-86	vimentin	Homo sapiens	873-881
35052852-0	2022	Puerarin Attenuates Obesity-Induced Inflammation and Dyslipidemia by Regulating Macrophages and TNF-Alpha in Obese Mice.	puerarin	0-8	tumor necrosis factor	Mus musculus	96-105
33583301-7	2021	In addition, puerarin enhanced the immunologic activity of cyclophosphamide-induced immunosuppression mice by increasing the secretion of NO, IFN-gamma, and IL-4, the serum half hemolysis value (HC50), the spleen and thymus index, and proliferation for splenic lymphocytes.	puerarin	13-21	interferon gamma	Mus musculus	142-151
35110976-0	2022	Puerarin Reduces Radiation-Induced Vascular Endothelial Cell Damage Via miR-34a/Placental Growth Factor.	puerarin	0-8	microRNA 34a	Homo sapiens	72-79
35110976-0	2022	Puerarin Reduces Radiation-Induced Vascular Endothelial Cell Damage Via miR-34a/Placental Growth Factor.	puerarin	0-8	placental growth factor	Homo sapiens	80-103
35110976-7	2022	Puerarin exerts a radioprotective effect by decreasing DNA damage and apoptosis through miR-34a-targeted PLGF.	puerarin	0-8	microRNA 34a	Homo sapiens	88-95
35110976-7	2022	Puerarin exerts a radioprotective effect by decreasing DNA damage and apoptosis through miR-34a-targeted PLGF.	puerarin	0-8	placental growth factor	Homo sapiens	105-109
35138214-1	2022	PRIMARY OBJECTIVE: This study aimed to investigate the effects of low-, medium-, and high-dose puerarin on cognitive impairment induced by 50% alcohol in mice and revealed the role of autophagy-related signaling pathways (mTOR and JNK pathways) in this process.	puerarin	95-103	mechanistic target of rapamycin kinase	Mus musculus	222-226
35138214-1	2022	PRIMARY OBJECTIVE: This study aimed to investigate the effects of low-, medium-, and high-dose puerarin on cognitive impairment induced by 50% alcohol in mice and revealed the role of autophagy-related signaling pathways (mTOR and JNK pathways) in this process.	puerarin	95-103	mitogen-activated protein kinase 8	Mus musculus	231-234
35242859-11	2022	Conclusions: Based on the network pharmacology analysis and experimental study, the study showed that puerarin not only had an anti-RV effect, but could also modulate the inflammatory response induced by RV infection via the TLR4/NF-kappaB signaling pathway.	puerarin	102-110	toll like receptor 4	Homo sapiens	225-229
35242859-11	2022	Conclusions: Based on the network pharmacology analysis and experimental study, the study showed that puerarin not only had an anti-RV effect, but could also modulate the inflammatory response induced by RV infection via the TLR4/NF-kappaB signaling pathway.	puerarin	102-110	nuclear factor kappa B subunit 1	Homo sapiens	230-239
33404196-0	2021	Puerarin prevents cadmium-induced disorder of testicular lactic acid metabolism in rats by activating 5" AMP-activated protein kinase (AMPK)/sirtuin 1 (SIRT1) signaling pathway.	puerarin	0-8	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	105-133
33404196-0	2021	Puerarin prevents cadmium-induced disorder of testicular lactic acid metabolism in rats by activating 5" AMP-activated protein kinase (AMPK)/sirtuin 1 (SIRT1) signaling pathway.	puerarin	0-8	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	135-139
33404196-0	2021	Puerarin prevents cadmium-induced disorder of testicular lactic acid metabolism in rats by activating 5" AMP-activated protein kinase (AMPK)/sirtuin 1 (SIRT1) signaling pathway.	puerarin	0-8	sirtuin 1	Rattus norvegicus	141-150
33404196-0	2021	Puerarin prevents cadmium-induced disorder of testicular lactic acid metabolism in rats by activating 5" AMP-activated protein kinase (AMPK)/sirtuin 1 (SIRT1) signaling pathway.	puerarin	0-8	sirtuin 1	Rattus norvegicus	152-157
33607539-7	2021	Attenuation of Cd-induced autophagy inhibition and autophagosome accumulation by PU was remarkably countered by Nrf2 silencing.	puerarin	81-83	nuclear factor, erythroid derived 2, like 2	Mus musculus	112-116
33607539-8	2021	Moreover, alleviation of Cd-induced NLRP3 inflammasome activation by PU was distinctly prevented by Nrf2 knockdown, assessed by protein levels of NLRP3 inflammosome complex and downstream IL-18 and IL-1beta production.	puerarin	69-71	NLR family, pyrin domain containing 3	Mus musculus	36-41
33607539-8	2021	Moreover, alleviation of Cd-induced NLRP3 inflammasome activation by PU was distinctly prevented by Nrf2 knockdown, assessed by protein levels of NLRP3 inflammosome complex and downstream IL-18 and IL-1beta production.	puerarin	69-71	nuclear factor, erythroid derived 2, like 2	Mus musculus	100-104
33607539-8	2021	Moreover, alleviation of Cd-induced NLRP3 inflammasome activation by PU was distinctly prevented by Nrf2 knockdown, assessed by protein levels of NLRP3 inflammosome complex and downstream IL-18 and IL-1beta production.	puerarin	69-71	NLR family, pyrin domain containing 3	Mus musculus	146-151
33607539-8	2021	Moreover, alleviation of Cd-induced NLRP3 inflammasome activation by PU was distinctly prevented by Nrf2 knockdown, assessed by protein levels of NLRP3 inflammosome complex and downstream IL-18 and IL-1beta production.	puerarin	69-71	interleukin 18	Mus musculus	188-193
33607539-8	2021	Moreover, alleviation of Cd-induced NLRP3 inflammasome activation by PU was distinctly prevented by Nrf2 knockdown, assessed by protein levels of NLRP3 inflammosome complex and downstream IL-18 and IL-1beta production.	puerarin	69-71	interleukin 1 alpha	Mus musculus	198-206
33607539-9	2021	Collectively, our data suggest that PU restores Cd-induced Nrf2 inhibition to prevent autophagy inhibition and NLRP3 inflammasome activation, providing novel insights into the protection of PU against Cd-induced hepatic cell damage.	puerarin	36-38	nuclear factor, erythroid derived 2, like 2	Mus musculus	59-63
33607539-9	2021	Collectively, our data suggest that PU restores Cd-induced Nrf2 inhibition to prevent autophagy inhibition and NLRP3 inflammasome activation, providing novel insights into the protection of PU against Cd-induced hepatic cell damage.	puerarin	36-38	NLR family, pyrin domain containing 3	Mus musculus	111-116
3055814-0	1988	[Effects of puerarin on blood pressure and plasma renin activity in spontaneously hypertensive rats].	puerarin	12-20	renin	Rattus norvegicus	50-55
33607539-0	2021	Puerarin induces Nrf2 as a cytoprotective mechanism to prevent cadmium-induced autophagy inhibition and NLRP3 inflammasome activation in AML12 hepatic cells.	puerarin	0-8	nuclear factor, erythroid derived 2, like 2	Mus musculus	17-21
33607539-0	2021	Puerarin induces Nrf2 as a cytoprotective mechanism to prevent cadmium-induced autophagy inhibition and NLRP3 inflammasome activation in AML12 hepatic cells.	puerarin	0-8	NLR family, pyrin domain containing 3	Mus musculus	104-109
33607539-4	2021	Data firstly showed that Cd-inhibited Nrf2 pathway was markedly restored by PU treatment, assessed by Nrf2 nuclear translocation, protein levels of Keap1 and Nrf2 downstream target genes.	puerarin	76-78	nuclear factor, erythroid derived 2, like 2	Mus musculus	38-42
33607539-4	2021	Data firstly showed that Cd-inhibited Nrf2 pathway was markedly restored by PU treatment, assessed by Nrf2 nuclear translocation, protein levels of Keap1 and Nrf2 downstream target genes.	puerarin	76-78	nuclear factor, erythroid derived 2, like 2	Mus musculus	102-106
33607539-4	2021	Data firstly showed that Cd-inhibited Nrf2 pathway was markedly restored by PU treatment, assessed by Nrf2 nuclear translocation, protein levels of Keap1 and Nrf2 downstream target genes.	puerarin	76-78	kelch-like ECH-associated protein 1	Mus musculus	148-153
33607539-4	2021	Data firstly showed that Cd-inhibited Nrf2 pathway was markedly restored by PU treatment, assessed by Nrf2 nuclear translocation, protein levels of Keap1 and Nrf2 downstream target genes.	puerarin	76-78	nuclear factor, erythroid derived 2, like 2	Mus musculus	102-106
33607539-6	2021	Next, Nrf2 silencing cellular model was established to further elucidate the role of Nrf2 in the protection of PU against Cd-induced hepatic damage.	puerarin	111-113	nuclear factor, erythroid derived 2, like 2	Mus musculus	6-10
33607539-6	2021	Next, Nrf2 silencing cellular model was established to further elucidate the role of Nrf2 in the protection of PU against Cd-induced hepatic damage.	puerarin	111-113	nuclear factor, erythroid derived 2, like 2	Mus musculus	85-89
33583301-7	2021	In addition, puerarin enhanced the immunologic activity of cyclophosphamide-induced immunosuppression mice by increasing the secretion of NO, IFN-gamma, and IL-4, the serum half hemolysis value (HC50), the spleen and thymus index, and proliferation for splenic lymphocytes.	puerarin	13-21	interleukin 4	Mus musculus	157-161
33753826-8	2021	In addition, puerarin reduced the activities of aspartate aminotransferase and alkaline phosphatase, the ratio of serum aspartate aminotransferase to serum alanine aminotransferase, the number of white blood cells and neutrophils, and the plasma concentrations of interleukin-6, interleukin-8 and tumor necrosis factor-alpha, as well as protein abundances of heat shock protein-70 in PEDV-infected piglets.	puerarin	13-21	interleukin 6	Homo sapiens	264-277
33753826-8	2021	In addition, puerarin reduced the activities of aspartate aminotransferase and alkaline phosphatase, the ratio of serum aspartate aminotransferase to serum alanine aminotransferase, the number of white blood cells and neutrophils, and the plasma concentrations of interleukin-6, interleukin-8 and tumor necrosis factor-alpha, as well as protein abundances of heat shock protein-70 in PEDV-infected piglets.	puerarin	13-21	C-X-C motif chemokine ligand 8	Homo sapiens	279-292
33753826-8	2021	In addition, puerarin reduced the activities of aspartate aminotransferase and alkaline phosphatase, the ratio of serum aspartate aminotransferase to serum alanine aminotransferase, the number of white blood cells and neutrophils, and the plasma concentrations of interleukin-6, interleukin-8 and tumor necrosis factor-alpha, as well as protein abundances of heat shock protein-70 in PEDV-infected piglets.	puerarin	13-21	glutamic--pyruvic transaminase	Homo sapiens	156-180
33753826-8	2021	In addition, puerarin reduced the activities of aspartate aminotransferase and alkaline phosphatase, the ratio of serum aspartate aminotransferase to serum alanine aminotransferase, the number of white blood cells and neutrophils, and the plasma concentrations of interleukin-6, interleukin-8 and tumor necrosis factor-alpha, as well as protein abundances of heat shock protein-70 in PEDV-infected piglets.	puerarin	13-21	tumor necrosis factor	Homo sapiens	297-324
33753826-10	2021	Puerarin increased the activities of total superoxide dismutase, glutathione peroxidase and catalase, while decreasing the activities of myeloperoxidase and concentration of hydrogen peroxide in both the intestine and plasma of PEDV-infected piglets.	puerarin	0-8	myeloperoxidase	Homo sapiens	137-152
33333215-9	2021	However, Puerarin ameliorated the effects of CHD model construction, suppressed nuclear factor-(NF-)kappaB expression, and enhanced the expressions of Farnesoid X Receptor (FXR), phosphorylated-AKT (p-AKT) and phosphorylated-signal transducer and activator of transcription 3 (p-STAT3).	puerarin	9-17	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	151-171
33543180-0	2021	Puerarin suppresses inflammation and ECM degradation through Nrf2/HO-1 axis in chondrocytes and alleviates pain symptom in osteoarthritic mice.	puerarin	0-8	nuclear factor, erythroid derived 2, like 2	Mus musculus	61-65
33543180-0	2021	Puerarin suppresses inflammation and ECM degradation through Nrf2/HO-1 axis in chondrocytes and alleviates pain symptom in osteoarthritic mice.	puerarin	0-8	heme oxygenase 1	Mus musculus	66-70
33543180-7	2021	The mechanism study revealed that Nrf2/HO-1 pathway is involved in Puerarin induced inhibition of NF-kappaB signaling pathway.	puerarin	67-75	nuclear factor, erythroid derived 2, like 2	Mus musculus	34-38
33543180-7	2021	The mechanism study revealed that Nrf2/HO-1 pathway is involved in Puerarin induced inhibition of NF-kappaB signaling pathway.	puerarin	67-75	heme oxygenase 1	Mus musculus	39-43
33543180-7	2021	The mechanism study revealed that Nrf2/HO-1 pathway is involved in Puerarin induced inhibition of NF-kappaB signaling pathway.	puerarin	67-75	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	98-107
33333215-9	2021	However, Puerarin ameliorated the effects of CHD model construction, suppressed nuclear factor-(NF-)kappaB expression, and enhanced the expressions of Farnesoid X Receptor (FXR), phosphorylated-AKT (p-AKT) and phosphorylated-signal transducer and activator of transcription 3 (p-STAT3).	puerarin	9-17	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	173-176
33333215-9	2021	However, Puerarin ameliorated the effects of CHD model construction, suppressed nuclear factor-(NF-)kappaB expression, and enhanced the expressions of Farnesoid X Receptor (FXR), phosphorylated-AKT (p-AKT) and phosphorylated-signal transducer and activator of transcription 3 (p-STAT3).	puerarin	9-17	AKT serine/threonine kinase 1	Rattus norvegicus	194-197
33333215-9	2021	However, Puerarin ameliorated the effects of CHD model construction, suppressed nuclear factor-(NF-)kappaB expression, and enhanced the expressions of Farnesoid X Receptor (FXR), phosphorylated-AKT (p-AKT) and phosphorylated-signal transducer and activator of transcription 3 (p-STAT3).	puerarin	9-17	AKT serine/threonine kinase 1	Rattus norvegicus	201-204
33333215-9	2021	However, Puerarin ameliorated the effects of CHD model construction, suppressed nuclear factor-(NF-)kappaB expression, and enhanced the expressions of Farnesoid X Receptor (FXR), phosphorylated-AKT (p-AKT) and phosphorylated-signal transducer and activator of transcription 3 (p-STAT3).	puerarin	9-17	signal transducer and activator of transcription 3	Rattus norvegicus	225-275
33333215-9	2021	However, Puerarin ameliorated the effects of CHD model construction, suppressed nuclear factor-(NF-)kappaB expression, and enhanced the expressions of Farnesoid X Receptor (FXR), phosphorylated-AKT (p-AKT) and phosphorylated-signal transducer and activator of transcription 3 (p-STAT3).	puerarin	9-17	signal transducer and activator of transcription 3	Rattus norvegicus	279-284
33242606-0	2021	Up-regulation of thioredoxin system by puerarin inhibits lipid uptake in macrophages.	puerarin	39-47	thioredoxin 1	Mus musculus	17-28
33602885-0	2021	Puerarin pretreatment attenuates cardiomyocyte apoptosis induced by coronary microembolization in rats by activating the PI3K/Akt/GSK-3beta signaling pathway.	puerarin	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	126-129
33602885-0	2021	Puerarin pretreatment attenuates cardiomyocyte apoptosis induced by coronary microembolization in rats by activating the PI3K/Akt/GSK-3beta signaling pathway.	puerarin	0-8	glycogen synthase kinase 3 alpha	Rattus norvegicus	130-139
33141989-0	2021	Puerarin sensitized K562/ADR cells by inhibiting NF-kappaB pathway and inducing autophagy.	puerarin	0-8	nuclear factor kappa B subunit 1	Homo sapiens	49-58
32720917-0	2021	Puerarin Exerts the Hepatoprotection from Chronic Alcohol-Induced Liver Injury via Inhibiting the Cyclooxygenase-2 and the 5-Lipoxygenase Pathway in Rats.	puerarin	0-8	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	98-114
32720917-0	2021	Puerarin Exerts the Hepatoprotection from Chronic Alcohol-Induced Liver Injury via Inhibiting the Cyclooxygenase-2 and the 5-Lipoxygenase Pathway in Rats.	puerarin	0-8	arachidonate 5-lipoxygenase	Rattus norvegicus	123-137
32720917-9	2021	CONCLUSION: The possible cytoprotective mechanisms of PR may be involved inhibition of the Cox-2 pathway and the 5-Lox pathway to suppress inflammatory response and regulate the protective factor PPAR-gamma expression.	puerarin	54-56	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	91-96
32720917-9	2021	CONCLUSION: The possible cytoprotective mechanisms of PR may be involved inhibition of the Cox-2 pathway and the 5-Lox pathway to suppress inflammatory response and regulate the protective factor PPAR-gamma expression.	puerarin	54-56	arachidonate 5-lipoxygenase	Rattus norvegicus	113-118
32720917-9	2021	CONCLUSION: The possible cytoprotective mechanisms of PR may be involved inhibition of the Cox-2 pathway and the 5-Lox pathway to suppress inflammatory response and regulate the protective factor PPAR-gamma expression.	puerarin	54-56	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	196-206
32504066-0	2021	Puerarin ameliorated pressure overload-induced cardiac hypertrophy in ovariectomized rats through activation of the PPARalpha/PGC-1 pathway.	puerarin	0-8	peroxisome proliferator activated receptor alpha	Rattus norvegicus	116-125
32504066-7	2021	We showed that puerarin administration significantly attenuated cardiac hypertrophy and remodeling in AAC-treated OVX rats, which could be attributed to activation of PPARalpha/PPARgamma coactivator-1 (PGC-1) pathway.	puerarin	15-23	peroxisome proliferator activated receptor alpha	Rattus norvegicus	167-200
32504066-8	2021	Puerarin administration significantly increased the expression of estrogen-related receptor alpha, nuclear respiratory factor 1, and mitochondrial transcription factor A in hearts.	puerarin	0-8	estrogen related receptor, alpha	Rattus norvegicus	66-97
32504066-8	2021	Puerarin administration significantly increased the expression of estrogen-related receptor alpha, nuclear respiratory factor 1, and mitochondrial transcription factor A in hearts.	puerarin	0-8	nuclear respiratory factor 1	Rattus norvegicus	99-127
32504066-10	2021	Hypertrophic changes could be induced in neonatal rat cardiomyocytes (NRCM) in vitro by treatment with angiotensin II (Ang II, 1 muM), which was attenuated by co-treatemnt with puerarin (100 muM).	puerarin	177-185	angiotensinogen	Rattus norvegicus	119-125
32504066-12	2021	Furthermore, addition of PPARalpha antagonist GW6471 (10 muM) partially abolished the anti-hypertrophic effects and metabolic effects of puerarin in NRCM.	puerarin	137-145	peroxisome proliferator activated receptor alpha	Rattus norvegicus	25-34
33242606-9	2021	In addition, we analyzed the upstream regulation and found puerarin induced Nrf2 activity; cooperation between Nrf2 and ATF4 facilitated the puerarin effects.	puerarin	59-67	nuclear factor, erythroid derived 2, like 2	Mus musculus	76-80
33199995-0	2020	Puerarin protects vascular smooth muscle cells from oxidized low-density lipoprotein-induced reductions in viability via inhibition of the p38 MAPK and JNK signaling pathways.	puerarin	0-8	mitogen-activated protein kinase 8	Homo sapiens	152-155
33199995-11	2020	Puerarin also inhibited ox-LDL-induced phosphorylation of p38 and JNK in VSMCs.	puerarin	0-8	mitogen-activated protein kinase 14	Homo sapiens	58-61
33199995-11	2020	Puerarin also inhibited ox-LDL-induced phosphorylation of p38 and JNK in VSMCs.	puerarin	0-8	mitogen-activated protein kinase 8	Homo sapiens	66-69
32950828-5	2020	Real time-PCR and western blot suggested that rutin, puerarin and 100 mg/(kg bw)/day silymarin could decrease the AlCl3-induced high expression of Bcl-2 associated X protein (Bax) mRNA and protein in hippocampus, but the expression of B cell lymphoma/leukemia-2 (Bcl-2) mRNA and protein was not significantly different among groups.	puerarin	53-61	BCL2 associated X, apoptosis regulator	Rattus norvegicus	147-173
33049496-0	2020	Puerarin alleviates vincristine-induced neuropathic pain and neuroinflammation via inhibition of nuclear factor-kappaB and activation of the TGF-beta/Smad pathway in rats.	puerarin	0-8	transforming growth factor alpha	Rattus norvegicus	141-149
32860809-0	2020	Puerarin attenuates the endothelial-mesenchymal transition induced by oxidative stress in human coronary artery endothelial cells through PI3K/AKT pathway.	puerarin	0-8	AKT serine/threonine kinase 1	Homo sapiens	143-146
32860809-9	2020	Puerarin mitigated H2O2-induced EndMT as indicated by alleviating the reduced expression of CD31 and VE-cadherin and inhibiting the upregulation of alpha-SMA and FSP1.	puerarin	0-8	platelet and endothelial cell adhesion molecule 1	Homo sapiens	92-96
32860809-9	2020	Puerarin mitigated H2O2-induced EndMT as indicated by alleviating the reduced expression of CD31 and VE-cadherin and inhibiting the upregulation of alpha-SMA and FSP1.	puerarin	0-8	cadherin 5	Homo sapiens	101-112
32860809-9	2020	Puerarin mitigated H2O2-induced EndMT as indicated by alleviating the reduced expression of CD31 and VE-cadherin and inhibiting the upregulation of alpha-SMA and FSP1.	puerarin	0-8	actin alpha 1, skeletal muscle	Homo sapiens	148-157
32860809-9	2020	Puerarin mitigated H2O2-induced EndMT as indicated by alleviating the reduced expression of CD31 and VE-cadherin and inhibiting the upregulation of alpha-SMA and FSP1.	puerarin	0-8	atlastin GTPase 1	Homo sapiens	162-166
32860809-13	2020	These results implicated that puerarin exhibited cytoprotective effects against H2O2-induced EndMT in HCAECs through alleviating oxidative stress, activating the PI3K/AKT pathway and limiting cell migration.	puerarin	30-38	AKT serine/threonine kinase 1	Homo sapiens	167-170
33049496-11	2020	Treatment with Pue restored the levels of tumor necrosis factor-alpha (TNF-alpha), and IL-1beta and increased the levels of transforming growth factor-beta (TGF-beta), and interleukin-10 (IL-10).	puerarin	15-18	tumor necrosis factor	Rattus norvegicus	42-69
33049496-11	2020	Treatment with Pue restored the levels of tumor necrosis factor-alpha (TNF-alpha), and IL-1beta and increased the levels of transforming growth factor-beta (TGF-beta), and interleukin-10 (IL-10).	puerarin	15-18	tumor necrosis factor	Rattus norvegicus	71-80
33049496-11	2020	Treatment with Pue restored the levels of tumor necrosis factor-alpha (TNF-alpha), and IL-1beta and increased the levels of transforming growth factor-beta (TGF-beta), and interleukin-10 (IL-10).	puerarin	15-18	interleukin 1 alpha	Rattus norvegicus	87-95
33049496-11	2020	Treatment with Pue restored the levels of tumor necrosis factor-alpha (TNF-alpha), and IL-1beta and increased the levels of transforming growth factor-beta (TGF-beta), and interleukin-10 (IL-10).	puerarin	15-18	transforming growth factor alpha	Rattus norvegicus	157-165
33049496-11	2020	Treatment with Pue restored the levels of tumor necrosis factor-alpha (TNF-alpha), and IL-1beta and increased the levels of transforming growth factor-beta (TGF-beta), and interleukin-10 (IL-10).	puerarin	15-18	interleukin 10	Rattus norvegicus	172-186
33049496-11	2020	Treatment with Pue restored the levels of tumor necrosis factor-alpha (TNF-alpha), and IL-1beta and increased the levels of transforming growth factor-beta (TGF-beta), and interleukin-10 (IL-10).	puerarin	15-18	interleukin 10	Rattus norvegicus	188-193
33068868-0	2020	Puerarin protects against myocardial ischemia/reperfusion injury by inhibiting inflammation and the NLRP3 inflammasome: The role of the SIRT1/NF-kappaB pathway.	puerarin	0-8	NLR family, pyrin domain containing 3	Mus musculus	100-105
33068868-0	2020	Puerarin protects against myocardial ischemia/reperfusion injury by inhibiting inflammation and the NLRP3 inflammasome: The role of the SIRT1/NF-kappaB pathway.	puerarin	0-8	sirtuin 1	Mus musculus	136-141
33068868-0	2020	Puerarin protects against myocardial ischemia/reperfusion injury by inhibiting inflammation and the NLRP3 inflammasome: The role of the SIRT1/NF-kappaB pathway.	puerarin	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	142-151
33068868-8	2020	More importantly, the SIRT1 inhibitor nicotinamide prevented these puerarin-induced cardioprotective effects and regulation of the SIRT1/NF-kappaB pathway, as well as the NLRP3 inflammasome activation.	puerarin	67-75	sirtuin 1	Mus musculus	22-27
33068868-8	2020	More importantly, the SIRT1 inhibitor nicotinamide prevented these puerarin-induced cardioprotective effects and regulation of the SIRT1/NF-kappaB pathway, as well as the NLRP3 inflammasome activation.	puerarin	67-75	sirtuin 1	Mus musculus	131-136
33068868-8	2020	More importantly, the SIRT1 inhibitor nicotinamide prevented these puerarin-induced cardioprotective effects and regulation of the SIRT1/NF-kappaB pathway, as well as the NLRP3 inflammasome activation.	puerarin	67-75	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	137-146
33068868-8	2020	More importantly, the SIRT1 inhibitor nicotinamide prevented these puerarin-induced cardioprotective effects and regulation of the SIRT1/NF-kappaB pathway, as well as the NLRP3 inflammasome activation.	puerarin	67-75	NLR family, pyrin domain containing 3	Mus musculus	171-176
33068868-9	2020	CONCLUSION: Puerarin protected against MI/R injury by inhibiting inflammatory responses probably via the SIRT1/NF-kappaB pathway, and inhibition of the NLRP3 inflammasome was also involved in puerarin-induced cardioprotective effects.	puerarin	12-20	sirtuin 1	Mus musculus	105-110
33068868-9	2020	CONCLUSION: Puerarin protected against MI/R injury by inhibiting inflammatory responses probably via the SIRT1/NF-kappaB pathway, and inhibition of the NLRP3 inflammasome was also involved in puerarin-induced cardioprotective effects.	puerarin	12-20	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	111-120
33068868-9	2020	CONCLUSION: Puerarin protected against MI/R injury by inhibiting inflammatory responses probably via the SIRT1/NF-kappaB pathway, and inhibition of the NLRP3 inflammasome was also involved in puerarin-induced cardioprotective effects.	puerarin	192-200	NLR family, pyrin domain containing 3	Mus musculus	152-157
33155599-0	2020	Puerarin induces mouse mesenteric vasodilation and ameliorates hypertension involving endothelial TRPV4 channels.	puerarin	0-8	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	98-103
33176281-0	2020	Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-kappaB signaling pathways.	puerarin	0-8	TNF receptor-associated factor 6	Mus musculus	117-122
33176281-2	2020	Puerarin-treated OVX mice exhibited higher bone density, fewer tartrate-resistant acid phosphatase (TRAcP)-positive osteoclasts, and levels of lower reactive oxygen species (ROS) within bone tissues than vehicle-treated OVX mice.	puerarin	0-8	acid phosphatase 5, tartrate resistant	Mus musculus	63-98
33176281-2	2020	Puerarin-treated OVX mice exhibited higher bone density, fewer tartrate-resistant acid phosphatase (TRAcP)-positive osteoclasts, and levels of lower reactive oxygen species (ROS) within bone tissues than vehicle-treated OVX mice.	puerarin	0-8	acid phosphatase 5, tartrate resistant	Mus musculus	100-105
33176281-3	2020	Puerarin suppressed in vitro osteoclast differentiation, hydroxyapatite resorption activity, and expression of osteoclastogenesis-related genes, such as NFATc1, MMP9, CTSK, Acp5 and c-Fos, in RANKL-induced bone marrow macrophages (BMMs) and RAW264.7 cells.	puerarin	0-8	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	153-159
33176281-3	2020	Puerarin suppressed in vitro osteoclast differentiation, hydroxyapatite resorption activity, and expression of osteoclastogenesis-related genes, such as NFATc1, MMP9, CTSK, Acp5 and c-Fos, in RANKL-induced bone marrow macrophages (BMMs) and RAW264.7 cells.	puerarin	0-8	matrix metallopeptidase 9	Mus musculus	161-165
33176281-3	2020	Puerarin suppressed in vitro osteoclast differentiation, hydroxyapatite resorption activity, and expression of osteoclastogenesis-related genes, such as NFATc1, MMP9, CTSK, Acp5 and c-Fos, in RANKL-induced bone marrow macrophages (BMMs) and RAW264.7 cells.	puerarin	0-8	cathepsin K	Mus musculus	167-171
33176281-3	2020	Puerarin suppressed in vitro osteoclast differentiation, hydroxyapatite resorption activity, and expression of osteoclastogenesis-related genes, such as NFATc1, MMP9, CTSK, Acp5 and c-Fos, in RANKL-induced bone marrow macrophages (BMMs) and RAW264.7 cells.	puerarin	0-8	acid phosphatase 5, tartrate resistant	Mus musculus	173-177
33176281-3	2020	Puerarin suppressed in vitro osteoclast differentiation, hydroxyapatite resorption activity, and expression of osteoclastogenesis-related genes, such as NFATc1, MMP9, CTSK, Acp5 and c-Fos, in RANKL-induced bone marrow macrophages (BMMs) and RAW264.7 cells.	puerarin	0-8	FBJ osteosarcoma oncogene	Mus musculus	182-187
33176281-3	2020	Puerarin suppressed in vitro osteoclast differentiation, hydroxyapatite resorption activity, and expression of osteoclastogenesis-related genes, such as NFATc1, MMP9, CTSK, Acp5 and c-Fos, in RANKL-induced bone marrow macrophages (BMMs) and RAW264.7 cells.	puerarin	0-8	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	192-197
33176281-5	2020	Puerarin inhibited TRAF6/ROS-dependent activation of the MAPK and NF-kappaB signaling pathways in RANKL-induced RAW264.7 cells, and these effects were partially reversed by HO-1 silencing or TRAF6 overexpression.	puerarin	0-8	TNF receptor-associated factor 6	Mus musculus	19-24
33176281-5	2020	Puerarin inhibited TRAF6/ROS-dependent activation of the MAPK and NF-kappaB signaling pathways in RANKL-induced RAW264.7 cells, and these effects were partially reversed by HO-1 silencing or TRAF6 overexpression.	puerarin	0-8	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	98-103
33176281-5	2020	Puerarin inhibited TRAF6/ROS-dependent activation of the MAPK and NF-kappaB signaling pathways in RANKL-induced RAW264.7 cells, and these effects were partially reversed by HO-1 silencing or TRAF6 overexpression.	puerarin	0-8	heme oxygenase 1	Mus musculus	173-177
33176281-5	2020	Puerarin inhibited TRAF6/ROS-dependent activation of the MAPK and NF-kappaB signaling pathways in RANKL-induced RAW264.7 cells, and these effects were partially reversed by HO-1 silencing or TRAF6 overexpression.	puerarin	0-8	TNF receptor-associated factor 6	Mus musculus	191-196
33176281-6	2020	These findings suggest puerarin alleviates loss of bone mass in the OVX-model mice by suppressing osteoclastogenesis via inhibition of the TRAF6/ROS-dependent MAPK/NF-kappaB signaling pathway.	puerarin	23-31	TNF receptor-associated factor 6	Mus musculus	139-144
32950828-5	2020	Real time-PCR and western blot suggested that rutin, puerarin and 100 mg/(kg bw)/day silymarin could decrease the AlCl3-induced high expression of Bcl-2 associated X protein (Bax) mRNA and protein in hippocampus, but the expression of B cell lymphoma/leukemia-2 (Bcl-2) mRNA and protein was not significantly different among groups.	puerarin	53-61	BCL2 associated X, apoptosis regulator	Rattus norvegicus	175-178
32950828-5	2020	Real time-PCR and western blot suggested that rutin, puerarin and 100 mg/(kg bw)/day silymarin could decrease the AlCl3-induced high expression of Bcl-2 associated X protein (Bax) mRNA and protein in hippocampus, but the expression of B cell lymphoma/leukemia-2 (Bcl-2) mRNA and protein was not significantly different among groups.	puerarin	53-61	BCL2, apoptosis regulator	Rattus norvegicus	235-261
32950828-5	2020	Real time-PCR and western blot suggested that rutin, puerarin and 100 mg/(kg bw)/day silymarin could decrease the AlCl3-induced high expression of Bcl-2 associated X protein (Bax) mRNA and protein in hippocampus, but the expression of B cell lymphoma/leukemia-2 (Bcl-2) mRNA and protein was not significantly different among groups.	puerarin	53-61	BCL2, apoptosis regulator	Rattus norvegicus	147-152
32236896-0	2020	Puerarin Alleviates Lipopolysaccharide-Induced Myocardial Fibrosis by Inhibiting PARP-1 to Prevent HMGB1-Mediated TLR4-NF-kappaB Signaling Pathway.	puerarin	0-8	high mobility group box 1	Rattus norvegicus	99-104
33123315-0	2020	Botanical Drug Puerarin Promotes Neuronal Survival and Neurite Outgrowth against MPTP/MPP+-Induced Toxicity via Progesterone Receptor Signaling.	puerarin	15-23	progesterone receptor	Rattus norvegicus	112-133
33123315-2	2020	Objectives: The present study was designed to determine whether botanical drug puerarin could exhibit neuroprotective and neurorestorative activities via PR signaling.	puerarin	79-87	progesterone receptor	Rattus norvegicus	154-156
33123315-10	2020	RU486 and PR-siRNA could inhibit the effect of puerarin.	puerarin	47-55	progesterone receptor	Rattus norvegicus	10-12
33123315-11	2020	Puerarin and progesterone could enhance the PR promoter.	puerarin	0-8	progesterone receptor	Rattus norvegicus	44-46
33123315-12	2020	Conclusion: Puerarin attenuated MPTP- and MPP+-induced toxicity and potentiated neurite outgrowth via PR.	puerarin	12-20	progesterone receptor	Rattus norvegicus	102-104
32236896-0	2020	Puerarin Alleviates Lipopolysaccharide-Induced Myocardial Fibrosis by Inhibiting PARP-1 to Prevent HMGB1-Mediated TLR4-NF-kappaB Signaling Pathway.	puerarin	0-8	poly (ADP-ribose) polymerase 1	Rattus norvegicus	81-87
32236896-0	2020	Puerarin Alleviates Lipopolysaccharide-Induced Myocardial Fibrosis by Inhibiting PARP-1 to Prevent HMGB1-Mediated TLR4-NF-kappaB Signaling Pathway.	puerarin	0-8	toll-like receptor 4	Rattus norvegicus	114-118
32236896-8	2020	In addition, we proved that puerarin could weaken MFs, and PARP-1 and HMGB1 expressions, which were induced by LPS in primary CFs.	puerarin	28-36	poly (ADP-ribose) polymerase 1	Rattus norvegicus	59-65
32236896-8	2020	In addition, we proved that puerarin could weaken MFs, and PARP-1 and HMGB1 expressions, which were induced by LPS in primary CFs.	puerarin	28-36	high mobility group box 1	Rattus norvegicus	70-75
32236896-9	2020	In terms of mechanism, HMGB1 expression could be promoted by PARP-1, and PARP-1 could attenuate the therapeutic effect of puerarin on LPS-induced MFs.	puerarin	122-130	poly (ADP-ribose) polymerase 1	Rattus norvegicus	73-79
32236896-10	2020	Besides, PARP-1-HMGB1-NF-kappaB pathway was related to the protective effect of puerarin on MFs.	puerarin	80-88	poly (ADP-ribose) polymerase 1	Rattus norvegicus	9-15
32236896-10	2020	Besides, PARP-1-HMGB1-NF-kappaB pathway was related to the protective effect of puerarin on MFs.	puerarin	80-88	high mobility group box 1	Rattus norvegicus	16-21
32236896-11	2020	In vivo, we also verified the protective efficacy of puerarin on MFs induced by TAC, and puerarin also regulated HMGB1-mediated TLR4-NF-kappaB signaling pathway.	puerarin	89-97	high mobility group box 1	Rattus norvegicus	113-118
32236896-11	2020	In vivo, we also verified the protective efficacy of puerarin on MFs induced by TAC, and puerarin also regulated HMGB1-mediated TLR4-NF-kappaB signaling pathway.	puerarin	89-97	toll-like receptor 4	Rattus norvegicus	128-132
32236896-12	2020	We demonstrated that puerarin could ameliorate MFs by downregulating PARP-1 to inhibit HMGB1-mediated TLR4-NF-kappaB signaling pathway in LPS-induced primary CFs and TAC-induced MFs rats" model.	puerarin	21-29	poly (ADP-ribose) polymerase 1	Rattus norvegicus	69-75
32236896-12	2020	We demonstrated that puerarin could ameliorate MFs by downregulating PARP-1 to inhibit HMGB1-mediated TLR4-NF-kappaB signaling pathway in LPS-induced primary CFs and TAC-induced MFs rats" model.	puerarin	21-29	high mobility group box 1	Rattus norvegicus	87-92
32236896-12	2020	We demonstrated that puerarin could ameliorate MFs by downregulating PARP-1 to inhibit HMGB1-mediated TLR4-NF-kappaB signaling pathway in LPS-induced primary CFs and TAC-induced MFs rats" model.	puerarin	21-29	toll-like receptor 4	Rattus norvegicus	102-106
32763437-0	2020	Puerarin suppresses MPP+/MPTP-induced oxidative stress through an Nrf2-dependent mechanism.	puerarin	0-8	NFE2 like bZIP transcription factor 2	Rattus norvegicus	66-70
32855680-0	2020	Puerarin alleviates cisplatin-induced acute renal damage and upregulates microRNA-31-related signaling.	puerarin	0-8	microRNA 31	Rattus norvegicus	73-84
32763437-1	2020	In this study, we hypothesized that anti-parkinsonian effect of puerarin is attributable to its antioxidant properties via Nrf2-dependent glutathione (GSH) biosynthesis mechanism.	puerarin	64-72	NFE2 like bZIP transcription factor 2	Rattus norvegicus	123-127
32855680-9	2020	Taken together, the results of the present study suggest that puerarin exhibits a renal protective effect against DDP-induced AKI by upregulating miR-31 expression and inhibiting the Numb/Notch1 signaling pathway.	puerarin	62-70	microRNA 31	Rattus norvegicus	146-152
32763437-4	2020	Furthermore, puerarin induced accumulation of Nrf2 in the nucleus via inhibiting its nuclear exclusion.	puerarin	13-21	NFE2 like bZIP transcription factor 2	Rattus norvegicus	46-50
32855680-9	2020	Taken together, the results of the present study suggest that puerarin exhibits a renal protective effect against DDP-induced AKI by upregulating miR-31 expression and inhibiting the Numb/Notch1 signaling pathway.	puerarin	62-70	NUMB, endocytic adaptor protein	Rattus norvegicus	183-187
32959235-12	2020	Resveratrol and puerarin loaded nanoparticles decreases GSH, SOD and CAT antioxidant level, which helps in overall health improvement of patients.	puerarin	16-24	superoxide dismutase 1	Homo sapiens	61-64
32855680-9	2020	Taken together, the results of the present study suggest that puerarin exhibits a renal protective effect against DDP-induced AKI by upregulating miR-31 expression and inhibiting the Numb/Notch1 signaling pathway.	puerarin	62-70	notch receptor 1	Rattus norvegicus	188-194
32896108-0	2020	Puerarin inhibits titanium particle-induced osteolysis and RANKL-induced osteoclastogenesis via suppression of the NF-kappaB signaling pathway.	puerarin	0-8	TNF superfamily member 11	Rattus norvegicus	59-64
32896108-6	2020	In vitro, puerarin prevented RANKL-induced osteoclast differentiation, bone resorption and F-actin ring formation in a concentration-dependent manner.	puerarin	10-18	TNF superfamily member 11	Rattus norvegicus	29-34
32959235-12	2020	Resveratrol and puerarin loaded nanoparticles decreases GSH, SOD and CAT antioxidant level, which helps in overall health improvement of patients.	puerarin	16-24	catalase	Homo sapiens	69-72
32705200-7	2020	Cd induced the activation of nuclear factor erythroid 2-related factor 2 (NRF2), an obstruction of autophagic flux and ERS, which were attenuated by puerarin administration.	puerarin	149-157	NFE2 like bZIP transcription factor 2	Rattus norvegicus	29-72
32526286-0	2020	Puerarin ameliorates retinal ganglion cell damage induced by retinal ischemia/reperfusion through inhibiting the activation of TLR4/NLRP3 inflammasome.	puerarin	0-8	toll-like receptor 4	Rattus norvegicus	127-131
32526286-0	2020	Puerarin ameliorates retinal ganglion cell damage induced by retinal ischemia/reperfusion through inhibiting the activation of TLR4/NLRP3 inflammasome.	puerarin	0-8	NLR family, pyrin domain containing 3	Rattus norvegicus	132-137
32705200-7	2020	Cd induced the activation of nuclear factor erythroid 2-related factor 2 (NRF2), an obstruction of autophagic flux and ERS, which were attenuated by puerarin administration.	puerarin	149-157	NFE2 like bZIP transcription factor 2	Rattus norvegicus	74-78
32705200-10	2020	Taken together, these results indicate that puerarin administration restored the autophagic flux to alleviate ERS, via blocking the activation of NRF2.	puerarin	44-52	NFE2 like bZIP transcription factor 2	Rattus norvegicus	146-150
32765037-9	2020	Compared with DN model mice, puerarin-treated mice showed an increased expression of podocyte functional proteins, including nephrin, podocin, and podocalyxin.	puerarin	29-37	nephrosis 1, nephrin	Mus musculus	125-132
33164393-14	2020	This series of studies confirm that puerarin can treat hepatocellular carcinoma by blocking PTEN/Akt/GSK3beta cellular signaling pathway, so as to provide ideas for subsequent studies for the molecular mechanism of puerarin in the treatment of liver cancer.	puerarin	36-44	phosphatase and tensin homolog	Homo sapiens	92-96
33164393-14	2020	This series of studies confirm that puerarin can treat hepatocellular carcinoma by blocking PTEN/Akt/GSK3beta cellular signaling pathway, so as to provide ideas for subsequent studies for the molecular mechanism of puerarin in the treatment of liver cancer.	puerarin	36-44	AKT serine/threonine kinase 1	Homo sapiens	97-100
33164393-14	2020	This series of studies confirm that puerarin can treat hepatocellular carcinoma by blocking PTEN/Akt/GSK3beta cellular signaling pathway, so as to provide ideas for subsequent studies for the molecular mechanism of puerarin in the treatment of liver cancer.	puerarin	36-44	glycogen synthase kinase 3 alpha	Homo sapiens	101-109
32765037-9	2020	Compared with DN model mice, puerarin-treated mice showed an increased expression of podocyte functional proteins, including nephrin, podocin, and podocalyxin.	puerarin	29-37	nephrosis 2, podocin	Mus musculus	134-141
32765037-9	2020	Compared with DN model mice, puerarin-treated mice showed an increased expression of podocyte functional proteins, including nephrin, podocin, and podocalyxin.	puerarin	29-37	podocalyxin-like	Mus musculus	147-158
32765037-12	2020	In addition, the levels of PERK, eIF2alpha, and ATF4 were reduced in the DN model, which was partially, but significantly, prevented by rapamycin and puerarin.	puerarin	150-158	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	27-31
32765037-12	2020	In addition, the levels of PERK, eIF2alpha, and ATF4 were reduced in the DN model, which was partially, but significantly, prevented by rapamycin and puerarin.	puerarin	150-158	eukaryotic translation initiation factor 2A	Mus musculus	33-42
32765037-12	2020	In addition, the levels of PERK, eIF2alpha, and ATF4 were reduced in the DN model, which was partially, but significantly, prevented by rapamycin and puerarin.	puerarin	150-158	activating transcription factor 4	Mus musculus	48-52
32765037-13	2020	Conclusion: This study emphasizes the renal-protective effects of puerarin in DN mice, particularly in the modulation of autophagy under ERS conditions, which may be associated with activation of the PERK/eIF2alpha/ATF4 signaling pathway.	puerarin	66-74	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	200-204
32765037-13	2020	Conclusion: This study emphasizes the renal-protective effects of puerarin in DN mice, particularly in the modulation of autophagy under ERS conditions, which may be associated with activation of the PERK/eIF2alpha/ATF4 signaling pathway.	puerarin	66-74	eukaryotic translation initiation factor 2A	Mus musculus	205-214
32765037-13	2020	Conclusion: This study emphasizes the renal-protective effects of puerarin in DN mice, particularly in the modulation of autophagy under ERS conditions, which may be associated with activation of the PERK/eIF2alpha/ATF4 signaling pathway.	puerarin	66-74	activating transcription factor 4	Mus musculus	215-219
32457606-0	2020	Puerarin Increases Survival and Protects Against Organ Injury by Suppressing NF-kappaB/JNK Signaling in Experimental Sepsis.	puerarin	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	77-86
32154764-0	2020	Puerarin inhibits the migration of osteoclast precursors and osteoclastogenesis by inhibiting MCP-1 production.	puerarin	0-8	C-C motif chemokine ligand 2	Homo sapiens	94-99
32154764-3	2020	The results showed that puerarin reduced MCP-1 production in OCPs, while inhibiting OCPs migration based on MCP-1.	puerarin	24-32	C-C motif chemokine ligand 2	Homo sapiens	41-46
32154764-3	2020	The results showed that puerarin reduced MCP-1 production in OCPs, while inhibiting OCPs migration based on MCP-1.	puerarin	24-32	C-C motif chemokine ligand 2	Homo sapiens	108-113
32154764-4	2020	Puerarin reversed MCP-1-promoted osteoclastogenesis.	puerarin	0-8	C-C motif chemokine ligand 2	Homo sapiens	18-23
32154764-6	2020	Therefore, puerarin prevents OCPs migration by reducing MCP-1, whereby inhibiting osteoclastogenesis.	puerarin	11-19	C-C motif chemokine ligand 2	Homo sapiens	56-61
32536996-10	2020	Puerarin treatment reduced serum levels of IL-1beta, TNF-alpha and IL-6, in addition to reducing MPO activity and MDA levels in myocardial tissues.	puerarin	0-8	interleukin 1 alpha	Rattus norvegicus	43-51
32536996-10	2020	Puerarin treatment reduced serum levels of IL-1beta, TNF-alpha and IL-6, in addition to reducing MPO activity and MDA levels in myocardial tissues.	puerarin	0-8	tumor necrosis factor	Rattus norvegicus	53-62
32536996-10	2020	Puerarin treatment reduced serum levels of IL-1beta, TNF-alpha and IL-6, in addition to reducing MPO activity and MDA levels in myocardial tissues.	puerarin	0-8	interleukin 6	Rattus norvegicus	67-71
32536996-10	2020	Puerarin treatment reduced serum levels of IL-1beta, TNF-alpha and IL-6, in addition to reducing MPO activity and MDA levels in myocardial tissues.	puerarin	0-8	myeloperoxidase	Rattus norvegicus	97-100
32536996-12	2020	In conclusion, puerarin improved cardiac function in rats following severe burn injury, which may be due to reduced myocardial injury, inhibition of cardiomyocyte apoptosis and reduced oxidative inflammatory stress; the MAPK and AKT signaling pathways are proposed to the underlying mechanism of these findings.	puerarin	15-23	AKT serine/threonine kinase 1	Rattus norvegicus	229-232
32243976-3	2020	Photo-crosslinked gelatin hydrogel (GelMA) loaded with Puerarin (Pue) regulate inflammation by inhibiting the aggregation of neutrophils and eosinophils, simultaneously intervene the matrix regenerating/remodeling via TGF-beta/MMPs pathway to repair the fascia of pelvic floor in rabbit models (POP model).	puerarin	55-63	transforming growth factor alpha	Homo sapiens	218-226
32243976-3	2020	Photo-crosslinked gelatin hydrogel (GelMA) loaded with Puerarin (Pue) regulate inflammation by inhibiting the aggregation of neutrophils and eosinophils, simultaneously intervene the matrix regenerating/remodeling via TGF-beta/MMPs pathway to repair the fascia of pelvic floor in rabbit models (POP model).	puerarin	55-63	matrix metallopeptidase 2	Homo sapiens	227-231
32243976-3	2020	Photo-crosslinked gelatin hydrogel (GelMA) loaded with Puerarin (Pue) regulate inflammation by inhibiting the aggregation of neutrophils and eosinophils, simultaneously intervene the matrix regenerating/remodeling via TGF-beta/MMPs pathway to repair the fascia of pelvic floor in rabbit models (POP model).	puerarin	55-58	transforming growth factor alpha	Homo sapiens	218-226
32243976-3	2020	Photo-crosslinked gelatin hydrogel (GelMA) loaded with Puerarin (Pue) regulate inflammation by inhibiting the aggregation of neutrophils and eosinophils, simultaneously intervene the matrix regenerating/remodeling via TGF-beta/MMPs pathway to repair the fascia of pelvic floor in rabbit models (POP model).	puerarin	55-58	matrix metallopeptidase 2	Homo sapiens	227-231
32457606-0	2020	Puerarin Increases Survival and Protects Against Organ Injury by Suppressing NF-kappaB/JNK Signaling in Experimental Sepsis.	puerarin	0-8	mitogen-activated protein kinase 8	Mus musculus	87-90
32457606-7	2020	In vitro, puerarin inhibited LPS-induced inflammation in LO2 hepatocytes, prevented TNF-alpha-mediated cell apoptosis and promoted an M2 phenotype revealed by M2 marker IL-10 and Arginase-1 (Arg-1) in LPS challenged Raw 264.7 macrophages, through the inhibition of TLR4/NF-kappaB/JNK pathway.	puerarin	10-18	tumor necrosis factor	Mus musculus	84-93
32457606-7	2020	In vitro, puerarin inhibited LPS-induced inflammation in LO2 hepatocytes, prevented TNF-alpha-mediated cell apoptosis and promoted an M2 phenotype revealed by M2 marker IL-10 and Arginase-1 (Arg-1) in LPS challenged Raw 264.7 macrophages, through the inhibition of TLR4/NF-kappaB/JNK pathway.	puerarin	10-18	interleukin 10	Mus musculus	169-174
32457606-7	2020	In vitro, puerarin inhibited LPS-induced inflammation in LO2 hepatocytes, prevented TNF-alpha-mediated cell apoptosis and promoted an M2 phenotype revealed by M2 marker IL-10 and Arginase-1 (Arg-1) in LPS challenged Raw 264.7 macrophages, through the inhibition of TLR4/NF-kappaB/JNK pathway.	puerarin	10-18	arginase, liver	Mus musculus	179-189
32457606-7	2020	In vitro, puerarin inhibited LPS-induced inflammation in LO2 hepatocytes, prevented TNF-alpha-mediated cell apoptosis and promoted an M2 phenotype revealed by M2 marker IL-10 and Arginase-1 (Arg-1) in LPS challenged Raw 264.7 macrophages, through the inhibition of TLR4/NF-kappaB/JNK pathway.	puerarin	10-18	arginase, liver	Mus musculus	191-196
32457606-7	2020	In vitro, puerarin inhibited LPS-induced inflammation in LO2 hepatocytes, prevented TNF-alpha-mediated cell apoptosis and promoted an M2 phenotype revealed by M2 marker IL-10 and Arginase-1 (Arg-1) in LPS challenged Raw 264.7 macrophages, through the inhibition of TLR4/NF-kappaB/JNK pathway.	puerarin	10-18	toll-like receptor 4	Mus musculus	265-269
32457606-7	2020	In vitro, puerarin inhibited LPS-induced inflammation in LO2 hepatocytes, prevented TNF-alpha-mediated cell apoptosis and promoted an M2 phenotype revealed by M2 marker IL-10 and Arginase-1 (Arg-1) in LPS challenged Raw 264.7 macrophages, through the inhibition of TLR4/NF-kappaB/JNK pathway.	puerarin	10-18	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	270-279
32457606-7	2020	In vitro, puerarin inhibited LPS-induced inflammation in LO2 hepatocytes, prevented TNF-alpha-mediated cell apoptosis and promoted an M2 phenotype revealed by M2 marker IL-10 and Arginase-1 (Arg-1) in LPS challenged Raw 264.7 macrophages, through the inhibition of TLR4/NF-kappaB/JNK pathway.	puerarin	10-18	mitogen-activated protein kinase 8	Mus musculus	280-283
32006903-0	2020	Chronopharmacological targeting of Rev-erbalpha by puerarin alleviates hyperhomocysteinemia in mice.	puerarin	51-59	nuclear receptor subfamily 1, group D, member 1	Mus musculus	35-47
32006903-4	2020	Here, we uncovered that puerarin targeted the circadian clock protein Rev-erbalpha to alleviate hyperhomocysteinemia in mice in a circadian time-dependent manner.	puerarin	24-32	nuclear receptor subfamily 1, group D, member 1	Mus musculus	70-82
32006903-5	2020	We first identified puerarin as an antagonist of Rev-erbalpha based on luciferase reporter, Gal4 co-transfection and target gene expression assays.	puerarin	20-28	nuclear receptor subfamily 1, group D, member 1	Mus musculus	49-61
32006903-5	2020	We first identified puerarin as an antagonist of Rev-erbalpha based on luciferase reporter, Gal4 co-transfection and target gene expression assays.	puerarin	20-28	lectin, galactose binding, soluble 4	Mus musculus	92-96
32006903-6	2020	Consistent with an antagonistic effect, puerarin induced mRNA and protein expressions of Bhmt, Cbs and Cth (three enzymes involved in homocysteine catabolism and known targets of Rev-erbalpha) in Hepa-1c1c7 cells.	puerarin	40-48	betaine-homocysteine methyltransferase	Mus musculus	89-93
32006903-6	2020	Consistent with an antagonistic effect, puerarin induced mRNA and protein expressions of Bhmt, Cbs and Cth (three enzymes involved in homocysteine catabolism and known targets of Rev-erbalpha) in Hepa-1c1c7 cells.	puerarin	40-48	cystathionine beta-synthase	Mus musculus	95-98
32006903-6	2020	Consistent with an antagonistic effect, puerarin induced mRNA and protein expressions of Bhmt, Cbs and Cth (three enzymes involved in homocysteine catabolism and known targets of Rev-erbalpha) in Hepa-1c1c7 cells.	puerarin	40-48	nuclear receptor subfamily 1, group D, member 1	Mus musculus	179-191
32006903-7	2020	These induction effects of puerarin were lost in Rev-erbalpha-deficient cells.	puerarin	27-35	nuclear receptor subfamily 1, group D, member 1	Mus musculus	49-61
32006903-10	2020	Moreover, puerarin dosed at ZT10 generated stronger pharmacological effects than drug dosed at ZT22 consistent with diurnally rhythmic expression of Rev-erbalpha (a high expression at ZT10 and a low expression at ZT22).	puerarin	10-18	nuclear receptor subfamily 1, group D, member 1	Mus musculus	149-161
32006903-11	2020	In conclusion, puerarin targets Rev-erbalpha to alleviate hyperhomocysteinemia in mice in a circadian time-dependent manner.	puerarin	15-23	nuclear receptor subfamily 1, group D, member 1	Mus musculus	32-44
32361558-0	2020	Puerarin ameliorates hyperglycemia in HFD diabetic mice by promoting beta-cell neogenesis via GLP-1R signaling activation.	puerarin	0-8	glucagon-like peptide 1 receptor	Mus musculus	94-100
32361558-7	2020	PURPOSE: The present study aims to investigate whether anti-diabetic effect of puerarin is dependent on promoting beta-cell neogenesis via GLP-1R signaling activation.	puerarin	79-87	glucagon-like peptide 1 receptor	Mus musculus	139-145
32361558-11	2020	Markers of new beta-cell formation (insulin, PDX1 and Ngn3) were observed in pancreatic ducts of HFD mice treated by puerarin.	puerarin	117-125	pancreatic and duodenal homeobox 1	Mus musculus	45-49
32361558-11	2020	Markers of new beta-cell formation (insulin, PDX1 and Ngn3) were observed in pancreatic ducts of HFD mice treated by puerarin.	puerarin	117-125	neurogenin 3	Mus musculus	54-58
32272553-5	2020	Puerarin administration improved intestinal morphology, cell proliferation, and barrier function, and increased Nrf2 and its downstream enzymes.	puerarin	0-8	NFE2 like bZIP transcription factor 2	Homo sapiens	112-116
32272553-6	2020	These findings indicate that the dietary supplementation of puerarin attenuates the oxidative stress involving Nrf2 signaling pathways in diquat-challenged piglets.	puerarin	60-68	NFE2 like bZIP transcription factor 2	Homo sapiens	111-115
31981944-4	2020	Administration of puerarin alleviated colon shortening, pathological damage to the colon, and myeloperoxidase (MPO) activity.	puerarin	18-26	myeloperoxidase	Mus musculus	94-109
31981944-4	2020	Administration of puerarin alleviated colon shortening, pathological damage to the colon, and myeloperoxidase (MPO) activity.	puerarin	18-26	myeloperoxidase	Mus musculus	111-114
31981944-6	2020	Moreover, puerarin showed anti-oxidative effects through the regulation of the expression of the NF-E2 p45-related factor 2 (Nrf2) pathway and antioxidant enzymes.	puerarin	10-18	nuclear factor, erythroid derived 2, like 2	Mus musculus	97-123
31981944-6	2020	Moreover, puerarin showed anti-oxidative effects through the regulation of the expression of the NF-E2 p45-related factor 2 (Nrf2) pathway and antioxidant enzymes.	puerarin	10-18	nuclear factor, erythroid derived 2, like 2	Mus musculus	125-129
32116781-2	2020	In the previous studies, we showed that puerarin exerts renoprotective effects in Streptozocin (STZ)-induced diabetic mice through activation of Sirt1 and anti-oxidative effects.	puerarin	40-48	sirtuin 1	Mus musculus	145-150
31987162-0	2020	A novel molecularly imprinted sensor based on PtCu bimetallic nanoparticle deposited on PSS functionalized graphene with peroxidase-like activity for selective determination of puerarin.	puerarin	177-185	PSS	Homo sapiens	88-91
32294699-0	2020	Puerarin inhibits hepatocellular carcinoma invasion and metastasis through miR-21-mediated PTEN/AKT signaling to suppress the epithelial-mesenchymal transition.	puerarin	0-8	microRNA 21	Homo sapiens	75-81
32294699-0	2020	Puerarin inhibits hepatocellular carcinoma invasion and metastasis through miR-21-mediated PTEN/AKT signaling to suppress the epithelial-mesenchymal transition.	puerarin	0-8	phosphatase and tensin homolog	Homo sapiens	91-95
32294699-0	2020	Puerarin inhibits hepatocellular carcinoma invasion and metastasis through miR-21-mediated PTEN/AKT signaling to suppress the epithelial-mesenchymal transition.	puerarin	0-8	AKT serine/threonine kinase 1	Homo sapiens	96-99
32294699-9	2020	Additionally, puerarin inhibited the EMT process of HCC by affecting the expression of Slug and Snail.	puerarin	14-22	snail family transcriptional repressor 2	Homo sapiens	87-91
32294699-9	2020	Additionally, puerarin inhibited the EMT process of HCC by affecting the expression of Slug and Snail.	puerarin	14-22	snail family transcriptional repressor 1	Homo sapiens	96-101
31668999-9	2020	The merit of the method is proved by discovering two new JMJD3 inhibitors: salvianic acid A and puerarin 6""-O-xyloside.	puerarin	96-119	lysine demethylase 6B	Homo sapiens	57-62
32116781-6	2020	We found that expression of heme oxygenase 1 (HMOX-1) and Sirt1 was suppressed in diabetic glomeruli but restored by puerarin treatment at both mRNA and protein levels.	puerarin	117-125	heme oxygenase 1	Mus musculus	28-44
32060654-8	2020	Combining the results mentioned above, we can conclude that the Box-Behnken design benefits the optimization for preparation of nanocrystals, and the nanocrystals could enhance the intestinal absorption of puerarin by enhanced permeability and inhibited P-gp efflux.	puerarin	206-214	phosphoglycolate phosphatase	Homo sapiens	254-258
32116781-6	2020	We found that expression of heme oxygenase 1 (HMOX-1) and Sirt1 was suppressed in diabetic glomeruli but restored by puerarin treatment at both mRNA and protein levels.	puerarin	117-125	heme oxygenase 1	Mus musculus	46-52
32116781-6	2020	We found that expression of heme oxygenase 1 (HMOX-1) and Sirt1 was suppressed in diabetic glomeruli but restored by puerarin treatment at both mRNA and protein levels.	puerarin	117-125	sirtuin 1	Mus musculus	58-63
32116781-8	2020	In conditionally immortalized mouse podocytes, puerarin inhibited HG-induced apoptosis and restored the mRNA and protein levels of HMOX-1 and Sirt1.	puerarin	47-55	heme oxygenase 1	Mus musculus	131-137
32116781-8	2020	In conditionally immortalized mouse podocytes, puerarin inhibited HG-induced apoptosis and restored the mRNA and protein levels of HMOX-1 and Sirt1.	puerarin	47-55	sirtuin 1	Mus musculus	142-147
32116781-10	2020	Knockdown of HMOX-1 and Sirt1 expression or treatment with the autophagy inhibitor 3-methyladenine abolished the protective effects of puerarin in HG-treated podocytes.	puerarin	135-143	heme oxygenase 1	Mus musculus	13-19
32116781-10	2020	Knockdown of HMOX-1 and Sirt1 expression or treatment with the autophagy inhibitor 3-methyladenine abolished the protective effects of puerarin in HG-treated podocytes.	puerarin	135-143	sirtuin 1	Mus musculus	24-29
32116781-11	2020	Taken together, these results suggest that puerarin protects podocytes from diabetes-induced injury through HMOX1 and Sirt1-mediated upregulation of autophagy, a novel mechanism explaining its renal protective effects in DN.	puerarin	43-51	heme oxygenase 1	Mus musculus	108-113
32116781-11	2020	Taken together, these results suggest that puerarin protects podocytes from diabetes-induced injury through HMOX1 and Sirt1-mediated upregulation of autophagy, a novel mechanism explaining its renal protective effects in DN.	puerarin	43-51	sirtuin 1	Mus musculus	118-123
31952126-0	2020	Simultaneous Determination of Six Isoflavones from Puerariae Lobatae Radix by CPE-HPLC and Effect of Puerarin on Tyrosinase Activity.	puerarin	101-109	tyrosinase	Homo sapiens	113-123
31786468-6	2020	Moreover, puerarin inhibited the phosphorylation of p38 and ERK mitogen-activated protein kinases (MAPKs) and signal transducer and activator of transcription 3 (STAT3), thereby protecting the retinal cells from apoptosis by suppressing cytochrome c release, caspase activation, and poly (ADP-ribose) polymerase cleavage in vivo.	puerarin	10-18	mitogen-activated protein kinase 14	Mus musculus	52-55
31786468-6	2020	Moreover, puerarin inhibited the phosphorylation of p38 and ERK mitogen-activated protein kinases (MAPKs) and signal transducer and activator of transcription 3 (STAT3), thereby protecting the retinal cells from apoptosis by suppressing cytochrome c release, caspase activation, and poly (ADP-ribose) polymerase cleavage in vivo.	puerarin	10-18	mitogen-activated protein kinase 1	Mus musculus	60-63
31786468-6	2020	Moreover, puerarin inhibited the phosphorylation of p38 and ERK mitogen-activated protein kinases (MAPKs) and signal transducer and activator of transcription 3 (STAT3), thereby protecting the retinal cells from apoptosis by suppressing cytochrome c release, caspase activation, and poly (ADP-ribose) polymerase cleavage in vivo.	puerarin	10-18	signal transducer and activator of transcription 3	Mus musculus	110-160
31786468-6	2020	Moreover, puerarin inhibited the phosphorylation of p38 and ERK mitogen-activated protein kinases (MAPKs) and signal transducer and activator of transcription 3 (STAT3), thereby protecting the retinal cells from apoptosis by suppressing cytochrome c release, caspase activation, and poly (ADP-ribose) polymerase cleavage in vivo.	puerarin	10-18	signal transducer and activator of transcription 3	Mus musculus	162-167
31786468-8	2020	The experimental data verify the protective role of puerarin in the treatment of retinal injury caused by iron overload; its possible mechanisms might be associated with regulation of iron-handling proteins, enhancement of the antioxidant capacity, and the inhibition of MAPK and STAT3 activation and the apoptotic pathways under iron overload conditions.	puerarin	52-60	mitogen-activated protein kinase 1	Mus musculus	271-275
31786468-8	2020	The experimental data verify the protective role of puerarin in the treatment of retinal injury caused by iron overload; its possible mechanisms might be associated with regulation of iron-handling proteins, enhancement of the antioxidant capacity, and the inhibition of MAPK and STAT3 activation and the apoptotic pathways under iron overload conditions.	puerarin	52-60	signal transducer and activator of transcription 3	Mus musculus	280-285
32010248-0	2020	Puerarin promotes the viability and differentiation of MC3T3-E1 cells by enhancing LC3B-mediated autophagy through downregulation of miR-204.	puerarin	0-8	microtubule-associated protein 1 light chain 3 beta	Mus musculus	83-87
32010248-0	2020	Puerarin promotes the viability and differentiation of MC3T3-E1 cells by enhancing LC3B-mediated autophagy through downregulation of miR-204.	puerarin	0-8	microRNA 204	Mus musculus	133-140
32010248-7	2020	Treatment with 1 microM puerarin for 72 h led to a significant upregulation in the expression level of microtubule-associated light chain 3 (LC3)B and Beclin1 proteins.	puerarin	24-32	microtubule-associated protein 1 light chain 3 beta	Mus musculus	103-146
32010248-7	2020	Treatment with 1 microM puerarin for 72 h led to a significant upregulation in the expression level of microtubule-associated light chain 3 (LC3)B and Beclin1 proteins.	puerarin	24-32	beclin 1, autophagy related	Mus musculus	151-158
32010248-12	2020	In the present study, the expression level of miR-204 was decreased by puerarin.	puerarin	71-79	microRNA 204	Mus musculus	46-53
32010248-14	2020	To conclude, the results of the present study suggest that puerarin promotes the viability and differentiation of MC3T3-E1 cells through autophagy, which is possibly associated with miR-204-regulated LC3B upregulation.	puerarin	59-67	microRNA 204	Mus musculus	182-189
32010248-14	2020	To conclude, the results of the present study suggest that puerarin promotes the viability and differentiation of MC3T3-E1 cells through autophagy, which is possibly associated with miR-204-regulated LC3B upregulation.	puerarin	59-67	microtubule-associated protein 1 light chain 3 beta	Mus musculus	200-204
31786468-4	2020	We found that puerarin reduced serum and retinal iron content, attenuated the pathophysiological changes and retinal iron deposition, and partially prevented the decrease of rhodopsin and retinal pigment epithelium-specific 65 kDa protein expression in retinas of iron-overload mice.	puerarin	14-22	rhodopsin	Mus musculus	174-183
31786468-4	2020	We found that puerarin reduced serum and retinal iron content, attenuated the pathophysiological changes and retinal iron deposition, and partially prevented the decrease of rhodopsin and retinal pigment epithelium-specific 65 kDa protein expression in retinas of iron-overload mice.	puerarin	14-22	retinal pigment epithelium 65	Mus musculus	188-238
31786468-5	2020	Puerarin rescued the abnormal expression of iron-handling proteins in the mouse retina and suppressed the oxidative stress induced by iron overload, as evident from the enhanced activity of superoxide dismutase, catalase, and glutathione peroxidase and decreased content of malondialdehyde.	puerarin	0-8	catalase	Mus musculus	212-220
32000461-0	2020	Puerarin inhibits angiotensin II-induced abdominal aortic aneurysm formation by promoting proliferation of vascular smooth muscle cells via NF-kB pathway.	puerarin	0-8	angiotensinogen	Homo sapiens	18-32
31952126-5	2020	Using l-tyrosine and l-dopa as substrates, the effects of puerarin on the monophenolase and diphenolase activity of tyrosinase activity were investigated by the enzyme kinetics method.	puerarin	58-66	tyrosinase	Homo sapiens	116-126
31952126-8	2020	Therefore, puerarin can be used as both a tyrosinase inhibitor and a tyrosinase activator.	puerarin	11-19	tyrosinase	Homo sapiens	42-52
31952126-8	2020	Therefore, puerarin can be used as both a tyrosinase inhibitor and a tyrosinase activator.	puerarin	11-19	tyrosinase	Homo sapiens	69-79
32106804-5	2020	Several mechanisms account for anticancer activity of puerarin which include downregulation of NF-kB signalling pathway, mTOR signalling pathway, PI3K and BCl-2 proteins and upregulation of miR-16, caspase proteins, c-Jun N terminal kinase and extracellular signal regulated kinase 1/2.	puerarin	54-62	mechanistic target of rapamycin kinase	Homo sapiens	121-125
32399049-0	2020	Puerarin Relieved Compression-Induced Apoptosis and Mitochondrial Dysfunction in Human Nucleus Pulposus Mesenchymal Stem Cells via the PI3K/Akt Pathway.	puerarin	0-8	AKT serine/threonine kinase 1	Homo sapiens	140-143
32106804-5	2020	Several mechanisms account for anticancer activity of puerarin which include downregulation of NF-kB signalling pathway, mTOR signalling pathway, PI3K and BCl-2 proteins and upregulation of miR-16, caspase proteins, c-Jun N terminal kinase and extracellular signal regulated kinase 1/2.	puerarin	54-62	BCL2 apoptosis regulator	Homo sapiens	155-160
32106804-5	2020	Several mechanisms account for anticancer activity of puerarin which include downregulation of NF-kB signalling pathway, mTOR signalling pathway, PI3K and BCl-2 proteins and upregulation of miR-16, caspase proteins, c-Jun N terminal kinase and extracellular signal regulated kinase 1/2.	puerarin	54-62	glycerophosphodiester phosphodiesterase 1	Homo sapiens	190-196
32106804-5	2020	Several mechanisms account for anticancer activity of puerarin which include downregulation of NF-kB signalling pathway, mTOR signalling pathway, PI3K and BCl-2 proteins and upregulation of miR-16, caspase proteins, c-Jun N terminal kinase and extracellular signal regulated kinase 1/2.	puerarin	54-62	mitogen-activated protein kinase 3	Homo sapiens	244-285
33200026-0	2020	Chinese herbal compounds against SARS-CoV-2: puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor.	puerarin	45-53	vitronectin	Homo sapiens	96-105
33200026-0	2020	Chinese herbal compounds against SARS-CoV-2: puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor.	puerarin	45-53	angiotensin converting enzyme 2	Homo sapiens	109-113
33200026-3	2020	Here, we identified puerarin (PubChem CID: 5281807), quercetin (PubChem CID: 5280343) and kaempferol (PubChem CID: 5280863) as potential compounds with binding activity to ACE2 by using Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP).	puerarin	20-28	angiotensin converting enzyme 2	Homo sapiens	172-176
33200026-4	2020	Molecular docking analysis showed that puerarin and quercetin exhibit good binding affinity to ACE2, which was validated by surface plasmon resonance (SPR) assay.	puerarin	39-47	angiotensin converting enzyme 2	Homo sapiens	95-99
33200026-5	2020	Furthermore, SPR-based competition assay revealed that puerarin and quercetin could significantly affect the binding of viral S-protein to ACE2 receptor.	puerarin	55-63	vitronectin	Homo sapiens	126-135
33200026-5	2020	Furthermore, SPR-based competition assay revealed that puerarin and quercetin could significantly affect the binding of viral S-protein to ACE2 receptor.	puerarin	55-63	angiotensin converting enzyme 2	Homo sapiens	139-143
33132350-3	2020	We previously demonstrated that kakkonto, a Japanese traditional herbal medicine, and its constituent puerarin induce the expression of ALDH1A1 mRNA in colonic IECs and thereby attenuate food allergy symptoms in mice.	puerarin	102-110	aldehyde dehydrogenase 1 family member A1	Homo sapiens	136-143
31847138-3	2019	Like 17beta-estradiol, puerarin also inhibited ovariectomy-induced suppression of neurogenesis in the dentate gyrus of the hippocampus (increased the number of doublecortin (DCX)-immunosuppressive cells).	puerarin	23-31	doublecortin	Mus musculus	174-177
31230510-7	2019	Discussion and conclusions: Puerarin could significantly change the pharmacokinetic profiles of triptolide in rats, and it might exert these effects through increasing the absorption of triptolide by inhibiting the activity of P-gp, or through inhibiting the metabolism of triptolide in rat liver.	puerarin	28-36	phosphoglycolate phosphatase	Rattus norvegicus	227-231
31820224-6	2019	It was inferred that puerarin formed simple eutectic mixtures with PEG 4000 and that puerarin dispersed into the carrier based on DSC and X-Ray powder diffraction (XRD).	puerarin	21-29	progestagen associated endometrial protein	Homo sapiens	67-70
31820224-7	2019	This highlights the combined advantage of PEG as a soluble polymer with TE 3D printing and provides a suitable system for rapid puerarin release.	puerarin	128-136	progestagen associated endometrial protein	Homo sapiens	42-45
31282213-0	2019	Puerarin attenuates hypoxia-resulted damages in neural stem cells by up-regulating microRNA-214.	puerarin	0-8	microRNA 214	Homo sapiens	83-95
31282213-11	2019	Hypoxia-evoked up-regulation of miR-214 was further enhanced by puerarin.	puerarin	64-72	microRNA 214	Homo sapiens	32-39
31282213-12	2019	By contrast, miR-214-deficient NSCs showed the reduction in cell viability and the facilitation in apoptosis progress after pre-treatment with puerarin and stimulation in a hypoxia circumstance.	puerarin	143-151	microRNA 214	Homo sapiens	13-20
31282213-16	2019	Molecularly, miR-214 might be implicated in the protective roles of puerarin.	puerarin	68-76	microRNA 214	Homo sapiens	13-20
31602208-0	2019	Puerarin inhibits apoptosis and inflammation in myocardial cells via PPARalpha expression in rats with chronic heart failure.	puerarin	0-8	peroxisome proliferator activated receptor alpha	Rattus norvegicus	69-78
31602208-10	2019	Additionally, puerarin decreased the levels inflammatory factors, including tumor necrosis factor alpha, interleukin (IL)-1beta and IL-6 in serum and myocardial tissue compared with the PBS group.	puerarin	14-22	tumor necrosis factor	Rattus norvegicus	76-103
31602208-10	2019	Additionally, puerarin decreased the levels inflammatory factors, including tumor necrosis factor alpha, interleukin (IL)-1beta and IL-6 in serum and myocardial tissue compared with the PBS group.	puerarin	14-22	interleukin 1 beta	Rattus norvegicus	105-127
31602208-10	2019	Additionally, puerarin decreased the levels inflammatory factors, including tumor necrosis factor alpha, interleukin (IL)-1beta and IL-6 in serum and myocardial tissue compared with the PBS group.	puerarin	14-22	interleukin 6	Rattus norvegicus	132-136
31602208-11	2019	Puerarin upregulated peroxisome proliferator-activated receptor alpha (PPARalpha) and its downstream target genes nuclear respiratory factor 1, FOS proto-oncogene, YY1 transcription factor, acetyl-coenzyme A carboxylase a, Fas cell surface death receptor, L-type pyruvate kinase and acetyl-coenzyme A dehydrogenase medium chain in myocardial cells from rats with chronic heart failure.	puerarin	0-8	peroxisome proliferator activated receptor alpha	Rattus norvegicus	71-80
31602208-11	2019	Puerarin upregulated peroxisome proliferator-activated receptor alpha (PPARalpha) and its downstream target genes nuclear respiratory factor 1, FOS proto-oncogene, YY1 transcription factor, acetyl-coenzyme A carboxylase a, Fas cell surface death receptor, L-type pyruvate kinase and acetyl-coenzyme A dehydrogenase medium chain in myocardial cells from rats with chronic heart failure.	puerarin	0-8	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	144-147
31602208-11	2019	Puerarin upregulated peroxisome proliferator-activated receptor alpha (PPARalpha) and its downstream target genes nuclear respiratory factor 1, FOS proto-oncogene, YY1 transcription factor, acetyl-coenzyme A carboxylase a, Fas cell surface death receptor, L-type pyruvate kinase and acetyl-coenzyme A dehydrogenase medium chain in myocardial cells from rats with chronic heart failure.	puerarin	0-8	YY1 transcription factor	Rattus norvegicus	164-167
31602208-12	2019	These results demonstrated that puerarin inhibited apoptosis and inflammation in myocardial cells via the PPARalpha pathway.	puerarin	32-40	peroxisome proliferator activated receptor alpha	Rattus norvegicus	106-115
31602208-13	2019	In conclusion, the present study indicated that puerarin may exhibit antiapoptotic and anti-inflammatory activity through the PPARalpha pathway in rats with chronic heart failure.	puerarin	48-56	peroxisome proliferator activated receptor alpha	Rattus norvegicus	126-135
31408784-0	2019	Puerarin protects pulmonary arteries from hypoxic injury through the BMPRII and PPARgamma signaling pathways in endothelial cells.	puerarin	0-8	bone morphogenetic protein receptor type 2	Homo sapiens	69-75
31615565-0	2019	Puerarin inhibits the osteoclastogenesis by inhibiting RANKL-dependent and -independent autophagic responses.	puerarin	0-8	TNF superfamily member 11	Homo sapiens	55-60
31251937-0	2019	FGF-2 signaling activation in the hippocampus contributes to the behavioral and cellular responses to puerarin.	puerarin	102-110	fibroblast growth factor 2	Mus musculus	0-5
31251937-8	2019	On the contrary, SU5402, an FGFR1 inhibitor, infusion into the brain could not only block the antidepressant-like effect of puerarin, but also abolish the effect of puerarin on hippocampal neurogenesis enhancement and neuroinflammation inhibition.	puerarin	124-132	fibroblast growth factor receptor 1	Mus musculus	28-33
31251937-8	2019	On the contrary, SU5402, an FGFR1 inhibitor, infusion into the brain could not only block the antidepressant-like effect of puerarin, but also abolish the effect of puerarin on hippocampal neurogenesis enhancement and neuroinflammation inhibition.	puerarin	165-173	fibroblast growth factor receptor 1	Mus musculus	28-33
31251937-9	2019	Taken together, these findings provide new insights into the mechanism that the antidepressant-like actions of puerarin require FGF-2/FGFR signaling for the regulation of neurogenesis and neuroinflammation.	puerarin	111-119	fibroblast growth factor 2	Mus musculus	128-133
31632268-3	2019	However, the underlying molecular mechanism by which puerarin interacts with receptor activator of nuclear factor kappa-B ligand (RANKL)-mediated osteoclast formation in vitro and wear particle-stimulated osteolysis in vivo has not been reported.	puerarin	53-61	TNF superfamily member 11	Homo sapiens	77-128
31632268-3	2019	However, the underlying molecular mechanism by which puerarin interacts with receptor activator of nuclear factor kappa-B ligand (RANKL)-mediated osteoclast formation in vitro and wear particle-stimulated osteolysis in vivo has not been reported.	puerarin	53-61	TNF superfamily member 11	Homo sapiens	130-135
31632268-6	2019	Additionally, puerarin inhibited RANKL-induced osteoclast activation, bone resorption ability, and F-actin ring formation in vitro as puerarin concentration increased.	puerarin	14-22	TNF superfamily member 11	Homo sapiens	33-38
31632268-6	2019	Additionally, puerarin inhibited RANKL-induced osteoclast activation, bone resorption ability, and F-actin ring formation in vitro as puerarin concentration increased.	puerarin	134-142	TNF superfamily member 11	Homo sapiens	33-38
31632268-7	2019	Furthermore, mechanistic investigation indicated that reduced RANKL-stimulated MEK/ERK/NFATc1 signaling cascades might regulate the protective effect of puerarin.	puerarin	153-161	TNF superfamily member 11	Homo sapiens	62-67
31632268-7	2019	Furthermore, mechanistic investigation indicated that reduced RANKL-stimulated MEK/ERK/NFATc1 signaling cascades might regulate the protective effect of puerarin.	puerarin	153-161	mitogen-activated protein kinase kinase 7	Homo sapiens	79-82
31632268-7	2019	Furthermore, mechanistic investigation indicated that reduced RANKL-stimulated MEK/ERK/NFATc1 signaling cascades might regulate the protective effect of puerarin.	puerarin	153-161	mitogen-activated protein kinase 1	Homo sapiens	83-86
31632268-7	2019	Furthermore, mechanistic investigation indicated that reduced RANKL-stimulated MEK/ERK/NFATc1 signaling cascades might regulate the protective effect of puerarin.	puerarin	153-161	nuclear factor of activated T cells 1	Homo sapiens	87-93
31615565-7	2019	Importantly, overexpression of autophagic genes Atg5, Atg7 and BECN1 reversed Puerarin-inhibited OCP autophagy and proliferation.	puerarin	78-86	autophagy related 5	Homo sapiens	48-52
31615565-7	2019	Importantly, overexpression of autophagic genes Atg5, Atg7 and BECN1 reversed Puerarin-inhibited OCP autophagy and proliferation.	puerarin	78-86	autophagy related 7	Homo sapiens	54-58
31615565-7	2019	Importantly, overexpression of autophagic genes Atg5, Atg7 and BECN1 reversed Puerarin-inhibited OCP autophagy and proliferation.	puerarin	78-86	beclin 1	Homo sapiens	63-68
31615565-8	2019	What"s more, RANKL could promote the autography of OCPs, which was recovered by Puerarin treatment.	puerarin	80-88	TNF superfamily member 11	Homo sapiens	13-18
31615565-9	2019	Interestingly, different from single-Puerarin treatment, we found that in the presence of RANKL, only BECN1 overexpression significantly reversed Puerarin-inhibited osteoclast differentiation and OCP autophagy.	puerarin	146-154	beclin 1	Homo sapiens	102-107
31615565-10	2019	CONCLUSION: In conclusion, Puerarin could inhibit the OCP autophagy in the presence or absence of RANKL, which blocked the OCP proliferation and osteoclast differentiation respectively.	puerarin	27-35	TNF superfamily member 11	Homo sapiens	98-103
31615565-11	2019	Moreover, BECN1 plays an essential role in Puerarin-inhibited osteoclastogenesis.	puerarin	43-51	beclin 1	Homo sapiens	10-15
31408784-0	2019	Puerarin protects pulmonary arteries from hypoxic injury through the BMPRII and PPARgamma signaling pathways in endothelial cells.	puerarin	0-8	peroxisome proliferator activated receptor gamma	Homo sapiens	80-89
31408784-9	2019	Puerarin increases NO and decreases ET-1 to prevent the imbalance between vasoactive substances induced by hypoxia in HPAECs.	puerarin	0-8	endothelin 1	Homo sapiens	36-40
31408784-11	2019	The results from the Western blot show that Puerarin activates the BMPRII/Smad and PPARgamma/PI3K/Akt signaling pathways.	puerarin	44-52	bone morphogenetic protein receptor type 2	Homo sapiens	67-73
31408784-11	2019	The results from the Western blot show that Puerarin activates the BMPRII/Smad and PPARgamma/PI3K/Akt signaling pathways.	puerarin	44-52	peroxisome proliferator activated receptor gamma	Homo sapiens	83-92
31408784-12	2019	CONCLUSION: In conclusion, Puerarin protects HPAECs from hypoxic injury through the inhibition of oxidative stress and the activation of the BMPRII and PPARgamma signaling pathways.	puerarin	27-35	bone morphogenetic protein receptor type 2	Homo sapiens	141-147
31408784-12	2019	CONCLUSION: In conclusion, Puerarin protects HPAECs from hypoxic injury through the inhibition of oxidative stress and the activation of the BMPRII and PPARgamma signaling pathways.	puerarin	27-35	peroxisome proliferator activated receptor gamma	Homo sapiens	152-161
31235250-0	2019	The isoflavone puerarin induces Foxp3+ regulatory T cells by augmenting retinoic acid production, thereby inducing mucosal immune tolerance in a murine food allergy model.	puerarin	15-23	forkhead box P3	Mus musculus	32-37
31233753-4	2019	In network data, the most significant targets of tyrosyl-DNA phosphodiesterase-1 (TDP1), aldehyde dehydrogenase 1 family member A-1 (ALDH1A1), muscleblind like splicing regulator 1 (MBNL1), aldehyde dehydrogenase-2 (ALDH2), and nicotinamide adenine dinucleotide (HPGD) were screened and defined in anti-CRC effects exerted by puerarin.	puerarin	326-334	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	49-80
31233753-4	2019	In network data, the most significant targets of tyrosyl-DNA phosphodiesterase-1 (TDP1), aldehyde dehydrogenase 1 family member A-1 (ALDH1A1), muscleblind like splicing regulator 1 (MBNL1), aldehyde dehydrogenase-2 (ALDH2), and nicotinamide adenine dinucleotide (HPGD) were screened and defined in anti-CRC effects exerted by puerarin.	puerarin	326-334	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	82-86
31233753-4	2019	In network data, the most significant targets of tyrosyl-DNA phosphodiesterase-1 (TDP1), aldehyde dehydrogenase 1 family member A-1 (ALDH1A1), muscleblind like splicing regulator 1 (MBNL1), aldehyde dehydrogenase-2 (ALDH2), and nicotinamide adenine dinucleotide (HPGD) were screened and defined in anti-CRC effects exerted by puerarin.	puerarin	326-334	muscleblind like splicing regulator 1	Homo sapiens	143-180
31233753-9	2019	Further, down-regulated expressions of TDP1, ALDH1A1 and proliferating cell nuclear antigen (PCNA) were detected in puerarin-treated CRC cells.	puerarin	116-124	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	39-43
31233753-9	2019	Further, down-regulated expressions of TDP1, ALDH1A1 and proliferating cell nuclear antigen (PCNA) were detected in puerarin-treated CRC cells.	puerarin	116-124	aldehyde dehydrogenase 1 family member A1	Homo sapiens	45-52
31233753-9	2019	Further, down-regulated expressions of TDP1, ALDH1A1 and proliferating cell nuclear antigen (PCNA) were detected in puerarin-treated CRC cells.	puerarin	116-124	proliferating cell nuclear antigen	Homo sapiens	57-91
31233753-9	2019	Further, down-regulated expressions of TDP1, ALDH1A1 and proliferating cell nuclear antigen (PCNA) were detected in puerarin-treated CRC cells.	puerarin	116-124	proliferating cell nuclear antigen	Homo sapiens	93-97
31273855-10	2019	Puerarin attenuated the PARP-1 expression in HFHS-fed mice, and PJ34, the PARP inhibitor, could mimic these protections of puerarin.	puerarin	0-8	poly (ADP-ribose) polymerase family, member 1	Mus musculus	24-30
31273855-10	2019	Puerarin attenuated the PARP-1 expression in HFHS-fed mice, and PJ34, the PARP inhibitor, could mimic these protections of puerarin.	puerarin	0-8	poly (ADP-ribose) polymerase family, member 1	Mus musculus	24-28
29790819-8	2019	The Caco-2 cell transwell experiments indicated that AS-IV could increase the efflux ratio of puerarin from 1.81 to 2.79 through inducing the activity of P-gp.	puerarin	94-102	phosphoglycolate phosphatase	Homo sapiens	154-158
29790819-9	2019	In conclusion, these results indicated that AS-IV could affect the pharmacokinetics of puerarin, possibly by decreasing the systemic exposure of puerarin by inducing the activity of P-gp.	puerarin	87-95	phosphoglycolate phosphatase	Rattus norvegicus	182-186
30173622-8	2019	In conclusion, these results indicated that verapamil could affect the pharmacokinetics of puerarin, possibly by increasing the systemic exposure of puerarin by inhibiting the activity of P-gp.	puerarin	91-99	phosphoglycolate phosphatase	Homo sapiens	188-192
31235250-10	2019	The proportions of Foxp3+CD4+ cells and CD103+CD11c+ dendritic cells (DCs) were significantly higher among the colonic lamina propria (cLP) cells of puerarin-treated FA mice than among those of untreated FA mice.	puerarin	149-157	forkhead box P3	Homo sapiens	19-24
31235250-10	2019	The proportions of Foxp3+CD4+ cells and CD103+CD11c+ dendritic cells (DCs) were significantly higher among the colonic lamina propria (cLP) cells of puerarin-treated FA mice than among those of untreated FA mice.	puerarin	149-157	CD4 molecule	Homo sapiens	25-28
31235250-10	2019	The proportions of Foxp3+CD4+ cells and CD103+CD11c+ dendritic cells (DCs) were significantly higher among the colonic lamina propria (cLP) cells of puerarin-treated FA mice than among those of untreated FA mice.	puerarin	149-157	integrin subunit alpha E	Homo sapiens	40-45
31235250-10	2019	The proportions of Foxp3+CD4+ cells and CD103+CD11c+ dendritic cells (DCs) were significantly higher among the colonic lamina propria (cLP) cells of puerarin-treated FA mice than among those of untreated FA mice.	puerarin	149-157	integrin subunit alpha X	Homo sapiens	46-51
31258646-0	2019	Puerarin alleviates liver fibrosis via inhibition of the ERK1/2 signaling pathway in thioacetamide-induced hepatic fibrosis in rats.	puerarin	0-8	mitogen activated protein kinase 3	Rattus norvegicus	57-63
31085237-5	2019	Puerarin also prevented the trans-differentiation of VSMCs into osteoblast-like cells, indicated by down-regulation of bone-related genes including Runx2 and BMP2.	puerarin	0-8	RUNX family transcription factor 2	Rattus norvegicus	148-153
31085237-5	2019	Puerarin also prevented the trans-differentiation of VSMCs into osteoblast-like cells, indicated by down-regulation of bone-related genes including Runx2 and BMP2.	puerarin	0-8	bone morphogenetic protein 2	Rattus norvegicus	158-162
31085237-7	2019	Puerarin treatment significantly prevented mineral deposition in rat aortas and down-regulated the expression of Runx2 and BMP2.	puerarin	0-8	RUNX family transcription factor 2	Rattus norvegicus	113-118
31085237-7	2019	Puerarin treatment significantly prevented mineral deposition in rat aortas and down-regulated the expression of Runx2 and BMP2.	puerarin	0-8	bone morphogenetic protein 2	Rattus norvegicus	123-127
31085237-9	2019	The levels of IL-1beta were remarkably increased in both calcified VSMCs and aortas of uremic rats, while puerarin treatment markedly decreased the expression of IL-1beta.	puerarin	106-114	interleukin 1 beta	Rattus norvegicus	162-170
31085237-10	2019	In addition, we found that puerarin reduced IL-1beta possibly through targeting NLRP3/Caspase1/IL-1beta and NF-kappaB signaling pathways and inhibiting the generation of reactive oxygen species.	puerarin	27-35	interleukin 1 beta	Rattus norvegicus	44-52
31085237-10	2019	In addition, we found that puerarin reduced IL-1beta possibly through targeting NLRP3/Caspase1/IL-1beta and NF-kappaB signaling pathways and inhibiting the generation of reactive oxygen species.	puerarin	27-35	NLR family, pyrin domain containing 3	Rattus norvegicus	80-85
31085237-10	2019	In addition, we found that puerarin reduced IL-1beta possibly through targeting NLRP3/Caspase1/IL-1beta and NF-kappaB signaling pathways and inhibiting the generation of reactive oxygen species.	puerarin	27-35	caspase 1	Rattus norvegicus	86-94
31085237-10	2019	In addition, we found that puerarin reduced IL-1beta possibly through targeting NLRP3/Caspase1/IL-1beta and NF-kappaB signaling pathways and inhibiting the generation of reactive oxygen species.	puerarin	27-35	interleukin 1 beta	Rattus norvegicus	95-103
31054509-0	2019	Puerarin alleviates streptozotocin (STZ)-induced osteoporosis in rats through suppressing inflammation and apoptosis via HDAC1/HDAC3 signaling.	puerarin	0-8	histone deacetylase 1	Rattus norvegicus	121-126
31054509-0	2019	Puerarin alleviates streptozotocin (STZ)-induced osteoporosis in rats through suppressing inflammation and apoptosis via HDAC1/HDAC3 signaling.	puerarin	0-8	histone deacetylase 3	Rattus norvegicus	127-132
31054509-5	2019	PU administration markedly attenuated bone loss and tartarate-resistant acid phosphatase (TRAP) activity in STZ-induced rats.	puerarin	0-2	acid phosphatase 5, tartrate resistant	Rattus norvegicus	52-88
31054509-5	2019	PU administration markedly attenuated bone loss and tartarate-resistant acid phosphatase (TRAP) activity in STZ-induced rats.	puerarin	0-2	acid phosphatase 5, tartrate resistant	Rattus norvegicus	90-94
31054509-10	2019	Additionally, STZ injection increased histone deacetylase (HDAC)-1 and -3 expressions in femoral heads of rats, which were relieved by PU treatment.	puerarin	135-137	histone deacetylase 1	Rattus norvegicus	38-73
31054509-12	2019	Inflammation and apoptosis were exacerbated by HDAC1/3 over-expression, which were markedly diminished by PU treatment.	puerarin	106-108	histone deacetylase 1	Rattus norvegicus	47-54
31054509-14	2019	Collectively, our data illustrated that PU is a potential therapeutic option to prevent diabetic osteoporosis by inhibiting HDAC1/HDAC3 signaling.	puerarin	40-42	histone deacetylase 1	Rattus norvegicus	124-129
31054509-14	2019	Collectively, our data illustrated that PU is a potential therapeutic option to prevent diabetic osteoporosis by inhibiting HDAC1/HDAC3 signaling.	puerarin	40-42	histone deacetylase 3	Rattus norvegicus	130-135
31173182-9	2019	Furthermore, puerarin administration decreased the expression levels of retinal vascular endothelial growth factor and interleukin-1beta and increased the mRNA expression levels of Nrf2 and HO-1, thus inhibiting oxidative stress.	puerarin	13-21	interleukin 1 beta	Rattus norvegicus	119-136
31173182-9	2019	Furthermore, puerarin administration decreased the expression levels of retinal vascular endothelial growth factor and interleukin-1beta and increased the mRNA expression levels of Nrf2 and HO-1, thus inhibiting oxidative stress.	puerarin	13-21	NFE2 like bZIP transcription factor 2	Rattus norvegicus	181-185
31173182-9	2019	Furthermore, puerarin administration decreased the expression levels of retinal vascular endothelial growth factor and interleukin-1beta and increased the mRNA expression levels of Nrf2 and HO-1, thus inhibiting oxidative stress.	puerarin	13-21	heme oxygenase 1	Rattus norvegicus	190-194
31173182-10	2019	The present findings suggested that puerarin had hypoglycemic effects and that it prevented cataract development and progression in diabetic rats by reducing oxidative stress through the Nrf2/HO-1 signaling pathway.	puerarin	36-44	NFE2 like bZIP transcription factor 2	Rattus norvegicus	187-191
31173182-10	2019	The present findings suggested that puerarin had hypoglycemic effects and that it prevented cataract development and progression in diabetic rats by reducing oxidative stress through the Nrf2/HO-1 signaling pathway.	puerarin	36-44	heme oxygenase 1	Rattus norvegicus	192-196
31258646-13	2019	These findings suggest that treatment with puerarin may reduce HSC activation and alleviate extracellular matrix protein expression levels by inhibiting the TGF-beta/ERK1/2 pathway in liver fibrosis.	puerarin	43-51	transforming growth factor, beta 1	Rattus norvegicus	157-165
31258646-13	2019	These findings suggest that treatment with puerarin may reduce HSC activation and alleviate extracellular matrix protein expression levels by inhibiting the TGF-beta/ERK1/2 pathway in liver fibrosis.	puerarin	43-51	mitogen activated protein kinase 3	Rattus norvegicus	166-172
31258692-0	2019	Puerarin suppresses cell growth and migration in HPV-positive cervical cancer cells by inhibiting the PI3K/mTOR signaling pathway.	puerarin	0-8	mechanistic target of rapamycin kinase	Homo sapiens	107-111
31258692-7	2019	In addition, it was observed that Puerarin significantly enhanced caspase-3/9 activities and significantly increased B-cell lymphoma 2-asscoiate X protein expression in HeLa cells.	puerarin	34-42	caspase 3	Homo sapiens	66-75
31258692-8	2019	Puerarin suppressed phosphatidylinositol-3 kinase (PI3K), phosphorylated (p)-protein kinase B (Akt) and p-mammalian target of rapamycin (mTOR) protein expression in HeLa cells.	puerarin	0-8	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	20-49
31258692-8	2019	Puerarin suppressed phosphatidylinositol-3 kinase (PI3K), phosphorylated (p)-protein kinase B (Akt) and p-mammalian target of rapamycin (mTOR) protein expression in HeLa cells.	puerarin	0-8	AKT serine/threonine kinase 1	Homo sapiens	95-98
31258692-8	2019	Puerarin suppressed phosphatidylinositol-3 kinase (PI3K), phosphorylated (p)-protein kinase B (Akt) and p-mammalian target of rapamycin (mTOR) protein expression in HeLa cells.	puerarin	0-8	mechanistic target of rapamycin kinase	Homo sapiens	104-135
31258692-8	2019	Puerarin suppressed phosphatidylinositol-3 kinase (PI3K), phosphorylated (p)-protein kinase B (Akt) and p-mammalian target of rapamycin (mTOR) protein expression in HeLa cells.	puerarin	0-8	mechanistic target of rapamycin kinase	Homo sapiens	137-141
31258692-9	2019	These results indicate that Puerarin induces apoptosis in HPV-positive HeLa cervical cancer cells via inhibiting PI3K/Akt/mTOR signaling.	puerarin	28-36	AKT serine/threonine kinase 1	Homo sapiens	118-121
31258692-9	2019	These results indicate that Puerarin induces apoptosis in HPV-positive HeLa cervical cancer cells via inhibiting PI3K/Akt/mTOR signaling.	puerarin	28-36	mechanistic target of rapamycin kinase	Homo sapiens	122-126
30906451-0	2019	Puerarin pre-conditioning on the expression levels of CK-MB, cTnI and inflammatory factors in patients undergoing cardiac valve replacement.	puerarin	0-8	troponin I3, cardiac type	Homo sapiens	61-65
30896685-9	2019	The cytotoxicity test revealed that the modified puerarin derivatives, PPue, exhibited good biocompatibility even at large doses of 100 mug mL-1 and the PPue@PTX NPs still maintained the excellent anti-cancer effect of PTX.	puerarin	49-57	L1 cell adhesion molecule	Mus musculus	140-144
31115556-0	2019	MicroRNA-21 contributes to the puerarin-induced cardioprotection via suppression of apoptosis and oxidative stress in a cell model of ischemia/reperfusion injury.	puerarin	31-39	microRNA 21	Rattus norvegicus	0-11
31115556-4	2019	Therefore, the purpose of the present study was to demonstrate the involvement of miR-21 in the cardioprotective mechanisms of puerarin using a cell model of I/R injury, generated by culturing rat H9c2 cardiomyocytes under H/R conditions.	puerarin	127-135	microRNA 21	Rattus norvegicus	82-88
31115556-5	2019	The results demonstrated that pre-treatment with puerarin significantly increased cell viability, decreased lactate dehydrogenase activity and upregulated miR-21 expression in H/R-treated H9c2 cells.	puerarin	49-57	microRNA 21	Rattus norvegicus	155-161
31115556-6	2019	Transfection of an miR-21 inhibitor led to an increase in H/R-induced cytotoxicity and reversed the protective effects of puerarin.	puerarin	122-130	microRNA 21	Rattus norvegicus	19-25
31115556-7	2019	Additionally, miR-21 inhibition attenuated the puerarin-induced decrease in the rate of apoptosis, caspase-3 activity and the expression of apoptosis regulator Bax, and increased apoptosis regulator Bcl-2 expression, under H/R conditions.	puerarin	47-55	microRNA 21	Rattus norvegicus	14-20
31115556-7	2019	Additionally, miR-21 inhibition attenuated the puerarin-induced decrease in the rate of apoptosis, caspase-3 activity and the expression of apoptosis regulator Bax, and increased apoptosis regulator Bcl-2 expression, under H/R conditions.	puerarin	47-55	caspase 3	Rattus norvegicus	99-108
31115556-7	2019	Additionally, miR-21 inhibition attenuated the puerarin-induced decrease in the rate of apoptosis, caspase-3 activity and the expression of apoptosis regulator Bax, and increased apoptosis regulator Bcl-2 expression, under H/R conditions.	puerarin	47-55	BCL2, apoptosis regulator	Rattus norvegicus	199-204
31115556-8	2019	Furthermore, puerarin mitigated H/R-induced oxidative stress as evidenced by the decrease in endogenous reactive oxygen species production, malondialdehyde content and NADPH oxidase 2 expression, and enhanced the antioxidative defense system as illustrated by the increase in superoxide dismutase activity, catalase and glutathione peroxidase levels.	puerarin	13-21	cytochrome b-245 beta chain	Rattus norvegicus	168-183
31115556-8	2019	Furthermore, puerarin mitigated H/R-induced oxidative stress as evidenced by the decrease in endogenous reactive oxygen species production, malondialdehyde content and NADPH oxidase 2 expression, and enhanced the antioxidative defense system as illustrated by the increase in superoxide dismutase activity, catalase and glutathione peroxidase levels.	puerarin	13-21	catalase	Rattus norvegicus	307-315
31115556-11	2019	Taken together, the results suggested that miR-21 mediated the cardioprotective effects of puerarin against myocardial H/R injury by inhibiting apoptosis and oxidative stress.	puerarin	91-99	microRNA 21	Rattus norvegicus	43-49
31162246-0	2019	Puerarin Decreases Collagen Secretion in AngII-Induced Atrial Fibroblasts Through Inhibiting Autophagy Via the JNK-Akt-mTOR Signaling Pathway.	puerarin	0-8	angiotensinogen	Homo sapiens	41-46
31162246-0	2019	Puerarin Decreases Collagen Secretion in AngII-Induced Atrial Fibroblasts Through Inhibiting Autophagy Via the JNK-Akt-mTOR Signaling Pathway.	puerarin	0-8	mitogen-activated protein kinase 8	Homo sapiens	111-114
31162246-0	2019	Puerarin Decreases Collagen Secretion in AngII-Induced Atrial Fibroblasts Through Inhibiting Autophagy Via the JNK-Akt-mTOR Signaling Pathway.	puerarin	0-8	AKT serine/threonine kinase 1	Homo sapiens	115-118
31162246-0	2019	Puerarin Decreases Collagen Secretion in AngII-Induced Atrial Fibroblasts Through Inhibiting Autophagy Via the JNK-Akt-mTOR Signaling Pathway.	puerarin	0-8	mechanistic target of rapamycin kinase	Homo sapiens	119-123
31162246-3	2019	In this study, we investigated the autophagy pathway and molecular changes in angiotensin II (AngII)-stimulated atrial fibroblasts in response to puerarin treatment.	puerarin	146-154	angiotensinogen	Homo sapiens	78-92
31162246-3	2019	In this study, we investigated the autophagy pathway and molecular changes in angiotensin II (AngII)-stimulated atrial fibroblasts in response to puerarin treatment.	puerarin	146-154	angiotensinogen	Homo sapiens	94-99
31162246-9	2019	Furthermore, phosphorylation of JNK was down-regulated in response to puerarin, whereas phosphorylation of Akt and mammalian target of rapamycin (mTOR) was upregulated.	puerarin	70-78	mitogen-activated protein kinase 8	Homo sapiens	32-35
31208179-8	2019	Results: The addition of puerarin significantly increased adipogenesis of bovine preadipocytes and enhanced the mRNA and protein level expression of PPARgamma (p&lt;0.01).	puerarin	25-33	peroxisome proliferator activated receptor gamma	Bos taurus	149-158
31208179-9	2019	The expression of P-Akt increased after adipogenic hormonal induction, whereas puerarin significantly increased PPARgamma expression by promoting the Akt signaling component, P-Akt.	puerarin	79-87	peroxisome proliferator activated receptor gamma	Bos taurus	112-121
30672062-0	2019	Exploring adverse effects of puerarin on catalase by multiple spectroscopic investigations and docking studies in vitro.	puerarin	29-37	catalase	Homo sapiens	41-49
30672062-2	2019	In this study, toxic mechanisms of puerarin on the structure and function of catalase were studied by multiple spectroscopic techniques, isothermal titration calorimetric measurement, and molecular docking methods in vitro.	puerarin	35-43	catalase	Homo sapiens	77-85
30672062-3	2019	Results showed puerarin could inhibit the activity of catalase due to direct interactions between puerarin and catalase, resulting in conformational and functional changes of the enzyme.	puerarin	15-23	catalase	Homo sapiens	54-62
30672062-3	2019	Results showed puerarin could inhibit the activity of catalase due to direct interactions between puerarin and catalase, resulting in conformational and functional changes of the enzyme.	puerarin	15-23	catalase	Homo sapiens	111-119
30672062-4	2019	To be specific, puerarin statically quenched catalase fluorescence, bound into the active site channel of catalase, hindered the path of the catalytic substrate (H2 O2 ), affected its skeleton conformation and secondary structure, and interacted with the enzymatically related residues through hydrophobic interactions (DeltaH &gt; 0 and DeltaS &gt; 0) spontaneously (DeltaG &lt; 0).	puerarin	16-24	catalase	Homo sapiens	45-53
30672062-4	2019	To be specific, puerarin statically quenched catalase fluorescence, bound into the active site channel of catalase, hindered the path of the catalytic substrate (H2 O2 ), affected its skeleton conformation and secondary structure, and interacted with the enzymatically related residues through hydrophobic interactions (DeltaH &gt; 0 and DeltaS &gt; 0) spontaneously (DeltaG &lt; 0).	puerarin	16-24	catalase	Homo sapiens	106-114
30347204-0	2019	Puerarin reverses cadmium-induced lysosomal dysfunction in primary rat proximal tubular cells via inhibiting Nrf2 pathway.	puerarin	0-8	NFE2 like bZIP transcription factor 2	Rattus norvegicus	109-113
30347204-7	2019	Cd-stimulated Nrf2 nuclear translocation and subsequent elevated expression of Nrf2-downstream targets were significantly inhibited by PU treatment.	puerarin	135-137	NFE2 like bZIP transcription factor 2	Rattus norvegicus	14-18
30347204-7	2019	Cd-stimulated Nrf2 nuclear translocation and subsequent elevated expression of Nrf2-downstream targets were significantly inhibited by PU treatment.	puerarin	135-137	NFE2 like bZIP transcription factor 2	Rattus norvegicus	79-83
30347204-9	2019	In conclusion, these observations indicate that PU alleviates Cd-induced cytotoxicity in rPT cells through restoring autophagy, blocking LMP and inhibiting Nrf2 pathway, which is intimately related with its antioxidant activity.	puerarin	48-50	NFE2 like bZIP transcription factor 2	Rattus norvegicus	156-160
30906451-10	2019	Puerarin preconditioning can reduce the NF-kappaB activation and the overexpression of IL-6 and IL-8 in neutrophils, and it inhibits the release of myocardial enzyme cTnI and CK-MB reflecting myocardial cell protection.	puerarin	0-8	nuclear factor kappa B subunit 1	Homo sapiens	40-49
30906451-10	2019	Puerarin preconditioning can reduce the NF-kappaB activation and the overexpression of IL-6 and IL-8 in neutrophils, and it inhibits the release of myocardial enzyme cTnI and CK-MB reflecting myocardial cell protection.	puerarin	0-8	interleukin 6	Homo sapiens	87-91
30906451-10	2019	Puerarin preconditioning can reduce the NF-kappaB activation and the overexpression of IL-6 and IL-8 in neutrophils, and it inhibits the release of myocardial enzyme cTnI and CK-MB reflecting myocardial cell protection.	puerarin	0-8	C-X-C motif chemokine ligand 8	Homo sapiens	96-100
30906451-10	2019	Puerarin preconditioning can reduce the NF-kappaB activation and the overexpression of IL-6 and IL-8 in neutrophils, and it inhibits the release of myocardial enzyme cTnI and CK-MB reflecting myocardial cell protection.	puerarin	0-8	troponin I3, cardiac type	Homo sapiens	166-170
30906451-6	2019	We found the mean serum cTnI and CK-MB levels of the puerarin group tended to decrease with time.	puerarin	53-61	troponin I3, cardiac type	Homo sapiens	24-28
30906451-7	2019	The positive rates of NF-kappaB, IL-6 and IL-8 at different time-points were lower in patients of the puerarin group than in those of the control group (and the differences at T3 were statistically significant).	puerarin	102-110	nuclear factor kappa B subunit 1	Homo sapiens	22-31
30906451-7	2019	The positive rates of NF-kappaB, IL-6 and IL-8 at different time-points were lower in patients of the puerarin group than in those of the control group (and the differences at T3 were statistically significant).	puerarin	102-110	interleukin 6	Homo sapiens	33-37
30906451-7	2019	The positive rates of NF-kappaB, IL-6 and IL-8 at different time-points were lower in patients of the puerarin group than in those of the control group (and the differences at T3 were statistically significant).	puerarin	102-110	C-X-C motif chemokine ligand 8	Homo sapiens	42-46
30385134-0	2019	Puerarin inhibits hyperglycemia-induced inter-endothelial junction through suppressing endothelial Nlrp3 inflammasome activation via ROS-dependent oxidative pathway.	puerarin	0-8	NLR family, pyrin domain containing 3	Mus musculus	99-104
30720093-4	2019	In addition, the present results suggested that puerarin suppressed the interleukin-1beta-induced production of inflammatory cytokines in OA chondrocytes and monocytes/macrophages, as assessed by ELISA.	puerarin	48-56	interleukin 1 beta	Mus musculus	72-89
30385134-9	2019	RESULTS: Our findings demonstrate that puerarin inhibits high glucose-induced Nlrp3 inflammasome formation and activation, as shown by fluorescence confocal microscopy and Western blot.	puerarin	39-47	NLR family, pyrin domain containing 3	Mus musculus	78-83
30385134-12	2019	Interestingly, thioredoxin-interacting protein (TXNIP) protein and TXNIP binding to Nlrp3 markedly decreased with puerarin treatment.	puerarin	114-122	thioredoxin interacting protein	Mus musculus	15-46
30385134-12	2019	Interestingly, thioredoxin-interacting protein (TXNIP) protein and TXNIP binding to Nlrp3 markedly decreased with puerarin treatment.	puerarin	114-122	thioredoxin interacting protein	Mus musculus	48-53
30385134-12	2019	Interestingly, thioredoxin-interacting protein (TXNIP) protein and TXNIP binding to Nlrp3 markedly decreased with puerarin treatment.	puerarin	114-122	thioredoxin interacting protein	Mus musculus	67-72
30385134-12	2019	Interestingly, thioredoxin-interacting protein (TXNIP) protein and TXNIP binding to Nlrp3 markedly decreased with puerarin treatment.	puerarin	114-122	NLR family, pyrin domain containing 3	Mus musculus	84-89
30385134-13	2019	Together with these changes, puerarin could decrease high mobility group box 1 (HMGB1) release from mouse vascular endothelial cell (mMVECs).	puerarin	29-37	high mobility group box 1	Mus musculus	53-78
30385134-13	2019	Together with these changes, puerarin could decrease high mobility group box 1 (HMGB1) release from mouse vascular endothelial cell (mMVECs).	puerarin	29-37	high mobility group box 1	Mus musculus	80-85
30385134-16	2019	In conclusion, we reveal a new protection mechanism of puerarin that inhibits Nlrp3 inflammasome activation and decreases subsequent caspase-1 activation, triggering the release of HMGB1 by reducing ROS generation.	puerarin	55-63	NLR family, pyrin domain containing 3	Mus musculus	78-83
30385134-16	2019	In conclusion, we reveal a new protection mechanism of puerarin that inhibits Nlrp3 inflammasome activation and decreases subsequent caspase-1 activation, triggering the release of HMGB1 by reducing ROS generation.	puerarin	55-63	high mobility group box 1	Mus musculus	181-186
30891078-4	2019	Pretreatment with puerarin, baicalin, and berberine hydrochloride improved the structure and morphology of IPEC-J2 cells and inhibited ETEC adhesion by downregulating specific adhesion molecules.	puerarin	18-26	ETEC	Sus scrofa	135-139
30675620-4	2019	The in silico study displayed that puerarin had the potential to penetrate across the blood-brain barrier and had high stability in molecular docking and dynamics simulation with acetylcholinesterase (AChE), cyclooxygenase-2 (COX-2) and caspase-3 (C3), which play a central role in the development of AD.	puerarin	35-43	acetylcholinesterase	Rattus norvegicus	179-199
30675620-4	2019	The in silico study displayed that puerarin had the potential to penetrate across the blood-brain barrier and had high stability in molecular docking and dynamics simulation with acetylcholinesterase (AChE), cyclooxygenase-2 (COX-2) and caspase-3 (C3), which play a central role in the development of AD.	puerarin	35-43	acetylcholinesterase	Rattus norvegicus	201-205
30675620-4	2019	The in silico study displayed that puerarin had the potential to penetrate across the blood-brain barrier and had high stability in molecular docking and dynamics simulation with acetylcholinesterase (AChE), cyclooxygenase-2 (COX-2) and caspase-3 (C3), which play a central role in the development of AD.	puerarin	35-43	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	208-224
30675620-4	2019	The in silico study displayed that puerarin had the potential to penetrate across the blood-brain barrier and had high stability in molecular docking and dynamics simulation with acetylcholinesterase (AChE), cyclooxygenase-2 (COX-2) and caspase-3 (C3), which play a central role in the development of AD.	puerarin	35-43	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	226-231
30675620-4	2019	The in silico study displayed that puerarin had the potential to penetrate across the blood-brain barrier and had high stability in molecular docking and dynamics simulation with acetylcholinesterase (AChE), cyclooxygenase-2 (COX-2) and caspase-3 (C3), which play a central role in the development of AD.	puerarin	35-43	caspase 3	Rattus norvegicus	237-246
30891078-6	2019	Pretreatment with puerarin, baicalin, and berberine hydrochloride protected IPEC-J2 cells from ETEC infection by inhibiting bacterial adhesion and inflammatory responses.	puerarin	18-26	ETEC	Sus scrofa	95-99
30562628-5	2019	Moreover, the intestinal absorption of puerarin and daidzin could be improved by GR extract and inhibitors of P-glycoprotein and multidrug resistanceassociated protein 2, respectively.	puerarin	39-47	ATP binding cassette subfamily C member 2	Rattus norvegicus	129-169
30666203-0	2018	Puerarin Relieves Paclitaxel-Induced Neuropathic Pain: The Role of Nav1.8 beta1 Subunit of Sensory Neurons.	puerarin	0-8	sodium voltage-gated channel alpha subunit 10	Rattus norvegicus	67-73
30666203-6	2018	In addition, puerarin had a stronger blocking effect on Nav1.8 channels in DRG neurons of neuropathic pain rats and beta1 subunit siRNA can abolish this selective blocking effect on Nav1.8.	puerarin	13-21	sodium voltage-gated channel alpha subunit 10	Rattus norvegicus	56-62
30666203-6	2018	In addition, puerarin had a stronger blocking effect on Nav1.8 channels in DRG neurons of neuropathic pain rats and beta1 subunit siRNA can abolish this selective blocking effect on Nav1.8.	puerarin	13-21	sodium voltage-gated channel alpha subunit 10	Rattus norvegicus	182-188
30666203-7	2018	Together, these results suggested that puerarin may preferentially block beta1 subunit of Nav1.8 in sensory neurons contributed to its anti-paclitaxel induced neuropathic pain effect.	puerarin	39-47	sodium voltage-gated channel alpha subunit 10	Rattus norvegicus	90-96
30612457-10	2019	High-dose puerarin increased the levels of the phosphorylated eNOS protein and decreased AT1 and Cav1 levels.	puerarin	10-18	angiotensin II receptor, type 1a	Rattus norvegicus	89-92
30612457-10	2019	High-dose puerarin increased the levels of the phosphorylated eNOS protein and decreased AT1 and Cav1 levels.	puerarin	10-18	caveolin 1	Rattus norvegicus	97-101
30551525-0	2019	Puerarin attenuates neurological deficits via Bcl-2/Bax/cleaved caspase-3 and Sirt3/SOD2 apoptotic pathways in subarachnoid hemorrhage mice.	puerarin	0-8	B cell leukemia/lymphoma 2	Mus musculus	46-51
30551525-0	2019	Puerarin attenuates neurological deficits via Bcl-2/Bax/cleaved caspase-3 and Sirt3/SOD2 apoptotic pathways in subarachnoid hemorrhage mice.	puerarin	0-8	BCL2-associated X protein	Mus musculus	52-55
30551525-0	2019	Puerarin attenuates neurological deficits via Bcl-2/Bax/cleaved caspase-3 and Sirt3/SOD2 apoptotic pathways in subarachnoid hemorrhage mice.	puerarin	0-8	sirtuin 3	Mus musculus	78-83
30551525-0	2019	Puerarin attenuates neurological deficits via Bcl-2/Bax/cleaved caspase-3 and Sirt3/SOD2 apoptotic pathways in subarachnoid hemorrhage mice.	puerarin	0-8	superoxide dismutase 2, mitochondrial	Mus musculus	84-88
30551525-2	2019	But whether puerarin can reduce brain nerve damage after SAH is not clear.In this study, we hypothesized that puerarin had the neuroprotective effect after SAH, and this protection could be mediated by bothBcl-2/Bax/Cleaved caspase-3 and SIRT3/SOD2 apoptotic signaling pathways.	puerarin	110-118	BCL2-associated X protein	Mus musculus	212-215
30551525-2	2019	But whether puerarin can reduce brain nerve damage after SAH is not clear.In this study, we hypothesized that puerarin had the neuroprotective effect after SAH, and this protection could be mediated by bothBcl-2/Bax/Cleaved caspase-3 and SIRT3/SOD2 apoptotic signaling pathways.	puerarin	110-118	sirtuin 3	Mus musculus	238-243
30551525-2	2019	But whether puerarin can reduce brain nerve damage after SAH is not clear.In this study, we hypothesized that puerarin had the neuroprotective effect after SAH, and this protection could be mediated by bothBcl-2/Bax/Cleaved caspase-3 and SIRT3/SOD2 apoptotic signaling pathways.	puerarin	110-118	superoxide dismutase 2, mitochondrial	Mus musculus	244-248
30551525-7	2019	In addition, obviously higher ratio of Blc-2/Bax and decreased expression of cleaved caspase-3 in puerarin-treated SAH micecomparing with vehicle-treated SAH animals had been found.	puerarin	98-106	BCL2-associated X protein	Mus musculus	45-48
30551525-9	2019	Also, puerarin can increase SOD activation after SAH and protect the expression of Sirt3 after SAH.	puerarin	6-14	superoxide dismutase 2, mitochondrial	Mus musculus	28-31
30551525-9	2019	Also, puerarin can increase SOD activation after SAH and protect the expression of Sirt3 after SAH.	puerarin	6-14	sirtuin 3	Mus musculus	83-88
30421463-3	2019	Moreover, Puerarin can upregulate melanin synthesis and microphthalmia-associated transcription factor (MITF) transcription by increasing cAMP level of intracellular cyclic adenosine monophosphate.	puerarin	10-18	melanocyte inducing transcription factor	Homo sapiens	56-102
30483784-0	2019	Puerarin promotes DUSP1 expression by regulating miR-133a-3p in breast cancer.	puerarin	0-8	dual specificity phosphatase 1	Homo sapiens	18-23
30483784-7	2019	The present results suggested that treatment with puerarin or miR-133a-3p mimics transfection affected the miR-133a-3p expression level and the activity of the DUSP1/p38 pathway, leading to inhibition of HCC38 cell viability and an increase in apoptosis.	puerarin	50-58	dual specificity phosphatase 1	Homo sapiens	160-165
30483784-7	2019	The present results suggested that treatment with puerarin or miR-133a-3p mimics transfection affected the miR-133a-3p expression level and the activity of the DUSP1/p38 pathway, leading to inhibition of HCC38 cell viability and an increase in apoptosis.	puerarin	50-58	mitogen-activated protein kinase 14	Homo sapiens	166-169
30483784-9	2019	In conclusion, puerarin may increase DUSP1 expression by promoting the miR-133a-3p expression level in HCC38 breast cancer cells.	puerarin	15-23	dual specificity phosphatase 1	Homo sapiens	37-42
30599907-4	2019	HYPOTHESIS/PURPOSE: It had been implied by some previous research that the absorption and the metabolism of puerarin were susceptible to liver issues due to changed P-gp and Ugt1a level, but pharmacokinetics of puerarin under such conditions were few concerned.	puerarin	108-116	phosphoglycolate phosphatase	Rattus norvegicus	165-169
30599907-4	2019	HYPOTHESIS/PURPOSE: It had been implied by some previous research that the absorption and the metabolism of puerarin were susceptible to liver issues due to changed P-gp and Ugt1a level, but pharmacokinetics of puerarin under such conditions were few concerned.	puerarin	108-116	Ugt1a@	Rattus norvegicus	174-179
30599907-12	2019	CONCLUSION: The results indicated that the HF originated overexpression of Ugt1a1, Ugt1a7, and P-gp level played important roles in pharmacokinetics of puerarin, suggested the clinical regimen of puerarin based on normal populations might be inappropriate for patients with chronic liver diseases.	puerarin	152-160	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	75-81
30599907-12	2019	CONCLUSION: The results indicated that the HF originated overexpression of Ugt1a1, Ugt1a7, and P-gp level played important roles in pharmacokinetics of puerarin, suggested the clinical regimen of puerarin based on normal populations might be inappropriate for patients with chronic liver diseases.	puerarin	152-160	UDP glucuronosyltransferase family 1 member A7	Homo sapiens	83-89
30599907-12	2019	CONCLUSION: The results indicated that the HF originated overexpression of Ugt1a1, Ugt1a7, and P-gp level played important roles in pharmacokinetics of puerarin, suggested the clinical regimen of puerarin based on normal populations might be inappropriate for patients with chronic liver diseases.	puerarin	152-160	phosphoglycolate phosphatase	Homo sapiens	95-99
30599907-12	2019	CONCLUSION: The results indicated that the HF originated overexpression of Ugt1a1, Ugt1a7, and P-gp level played important roles in pharmacokinetics of puerarin, suggested the clinical regimen of puerarin based on normal populations might be inappropriate for patients with chronic liver diseases.	puerarin	196-204	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	75-81
30599907-12	2019	CONCLUSION: The results indicated that the HF originated overexpression of Ugt1a1, Ugt1a7, and P-gp level played important roles in pharmacokinetics of puerarin, suggested the clinical regimen of puerarin based on normal populations might be inappropriate for patients with chronic liver diseases.	puerarin	196-204	UDP glucuronosyltransferase family 1 member A7	Homo sapiens	83-89
30599907-12	2019	CONCLUSION: The results indicated that the HF originated overexpression of Ugt1a1, Ugt1a7, and P-gp level played important roles in pharmacokinetics of puerarin, suggested the clinical regimen of puerarin based on normal populations might be inappropriate for patients with chronic liver diseases.	puerarin	196-204	phosphoglycolate phosphatase	Homo sapiens	95-99
30421463-3	2019	Moreover, Puerarin can upregulate melanin synthesis and microphthalmia-associated transcription factor (MITF) transcription by increasing cAMP level of intracellular cyclic adenosine monophosphate.	puerarin	10-18	melanocyte inducing transcription factor	Homo sapiens	104-108
30421463-6	2019	In this study, we found that after treating with puerarin at various concentrations of 40 mumol/L, the melanin content of human melanocytes increased significantly and the apparent level of protein and the RNA levels of MITF, tyrosinase (TYR), and tyrosinase-related protein 1 (TRP-1) were also increased.	puerarin	49-57	melanocyte inducing transcription factor	Homo sapiens	220-224
30421463-6	2019	In this study, we found that after treating with puerarin at various concentrations of 40 mumol/L, the melanin content of human melanocytes increased significantly and the apparent level of protein and the RNA levels of MITF, tyrosinase (TYR), and tyrosinase-related protein 1 (TRP-1) were also increased.	puerarin	49-57	tyrosinase	Homo sapiens	226-236
30421463-6	2019	In this study, we found that after treating with puerarin at various concentrations of 40 mumol/L, the melanin content of human melanocytes increased significantly and the apparent level of protein and the RNA levels of MITF, tyrosinase (TYR), and tyrosinase-related protein 1 (TRP-1) were also increased.	puerarin	49-57	tyrosinase	Homo sapiens	238-241
30421463-6	2019	In this study, we found that after treating with puerarin at various concentrations of 40 mumol/L, the melanin content of human melanocytes increased significantly and the apparent level of protein and the RNA levels of MITF, tyrosinase (TYR), and tyrosinase-related protein 1 (TRP-1) were also increased.	puerarin	49-57	tyrosinase related protein 1	Homo sapiens	248-276
30421463-6	2019	In this study, we found that after treating with puerarin at various concentrations of 40 mumol/L, the melanin content of human melanocytes increased significantly and the apparent level of protein and the RNA levels of MITF, tyrosinase (TYR), and tyrosinase-related protein 1 (TRP-1) were also increased.	puerarin	49-57	tyrosinase related protein 1	Homo sapiens	278-283
30421463-7	2019	Further, puerarin was shown to inhibit phosphorylation and activation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) without significantly affecting p38 and c-Jun N-terminal kinase phosphorylation.	puerarin	9-17	mitogen-activated protein kinase 1	Homo sapiens	73-118
30421463-7	2019	Further, puerarin was shown to inhibit phosphorylation and activation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) without significantly affecting p38 and c-Jun N-terminal kinase phosphorylation.	puerarin	9-17	mitogen-activated protein kinase 3	Homo sapiens	120-126
30421463-8	2019	These results demonstrated that puerarin stimulated melanogenesis in human melanocytes via inhibition of ERK1/2 signaling pathways, which leads to upregulation of MITF and TYR as well as TRP-1 subsequently.	puerarin	32-40	mitogen-activated protein kinase 3	Homo sapiens	105-111
30421463-8	2019	These results demonstrated that puerarin stimulated melanogenesis in human melanocytes via inhibition of ERK1/2 signaling pathways, which leads to upregulation of MITF and TYR as well as TRP-1 subsequently.	puerarin	32-40	melanocyte inducing transcription factor	Homo sapiens	163-167
30421463-8	2019	These results demonstrated that puerarin stimulated melanogenesis in human melanocytes via inhibition of ERK1/2 signaling pathways, which leads to upregulation of MITF and TYR as well as TRP-1 subsequently.	puerarin	32-40	tyrosinase	Homo sapiens	172-175
30421463-8	2019	These results demonstrated that puerarin stimulated melanogenesis in human melanocytes via inhibition of ERK1/2 signaling pathways, which leads to upregulation of MITF and TYR as well as TRP-1 subsequently.	puerarin	32-40	tyrosinase related protein 1	Homo sapiens	187-192
30466510-0	2018	Puerarin alleviate radicular pain from lumbar disc herniation by inhibiting ERK-dependent spinal microglia activation.	puerarin	0-8	Eph receptor B1	Rattus norvegicus	76-79
30655755-0	2019	Puerarin in inducing apoptosis of bladder cancer cells through inhibiting SIRT1/p53 pathway.	puerarin	0-8	sirtuin 1	Homo sapiens	74-79
30655755-0	2019	Puerarin in inducing apoptosis of bladder cancer cells through inhibiting SIRT1/p53 pathway.	puerarin	0-8	tumor protein p53	Homo sapiens	80-83
30655755-9	2019	Compared with those in the puerarin group, the apoptosis rate in the combination group was decreased, and the expression level of apoptosis-related protein Bax was also significantly decreased, but the expression level of Bcl-2 was increased, and SIRT1 and p53 protein expression levels were also remarkably increased.	puerarin	27-35	BCL2 associated X, apoptosis regulator	Homo sapiens	156-159
30655755-9	2019	Compared with those in the puerarin group, the apoptosis rate in the combination group was decreased, and the expression level of apoptosis-related protein Bax was also significantly decreased, but the expression level of Bcl-2 was increased, and SIRT1 and p53 protein expression levels were also remarkably increased.	puerarin	27-35	BCL2 apoptosis regulator	Homo sapiens	222-227
30655755-9	2019	Compared with those in the puerarin group, the apoptosis rate in the combination group was decreased, and the expression level of apoptosis-related protein Bax was also significantly decreased, but the expression level of Bcl-2 was increased, and SIRT1 and p53 protein expression levels were also remarkably increased.	puerarin	27-35	tumor protein p53	Homo sapiens	257-260
30655755-10	2019	Puerarin can inhibit the proliferation of bladder cancer T24 cells and induce apoptosis, and the possible mechanism is related to the inhibition of SIRT1/p53 signaling pathway.	puerarin	0-8	sirtuin 1	Homo sapiens	148-153
30655755-10	2019	Puerarin can inhibit the proliferation of bladder cancer T24 cells and induce apoptosis, and the possible mechanism is related to the inhibition of SIRT1/p53 signaling pathway.	puerarin	0-8	tumor protein p53	Homo sapiens	154-157
30466510-8	2018	Puerarin decreased p-ERK expression from day 7 to day 20 after surgery.	puerarin	0-8	Eph receptor B1	Rattus norvegicus	21-24
30466510-9	2018	Puerarin or ERK inhibitor PD98059 alleviated pain behaviors, decreased expression of microglia marker ionized calcium-binding adaptor molecule 1 (Iba-1) in rats with NP implantation.	puerarin	0-8	allograft inflammatory factor 1	Rattus norvegicus	146-151
30466510-10	2018	The results suggested puerarin may alleviate radicular pain by inhibiting ERK-dependent or accompanied spinal microglia activation.	puerarin	22-30	Eph receptor B1	Rattus norvegicus	74-77
29099639-14	2018	In conclusion, these results indicated that glycyrrhizin could affect the pharmacokinetics of puerarin, possibly by decreasing the systemic exposure of puerarin by inducing the activity of P-gp.	puerarin	94-102	phosphoglycolate phosphatase	Rattus norvegicus	189-193
30405406-0	2018	Effect of Puerarin Regulated mTOR Signaling Pathway in Experimental Liver Injury.	puerarin	10-18	mechanistic target of rapamycin kinase	Rattus norvegicus	29-33
30405406-4	2018	In the present study, Pue effectively ameliorated pathological injury of the liver, decreased serum enzyme (ALT, AST, gamma-GT, AKP, DBIL, and TBIL) levels, regulated the balance between pro-inflammatory (TNF-alpha, IL-1beta, IL-4, IL-6, and TGF-beta1) and anti-inflammatory cytokines (IL-10), restored the cell cycle and inhibited hepatocellular apoptosis and caspase-3 expression in rats with liver injury induced by 2-AAF/PH.	puerarin	22-25	tumor necrosis factor	Rattus norvegicus	205-214
30405406-4	2018	In the present study, Pue effectively ameliorated pathological injury of the liver, decreased serum enzyme (ALT, AST, gamma-GT, AKP, DBIL, and TBIL) levels, regulated the balance between pro-inflammatory (TNF-alpha, IL-1beta, IL-4, IL-6, and TGF-beta1) and anti-inflammatory cytokines (IL-10), restored the cell cycle and inhibited hepatocellular apoptosis and caspase-3 expression in rats with liver injury induced by 2-AAF/PH.	puerarin	22-25	interleukin 1 beta	Rattus norvegicus	216-224
30405406-4	2018	In the present study, Pue effectively ameliorated pathological injury of the liver, decreased serum enzyme (ALT, AST, gamma-GT, AKP, DBIL, and TBIL) levels, regulated the balance between pro-inflammatory (TNF-alpha, IL-1beta, IL-4, IL-6, and TGF-beta1) and anti-inflammatory cytokines (IL-10), restored the cell cycle and inhibited hepatocellular apoptosis and caspase-3 expression in rats with liver injury induced by 2-AAF/PH.	puerarin	22-25	interleukin 4	Rattus norvegicus	226-230
30405406-4	2018	In the present study, Pue effectively ameliorated pathological injury of the liver, decreased serum enzyme (ALT, AST, gamma-GT, AKP, DBIL, and TBIL) levels, regulated the balance between pro-inflammatory (TNF-alpha, IL-1beta, IL-4, IL-6, and TGF-beta1) and anti-inflammatory cytokines (IL-10), restored the cell cycle and inhibited hepatocellular apoptosis and caspase-3 expression in rats with liver injury induced by 2-AAF/PH.	puerarin	22-25	interleukin 6	Rattus norvegicus	232-236
30405406-4	2018	In the present study, Pue effectively ameliorated pathological injury of the liver, decreased serum enzyme (ALT, AST, gamma-GT, AKP, DBIL, and TBIL) levels, regulated the balance between pro-inflammatory (TNF-alpha, IL-1beta, IL-4, IL-6, and TGF-beta1) and anti-inflammatory cytokines (IL-10), restored the cell cycle and inhibited hepatocellular apoptosis and caspase-3 expression in rats with liver injury induced by 2-AAF/PH.	puerarin	22-25	transforming growth factor, beta 1	Rattus norvegicus	242-251
30405406-4	2018	In the present study, Pue effectively ameliorated pathological injury of the liver, decreased serum enzyme (ALT, AST, gamma-GT, AKP, DBIL, and TBIL) levels, regulated the balance between pro-inflammatory (TNF-alpha, IL-1beta, IL-4, IL-6, and TGF-beta1) and anti-inflammatory cytokines (IL-10), restored the cell cycle and inhibited hepatocellular apoptosis and caspase-3 expression in rats with liver injury induced by 2-AAF/PH.	puerarin	22-25	interleukin 10	Rattus norvegicus	286-291
30405406-4	2018	In the present study, Pue effectively ameliorated pathological injury of the liver, decreased serum enzyme (ALT, AST, gamma-GT, AKP, DBIL, and TBIL) levels, regulated the balance between pro-inflammatory (TNF-alpha, IL-1beta, IL-4, IL-6, and TGF-beta1) and anti-inflammatory cytokines (IL-10), restored the cell cycle and inhibited hepatocellular apoptosis and caspase-3 expression in rats with liver injury induced by 2-AAF/PH.	puerarin	22-25	caspase 3	Rattus norvegicus	361-370
30405406-5	2018	Pue inhibited p-mTOR, p-AKT and Raptor activity, and increased Rictor expression in the liver tissues of rats with experimental liver injury.	puerarin	0-3	mechanistic target of rapamycin kinase	Rattus norvegicus	16-20
30405406-5	2018	Pue inhibited p-mTOR, p-AKT and Raptor activity, and increased Rictor expression in the liver tissues of rats with experimental liver injury.	puerarin	0-3	regulatory associated protein of MTOR, complex 1	Rattus norvegicus	32-38
30405406-5	2018	Pue inhibited p-mTOR, p-AKT and Raptor activity, and increased Rictor expression in the liver tissues of rats with experimental liver injury.	puerarin	0-3	RPTOR independent companion of MTOR, complex 2	Rattus norvegicus	63-69
30386303-6	2018	Similarly, we also showed that puerarin, a Chinese herbal medicine compound, activates SIRT1 to provide renoprotection in mouse models of DKD.	puerarin	31-39	sirtuin 1	Mus musculus	87-92
30245282-3	2018	Therefore, we performed the clinical trial to assess the effect of puerarin on carotid intima-media thickness (CIMT) in RA.	puerarin	67-75	CIMT	Homo sapiens	111-115
30284466-0	2018	Activity Dependent Mammalian Target of Rapamycin Pathway and Brain Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Effects of Puerarin.	puerarin	155-163	mechanistic target of rapamycin kinase	Homo sapiens	19-48
30284466-0	2018	Activity Dependent Mammalian Target of Rapamycin Pathway and Brain Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Effects of Puerarin.	puerarin	155-163	brain derived neurotrophic factor	Homo sapiens	61-94
30284466-2	2018	Previous studies also show that puerarin can produce neuroprotective effect via activating the Akt or increased brain-derived neurotrophic factor (BDNF) expression.	puerarin	32-40	AKT serine/threonine kinase 1	Homo sapiens	95-98
30284466-2	2018	Previous studies also show that puerarin can produce neuroprotective effect via activating the Akt or increased brain-derived neurotrophic factor (BDNF) expression.	puerarin	32-40	brain derived neurotrophic factor	Homo sapiens	112-145
30284466-2	2018	Previous studies also show that puerarin can produce neuroprotective effect via activating the Akt or increased brain-derived neurotrophic factor (BDNF) expression.	puerarin	32-40	brain derived neurotrophic factor	Homo sapiens	147-151
30284466-5	2018	We aimed to investigate whether the antidepressant-like effect induced by puerarin would associate mTOR signaling pathway and BDNF release.	puerarin	74-82	mechanistic target of rapamycin kinase	Homo sapiens	99-103
30284466-5	2018	We aimed to investigate whether the antidepressant-like effect induced by puerarin would associate mTOR signaling pathway and BDNF release.	puerarin	74-82	brain derived neurotrophic factor	Homo sapiens	126-130
30284466-9	2018	Our present results show that puerarin exerted antidepressant-like responses that was mediated by AMPAR-induced mTOR signaling pathway and associated with increased BDNF release.	puerarin	30-38	mechanistic target of rapamycin kinase	Homo sapiens	112-116
30284466-9	2018	Our present results show that puerarin exerted antidepressant-like responses that was mediated by AMPAR-induced mTOR signaling pathway and associated with increased BDNF release.	puerarin	30-38	brain derived neurotrophic factor	Homo sapiens	165-169
30284466-10	2018	Moreover, a significant increase in the GluR1 phosphorylation at its PKA site was noted following puerarin treatment.	puerarin	98-106	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	40-45
30284466-11	2018	Our findings are the first to demonstrate that the antidepressant-like actions of puerarin require AMPAR-mTOR signaling pathway activation, are associated with an increased BDNF level and facilitate AMPAR membrane insertion.	puerarin	82-90	mechanistic target of rapamycin kinase	Homo sapiens	105-109
30284466-11	2018	Our findings are the first to demonstrate that the antidepressant-like actions of puerarin require AMPAR-mTOR signaling pathway activation, are associated with an increased BDNF level and facilitate AMPAR membrane insertion.	puerarin	82-90	brain derived neurotrophic factor	Homo sapiens	173-177
30245282-9	2018	A tiny but significant decrease of CIMT was observed in puerarin-treated patients at 24 weeks (-0.003 mm; 95% CI, -0.005 to -0.001vs 0.019 mm; 95% CI, -0.002 to 0.040; P &lt; 0.001).	puerarin	56-64	CIMT	Homo sapiens	35-39
30245282-10	2018	At 24 weeks, insulin resistance was indicated with more pronounced improvement in the puerarin group versus the control group (homeostasis model assessment, -0.40; 95% CI, -0.47 to -0.33vs -0.05; 95% CI, -0.08 to -0.01; P &lt; 0.001).	puerarin	86-94	insulin	Homo sapiens	13-20
30245282-11	2018	Correlation analysis indicated an interaction between the parallel reductions in CIMT and insulin resistance in the puerarin group (r = 0.878, P &lt; 0.001) but not in the control group.	puerarin	116-124	CIMT	Homo sapiens	81-85
30245282-11	2018	Correlation analysis indicated an interaction between the parallel reductions in CIMT and insulin resistance in the puerarin group (r = 0.878, P &lt; 0.001) but not in the control group.	puerarin	116-124	insulin	Homo sapiens	90-97
30245282-12	2018	IMPLICATIONS: In the study, 24 weeks of treatment with 400mg of puerarin exerted a significant effect against CIMT progression in patients with active RA, which may be associated with the improvement of insulin resistance.	puerarin	64-72	CIMT	Homo sapiens	110-114
30245282-12	2018	IMPLICATIONS: In the study, 24 weeks of treatment with 400mg of puerarin exerted a significant effect against CIMT progression in patients with active RA, which may be associated with the improvement of insulin resistance.	puerarin	64-72	insulin	Homo sapiens	203-210
30486537-0	2018	[Differentiated hypoglycemic effects of baicalin, berberine and puerarin on insulin-resistance HepG2 cells].	puerarin	64-72	insulin	Homo sapiens	76-83
30486537-1	2018	To investigate the hypoglycemic effects of baicalin, berberine, puerarin and liquiritin on the insulin resistance (IR) cells.	puerarin	64-72	insulin	Homo sapiens	95-102
30186426-13	2018	Puerarin regulated the mRNA level of TGF-betal, Smad3 and snail, suppresing the EMT process, which was accompanied by an increased mRNA level of E-cadherin and decreased levels of vimentin and fibronectin, along with increased levels of occludin, ZO-1 and claudin.	puerarin	0-8	fibronectin 1	Homo sapiens	193-204
30271082-0	2018	Mechanism of combined use of vitamin D and puerarin in anti-hepatic fibrosis by regulating the Wnt/beta-catenin signalling pathway.	puerarin	43-51	Wnt family member 1	Rattus norvegicus	95-98
30271082-0	2018	Mechanism of combined use of vitamin D and puerarin in anti-hepatic fibrosis by regulating the Wnt/beta-catenin signalling pathway.	puerarin	43-51	catenin beta 1	Rattus norvegicus	99-111
29422113-0	2018	Puerarin Inhibits Proliferation and Induces Apoptosis by Upregulation of miR-16 in Bladder Cancer Cell Line T24.	puerarin	0-8	glycerophosphodiester phosphodiesterase 1	Homo sapiens	73-79
29422113-10	2018	More importantly, puerarin deactivated the NF-kappaB signaling pathway via upregulation of miR-16.	puerarin	18-26	glycerophosphodiester phosphodiesterase 1	Homo sapiens	91-97
29422113-12	2018	This study demonstrated that puerarin could inhibit cell proliferation, promote cell apoptosis, and deactivate NF-kappaB signaling pathway via upregulation of miR-16 in T24 cells.	puerarin	29-37	glycerophosphodiester phosphodiesterase 1	Homo sapiens	159-165
30186426-0	2018	Baicalin and puerarin reverse epithelial-mesenchymal transition via the TGF-beta1/Smad3 pathway in vitro.	puerarin	13-21	transforming growth factor beta 1	Homo sapiens	72-81
30186426-13	2018	Puerarin regulated the mRNA level of TGF-betal, Smad3 and snail, suppresing the EMT process, which was accompanied by an increased mRNA level of E-cadherin and decreased levels of vimentin and fibronectin, along with increased levels of occludin, ZO-1 and claudin.	puerarin	0-8	occludin	Homo sapiens	237-245
30186426-0	2018	Baicalin and puerarin reverse epithelial-mesenchymal transition via the TGF-beta1/Smad3 pathway in vitro.	puerarin	13-21	SMAD family member 3	Homo sapiens	82-87
30186426-13	2018	Puerarin regulated the mRNA level of TGF-betal, Smad3 and snail, suppresing the EMT process, which was accompanied by an increased mRNA level of E-cadherin and decreased levels of vimentin and fibronectin, along with increased levels of occludin, ZO-1 and claudin.	puerarin	0-8	tight junction protein 1	Homo sapiens	247-251
30186426-8	2018	Baicalin and puerarin abrogated the increased expression of vimentin and fibronectin, and rescued E-cadherin expression in acetaldehyde-treated hepatocytes.	puerarin	13-21	vimentin	Homo sapiens	60-68
30186426-8	2018	Baicalin and puerarin abrogated the increased expression of vimentin and fibronectin, and rescued E-cadherin expression in acetaldehyde-treated hepatocytes.	puerarin	13-21	fibronectin 1	Homo sapiens	73-84
30186426-8	2018	Baicalin and puerarin abrogated the increased expression of vimentin and fibronectin, and rescued E-cadherin expression in acetaldehyde-treated hepatocytes.	puerarin	13-21	cadherin 1	Homo sapiens	98-108
29909234-5	2018	The inflammatory mediators such as IL-1beta, IL-6, TNF-alpha and vascular endothelial growth factor (VEGF) are significantly enhanced during inflammatory conditions, however, the Puerarin administration significantly altered (P &lt; 0.001) the mRNA expression levels of these mediators.	puerarin	179-187	vascular endothelial growth factor A	Homo sapiens	65-99
30186426-9	2018	It was further demonstrated that baicalin and puerarin reduced the gene expression of snail, TGF-beta1 and Smad3.	puerarin	46-54	snail family transcriptional repressor 1	Homo sapiens	86-91
30186426-9	2018	It was further demonstrated that baicalin and puerarin reduced the gene expression of snail, TGF-beta1 and Smad3.	puerarin	46-54	transforming growth factor beta 1	Homo sapiens	93-102
30186426-9	2018	It was further demonstrated that baicalin and puerarin reduced the gene expression of snail, TGF-beta1 and Smad3.	puerarin	46-54	SMAD family member 3	Homo sapiens	107-112
30186426-13	2018	Puerarin regulated the mRNA level of TGF-betal, Smad3 and snail, suppresing the EMT process, which was accompanied by an increased mRNA level of E-cadherin and decreased levels of vimentin and fibronectin, along with increased levels of occludin, ZO-1 and claudin.	puerarin	0-8	SMAD family member 3	Homo sapiens	48-53
30186426-13	2018	Puerarin regulated the mRNA level of TGF-betal, Smad3 and snail, suppresing the EMT process, which was accompanied by an increased mRNA level of E-cadherin and decreased levels of vimentin and fibronectin, along with increased levels of occludin, ZO-1 and claudin.	puerarin	0-8	snail family transcriptional repressor 1	Homo sapiens	58-63
30186426-13	2018	Puerarin regulated the mRNA level of TGF-betal, Smad3 and snail, suppresing the EMT process, which was accompanied by an increased mRNA level of E-cadherin and decreased levels of vimentin and fibronectin, along with increased levels of occludin, ZO-1 and claudin.	puerarin	0-8	cadherin 1	Homo sapiens	145-155
30186426-13	2018	Puerarin regulated the mRNA level of TGF-betal, Smad3 and snail, suppresing the EMT process, which was accompanied by an increased mRNA level of E-cadherin and decreased levels of vimentin and fibronectin, along with increased levels of occludin, ZO-1 and claudin.	puerarin	0-8	vimentin	Homo sapiens	180-188
29775893-0	2018	Puerarin prevents vascular endothelial injury through suppression of NF-kappaB activation in LPS-challenged human umbilical vein endothelial cells.	puerarin	0-8	nuclear factor kappa B subunit 1	Homo sapiens	69-78
29775893-9	2018	However, puerarin pre-treatment attenuated the vascular endothelial injury and reduced the levels of TNF-alpha, IL-1beta, MCP-1, IL-8, ICAM-1, TM and PAI-1 in cell supernatants of LPS-challenged HUVECs.	puerarin	9-17	tumor necrosis factor	Mus musculus	101-110
29775893-9	2018	However, puerarin pre-treatment attenuated the vascular endothelial injury and reduced the levels of TNF-alpha, IL-1beta, MCP-1, IL-8, ICAM-1, TM and PAI-1 in cell supernatants of LPS-challenged HUVECs.	puerarin	9-17	interleukin 1 beta	Mus musculus	112-120
29775893-9	2018	However, puerarin pre-treatment attenuated the vascular endothelial injury and reduced the levels of TNF-alpha, IL-1beta, MCP-1, IL-8, ICAM-1, TM and PAI-1 in cell supernatants of LPS-challenged HUVECs.	puerarin	9-17	chemokine (C-C motif) ligand 2	Mus musculus	122-127
29775893-9	2018	However, puerarin pre-treatment attenuated the vascular endothelial injury and reduced the levels of TNF-alpha, IL-1beta, MCP-1, IL-8, ICAM-1, TM and PAI-1 in cell supernatants of LPS-challenged HUVECs.	puerarin	9-17	chemokine (C-X-C motif) ligand 15	Mus musculus	129-133
29775893-9	2018	However, puerarin pre-treatment attenuated the vascular endothelial injury and reduced the levels of TNF-alpha, IL-1beta, MCP-1, IL-8, ICAM-1, TM and PAI-1 in cell supernatants of LPS-challenged HUVECs.	puerarin	9-17	intercellular adhesion molecule 1	Mus musculus	135-141
29775893-9	2018	However, puerarin pre-treatment attenuated the vascular endothelial injury and reduced the levels of TNF-alpha, IL-1beta, MCP-1, IL-8, ICAM-1, TM and PAI-1 in cell supernatants of LPS-challenged HUVECs.	puerarin	9-17	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	150-155
29775893-11	2018	Furthermore, puerarin pre-treatment reduced the nuclear translocation of NF-kappaB p65 elicited by LPS.	puerarin	13-21	RELA proto-oncogene, NF-kB subunit	Homo sapiens	73-86
29775893-12	2018	CONCLUSIONS: Puerarin prevented LPS-induced vascular endothelial injury, the mechanism of which might be related to the suppression of NF-kappaB activation and subsequently altered levels of inflammatory factors and coagulation-related factors.	puerarin	13-21	nuclear factor kappa B subunit 1	Homo sapiens	135-144
29945930-0	2018	Contributions of Nrf2 to Puerarin Prevention of Cardiac Hypertrophy and its Metabolic Enzymes Expression in Rats.	puerarin	25-33	NFE2 like bZIP transcription factor 2	Rattus norvegicus	17-21
29945930-4	2018	We confirmed that puerarin (50 mg/kg per day) significantly attenuated cardiac hypertrophy, upregulated Nrf2, and decreased Keap1 in the myocardium.	puerarin	18-26	NFE2 like bZIP transcription factor 2	Rattus norvegicus	104-108
29945930-4	2018	We confirmed that puerarin (50 mg/kg per day) significantly attenuated cardiac hypertrophy, upregulated Nrf2, and decreased Keap1 in the myocardium.	puerarin	18-26	Kelch-like ECH-associated protein 1	Rattus norvegicus	124-129
29945930-5	2018	Moreover, puerarin significantly promoted Nrf2 nuclear accumulation in parallel with the upregulated downstream proteins, including heme oxygenase 1, glutathione transferase P1, and NAD(P)H:quinone oxidoreductase 1.	puerarin	10-18	NFE2 like bZIP transcription factor 2	Rattus norvegicus	42-46
29945930-5	2018	Moreover, puerarin significantly promoted Nrf2 nuclear accumulation in parallel with the upregulated downstream proteins, including heme oxygenase 1, glutathione transferase P1, and NAD(P)H:quinone oxidoreductase 1.	puerarin	10-18	heme oxygenase 1	Rattus norvegicus	132-148
29945930-5	2018	Moreover, puerarin significantly promoted Nrf2 nuclear accumulation in parallel with the upregulated downstream proteins, including heme oxygenase 1, glutathione transferase P1, and NAD(P)H:quinone oxidoreductase 1.	puerarin	10-18	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	162-214
29945930-6	2018	Similar results were obtained in neonatal rat cardiomyocytes (NRCMs) treated with angiotensin II (Ang II; 1 muM) and puerarin (100 muM), whereas the silencing of Nrf2 abolished the antihypertrophic effects of puerarin.	puerarin	209-217	angiotensinogen	Rattus norvegicus	82-111
29945930-6	2018	Similar results were obtained in neonatal rat cardiomyocytes (NRCMs) treated with angiotensin II (Ang II; 1 muM) and puerarin (100 muM), whereas the silencing of Nrf2 abolished the antihypertrophic effects of puerarin.	puerarin	209-217	NFE2 like bZIP transcription factor 2	Rattus norvegicus	162-166
29945930-7	2018	The mRNA and protein levels of UGT1A1 and UGT1A9, enzymes for puerarin metabolism, were significantly increased in the liver and heart tissues of AAC rats and Ang II-treated NRCMs.	puerarin	62-70	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	31-37
29945930-7	2018	The mRNA and protein levels of UGT1A1 and UGT1A9, enzymes for puerarin metabolism, were significantly increased in the liver and heart tissues of AAC rats and Ang II-treated NRCMs.	puerarin	62-70	UDP glucuronosyltransferase family 1 member A9	Rattus norvegicus	42-48
29945930-7	2018	The mRNA and protein levels of UGT1A1 and UGT1A9, enzymes for puerarin metabolism, were significantly increased in the liver and heart tissues of AAC rats and Ang II-treated NRCMs.	puerarin	62-70	angiogenin	Rattus norvegicus	159-162
29945930-8	2018	Interestingly, the silencing of Nrf2 attenuated the puerarin-induced upregulation of UGT1A1 and UGT1A9.	puerarin	52-60	NFE2 like bZIP transcription factor 2	Rattus norvegicus	32-36
29945930-8	2018	Interestingly, the silencing of Nrf2 attenuated the puerarin-induced upregulation of UGT1A1 and UGT1A9.	puerarin	52-60	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	85-91
29945930-8	2018	Interestingly, the silencing of Nrf2 attenuated the puerarin-induced upregulation of UGT1A1 and UGT1A9.	puerarin	52-60	UDP glucuronosyltransferase family 1 member A9	Rattus norvegicus	96-102
29945930-9	2018	The results of chromatin immunoprecipitation-quantitative polymerase chain reaction indicated that the binding of Nrf2 to the promoter region of Ugt1a1 or Ugt1a9 was significantly enhanced in puerarin-treated cardiomyocytes.	puerarin	192-200	NFE2 like bZIP transcription factor 2	Rattus norvegicus	114-118
29945930-9	2018	The results of chromatin immunoprecipitation-quantitative polymerase chain reaction indicated that the binding of Nrf2 to the promoter region of Ugt1a1 or Ugt1a9 was significantly enhanced in puerarin-treated cardiomyocytes.	puerarin	192-200	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	145-151
29945930-9	2018	The results of chromatin immunoprecipitation-quantitative polymerase chain reaction indicated that the binding of Nrf2 to the promoter region of Ugt1a1 or Ugt1a9 was significantly enhanced in puerarin-treated cardiomyocytes.	puerarin	192-200	UDP glucuronosyltransferase family 1 member A9	Rattus norvegicus	155-161
29945930-10	2018	These results suggest that Nrf2 is the key regulator of antihypertrophic effects and upregulation of the metabolic enzymes UGT1A1 and UGT1A9 of puerarin.	puerarin	144-152	NFE2 like bZIP transcription factor 2	Rattus norvegicus	27-31
29945930-10	2018	These results suggest that Nrf2 is the key regulator of antihypertrophic effects and upregulation of the metabolic enzymes UGT1A1 and UGT1A9 of puerarin.	puerarin	144-152	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	123-129
29945930-10	2018	These results suggest that Nrf2 is the key regulator of antihypertrophic effects and upregulation of the metabolic enzymes UGT1A1 and UGT1A9 of puerarin.	puerarin	144-152	UDP glucuronosyltransferase family 1 member A9	Rattus norvegicus	134-140
29945930-11	2018	The autoregulatory circuits between puerarin and Nrf2-induced UGT1A1/1A9 are beneficial to attenuate adverse effects and maintain the pharmacologic effects of puerarin.	puerarin	36-44	NFE2 like bZIP transcription factor 2	Rattus norvegicus	49-53
29945930-11	2018	The autoregulatory circuits between puerarin and Nrf2-induced UGT1A1/1A9 are beneficial to attenuate adverse effects and maintain the pharmacologic effects of puerarin.	puerarin	36-44	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	62-68
30127931-0	2018	The protective effect of puerarin on angiotensin II-induced aortic aneurysm formation by the inhibition of NADPH oxidase activation and oxidative stress-triggered AP-1 signaling pathways.	puerarin	25-33	angiotensinogen	Homo sapiens	37-51
30127931-0	2018	The protective effect of puerarin on angiotensin II-induced aortic aneurysm formation by the inhibition of NADPH oxidase activation and oxidative stress-triggered AP-1 signaling pathways.	puerarin	25-33	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	163-167
30127931-2	2018	In the present study, the effect of puerarin on angiotensin II-induced aortic aneurysm formation and the potential underlying molecular mechanisms were examined.	puerarin	36-44	angiotensinogen	Homo sapiens	48-62
30127931-4	2018	Furthermore, treatment with puerarin significantly suppressed the production of reactive oxygen species (ROS) and the expression of matrix metalloproteinase-2 (MMP-2) protein in aneurysm cells.	puerarin	28-36	matrix metallopeptidase 2	Homo sapiens	132-158
30127931-4	2018	Furthermore, treatment with puerarin significantly suppressed the production of reactive oxygen species (ROS) and the expression of matrix metalloproteinase-2 (MMP-2) protein in aneurysm cells.	puerarin	28-36	matrix metallopeptidase 2	Homo sapiens	160-165
30127931-5	2018	Puerarin treatment significantly increased caspase-9 and -3 activity, induced the protein expression of phosphorylated (p)-Jun and inhibited the protein expression of activator protein 1 (AP-1) in aneurysm cells.	puerarin	0-8	caspase 9	Homo sapiens	43-59
30127931-5	2018	Puerarin treatment significantly increased caspase-9 and -3 activity, induced the protein expression of phosphorylated (p)-Jun and inhibited the protein expression of activator protein 1 (AP-1) in aneurysm cells.	puerarin	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	167-186
30127931-5	2018	Puerarin treatment significantly increased caspase-9 and -3 activity, induced the protein expression of phosphorylated (p)-Jun and inhibited the protein expression of activator protein 1 (AP-1) in aneurysm cells.	puerarin	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	188-192
30127931-7	2018	Therefore, it was demonstrated that puerarin on suppressed the cell growth of angiotensin II-induced aortic aneurysm formation by affecting the rate of apoptosis, the generation of ROS, MMP-2, AP-1 and p-Jun protein expression and NADPH oxidase.	puerarin	36-44	angiotensinogen	Homo sapiens	78-92
30127931-7	2018	Therefore, it was demonstrated that puerarin on suppressed the cell growth of angiotensin II-induced aortic aneurysm formation by affecting the rate of apoptosis, the generation of ROS, MMP-2, AP-1 and p-Jun protein expression and NADPH oxidase.	puerarin	36-44	matrix metallopeptidase 2	Homo sapiens	186-191
30127931-7	2018	Therefore, it was demonstrated that puerarin on suppressed the cell growth of angiotensin II-induced aortic aneurysm formation by affecting the rate of apoptosis, the generation of ROS, MMP-2, AP-1 and p-Jun protein expression and NADPH oxidase.	puerarin	36-44	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	193-197
29723698-0	2018	ERK5/KLF2 activation is involved in the reducing effects of puerarin on monocyte adhesion to endothelial cells and atherosclerotic lesion in apolipoprotein E-deficient mice.	puerarin	60-68	mitogen-activated protein kinase 7	Mus musculus	0-4
29723698-0	2018	ERK5/KLF2 activation is involved in the reducing effects of puerarin on monocyte adhesion to endothelial cells and atherosclerotic lesion in apolipoprotein E-deficient mice.	puerarin	60-68	Kruppel-like factor 2 (lung)	Mus musculus	5-9
29723698-4	2018	The results showed that puerarin dose- and time-dependently reduced oxLDL-induced monocyte THP-1 adhesion to HUVECs and the expression of adhesion-related genes such as VCAM-1, ICAM-1, MCP-1 and IL-8 in HUVECs.	puerarin	24-32	vascular cell adhesion molecule 1	Mus musculus	169-175
29723698-4	2018	The results showed that puerarin dose- and time-dependently reduced oxLDL-induced monocyte THP-1 adhesion to HUVECs and the expression of adhesion-related genes such as VCAM-1, ICAM-1, MCP-1 and IL-8 in HUVECs.	puerarin	24-32	intercellular adhesion molecule 1	Mus musculus	177-183
29723698-4	2018	The results showed that puerarin dose- and time-dependently reduced oxLDL-induced monocyte THP-1 adhesion to HUVECs and the expression of adhesion-related genes such as VCAM-1, ICAM-1, MCP-1 and IL-8 in HUVECs.	puerarin	24-32	mast cell protease 1	Mus musculus	185-190
29723698-4	2018	The results showed that puerarin dose- and time-dependently reduced oxLDL-induced monocyte THP-1 adhesion to HUVECs and the expression of adhesion-related genes such as VCAM-1, ICAM-1, MCP-1 and IL-8 in HUVECs.	puerarin	24-32	chemokine (C-X-C motif) ligand 15	Mus musculus	195-199
29723698-5	2018	Puerarin activated ERK5 phosphorylation and up-regulated expressions of downstream KLF2 and its targeted genes endothelial nitric oxide synthase and thrombomodulin.	puerarin	0-8	mitogen-activated protein kinase 7	Mus musculus	19-23
29723698-5	2018	Puerarin activated ERK5 phosphorylation and up-regulated expressions of downstream KLF2 and its targeted genes endothelial nitric oxide synthase and thrombomodulin.	puerarin	0-8	Kruppel-like factor 2 (lung)	Mus musculus	83-87
29723698-5	2018	Puerarin activated ERK5 phosphorylation and up-regulated expressions of downstream KLF2 and its targeted genes endothelial nitric oxide synthase and thrombomodulin.	puerarin	0-8	nitric oxide synthase 3, endothelial cell	Mus musculus	111-144
29723698-9	2018	Altogether, the data revealed that puerarin inhibited the monocyte adhesion in vitro and in vivo and thus reduced atherosclerotic lesions in apoE-/- mice; the protective effects were mediated by activation of ERK5/KLF2 signaling pathway.	puerarin	35-43	apolipoprotein E	Mus musculus	141-145
29723698-9	2018	Altogether, the data revealed that puerarin inhibited the monocyte adhesion in vitro and in vivo and thus reduced atherosclerotic lesions in apoE-/- mice; the protective effects were mediated by activation of ERK5/KLF2 signaling pathway.	puerarin	35-43	mitogen-activated protein kinase 7	Mus musculus	209-213
29723698-9	2018	Altogether, the data revealed that puerarin inhibited the monocyte adhesion in vitro and in vivo and thus reduced atherosclerotic lesions in apoE-/- mice; the protective effects were mediated by activation of ERK5/KLF2 signaling pathway.	puerarin	35-43	Kruppel-like factor 2 (lung)	Mus musculus	214-218
29909234-5	2018	The inflammatory mediators such as IL-1beta, IL-6, TNF-alpha and vascular endothelial growth factor (VEGF) are significantly enhanced during inflammatory conditions, however, the Puerarin administration significantly altered (P &lt; 0.001) the mRNA expression levels of these mediators.	puerarin	179-187	vascular endothelial growth factor A	Homo sapiens	101-105
29909234-6	2018	Additionally, the Puerarin treatment also significantly enhanced (P &lt; 0.001) the mRNA expressions levels of the anti-oxidant enzymes such as Nrf2, HO-1 and SOD2.	puerarin	18-26	NFE2 like bZIP transcription factor 2	Homo sapiens	144-148
29909234-6	2018	Additionally, the Puerarin treatment also significantly enhanced (P &lt; 0.001) the mRNA expressions levels of the anti-oxidant enzymes such as Nrf2, HO-1 and SOD2.	puerarin	18-26	heme oxygenase 1	Homo sapiens	150-154
29909234-6	2018	Additionally, the Puerarin treatment also significantly enhanced (P &lt; 0.001) the mRNA expressions levels of the anti-oxidant enzymes such as Nrf2, HO-1 and SOD2.	puerarin	18-26	superoxide dismutase 2	Homo sapiens	159-163
29802940-8	2018	Moreover, puerarin modulated mitochondrial fusion and fission, and rescued palmitate-impaired mitophagy via phosphatase and tensin homolog-induced putative kinase 1(PINK1)/Parkin pathway.	puerarin	10-18	PTEN induced kinase 1	Homo sapiens	165-170
29802940-9	2018	In addition, puerarin attenuated palmitate-induced inflammation through the inhibition of toll-like receptor 4/nuclear factor-kappaB signaling pathway.	puerarin	13-21	toll like receptor 4	Homo sapiens	90-110